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ABSTRACT 
 
JUSTIN THOMAS MALINOWSKI: Complexity-Building Reaction Development and the 
Total Synthesis of Pactamycin  
(Under the direction of Professor Jeffrey S. Johnson) 
 
I. Tandem Reformatsky/Quaternary Claisen Condensation of Silyl Glyoxylates and 
-Lactones - Application to Leustroducsin B 
 The diastereoselective synthesis of -hydroxy ketones via quaternary Claisen 
condensation is described. This was accomplished via three-component coupling technology 
incorporating a Reformatsky reagent, silyl glyoxylates, and enantioenriched -lactones. An 
unusual case of 1,4-stereoinduction was observed, transmitting the -lactone stereochemistry 
to the developing fully-substituted stereocenter. The product scaffold was designed for quick 
access to the common leustroducsin family core subunit and applied to the formal synthesis of 
leustroducsin B. 
 
II. Synthetic Studies Toward the Pactamycin Core 
 Several approaches for the construction of the pactamycin core are presented. A 
prevailing strategy includes the rapid formation of the fully-substituted C1 stereocenter with a 
iv 
 
pendant ketone functional handle for nucleophilic addition. Highly diastereoselective additions 
were permitted by the use of cerium trichloride, leading to a chelation-controlled 
stereochemical hypothesis. Four of the five core stereocenters were completed, but a 
challenging C2 amination could not be completed. The results of various strategies for the 
amino incorporation are discussed, and an optimized route to an advanced intermediate is 
described. 
 
III. -Amination of Keto-Nitrones via Multihetero-Cope Rearrangement 
  The amination problem faced in the pactamycin core synthesis led to the invention and 
development of a novel -amination protocol employing nitrones and imidoyl chlorides. Upon 
combination of the two reaction partners, spontaneous [3,3]-rearrangement occurred 
generating -carbamoyl enamides, or enediamide products based upon the availability of 
enolizable protons. Treatment of the products with sodium phenylthiolate induced hydrolysis 
to give protected -amino ketones in moderate yield.  
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IV. Total Synthesis of Pactamycin 
 The enantioselective total synthesis of pactamycin is detailed. A de novo approach to 
this target was pursued using an asymmetric Mannich addition to install the C2 amino 
functionality early in the route. A symmetry-breaking diketone monoreduction occurred with 
high selectivity allowing for rapid core construction. Several unanticipated stereochemical 
complexities allowing for the ultimate target completion were discovered ex post facto leading 
to a serendipitous, concise route to pactamycin. The molecule was completed in fifteen steps, 
less than half that of the single reported synthesis known to date. The flexibility and efficiency 
afforded by this route allow for derivatization toward analogue synthesis. These structural 
manipulations may attenuate pactamycin’s cytotoxicity which currently precludes its 
medicinal application. 
 
 
 
 
 
vi 
 
 
 
 
ACKNOWLEDGEMENTS 
 
I would first like to express my gratitude to my research advisor Jeffrey Johnson. Jeff’s 
emphatic love for chemistry has led to a research program and work environment driven by 
creativity, excitement, and passion for improving scientific knowledge. I am fortunate to have 
been a part of this experience and recognize that an advisor that “does things for the right 
reason” is hard to come by these days. Jeff’s humble demeanor is something that I strive to 
replicate, although this may not always be evident. Jeff is an ever-encouraging advisor. 
Countless times, when it seems that all ideas have failed and I’m feeling the pain of chemical 
research, a short trip to Jeff’s office fosters constructive conversation and produces, infallibly, 
an excited graduate student with a long list of reactions to run. Additionally, the freedom Jeff 
affords to explore our own desires and plan our own experiments is refreshing and has greatly 
contributed to my development. It was a privilege to work in the Johnson group.  
I would like to thank Professors Michel Gagné, Simon Meek, and Joseph Templeton 
for serving on my final defense committee, as well as David Lawrence, Marcey Waters, and 
Maurice Brookhart for serving on past committees and for reference writing. I am especially 
thankful to Prof. David Nicewicz for his committee service, work with silyl glyoxylates, 
helping to secure my postdoctoral position…and his career roadmap. 
vii 
 
I cannot say enough about my coworkers and friends at UNC. Through the years, the 
work environment has been encouraging, intellectual, and fun. Saturday morning Dunkin’ 
Donuts with Andrew Parsons, Austin Smith, and Andy Brus(c)oe rank among my favorite 
memories of grad school. I specifically thank Andrew for motivation, early mornings, and his 
contagious work ethic. Andy Satterfield, Chris Tarr, and Steve Greszler all had a major role in 
my early development and taught me how to “do chemistry.” Working side-by-side with Steve 
(not running columns together…FYI), not only allowed for the development of my skills, but 
was a lot of fun. I learned what a “Greszler-approved” method was, and “if the reaction fails, 
double the scale!” I was fortunate to spend several years with Dan Schmitt, Mike Slade, Greg 
Boyce, Austin, and Kim Steward where we existed as a tight-knit group and I really enjoyed 
the camaraderie. Austin, I wouldn’t be putting oats in my protein if it wasn’t for you; oh, you’re 
supposed to grind them. You have had a big influence on me and taught me everything I know 
about ordering. I’m looking forward to joining you at “emeritus status” as I pass on the duties 
to Guy Goodman, a worthy successor. The current roster has continued to exude Johnson 
Group excellence and has been a pleasure to work with: Michael Corbett, Dung Do, Scott 
Krabbe, Ericka Malow, Rani Ulrich, Ryan Carris, Robert Sharpe, Guy Goodman, Will 
Mackay, and Sam Bartlett. I owe thanks to my peer and former roommate Andy Brusoe for 
continually stimulating conversation, good times, and countless nights studying sophomore 
organic for orals. He has consistently been there for me since we roomed together at the 
Carolina Inn for visitation. This is a high-quality group of people with whom I look forward to 
maintaining relationships with in the years to come.  
I am thankful to those that I have worked closely with on research projects: Steve 
Greszler (3COM and leustro), Ericka Malow (the [3,3]!), Stefan McCarver (an exceptional 
viii 
 
undergraduate mentee), and Robert Sharpe (pacta). Each collaboration was unique, fulfilling, 
and effective. I am grateful to all of you for putting up with me. 
Next I would like to thank my friends and family from home. My college buddies Allen 
Parker (reeeesearch!) and Matt Lentner (silver platter) have kept in touch over the years and 
provide much-needed breaks from grad school every once in a while. Scott George, now a 
fellow scientist, has been an excellent friend and supporter since 7th grade and a welcome 
distraction from work. We will all be life-long friends. I would like to express my gratitude to 
my in-laws: Jim and Kathy Beswick, Matt, Veronica and the kids. These guys have accepted 
me into their family as one of their own and have shown support and interest in all of my 
endeavors (for God’s sake, Jim managed to invoke the pactamycin synthesis during his speech 
at our wedding!). I have enjoyed becoming a part of the family and look forward to living 
closer and spending more time together. I am thankful to all of my siblings who have endured 
me as a nerdy older brother: Jared, Amy, Ethan, and Caleb all showed support and interest in 
my career, even when they found out I don’t make sunscreen at work every day. Last, but not 
least, my parents Tom and Lisa have been exceptional sources of support and encouragement 
at every step of my life. They have had to deal with a lot from me, from hysterically crying 
whenever I had to part with my mom for preschool (Justin…lets go look at the fish tank) to 
leaving the family in New York for good to pursue my graduate studies in North Carolina. 
They have always had my best interests at heart, and for that I am grateful.  
Finally, I would like to acknowledge my wife Theresa for her love over the last ten 
years. Theresa is one seriously bold woman. First, she decides to pursue her ex-boyfriend’s 
best friend (don’t worry, I asked Scott for his blessing). She then allows proximity to my 
undergraduate college to “partially” influence her college choice, deciding to attend school 
ix 
 
fifteen minutes away from me. Lastly, after my move to North Carolina, she leaves her 
“spectacular” job in balmy Albany, NY, taking a leap of faith, and moving to the south with 
no solid employment in order for us to be together. The support and devotion she has shown 
throughout the years cannot be described with words. She is selfless, patient, understanding, 
and caring. She has to deal with a tired, dirty, and moody husband every night after her own 
long day of work. She has had an amazingly positive influence on my life. Thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
 
To my family 
and  
in honor of my grandparents, 
Carmela and August Franze 
on the celebration of their  
65th wedding anniversary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES .................................................................................................................xv 
LIST OF FIGURES AND SCHEMES ............................................................................... xvi 
LIST OF ABBREVIATIONS AND SYMBOLS ............................................................... xxi 
CHAPTER 1 TANDEM REFORMATSKY/QUATERNARY CLAISEN CONDENSATION OF 
SILYL GLYOXYLATES AND -LACTONES - APPLICATION TO 
LEUSTRODUCSIN B 
1.1 Introduction ....................................................................................................................1 
1.2 Background ....................................................................................................................2 
 1.2.1 Shortcomings of the Claisen Condensation .......................................................2 
 1.2.2 Silyl Glyoxylate Reactivity Profile ....................................................................4 
 1.2.3 Reformatsky Reagents: Uniquely-Effective Silyl Glyoxylate 
  Cascade Promoters .............................................................................................7 
 1.2.4 β-Lactones Present an Opportunity for Asymmetric Induction .........................9 
1.3 Results and Discussion ................................................................................................10 
 1.3.1 Mechanistic Proposal .......................................................................................10 
 1.3.2 Synthesis of β-Lactone Coupling Partners .......................................................12 
 1.3.3 Development of Reaction Conditions ..............................................................15 
 1.3.4 Stereochemical Analysis ..................................................................................17 
 1.3.5 Reaction Scope.................................................................................................18 
 1.3.6 Origin of Diastereoselectivity ..........................................................................21 
 1.3.7 Subsequent Transformations of β-Hydroxyketone Products ...........................22 
 1.3.8 Application to Leustroducsin B .......................................................................23 
1.4 Conclusion ...................................................................................................................31 
xii 
 
1.5 Experimental Details ....................................................................................................32 
1.6 References ....................................................................................................................83 
CHAPTER 2  SYNTHETIC STUDIES TOWARD THE PACTAMYCIN CORE 
2.1 Introduction ..................................................................................................................86 
2.2 Background ..................................................................................................................87 
 2.2.1 Biological Activity and Biosynthetic Proposal for Pactamycin Synthesis ......87 
 2.2.2 Prior Syntheses of Pactamycin.........................................................................89 
2.3 Results and Discussion ................................................................................................98 
 2.3.1 Preliminary Retrosynthetic Analysis ...............................................................98 
 2.3.2 Construction of the Northeast Quadrant – C1/C7 Stereocenters ...................100 
 2.3.3 Progress Toward a C5 Ketone Electrophile ...................................................102 
 2.3.4 Intermolecular C5 Nucleophilic Addition Approaches .................................104 
 2.3.5 Intramolecular C5 Nucleophilic Addition Approaches .................................105 
 2.3.6 Key Discoveries Enabling Nucleophile Introduction ....................................110 
 2.3.7 Revised Retrosynthetic Strategy – RCM Approach ......................................112 
 2.3.8 Screening of Vinyl Nucleophiles and Stereochemical Model .......................113 
 2.3.9 Construction of Cyclopentene Core via RCM Approach ..............................116 
 2.3.10 Proposal for C2/C3/C4 Functionalization ......................................................118 
 2.3.11 Alkene Oxidation Studies ..............................................................................119 
 2.3.12 Protecting Group Strategies and Acquisition of Crystal Structure ................123 
 2.3.13 Electrophilic Ketone -Functionalization Studies .........................................125 
 2.3.14 Manipulation of C3 Ketone ...........................................................................127 
 2.3.15 C2 Allylic Functionalization ..........................................................................128 
2.4 Conclusion .................................................................................................................130 
2.5 Experimental Details ..................................................................................................131 
2.6 References ..................................................................................................................154 
xiii 
 
CHAPTER 3 -AMINATION OF KETO-NITRONES VIA MULTIHETERO-COPE 
REARRANGEMENT 
3.1 Introduction ................................................................................................................156 
3.2 Background ................................................................................................................157 
 3.2.1 Pactamycin C2 Amination Problem...............................................................157 
 3.2.2 Extant Methods for Ketone -Amination ......................................................158 
 3.2.3 -Oxidation by Rearrangement .....................................................................159 
 3.2.4 Preliminary Reports of -Amination by Multihetero- 
  Cope Rearrangement. .....................................................................................161 
3.3 Results and Discussion ..............................................................................................163 
 3.3.1 Mechanistic Proposal .....................................................................................163 
 3.3.2 Synthesis of Original Imidoyl Chloride Reagent ...........................................164 
 3.3.3 Nitrone Synthetic Studies ..............................................................................167 
 3.3.4 Scope of Benzylhydroxylamine Condensation - Nitrone Synthesis ..............168 
 3.3.5 Initial [3,3]-Rearrangement Results ...............................................................170 
 3.3.6 Second Generation Imidoyl Chloride ............................................................171 
 3.3.7 Development of the Multihetero-Cope -Amination ....................................172 
 3.3.8 Scope of the -Amination Methodology .......................................................173 
 3.3.9 Secondary Transformations of Diamido Products .........................................176 
 3.3.10 Application to Pactamycin C3 -Amination Problem ...................................181 
3.4 Conclusion .................................................................................................................182 
3.5 Experimental Details ..................................................................................................183 
3.6 References ..................................................................................................................205 
CHAPTER 4  TOTAL SYNTHESIS OF PACTAMYCIN 
4.1 Introduction ................................................................................................................207 
4.2 Background ................................................................................................................208 
 4.2.1 Summary/Analysis of the Hanessian Total Synthesis ...................................208 
 4.2.2 Summary of Our Partial Core Synthesis ........................................................210 
xiv 
 
 4.2.3 Flexibility for Analogue Synthesis ................................................................211 
 4.2.4 Note on Stereochemistry ................................................................................212 
4.3 Results and Discussion ..............................................................................................212 
 4.3.1 Retrosynthesis – Early C2 Amino Introduction .............................................212 
 4.3.2 Synthesis of Mannich Precursors ...................................................................214 
 4.3.3 Development of an Asymmetric Mannich Reaction ......................................216 
 4.3.4 Discovery of a Symmetry-Breaking Diketone Monoreduction .....................222 
 4.3.5 Testing Nucleophilic Addition to the C5 Methyl Ketone ..............................226 
 4.3.6 C5 Enolate Additions .....................................................................................228 
 4.3.7 Cyclization Studies ........................................................................................229 
 4.3.8 Completion of Core Stereochemical Functionalization .................................237 
 4.3.9 Pactamycin Endgame .....................................................................................243 
 4.3.10 Stereochemical Analysis ................................................................................247 
4.4 Conclusion .................................................................................................................252 
4.5 Experimental Details ..................................................................................................253 
4.6 References ..................................................................................................................274 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF TABLES 
 
Table 1-1 Synthesis of β-Lactone Library ........................................................................14 
Table 1-2 Substrate Scope ................................................................................................20 
Table 2-1 Diketone Monoreduction Screen ...................................................................104 
Table 2-2 Nucleophilic Additions to the Methyl Ketone Electrophile ..........................105 
Table 2-3 Conjugate Reduction/Cyclization Strategy ....................................................109 
Table 2-4 Epoxidation Studies .......................................................................................120 
Table 2-5 Dihydroxylation Studies ................................................................................121 
Table 2-6 Rh-Catalyzed C–H Amination Attempts .......................................................123 
Table 3-1 Thermodynamic Analysis ..............................................................................164 
Table 3-2 Oxime [3,3]-Rearrangement Trials ................................................................166 
Table 3-3 Nitrone Scope.................................................................................................169 
Table 3-4 Initial [3,3]-Rearrangement Results ...............................................................170 
Table 3-5 Substrate Scope – Aliphatic Nitrones ............................................................174 
Table 3-6 Substrate Scope – Aryl Nitrones ....................................................................176 
Table 3-7 Hydrolysis of Enamide Products ...................................................................177 
Table 3-8 Hydrogenation/Reduction of Enamide Products ...........................................179 
Table 3-9 -Functionalization of Enamide Products .....................................................180 
Table 4-1 Screening of Mannich Conditions .................................................................219 
Table 4-2 -Halogenation Studies .................................................................................231 
Table 4-3 Aldol Cyclization of the -Ketoester .............................................................232 
Table 4-4 C5 Methyl Additions......................................................................................240 
Table 4-5 Aniline Introduction via Ring-Opening .........................................................244 
Table 4-6 Cbz Deprotection Studies ..............................................................................246 
 
 
xvi 
 
LIST OF FIGURES AND SCHEMES 
 
Figure 1-1 “Normal” vs. “Quaternary” Claisen Reaction ...................................................3 
Figure 1-2 Current Solutions to the Quaternary Claisen Problem .......................................3 
Figure 1-3 Reactivity of Silyl Glyoxylate ...........................................................................5 
Figure 1-4 Selected Products Obtained by Silyl Glyoxylate Cascades ...............................6 
Scheme 1-1 Greszler Double Reformatsky -Butyrolactone Synthesis.................................7 
Figure 1-5 Double Reformatsky Proposed Mechanism.......................................................9 
Figure 1-6 Proposed 1,4-Transfer of Chirality ..................................................................10 
Figure 1-7 Three-Component Coupling Chemoselectivity Challenges.............................11  
Scheme 1-2 Nelson’s Asymmetric β-Lactone Synthesis .....................................................12 
Scheme 1-3 Synthesis of Aluminum Triflamide Catalyst ...................................................12 
Scheme 1-4 Disubstituted β-Lactone and β-Lactam Synthesis ...........................................15  
Scheme 1-5 Three-Component Coupling Reaction .............................................................16 
Figure 1-8 Subsequent Ketone Reduction/Stereochemical Analysis ................................18 
Figure 1-9 Competing Transition State Models ................................................................22 
Scheme 1-6 Diester Functionalization .................................................................................23 
Figure 1-10 Leustroducsin and Related Natural Products ...................................................24 
Figure 1-11 Retrosynthetic Analysis ...................................................................................25 
Scheme 1-7 Synthesis of Dihydropyrone Precursor ............................................................26 
Scheme 1-8 Dihydropyrone Installation ..............................................................................28 
Scheme 1-9 Completion of Formal Synthesis .....................................................................30 
Figure 2-1 Structure of Pactamycin ...................................................................................87 
Scheme 2-1 Biosynthetic Synthesis of Pactamycin .............................................................89 
Scheme 2-2 Isobe Pactamycin Core Approach ....................................................................90 
Scheme 2-3 Knapp Pactamycin Core Approach ..................................................................91 
Scheme 2-4 Hanessian Cyclopentenone Assembly .............................................................92 
xvii 
 
Scheme 2-5 Hanessian Core Completion ............................................................................93 
Scheme 2-6 Hanessian Endgame .........................................................................................94 
Scheme 2-7 Looper Pactamycin Core Approach .................................................................95 
Scheme 2-8 Epoxide-Opening Cascade ...............................................................................96 
Scheme 2-9 Isobe’s Alternate Cyclization Strategy ............................................................97 
Figure 2-2 Mahmud Bioengineering Synthesis .................................................................97 
Figure 2-3 Retrosynthetic Analysis – Aldol Cascade Approach .......................................99 
Scheme 2-10 Construction of Allylation Precursor .............................................................100 
Scheme 2-11 Asymmetric Allylation...................................................................................101 
Scheme 2-12 Methylation Attempts ....................................................................................102 
Scheme 2-13 Diketone Strategy...........................................................................................103 
Figure 2-4 Intramolecular Addition Approaches .............................................................106 
Figure 2-5 Hydroxyl Tethered Additions ........................................................................107 
Figure 2-6 Olefin Tethered Additions .............................................................................108 
Figure 2-7 Two Important Discoveries ............................................................................110 
Figure 2-8 Ethyl Diazoacetate Addition - Revisited........................................................112 
Figure 2-9 Modified Retrosynthetic Approach – RCM Strategy ....................................113 
Scheme 2-14 Nucleophilic Addition to C5 Ketone Model Study........................................114 
Scheme 2-15 Reversed Nucleophilic Addition at C5 ..........................................................115 
Figure 2-10 Stereochemical Selectivity Model .................................................................116 
Figure 2-11 Functionalized Vinyl Addition ......................................................................117 
Scheme 2-16 Synthesis of Pactamycin Cyclopentene Core ................................................118 
Figure 2-12 Proposed Core Completion ............................................................................119 
Figure 2-13 Potential Mechanism for Isocyanate Formation ............................................120 
Scheme 2-17 Ketone and Protecting Group Schemes .........................................................124 
Figure 2-14 Diacetonide Crystal Structure ........................................................................124 
Figure 2-15 Electrophilic Amination Studies ....................................................................125 
xviii 
 
Scheme 2-18 Non-Amine C2 Functionalizations ................................................................126 
Scheme 2-19 Neber Rearrangement ....................................................................................127 
Scheme 2-20 Pd-Catalyzed Aniline Coupling .....................................................................128 
Figure 2-16 Allylic Functionalization ...............................................................................129 
Figure 2-17 Summary ........................................................................................................130 
Figure 3-1 Failed C2 Amination ......................................................................................157 
Figure 3-2 Azodicarboxylates as Electrophilic Amination Reagents ..............................158 
Scheme 3-1 House and Richey -Acetoxylation ...............................................................160 
Scheme 3-2 Cummins and Coates -Acetoxylation ..........................................................160 
Scheme 3-3 Single Step -Acetoxylation ..........................................................................161 
Figure 3-3 -Oxidation and -Amination by [3,3]-Rearrangement ...............................161 
Figure 3-4 Aryl vs. Alkyl -Amination by [3,3]-Rearrangement ...................................162 
Figure 3-5 Substrate Scope of Extant -Amination Reports ...........................................162 
Figure 3-6 Proposed Mechanism of -Amination ...........................................................163 
Scheme 3-4 Phthalimido Imidoyl Chloride .......................................................................165 
Figure 3-7 Possible Imidoyl Chloride Surrogates ...........................................................165 
Scheme 3-5 Synthesis of an Oxime Test Substrate ...........................................................166 
Figure 3-8 Commercial Hydroxylamine Results .............................................................167 
Scheme 3-6 Synthesis of a Benzyl-Hydroxylamine Series................................................167  
Scheme 3-7 Initial Nitrone Result......................................................................................168  
Figure 3-9 Incompatible Ketones for Nitrone Formation ................................................170 
Scheme 3-8 Second Generation Imidoyl Chloride Synthesis ............................................172  
Scheme 3-9 Initial Result ...................................................................................................172  
Figure 3-10 Proposed Mechanism for Enamide Formation ..............................................173 
Figure 3-11 Enediamide Formation from Aryl Nitrones ...................................................173 
Figure 3-12 Plausible Mechanism for -Chloro Product Formation .................................175 
Figure 3-13 Thiolate Hydrolyses .......................................................................................178 
xix 
 
Figure 3-14 Bromination Cascade .....................................................................................181 
Scheme 3-10 Application to Pactamycin .............................................................................182  
Figure 4-1 Structure of Pactamycin .................................................................................207 
Figure 4-2 Abridged Hanessian Synthesis .......................................................................208 
Figure 4-3 Our Previous Failed Route .............................................................................210 
Figure 4-4 Pactamycin Retrosynthesis ............................................................................213 
Scheme 4-1 Synthesis of Urea Pronucleophile ..................................................................214  
Scheme 4-2 Synthesis of Imine Electrophile .....................................................................215  
Figure 4-5 Schaus Organocatalyzed Mannich Additions ................................................216 
Scheme 4-3 Mannich Reaction Initial Result ....................................................................217  
Figure 4-6 Chiral Catalysts Screened for Enantioselective Mannich Addition ...............220 
Scheme 4-4 Optimized Mannich Addition ........................................................................222  
Figure 4-7 Stereochemical Possibilities for Monoreduction ...........................................223 
Figure 4-8 Selective Oxidations Shed Light on Stereochemical Problem ......................224 
Scheme 4-5 Reduction/Protection Sequence .....................................................................225  
Figure 4-9 Grignard Additions to the Diketone ...............................................................226 
Figure 4-10 Alternative Diketone Additions .....................................................................227 
Scheme 4-6 C5 Enolate Nucleophilic Additions ...............................................................228  
Figure 4-11 Aldol Cyclization Strategy .............................................................................230 
Figure 4-12 Surprising Epoxidation Result .......................................................................234 
Figure 4-13 Failed Subsequent Enone Transformations ...................................................235 
Figure 4-14 Aldol Cyclization of Other Ketones ..............................................................236 
Figure 4-15 Requirements to Complete Core ....................................................................237 
Figure 4-16 Diastereoselective Epoxidation ......................................................................239 
Scheme 4-7 Route to a Crystalline Derivative ...................................................................242  
Figure 4-17 Racemic Crystal Structure Revealing Six Correct Stereocenters ..................242 
Scheme 4-8 Cyanomethyl Ester Synthesis ........................................................................245  
xx 
 
Scheme 4-9 Salicylate Installation .....................................................................................245 
Figure 4-18 Presumed Transfer of Stereochemistry Through Synthesis ...........................248 
Figure 4-19 Deuterium Incorporation Studies ...................................................................249 
Scheme 4-10 Route to Crystalline Lactol Benzoate ............................................................249  
Figure 4-20 Reduction Product Absolute Crystal Structure ..............................................250 
Figure 4-21 Triply Serendipitous Stereochemical Conclusion ..........................................251 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
2D-NMR   two-dimensional nuclear magnetic resonance 
p-ABSA   para-acetamidobenzenesulfonyl azide 
Ac    acetate 
Ar    aryl 
aq    aqueous 
atm    atmospheres   
Bn    benzyl 
BOC    benzyloxycarbonyl 
br    broad 
br s    broad singlet 
nBu     normal-butyl 
tBu     tert-butyl 
Bz    benzoyl 
CSA    camphorsulfonic acid 
13C NMR    carbon nuclear magnetic resonance spectroscopy  
C–C    carbon-carbon bond 
cat    catalytic amount or catalyst 
conv    conversion  
COSY    correlated spectroscopy 
m-CPBA   meta-chloroperoxybenzoic acid 
d    doublet or days 
DBU    1,8-diazabicyclo[5.4.0]undec-7-ene 
xxii 
 
DCC    N,Nʹ-dicyclohexylcarbodiimide 
dd    doublet of doublet 
ddt    doublet of doublet of triplets 
DEAD    diethylazodicarboxylate 
DIAD    diisopropylazodicarboxylate 
DIBAL-H   diisobutylaluminum hydride 
DIPEA   ethyldiisopropylamine 
dq    doublet of quartet 
DMAP    4-N,N-dimethylaminopyridine 
DME    dimethoxyethane 
DMF    N,N-dimethylformamide 
DMSO    dimethyl sulfoxide 
d.r.    diastereomeric ratio 
dt    doublet of triplet 
E+ or El   electrophile 
eq     equation 
equiv    equivalents  
e.r.    enantiomeric ratio 
ESI    electrospray ionization 
Et    ethyl 
Et2O     diethyl ether 
EtOAc    ethyl acetate 
EWG    electron withdrawing group 
xxiii 
 
FID    flame ionization detector 
G2                                           Grubbs’ second generation catalyst 
h    hour 
1H NMR    proton nuclear magnetic resonance spectroscopy 
HOAc    acetic acid 
HMDS    hexamethyldisilazane 
HPLC    high performance liquid chromatography 
HRMS    high resolution mass spectroscopy 
Hz     hertz 
IR     infrared spectroscopy 
J    coupling constant 
kcal    kilocalorie 
L    liter or ligand 
LA    Lewis acid 
LAH    lithium aluminum hydride 
LDA    lithium diisopropylamide 
LiHMDS   lithium hexamethyldisilazide 
LRMS    low resolution mass spectroscopy 
M    metal or molarity 
m    multiplet 
Me     methyl 
MeCN    acetonitrile 
MeMgBr   Methylmagnesium bromide 
xxiv 
 
MeOH    methanol 
mg    milligram 
MHz    megahertz 
min     minutes 
mL    milliliter 
mmol     millimole 
mp     melting point 
n    number of atoms or counterions 
NBS    N-bromosuccinimide 
NIS    N-iodosuccinimide 
nd    not determined 
NHK    Nozaki-Hiyama-Kishi 
NMP    N-methylpyrrolidone 
nOe    nuclear Overhauser enhancement 
NOESY   nuclear Overhauser enhancement spectroscopy 
NR    no reaction 
Nu    nucleophile 
PCC    pyridinium chlorochromate 
PG    protecting group 
Ph    phenyl 
ppm    parts per million 
iPr    iso-propyl 
q    quartet 
xxv 
 
R    substituent 
Rf
    retention factor 
rac    racemic 
RCHO    aldehyde 
RCM    ring-closing metathesis 
rt    room temperature 
s    singlet 
SFC    supercritical fluid chromatography 
SN2    bimolecular nucleophilic substitution 
T    temperature 
t    triplet 
tr    retention time 
TBAF    tetrabutylammonium fluoride 
TBS    tert-butyldimethylsilyl 
TBDPS   tert-butyldiphenylsilyl 
TBSOTf   tert-butyldimethylsilyl trifluoromethanesulfonate 
TEA    triethylamine 
TEMPO   tetramethylpiperidine-N-oxide 
TES    triethylsilyl 
TMS    trimethylsilyl 
Tf    trifluoromethanesulfonyl 
THF    tetrahydrofuran 
TLC     thin-layer chromatography 
xxvi 
 
TMS    trimethylsilyl 
Tr    trityl or triphenylmethyl 
triflate    trifluoromethanesulfonate 
Ts    para-toluenesulfonyl 
UV    ultraviolet 
X    anionic ligand, halide, substituent, or number 
 []    optical rotation 
δ    chemical shift or partial charge 
L    microliter 
 
1 
 
 
CHAPTER ONE 
 
TANDEM REFORMATSKY/QUATERNARY CLAISEN CONDENSATION OF SILYL 
 GLYOXYLATES AND -LACTONES - APPLICATION TO LEUSTRODUCSIN B* 
 
1.1  Introduction 
 The -ketoester moiety is a fundamental building block in organic chemistry, 
displaying a useful ambiphilic reactivity profile and multiple nucleophilic sites to launch 
synthetic endeavors. Formation of complex fully-substituted -ketoesters by means of C–
acylation is, however, a largely unsolved problem. The prototypical -ketoester synthesis, the 
Claisen condensation, fails to provide a means for fully-substituted carbon synthesis except in 
rare cases of highly-regulated, limited systems1 largely due to thermodynamic constraints 
disfavoring productive reactivity. A general method enabling quaternary Claisen reactivity 
would provide machinery for rapid assembly of complexity as well as multiple functional 
handles for subsequent manipulation, a circumstance especially beneficial in natural product 
synthetic applications. In this chapter, we disclose a diastereoselective, multicomponent 
quaternary Claisen reaction, incorporating silyl glyoxylates as key conjunctive reagents. This 
Reformatsky-initiated cascade provides highly-functionalized -ketoester scaffolds when 
 
 
* Reprinted in part with permission from Greszler, S. N.; Malinowski, J. T.; Johnson, J. S. J. 
Am. Chem. Soc. 2010, 132, 17393, and Greszler, S. N.; Malinowski, J. T.; Johnson, J. S. Org. 
Lett. 2011, 13, 3206. 
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terminated with -lactone electrophiles and displays an unusual stereochemical 1,4-induction 
mode. The utility of this method is demonstrated by subsequent rapid access to the 
leustroducsin natural product family.  
1.2  Background 
1.2.1  Shortcomings of the Claisen Condensation 
 Discovered in 1887,2 the Claisen condensation is a fundamental reaction in organic 
chemistry. At first glance the reaction appears simple: enolization of a pronucleophile followed 
by attack on a carbonyl electrophile to form an important C–C bond. Upon detailed 
examination, the reaction is complicated by the fact that it is entirely governed by 
thermodynamics and is fully-reversible, leading to issues with -center stereocontrol, and 
more relevant in this context, quaternary center formation. Figure 1-1 illustrates two 
mechanistic features which disqualify quaternary Claisen reactivity under standard conditions. 
First, the fully-substituted enolate is more thermodynamically stable and less reactive than the 
corresponding tri-substituted species. This dictates a reactants-favored equilibrium resulting in 
little product formation. Second, as the Claisen condensation is fully-reversible, the drive to 
completion is only accomplished by an -deprotonation of the highly-acidic -ketoester 
product. This stabilized, tetrasubstituted enolate pushes equilibrium towards product 
formation. However, in the quaternary case, deprotonation of an ,-disubstituted product is 
impossible, disfavoring product formation.  
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Figure 1-1.  “Normal” vs. “Quaternary” Claisen Reaction 
 
 Two isolated approaches to this problem have been reported in the literature. The first 
uses highly activated, pre-formed silyl ketene acetal nucleophiles under Lewis acidic 
conditions to effect the desired transformation (Figure 1-2, A).1a-c The reaction presumably 
proceeds to completion via the formation of a stabilized enolsilane product. The second 
approach exploits an unusually strong Zr chelate effect that stabilizes the -ketoester product, 
driving the reaction to completion (Figure 2-1, B).1d  
Figure 1-2.  Current Solutions to the Quaternary Claisen Problem 
 
 While these creative approaches enable formation of quaternary centers in specific 
cases, they are limited to specific substitution patterns, prefunctionalization of components 
(former case), and dimerizations (latter case). A de novo solution to the quaternary Claisen 
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condensation from which molecular complexity could be generated in a general sense is 
particularly attractive and remains elusive to researchers.  
1.2.2  Silyl Glyoxylate Reactivity Profile 
 The title reaction features a key conjunctive reagent based upon the -silyl--ketoester 
scaffold, termed “silyl glyoxylate” (1.1).3 These reagents have been developed by the Johnson 
research group as linchpins for the coupling of nucleophilic reagents with electrophiles at a 
glycolic acid junction, and have provided numerous complexity-building, diastereoselective 
coupling methodologies since the seminal work reported by Nicewicz in 2005.4 The unique 
reactivity pattern displayed by these reagents is facilitated by the [1,2]-Brook rearrangement 
(C  O silyl migration).5 As shown in Figure 1-3, nucleophilic attack on silyl glyoxylate 
provides initial adduct 1.2 which undergoes facile silyl migration (driven by an increased Si–
O bond strength of ~ 40 kcal/mol and the resonance stabilization of the developing negative 
charge by the ester moiety) to provide a nucleophilic glycolate enolate species (1.3). Addition 
of a “secondary” electrophile then provides the three-component coupled product 1.4. The 
electron-withdrawing vicinal ester renders silyl glyoxylates exceptionally electrophilic, a 
circumstance which permits chemoselective attack in the presence of other electrophiles 
(aldehydes, ketones, Michael acceptors) in most cases. 
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Figure 1-3.  Reactivity of Silyl Glyoxylate 
C-Si C=O
 
 Extant coupling reactions featuring silyl glyoxylates are initiated by metal acetylides3 
Grignard reagents,6 hydride donors,7 and enolates.8 Compatible secondary electrophilic 
partners include: aldehydes, ketones, nitroalkenes, and enones. Permutations of these coupling 
partners have opened access to a wide range of stereodefined complex building blocks and 
fragments useful in natural product chemistry (Figure 1-4).  
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Figure 1-4.  Selected Products Obtained by Silyl Glyoxylate Cascades 
 
 In this chapter, we discuss our work on the development and application of a highly 
diastereoselective quaternary Claisen coupling reaction enabled by silyl glyoxylate 
technology. The Reformatsky initiation of this cascade is analogous to chemistry developed 
previously in the group, but differs in the secondary electrophile selection and corresponding 
product scaffold.8b Our hypothesis for the successful execution of a quaternary Claisen 
pathway was that ring-strain relief could drive the reaction to completion. To test this proposal, 
we chose -lactones as terminating electrophiles. We speculated that inherent ring-strain, as 
well as irreversible ring-opening might allow for a terminating C–C bond construction 
completing the desired silyl glyoxylate cascade. 
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1.2.3  Reformatsky Reagents: Uniquely-Effective Silyl Glyoxylate Cascade Promoters 
 In early optimization studies, Greszler identified Reformatsky reagents as capable 
nucleophiles for the initiation of a double Reformatsky -butyrolactone synthesis (Scheme 1-
1).8b Lithium and magnesium enolates showed high reactivity and low selectivity, typically 
giving complex product mixtures, but the tempered nucleophilicity of the Reformatsky enolate 
allowed for successful execution of the cascade under carefully controlled conditions. 
Although this reaction proceeded with modest yields, the complexity generated and unusually 
high diastereoselectivity is noteworthy.  
Scheme 1-1.  Greszler Double Reformatsky -Butyrolactone Synthesis 
 
 The Reformatsky reaction, formally an oxidative addition of Zn0 into an -haloester 
followed by electrophilic trapping, has enjoyed myriad applications since its discovery in the 
late nineteenth century.9 Its benefits include the generation of reactive enolate species under 
neutral conditions, use of inexpensive reagents, and typically good chemoselectivities in 
complex systems. Reproducibility is sometimes problematic in this reaction and is typically 
attributed to generation of the Reformatsky reagent. Commercial zinc dust has been shown 
effective in this reaction, provided that a successful activation protocol is employed. The 
purpose of this activation is to remove the Zn-oxide coating on the dust, allowing for 
untempered reactivity. Several activation methods have been reported, including trimethylsilyl 
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chloride,10 dibromoethane,11 and bromine,12 and the method of choice is critical and sometimes 
empirical in nature (vide infra).  
 In solution, Reformatsky reagents typically exist as dimeric complexes as the C–Zn 
metalated species, a feature pertinent to mechanistic considerations.13 A reversible C  O zinc 
migration is facile and gives the reactive zinc enolate, which participates in the C–C bond 
forming event. This stability of the C–Zn metalated species and low barrier for C–O migrations 
are invoked to explain the highly diastereoselectivity observed in the Greszler system (Figure 
1-5). The mechanism begins with nucleophilic attack on silyl glyoxylate and subsequent Brook 
rearrangement, providing the proposed five-membered zinc chelate (1.5). This species can 
undergo O  C zinc migration to give the acyclic C-metalated species 1.6, which allows for 
isomerization to the more stable (E)-enolate, proposed to exist as a seven-membered chelate 
after a second C  O zinc migration (1.7). High levels of diastereoselectivity were observed 
only when an -alkyl substituent was placed on the Reformatsky reagent. This directing group 
was imperative as facial approach of the ketone comes opposite that of the -alkyl substituent 
with the larger aryl substituent occupying a pseudo-equatorial conformation (1.8), providing 
the observed diastereoselection. 
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Figure 1-5.  Double Reformatsky Proposed Mechanism  
 
1.2.4  β-Lactones Present an Opportunity for Asymmetric Induction 
 β-Lactones display a variety of unique properties which render them attractive for this 
coupling reaction. The built-in ring strain of a four-membered ring both increases 
electrophilicity at the carbonyl for nucleophilic attack and could lead to an irreversible Claisen 
pathway upon its release. Additionally, a plausible means for asymmetric induction is available 
through substrate control. While most of the known silyl glyoxylate coupling reactions are 
highly diastereoselective, they lack absolute stereocontrol and provide racemic products. 
While an enantioselective protocol has been elusive, use of an asymmetric starting material 
could in principle provide transfer of stereochemical information to the products. β-Lactones 
were especially attractive to us due to the breadth of asymmetric methods for their synthesis.14 
The challenge we faced was the distance of the developing stereocenter from the β-lactone 
chiral site. The stereochemical 1,4-induction we proposed was previously undocumented in 
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the literature. Shown in Figure 1-6, the initial glycolate enolate adduct 1.9 (formed by 
Reformatsky attack on silyl glyoxylate, followed by Brook rearrangement) could attack a chiral 
β-lactone (1.10) giving β-hydroxyketone product 1.11. The question we sought to explore was 
the stereochemical outcome at the developing fully-substituted center. Transfer of chiral 
information from the distal hydroxyl stereocenter would provide a diastereoselective 
quaternary Claisen condensation, with desired absolute stereocontrol achieved by judicious β-
lactone selection.  
Figure 1-6.  Proposed 1,4-Transfer of Chirality 
 
1.3  Results and Discussion 
1.3.1  Mechanistic Proposal 
 The purpose of this investigation was to address the quaternary Claisen condensation 
problem through an expansion of the silyl glyoxylate three-component coupling research 
program. Additionally, the predicted products accessed by this methodology could be highly 
relevant in natural product applications (vide infra). The anticipated chemoselectivity 
challenges of this multicomponent reaction are illustrated in Figure 1-7.  
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Figure 1-7.  Three-Component Coupling Chemoselectivity Challenges  
 
 The Reformatsky reagent will be in solution with two electrophilic species, silyl 
glyoxylate (1.1) and the β-lactone (1.10). The first mandate requires chemoselective 
nucleophilic attack on silyl glyoxylate (path b) to give glycolate enolate 1.9. Direct attack on 
the β-lactone would provide β-hydroxyketone 1.13, an unproductive pathway (path a). Next, 
the glycolate enolate must show preference for the β-lactone over another equivalent of silyl 
glyoxylate to provide the desired product 1.11 (path d). Incorporation of a second equivalent 
of silyl glyoxylate could lead to an undesired oligimerization pathway (path c).  
Silyl glyoxylate chemoselectivity challenges have been overcome with temperature 
control, stoichiometry, and order of addition. For instance, in the related Greszler -
butyrolactone synthesis,8b excess Refomatsky reagent was added to silyl glyoxylate at -20 °C 
and allowed to run until the glyoxylate was fully consumed. The secondary electrophile was 
then added, and the reaction was warmed to effect Brook rearrangement and the subsequent, 
terminating nucleophilic attack. Ideally, we hoped to develop a protocol in which the three 
components could be combined synchronously with complete chemoselectivity.  
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1.3.2  Synthesis of β-Lactone Coupling Partners 
 The ketene-aldehyde coupling reported by Nelson14a,b proved most effective for rapid 
generation of an enantioenriched β-lactone library for screening. The parent reaction is shown 
in Scheme 1-2 and involves generation of ketene followed by a formal [2 + 2] cycloaddition 
with an aldehyde catalyzed by a chiral aluminum triflamide complex.  
Scheme 1-2.  Nelson’s Asymmetric β-Lactone Synthesis 
 
 Catalyst 1.15 was prepared on multigram scale by the following three-step sequence 
from the chiral pool (Scheme 1-3).15 L-Valinol was first converted to the chiral aziridine 1.17 
upon treatment with excess triflic anhydride. Subsequent bis-ring opening by benzylamine 
(neat) at elevated temperatures afforded bis(triflamide) 1.18. Ensuing treatment with 
trimethylaluminum provided the desired catalyst 1.15 in excellent yield (>4 g per sequence).  
Scheme 1-3.  Synthesis of Aluminum Triflamide Catalyst 
 
 Aldehydes were purchased or independently synthesized and subjected to the reaction 
conditions to provide the corresponding β-lactones 1.19a – 1.19f (Table 1-1). We were 
interested in the potential influence of a lactone -substituent on the diastereochemical 
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outcome of the reaction, so cis and trans β-lactones 1.19g16 and 1.19h17 were prepared (Scheme 
1-4). In addition, we questioned whether β-lactams would be sufficiently electrophilic to 
participate in the title reaction. To this end, lactams 1.20a – 1.20c were prepared with nitrogen 
protecting groups with varied electronic properties via known methods.18  
 The enantioselectivity of the Nelson Al-catalyzed formal [2 + 2] cycloaddition was 
assayed for model lactone 1.19a by supercritical fluid chromatography (SFC) analysis of the 
corresponding β-hydroxyketone product (vide infra). The ee value was determined to be 83%, 
indicating successful asymmetric β-lactone synthesis.  
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Table 1-1. Synthesis of β-Lactone Library  
 
Aldehyde Lactone  Yield (%) 
 
 
1.19a 59 
 
 
1.19b 57 
  
1.19c 50 
  
1.19d 72 
  
1.19e 24 
 
 
1.19f* 63 
* Propionyl bromide used in place of AcBr 
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Scheme 1-4.  Disubstituted β-Lactone and β-Lactam Synthesis 
 
1.3.3  Development of Reaction Conditions 
 Reaction optimization was initially focused upon efficient, reproducible generation of 
the Reformatsky reagent. As we had aspirations for natural product synthesis applications, 
scalability was also a requirement for the title reaction. Ethyl bromoacetate was selected as the 
reagent precursor and was added dropwise to an activated suspension of zinc dust refluxing in 
diethyl ether. The reaction was maintained at reflux for several hours to ensure completion and 
titrated with iodine to assess active reagent concentration. For small-scale screening purposes, 
TMSCl activation10 of the zinc dust was sufficient; however, upon scale-up (multigram), this 
method typically failed or gave widely-varied Reformatsky reagent concentrations. For these 
large scale applications, the bromine activation method12 was employed, typically giving 
reagent concentrations corresponding to 81-100% yield. The Reformatsky reagent was 
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typically prepared immediately prior to use, but could be stored for up to one week in the 
freezer without significant deterioration.  
 Initial reaction screening was performed with β-lactone 1.19a and silyl glyoxylate 1.21. 
Mirroring the method used for the previous double Reformatsky reaction, silyl glyoxylate 1.21 
was added dropwise to a cooled solution of Reformatsky reagent. Upon full conversion (TLC 
analysis or disappearance of characteristic bright yellow color of the silyl glyoxylate), a 
solution of lactone 1.19a was introduced and the reaction was warmed until judged complete 
by TLC. Initial reaction trials proceeded to form the desired β-hydroxyketone product 1.22 
with excellent diastereoselectivity. A minor enone byproduct was observed (1.23) presumably 
resulting from elimination of the intermediate zinc alkoxide. We were pleased to note that 
addition of a solution of both silyl glyoxylate and β-lactone to the Reformatsky reagent 
proceeded with complete chemoselectivity and identical yield, simplifying the experimental 
protocol. Temperature studies revealed -30 °C as optimal for the initial Reformatsky attack on 
silyl glyoxylate, and slow warming typically resulted in Brook rearrangement and reaction 
completion upon reaching 0 °C. 
Scheme 1-5.  Three-Component Coupling Reaction 
 
17 
1.3.4  Stereochemical Analysis 
 Prior to exploration of the reaction scope we endeavored to analyze the high level of 
1,4-stereoinduction observed in the three component coupling reaction. To this end, the TBS 
derivative of coupling product 1.23 (1.24) was subjected to two diastereoselective directed 
reductions (Figure 1-8). The Evan’s anti reduction19 proceeded with excellent 
diastereoselection, affording 1,3-anti-diol 1.25. The Prasad syn reduction20 cleanly gave 1,3-
syn-diol 1.26. Both diols were subjected to acid-catalyzed lactonizations in order to obtain 
rotation-restricted compounds for 2D NMR analysis. Cyclization of diol 1.25 gave the 
corresponding mono(lactone) 1.27, while the syn-diol 1.26 gave a bis(lactone) (1.28). This 
divergence in reactivity can be rationalized by the relatively-high energy barrier for formation 
of a trans-fused bicycle in the anti diol case. We used nOesy analysis of each lactone to provide 
conclusive evidence for the assignment of the relative configuration of the fully-substituted 
center, which is depicted in Figure 1-8. 
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Figure 1-8.  Subsequent Ketone Reduction/Stereochemical Analysis 
 
1.3.5  Reaction Scope 
 With a highly-diastereoselective method in hand for a quaternary Claisen/β-
hydroxyketone synthesis, we set out to investigate the reaction scope (Table 1-2). First, three 
silyl glyoxylates were tested with β-lactone 1.19a. While the TBS/Bn and TES/Bn showed 
similar efficiencies (61%/67% yield; 1.22, 1.29a), the TBS/tBu case showed a highly 
diminished yield (35%; 1.29b). This may be attributed to the added steric bulk proximal to the 
reactive centers, hindering both the initial nucleophilic attack by the Reformatsky reagent and 
second C–C bond formation with the β-lactone. Next, a series of β-substituted-β-lactones 
(1.19b – 1.19e) were screened. The reaction proved tolerant of alkyl, aryl, and protected 
hydroxyl functionalities with yields ranging from 33-64% and complete diastereoselection in 
all cases. Disubstituted β-lactones also performed well, with the cis and trans hydrocinnamyl 
derivatives showing good yields, but reduced, identical diastereoselection (1.29h, 1.29i; 5.1 
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dr). A disubstituted alkynyl β-lactone, however, maintained complete diastereoselection 
(1.29j).  
 Protecting group identity on the β-lactam substrates proved important. While the 
electron deficient Boc and Tosyl groups showed analogous reactivity to the β-lactones, albeit 
with no diastereocontrol, the TBS-protected lactam failed to react. Presumably this is an 
electronic effect, although steric encumbrance cannot be ruled out. Additional five-membered 
ring electrophiles were tested with varying results. -Butyrolactone reacted smoothly under the 
reaction conditions (1.29g), but gave an unstable product that required immediate silyl 
protection due to a dominant retro-Claisen pathway. A furanone (1.29n) and oxazolinone 
(1.29o) were tested; each would provide useful functional handles. Unfortunately, neither 
reaction provided desired product. 
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Table 1-2.  Substrate Scopea,b 
 
Product  Yield   dr Product  Yield dr 
 
1.22 61% >20:1 
 
1.29hd 49% 5:1 
 
1.29a 67% >20:1 
 
1.29id 72% 5:1 
 
1.29b 35% >20:1 
 
1.29jd 63% >20:1 
 
1.29c 64% >20:1 
 
1.29k 65% 1:1 
 
1.29d 33% >20:1  1.29l 55% 1:1 
 
1.29e 48% >20:1 
 
1.29m 0% N/D 
 
1.29f 59% >20:1 
 
1.29n 0% N/D 
 
1.29g 28%c N/A 
 
1.29od 0% N/D 
a. All reactions: 2.3 equiv 1.12, 1.0 equiv silyl glyoxylate, 1.6 equiv lactone/lactam, [silyl 
glyoxylate]0 = 0.5M. 
b. See section 1.5 Experimental Details for more information. c. Yield 
reported over two steps. d. Si = TES. 
The effect of lithium chloride was tested during the course of this investigation. 
Reported by Knochel, Reformatsky reagents can often exhibit enhanced reactivity due to the 
formation of a zincate complex.21 This additive had a minor effect on yield for some substrates, 
but no pattern or predictability was observed in terms of structures that would benefit from the 
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addition of this salt (See section 1.5 Experimental Details). A final perturbation of the title 
reaction tested was the initiation via allylzinc bromide. In this experiment, the zinc nucleophile 
reacted without discrimination, yielding a complex mixture.   
1.3.6  Origin of Diastereoselectivity 
 The impressive stereochemical outcome of this reaction may be explained by the 
borrowing of some key features from the initial Greszler double Reformatsky reaction (1.8, 
Figure 1-5). After Reformatsky attack on silyl glyoxylate and subsequent Brook 
rearrangement, isomerization to the seven-membered (E)-glycolate enolate chelate structure 
occurs to give the second, active nucleophilic species. In this event, diastereofacial approach 
of the β-lactone will dictate the stereochemical outcome of the emerging fully-substituted 
center. Here, we deviate from the previous model wherein the -methyl substituent of the 
Reformatsky reagent dictated approach of the ketone electrophiles. In the present case, it seems 
plausible that the β-lactone will approach with its β-substituent pointing away from the enolate, 
but a second controlling element must be at play to distinguish between transition structures 
1.30 and 1.31 (Figure 1-9).  
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Figure 1-9.  Competing Transition State Models 
 
 We propose a subtle, electrostatic effect governs the complete diastereoselection of the 
title reaction. As depicted in Figure 1-9, a lone pair repulsion between the β-lactone ring 
oxygen, and the benzyloxy substituent on the glycolate enolate might provide enough of a 
barrier to encourage reactivity through 1.30, providing the observed diastereomer. More 
experimentation would be necessary to confirm this or alternative models of 
diastereoselectivity. With the lack of diasterocontrol observed for the β-lactam substrates, it is 
apparent they are poorly differentiated in our working model or react through an orthogonal 
transition state. 
1.3.7  Subsequent Transformations of β-Hydroxyketone Products 
 The β-hydroxyketone product scaffold obtained from the title reaction provides unique 
opportunities for subsequent manipulation. Functionality present includes: two differentiated 
esters, a highly-substituted ketone, β-hydroxyl group, and the moiety provided by the β-lactone 
substrate selection. In addition to the derivations described in Figure 1-8 (directed ketone 
reductions/cyclizations to form mono or bis(lactones)), we have shown selective manipulation 
of the ester functionality (Scheme 1-6). A two-step sequence beginning with Prasad reduction 
followed by acetonide protection provides diester 1.32. At this stage, selective reduction of the 
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ethyl ester was achieved upon treatment with  DIBAL-H to provide monoalcohol 1.33. 
Alternatively, subjection of the diester to lithium triethylborohydride (Super-Hydride) 
afforded diol 1.34 for further transformation.  
Scheme 1-6.  Diester Functionalization 
 
1.3.8  Application to Leustroducsin B† 
 Background. The three-component coupling reaction was designed with application to 
targeted natural product synthesis in mind. Specifically, we were interested in the core structure 
of the phoslactomycin22 and leustroducsin23 natural product families (Figure 1-10). Isolated in 
1993 by Kohama et al., these natural products have been shown to exhibit interesting biological 
activities across multiple phyla. We were particularly interested in the array of congested 
functionality that comprises the common core of these targets.  
 
 
 
† This topic is purposely presented in brevity. For a full discussion see: Greszler, S. N. Ph. D. 
Dissertation, University of North Carolina at Chapel Hill. Chapel Hill, NC, 2010.  
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Figure 1-10.  Leustroducsin and Related Natural Products 
 
 Each natural product boasts a stereodefined tertiary alcohol (C8) with flanking 
dihydropyrone and phosphate functionality. Distal amino and allylic alcohol functionalities 
complete the core structure. The individual members of these families are distinguished by the 
ester substituents stemming from C18, with leustroducsin B among the most complex with a 
6-methyl octanoate subunit. Additionally, leustroducsin B possesses the most intriguing 
biological activity and was therefore chosen as our target for synthesis. Although three extant 
syntheses have been reported: Fukuyama (2003, 47 steps),24 Imanishi (2006, 32 steps),25 and 
Cossy (2008, formal – 27 steps),26 we identified the congested core as a central challenge and 
believed our methodology could provide unprecedented, rapid access. 
 Retrosynthetic analysis. The products derived from our three-component coupling 
reaction, specifically 1.22, map onto the leustroducsin core with minimal refunctionalization 
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required. As shown in Figure 1-11, the fully-substituted C8 stereocenter is fully-assembled 
with the C9 ketone in place, poised for directed reduction by the C11 hydroxyl. The ethyl ester 
can be converted into amino functionality, and the alkyne functionality can be downstream 
functionalized to reveal the (Z,Z)-diene. The only obvious discrepancy is the incorrect 
stereochemistry at C11. This was not considered problematic in our analysis, as we anticipated 
using this feature for our reported syn directed reduction. A Mitsunobu inversion could be 
employed late-stage to correct the hydroxyl center.  
Figure 1-11.  Retrosynthetic Analysis 
 
 Our general strategy for assembly of leustroducsin B was to first manipulate β-
hydroxyketone 1.22 in order to generate an intermediate adequately protected and in the correct 
oxidation state. Next, the dihydropyrone element would be installed using a method inspired 
by the efficient route in the Cossy synthesis. This would be followed by manipulation of the 
protected alkyne to reveal an appropriate coupling partner to participate in an organometallic 
cross-coupling reaction to install the eastern fragment. This convergent approach would ideally 
provide the shortest total synthesis to date.  
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 Synthetic endeavors. Synthesis from three-component coupling product 1.22 began 
with the syn reduction/acetonide protection outlined in Scheme 1-6. This provided diester 1.32, 
which was subjected to excess Super-Hydride to furnish the corresponding diol (1.34, Scheme 
1-7). Selective silyl protection of the less-hindered primary alcohol followed by Dess-Martin 
periodinane oxidation provided aldehyde 1.35 as a functional handle from which to install the 
(E)-alkene bridge to the dihydropyrone moiety. A two-carbon homologation sequence was 
performed beginning with a Horner-Wadsworth-Emmons olefination to install an unsaturated 
nitrile. Subsequent reduction and hydrolysis provided acrolein 1.36 in excellent yield, giving 
an appropriate electrophile from which to begin dihydropyrone synthesis.  
Scheme 1-7.  Synthesis of Dihydropyrone Precursor 
 
 After numerous failed alternatives, we turned to the sequence reported by Cossy27a to 
install the important dihydropyrone moiety. We began with an asymmetric Brown-type 
pentenylation (1.37). This occurred in excellent yield with high enantioselectivity, and allowed 
for enantioenrichment after diastereomeric removal of the minor enantiomer (present from 
incomplete β-lactam enantioenrichment). The secondary alcohol was then esterified with 
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acryloyl chloride setting up a ring-closing metathesis (RCM) to close the six-membered ring. 
Unfortunately, conditions to effect this transformation were never realized due to 
complications we attributed to the alkyne. Indeed, upon investigation of the literature, 
numerous research groups had encountered similar issues with failed metathesis reactions.27  
Further experiments revealed that a silyl deprotection of the alkyne must precede the allylic 
alcohol esterification. Only through this sequence was terminal alkyne 1.38 obtained cleanly. 
A dicobalt-hexacarbonyl protection of the alkyne was pursued in order to accomplish the ring-
closing metathesis and was ultimately successful (1.39  1.40). Although two 
protection/deprotection steps were added to our route to accomplish the RCM, it is important 
to note each occurs in near-quantitative yield. The installation of the dihydropyrone took six 
steps in total with an average yield of 90% per transformation. 
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Scheme 1-8.  Dihydropyrone Installation 
 
 At this stage of the synthesis, three challenges remained: (1) introduction of the western 
amino functionality; (2) epimerization of the C11 hydroxyl; and (3) conversion of the alkyne 
to the requisite (Z,Z)-diene. Numerous proceeding studies and attempts to complete any of 
these goals were met with failure as the current protecting group scheme proved intractable. 
The decision was made to swap the central dioxane (six-membered) for a dioxolane (five-
membered) protected diol. Additionally, TBS protecting groups on the exterior alcohols were 
significantly easier to manipulate.  
 To this end, dioxane 1.40 was globally deprotected with CSA in methanol, providing 
the unstable tetraol 1.41 (Scheme 1-9). Selective TBS protection of the primary and 
propargylic alcohols was accomplished followed by acetonide formation, giving the desired, 
fully-protected tetraol 1.42. Due to numerous constraints, we looked to the Imanishi synthesis 
for an endgame strategy and determined that a late-stage intermediate was within reach, 
requiring minimal change to our strategy. The first task at hand was installation of an 
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orthogonal, robust protecting moiety on the western hydroxyl which would permit 
manipulations at the propargylic site. For this task we selected the triphenylmethane (trityl) 
group and began its introduction with a two-step deprotection/protection sequence. Both TBS 
protecting groups were removed upon treatment with HF-pyr, revealing an intermediate diol. 
The primary alcohol showed significantly higher reactivity, allowing for selective protection 
employing trityl chloride (1.43) in an excellent yield over the two step sequence. Next, we 
focused on the inversion of the incorrect propargyl stereocenter. At this stage, this was the sole 
unprotected alcohol providing a suitable substrate for Mitsunobu inversion. This 
transformation was accomplished with chloroacetic acid providing the leustroducsin core with 
full stereochemical integrity (1.44). 
 The Imanishi intermediate we were pursuing featured a TBS ether at the propargylic 
site, so a two-step deprotection/silylation sequence was developed to accomplish this 
requirement. Clean saponification of the chloroacetate proved challenging until ammonium 
hydroxide/methanolic conditions were discovered to effect this transformation. The 
deacylation was followed by silyl ether formation, uneventfully providing alkyne 1.45 for final 
manipulations. The last task entailed conversion of the alkyne functionality to a (Z)-vinyl 
iodide. First, we performed an iodination of the alkyne using N-iodosuccinimide/silver nitrate, 
which was followed by a diimide reduction of the alkyne using o-
nitrobenzenesulfonylhydrazide (NBSH).28 This syn reduction was selective for the Z geometry 
of the vinyl iodide moiety. Finally, deprotection of the trityl group with boron trichloride 
proceeded cleanly, with our advanced intermediate displaying a high level of structural 
integrity. This deprotection provided vinyl iodide intermediate 1.46, intercepting Imanishi’s 
route and constituting a formal synthesis of leustroducsin B. 
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Scheme 1-9.  Completion of Formal Synthesis 
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1.4  Conclusion 
 We have developed a highly-diastereoselective three-component coupling silyl 
glyoxylate cascade. This methodology is a formal solution to the quaternary Claisen reaction, 
as a fully-substituted β-ketoester is established with high efficiency. The advantageous 
selection of enantioenriched β-lactones as secondary electrophiles resulted in a unique 1,4-
transfer of stereochemical information to the emerging -stereocenter. The yields for this 
transformation are generally moderate but may be justified by the level of complexity 
generated. Two C–C bonds are formed with high fidelity at a quaternary center; additionally, 
ketone, hydroxyl, and two differentiated ester functional handles are obtained for subsequent 
manipulation. Extension to alternate terminating electrophiles was met with mixed results, but 
β-lactam and -butyrolactone substrates showed promise. The applicability of this research was 
demonstrated by numerous secondary transformations, including 1,3-syn- and anti-diol 
syntheses as well as selective ester manipulation and was showcased in a formal synthesis of 
leustroducsin B, including one of the most rapid routes for core access to date. 
 
 
 
 
 
 
32 
1.5  Experimental Details 
Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker model Avance 400 (1H NMR at 400 MHz and 13C at 100 
MHz) or a Bruker model Avance 500 (1H NMR at 500 MHz and 13C NMR at 125 MHz) 
spectrometer with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 77.0 ppm). 
1H NMR data are reported as follows: chemical shift, 
multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, br t = broad triplet, q = 
quartet, m = multiplet), coupling constants (Hz), and integration. Mass spectra were obtained 
using a Bruker BioTOF II spectrometer with electrospray ionization calibrated with CsOAc. 
All samples were prepared in methanol. Analytical thin layer chromatography (TLC) was 
performed on Sorbent Technologies 0.20 mm Silica G TLC plates. Visualization was 
accomplished with UV light and/or aqueous ceric ammonium nitrate solution followed by 
heating. Purification of the reaction products was carried out by flash chromatography using 
Siliaflash-P60 silica gel (40-63μm) purchased from Silicycle. Purification via HPLC was 
performed on a Varian Prepstar SD-1 Solvent Delivery System equipped with a Cyano 60 Å 
6u column from Berger Instruments. Specific parameters used in the separation of compounds 
are detailed under applicable entries. Unless otherwise noted, all reactions were carried out 
under an atmosphere of dry nitrogen in oven-dried glassware with magnetic stirring. Yield 
refers to isolated yield of analytically pure material unless otherwise noted. Yields are reported 
for a specific experiment and as a result may differ slightly from those found in the tables, 
which are averages of at least two experiments 
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Materials: General.  Tetrahydrofuran, diethyl ether, dichloromethane, and toluene were dried 
by passage through a column of neutral alumina under nitrogen prior to use. Zinc metal was 
washed with 1 M HCl, water, acetone, and diethyl ether and then dried under vacuum at 60 °C 
for 16 h prior to storage in a nitrogen-filled glove box. Lithium chloride was dried and stored 
in a 100 °C oven. Diisopropylethylamine and triethylamine were freshly distilled from calcium 
hydride prior to use. Propionyl chloride, propionyl bromide, acetyl bromide, and 
hydrocinnimaldehyde were distilled under nitrogen immediately before use. β-Lactones and 
lactams were obtained using known procedures.29-35 Silyl glyoxylates were prepared according 
to the published procedures.29,30 All other reagents were purchased from commercial sources 
and were used as received unless otherwise noted. 
Preparation of 1.19a: 
 
(S)-4-((trimethylsilyl)ethynyl)oxetan-2-one (1.19a): 
The title compound was prepared according to the procedure described by Nelson1 with the 
following modifications: 
1.  Instead of purification via Kugelrohr distillation, the crude -lactone was purified via flash 
chromatography (92.5:7.5 to 85:15 hexanes:ethyl acetate), affording the title compound (67% 
yield) as a light yellow oil whose spectral properties matched those reported in the literature.1   
34 
2.  The enantiomeric excess of the prepared lactone was assayed via supercritical fluid 
chromatographic (SFC) analysis of the corresponding -hydroxyketone 1.22 (vide infra).  
Enantiomeric excesses ranged from 78-83% using this method.  CSP-SFC analysis of a sample 
of 1.22 showed that the product was enriched to 78% ee (Chiralpak OD column, 3.0% MeOH, 
1.0 mL/min, 150 psi, 24 °C, 210 nm, tr-major enantiomer: 12.9 min, tr-minor enantiomer:  25.9 
min; CSP-SFC traces for a mixture of enantiomers and of the enantioenriched product are 
attached below: 
Enantiomeric Mixture:    Enantioenriched Sample: 
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Preparation of Reformatsky Reagent (1.12): 
 
An oven-dried 100-mL round-bottomed flask equipped with a magnetic stir bar was charged 
with zinc dust (1.41 g, 21.6 mmol, 2 equiv) and diethyl ether (25 mL). The flask was fitted 
with a condenser and purged with nitrogen. Br2 (0.07 mL, 1.4 mmol, 0.13 equiv) was added 
dropwise over 5 min with stirring (exotherm observed). The suspension was heated to reflux, 
and ethylbromoacetate (1.2 mL, 10.8 mmol, 1.0 equiv) was added dropwise over 15 min. The 
solution was stirred at this temperature for 4 h then cooled to RT. An aliquot was titrated with 
I2, typically reflecting concentrations of active reagent of 0.35-0.43 M (81-100% yield). The 
solution was stored under nitrogen at 0 °C for up to one week and titrated immediately prior 
to each subsequent use.  
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General Procedure A for the Reformatsky Initiated Cascade Coupling of Silyl Glyoxylate 
and -Lactones Affording -hydroxyketones 1.22, 1.29 
 
 
An oven-dried 20-mL scintillation vial equipped with magnetic stir bar was purged with 
nitrogen and a solution of Reformatsky reagent (0.38 M, 1.09 mL, 2.3 equiv) was added. The 
resulting suspension was diluted with diethyl ether (1.0 mL) and cooled to -30 °C in an 
acetone/dry ice bath (bath temperature, monitored with a thermocouple probe). A second oven-
dried vial was charged with silyl glyoxylate 1.21 (0.18 mmol, 1.0 equiv) and -lactone 1.19 
(0.29 mmol, 1.6 equiv). The vial was purged with nitrogen, and diethyl ether (1.5 mL) was 
added. This solution was cooled and added to the solution of Reformatsky reagent.  Additional 
diethyl ether (0.5 mL) was used to rinse the vial. The reaction was allowed to warm slowly in 
the acetone bath (generally over 30 min from -30 °C to 0 °C).  Consumption of the silyl 
glyoxylate was generally observed by TLC analysis and disappearance of yellow color 
between -20 °C and -15 °C. The reaction was then held at 0 °C until judged complete by TLC 
analysis, generally 30 min. Saturated aqueous ammonium chloride (0.5 mL) was then added 
and the reaction was stirred until clear layers were observed.  The organic layer was removed, 
and the aqueous layer was extracted with diethyl ether (3 x 1.0 mL).  The combined organic 
extracts were washed with brine, dried with magnesium sulfate, and concentrated in vacuo. 
The crude product was purified via flash chromatography to give the desired product. 
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(S)-1-benzyl-4-ethyl-2-((S)-3-hydroxy-5-(trimethylsilyl)pent-4-ynoyl)-2-
((triethylsilyl)oxy)succinate (1.22): The title compound was prepared according to General 
Procedure A using silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 1.0 equiv) and (S)-4-
((trimethylsilyl)ethynyl)oxetan-2-one (1.19a, 49 mg, 0.29 mmol, 1.6 equiv). Purification via 
flash chromatography (93.5:7.5 to 70:30 petroleum ether: diethyl ether) provided the desired 
product as a light yellow oil with > 20:1 diastereomeric ratio (59 mg, 61%). Analytical data: 
[]D25.3 -5.30 (c 1.25, CHCl3); 1H NMR  (500 MHz, CDCl3): δ 7.36-7.31 (m, 5H), 5.17 (d, J 
= 12.0 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 4.87 (dd, J = 6.5, 4.5 Hz, 1H), 4.09 (q, J = 7.5 Hz, 
2H), 3.47 (d, J = 17 Hz, 1H), 3.36 (dd, J = 18.5, 2.5 Hz, 1H), 3.12 (dd, J = 18.5, 9.0 Hz, 1H), 
2.91 (d, J = 17.0 Hz, 2H), 1.22 (t, J = 7.0 Hz, 3H), 0.89 (t, J = 8.0 Hz, 9H), 0.56 (q, J = 8.0 Hz,  
6H), 0.56 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 208.8, 169.3, 168.5, 134.4, 128.7, 128.6, 
128.5, 104.8, 89.3, 83.7, 68.1, 61.1, 58.8, 46.0, 42.5, 14.0, 6.7, 5.7, -0.2;  LRMS (ESI+) Calcd. 
for C27H42O7Si2+H, 535.3; Found, 535.3; IR (thin film, cm
-1) 3515, 2958, 2911, 2878, 2176, 
1738, 1456, 1373, 1343, 1250, 1181, 844, 699;  TLC (80:20 Hex:EtOAc): Rf = 0.42. 
 
(R)-1-benzyl 4-ethyl 2-((tert-butyldimethylsilyl)oxy)-2-((R)-3-hydroxy-5- (trimethylsilyl) 
pent-4-ynoyl)succinate (1.29a): The title compound was prepared according to General 
Procedure A using silyl glyoxylate (1.21a, 50 mg, 0.18 mmol, 1.0 equiv) and (S)-4-
((trimethylsilyl)ethynyl)oxetan-2-one (1.19a, 49 mg, 0.29 mmol, 1.6 equiv). Purification via 
flash chromatography (93.5:7.5 to 70:30 petroleum ether: diethyl ether) provided the desired 
product as a light yellow oil with > 20:1 diastereomeric ratio (67 mg, 70%). Analytical data: 
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[]D25.2 + 7.8 (c 0.43, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 7.38-7.27 (m, 5H), 5.17 (d, J 
= 12.0 Hz, 1H), 5.09 (d, J = 12.0 Hz, 1H), 4.86 (dd, J = 9.2, 4.8 Hz, 1H), 4.08 (q, J = 7.2 Hz, 
2H), 3.46 (d, J = 16.8 Hz, 1H), 3.37 (dd, J = 18.8, 2.4 Hz, 1H), 3.13 (dd, J = 18.4, 8.8 Hz, 1H), 
2.95 (d, J = 17.2, 1H), 2.91 (d, J = 4.4, 1H), 1.22 (t, J = 7.2 Hz, 3H), 0.86 (s, 9H), 0.15 (s, 9H), 
0.04 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 208.8, 169.3, 168.3, 134.3, 128.7, 
128.6, 128.5, 104.9, 89.3, 83.6, 68.1, 61.1, 58.7, 46.3, 42.2, 25.5, 18.2, 14.0, -0.3, -3.6, -4.2;  
LRMS (ESI+) Calcd. for C27H42O7Si2+Na, 557.3; Found, 557.2; IR (thin film, cm
-1) 3433, 
2844, 2386, 2100, 1646, 1558, 1541, 1456, 1250, 1013, 494;  TLC (80:20 Hexanes:EtOAc): 
Rf = 0.42. 
 
1-tert-butyl 4-ethyl 2-((tert-butyldimethylsilyl)oxy)-2-(3-hydroxy-5-(trimethylsilyl)pent-
4-ynoyl)succinate (1.29b): The title compound was prepared according to General Procedure 
A using silyl glyoxylate (1.21b, 44 mg, 0.18 mmol, 1.0 equiv) and (S)-4-
((trimethylsilyl)ethynyl)oxetan-2-one (1.19a, 49 mg, 0.29 mmol, 1.6 equiv). Purification via 
flash chromatography (93.5:7.5 hexanes:ethyl acetate) provided the desired product as a light 
yellow oil with > 20:1 diastereomeric ratio (31 mg, 34%). Analytical data: 1H NMR  (500 
MHz, CDCl3): δ 4.88-4.86 (m, 1H), 4.08 (q, J = 7.0 Hz, 2H), 3.43 (d, J = 17.5 Hz, 1H), 3.39 
(dd, J = 18.5, 2.5 Hz, 1H), 3.10 (dd, J = 18.5, 9.0 Hz, 1H), 3.02 (d, J = 5.0 Hz, 1H), 2.88 (d, J 
= 17.5 Hz, 1H), 1.44 (s, 9H), 1.23 (t, J = 7.5 Hz, 3H), 0.91 (s, 9H), 0.16 (s, 3H), 0.15 (s, 9H), 
0.05 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 209.6, 169.6, 167.4, 105.0, 89.2, 84.2, 83.7, 61.0, 
58.7, 46.1, 42.0, 27.7, 25.6, 18.3, 14.1, -0.2, -3.4, -3.7;  LRMS (ESI+) Calcd. for 
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C24H24O7Si2+Na, 523.3; Found, 523.2; IR (thin film, cm
-1) 3432, 2959, 2858, 2359, 1737, 
1641, 1371, 1251, 1157, 911, 841, 733;  TLC(75:25 Hex:EtOAc): Rf = 0.48. 
 
1-benzyl 4-ethyl 2-(4-((tert-butyldimethylsilyl)oxy)butanoyl)-2-
((triethylsilyl)oxy)succinate (1.29g): The title compound was prepared according to General 
Procedure A using LiCl (38 mg, 0.9 mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 
1.0 equiv), and -butyrolactone (25 mg, 0.29 mmol, 1.6 equiv). The crude product was added 
to an oven-dried vial, which was purged with nitrogen. CH2Cl2 (1.5 mL) was added, and the 
resulting solution was cooled to -78 °C. 2,6-lutidine (0.02 mL, 0.17 mmol, 2 equiv) was then 
added, followed by tert-butyldimethylsilyl trifluoromethanesulfonate (0.02 mL, 0.09 mmol, 
1.1 equiv). The reaction was allowed to stir for 20 min and was then quenched by the addition 
of an aqueous solution of HCl (1M, 0.5 mL). The layers were separated, and the organic layer 
was washed with brine, dried with magnesium sulfate, and concentrated in vacuo. Purification 
via flash chromatography (100:0 to 95:5 hexanes: ethyl acetate) provided the desired product 
as a light yellow oil (31 mg, 30%, 2 steps). Analytical data: 1H NMR  (500 MHz, CDCl3): δ 
7.35-7.29 (m, 5H), 5.18 (d, J = 12.5 Hz, 1H), 5.09 (d, J = 12.5 Hz, 1H), 4.07 (q, J = 7.5 Hz, 
2H), 3.60 (t, J = 6.5 Hz, 2H), 3.41 (d, J = 16.5 Hz, 1H), 2.99-2.95 (m, 1H), 2.91 (d, J = 16.5 
Hz, 1H), 2.91-2.75 (m, 1H), 1.77-1.74 (m, 2H), 1.21 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 7.0 Hz, 
9H), 0.88 (s, 9H), 0.57 (q, J = 7.5 Hz, 6H), 0.03 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 209.3, 
169.3, 169.1, 134.7, 128.6, 128.5, 128.4, 83.8, 67.8, 62.2, 60.8, 42.5, 34.5, 26.4, 25.9, 18.2, 
14.0, 6.8, 5.8, -5.4; LRMS (ESI+) Calcd. for C29H50O7Si2+Na, 589.3; Found, 589.3; IR (thin 
40 
film, cm-1) 3433, 3054, 2121, 1641, 1422, 126, 895, 738, 704; TLC(75:25 Hex:EtOAc): Rf = 
0.58. 
 
1-benzyl 4-ethyl 2-3-hydroxy-2-methyl-5-phenylpentanoyl)-2-
((triethylsilyl)oxy)succinate (1.29h): The title compound was prepared according to General 
Procedure A using silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 1.0 equiv) and trans-3-methyl-4-
phenethyloxetan-2-one (1.19h, 55 mg, 0.29 mmol, 1.6 equiv). Purification via flash 
chromatography (50:50:0 to 0:100:0 to 0:95:5 hexanes: CH2Cl2: MeOH) provided the desired 
product as a light yellow oil with 5:1 diastereomeric ratio (56 mg, 56%). Analytical data: 1H 
NMR  (400 MHz, CDCl3): δ 7.43-7.09 (m, 10H), 5.17 (d, J = 12.0 Hz, 1H), 5.12 (d, J = 12.0 
Hz, 1H), 4.10 (q, J = 7.2 Hz, 2H), 3.84-3.82 (m, 1H), 3.59-3.51 (m, 2H), 3.12 (d, J = 4.8 Hz, 
1H), 2.93-2.84 (m, 2H), 2.75-2.67 (m, 1H), 1.97-1.78 (m, 1H), 1.78-1.59 (m, 1H), 1.23 (t, J = 
7.2 Hz, 3H), 0.97 (d, J = 7.2 Hz, 3H), 0.92 (t, J = 8.0 Hz, 9H), 0.70-0.54 (m, 6H); 13C NMR 
(125 MHz, CDCl3): δ 212.2, 169.8, 169.2, 142.6, 134.4, 128.7, 128.6, 128.5, 125.6, 84.1, 72.2, 
68.2, 61.3, 46.4, 42.9, 36.0, 31.6, 14.4, 14.0, 6.8, 5.9; LRMS (ESI+) Calcd. for 
C31H44O7Si+Na, 579.3; Found, 579.2; IR (thin film, cm
-1) 3528, 3028, 2855, 2912, 2877, 2733, 
2359, 2249, 1950, 1740, 1455, 1373, 1343, 1211, 1020, 830, 737, 699; TLC(75:25 
Hex:EtOAc): Rf = 0.42. 
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1-benzyl 4-ethyl 2-3-hydroxy-2-methyl-5-phenylpentanoyl)-2-
((triethylsilyl)oxy)succinate (1.29i): The title compound was prepared according to General 
Procedure A using silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 1.0 equiv) and cis-3-methyl-4-
phenethyloxetan-2-one (1.19g, 55 mg, 0.29 mmol, 1.6 equiv). Purification via flash 
chromatography (50:50:0 to 0:100:0 to 0:95:5 hexanes: CH2Cl2: MeOH) provided the desired 
product as a light yellow oil with 5:1 diastereomeric ratio (79 mg, 79%). Analytical data: 1H 
NMR  (500 MHz, CDCl3): δ 7.35-7.14 (m, 10H), 5.16 (d, J = 12.0 Hz, 1H), 5.05 (d, J = 12.0 
Hz, 1H), 4.23 (dd, J = 10.0, 2.0 Hz, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.61 (d, J = 17.0 Hz, 1H), 
3.44-3.43 (m, 1H), 2.88-2.84 (m, 2H), 2.62-2.60 (m, 1H), 1.91-1.88 (m, 1H), 1.59-1.57 (m, 
1H), 1.21 (t, J = 7.0 Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H), 0.87 (t, J = 7.5 Hz, 9H), 0.57-0.51 (m, 
6H); 13C NMR (125 MHz, CDCl3): δ 213.2, 169.7, 168.9, 142.4, 134.3, 128.7, 128.6, 128.5, 
128.3, 125.7, 84.2, 70.1, 68.1, 61.1, 45.9, 42.5, 36.0, 32.8, 14.1, 8.9, 6.7, 5.6;  LRMS (ESI+) 
Calcd. for C31H44O7Si+Cs, 689.2; Found, 689.1; IR (thin film, cm
-1) 3440, 2955, 2877, 2247, 
1735, 1642, 1455, 1374, 1343, 1210, 1022, 834, 733, 699;  TLC(75:25 Hex:EtOAc): Rf = 0.34. 
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1-benzyl 4-ethyl 2-3-hydroxy-2-methyl-5-(trimethylsilyl)pent-4-ynoyl)-2-
((triethylsilyl)oxy)succinate (1.29j): The title compound was prepared according to General 
Procedure A using silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 1.0 equiv) and (3S,4S)-3-methyl-
4-((trimethylsilyl)ethynyl)oxetan-2-one (1.19f, 56 mg, 0.29 mmol, 1.6 equiv). Purification via 
flash chromatography (92.5:7.5 hexanes: ethyl acetate) provided the desired product as a light 
yellow oil with > 20:1 diastereomeric ratio (64 mg, 64%). Analytical data: 1H NMR  (400 
MHz, CDCl3): δ 7.37-7.29 (m, 5H), 5.19 (d, J = 12.0 Hz, 1H), 5.13-5.12 (m, 1H), 5.07 (d, J = 
12.0 Hz, 1H), 4.09 (q, J = 7.2 Hz, 2H), 3.62-3.59 (m, 1H), 3.61 (d, J = 21.6 Hz, 1H), 3.19 (d, 
J = 4.4 Hz, 1H), 2.89 (d, J = 17.2 Hz, 1H), 1.23 (t, J = 7.2 Hz, 3H), 1.20 (d, J = 7.2 Hz, 3H), 
0.92 (t, J = 8.0 Hz, 9H), 0.63-0.56 (m, 6H), 0.16 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 
211.7, 170.0, 168.6, 134.3, 128.8, 128.6, 104.2, 89.3, 84.2, 68.2, 63.3, 61.4, 47.2, 42.6, 14.0, 
9.7, 6.7, 5.6, -0.2;  LRMS (ESI+) Calcd. for C28H44O7Si2+Na, 571.3; Found, 571.2; IR (thin 
film, cm-1) 3543, 2959, 2878, 2361, 2178, 1731, 1374, 1212, 1020, 844;  TLC(75:25 
Hex:EtOAc): Rf = 0.45. 
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General Procedure B for the Reformatsky Initiated Cascade Coupling of Silyl Glyoxylate 
and -Lactones Affording -hydroxyketones 1.29 
 
 
An oven-dried 20-mL scintillation vial equipped with magnetic stir bar was charged with LiCl 
(0.0-0.9 mmol, 0-5 equiv). The vial was purged with nitrogen, and a solution of Reformatsky 
reagent (0.38 M, 1.09 mL, 2.3 equiv) was added. The resulting suspension was diluted with 
diethyl ether (1.0 mL) and cooled to -30 °C in an acetone/dry ice bath (bath temperature, 
monitored with a thermocouple probe). A second oven-dried vial was charged with silyl 
glyoxylate 1.21 (0.18 mmol, 1.0 equiv) and -lactone 1.19 (0.29 mmol, 1.6 equiv). The vial 
was purged with nitrogen, and diethyl ether (1.5 mL) was added. The resulting solution was 
cooled and added to the solution of Reformatsky reagent.  Additional diethyl ether (0.5 mL) 
was used to rinse the vial. The reaction was allowed to warm slowly in the acetone bath 
(generally over 30 min from -30 °C to 0 °C).  Consumption of the silyl glyoxylate was 
generally observed by TLC analysis and disappearance of yellow color between -30 °C and -
25 °C. The reaction was then held at 0 °C until judged complete by TLC analysis, generally 30 
min. Saturated aqueous ammonium chloride (0.5 mL) was then added to quench the reaction, 
and it was stirred until clear layers were observed.  The organic layer was removed, and the 
aqueous layer was extracted with diethyl ether (3x1.0 mL).  The combined organic extracts 
were washed with brine, dried with magnesium sulfate, and concentrated in vacuo. The crude 
product was purified via flash chromatography to give the desired product. 
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1-benzyl 4-ethyl 2-(3-hydroxy-5-phenylpentanoyl)-2-((triethylsilyl)oxy)succinate (1.29c): 
The title compound was prepared according to General Procedure B using LiCl (38 mg, 0.9 
mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 1.0 equiv), and (S)-4-
phenethyloxetan-2-one (1.19b, 50 mg, 0.29 mmol, 1.6 equiv). Purification via flash 
chromatography (CH2Cl2) provided the desired product as a light yellow oil with > 20:1 
diastereomeric ratio (63 mg, 65%). Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.36-7.16 
(m, 10H), 5.19 (d, J = 12.0 Hz, 1H), 5.10 (d, J = 12.4 Hz, 1H), 4.13 (s, 1H), 4.08 (q, J = 7.2 
Hz, 2H), 3.48 (d, J = 16.8 Hz, 1H), 3.17 (dd, J = 18.0, 1.6 Hz, 1H), 3.05 (d, J = 1.2 Hz, 1H), 
2.90 (d, J = 16.8 Hz, 1H), 2.87-2.57 (m, 3H), 1.90-1.51 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H), 0.88 
(t, J = 8.0 Hz, 9H), 0.55 (q, J = 7.6 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 210.7, 169.3, 
168.7, 142.1, 134.3, 128.7, 128.6, 128.5, 128.4, 128.3, 125.7, 83.8, 68.1, 66.9, 61.0, 45.3, 42.4, 
38.3, 31.9, 14.0, 6.7, 5.7;  LRMS (ESI+) Calcd. for C30H42O7Si+Na, 565.3; Found, 565.2; IR 
(thin film, cm-1) 3459, 3028, 2955, 2877, 2360, 1737, 1455, 1373, 1213;  TLC(75:25 
Hex:EtOAc): Rf = 0.44. 
 
1-benzyl 4-ethyl 2-(3-hydroxy-3-(4-nitrophenyl)propanoyl)-2-
((triethylsilyl)oxy)succinate (1.29d): The title compound was prepared according to General 
Procedure B using LiCl (38 mg, 0.9 mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 
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1.0 equiv), and (S)-4-(4-nitrophenyl)oxetan-2-one (1.19e, 56 mg, 0.29 mmol, 1.6 equiv). 
Purification via flash chromatography (93.5:7.5 to 85:15 petroleum ether: diethyl ether) 
provided the desired product as a light yellow oil with > 20:1 diastereomeric ratio (35 mg, 
35%). Analytical data: 1H NMR  (400 MHz, CDCl3): δ 8.19 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 
8.8 Hz, 2H), 7.39-7.30 (m, 5H), 5.30 (d, J = 9.6 Hz, 1H), 5.20 (d, J = 12.4 Hz, 1H), 5.10 (d, J 
= 12.0 Hz, 1H), 4.11 (q, J = 7.2 Hz, 2H), 3.57 (s, 1H), 3.54 (d, J = 13.2 Hz, 1H), 3.44 (dd, J = 
18.0, 2.4 Hz, 1H), 2.95 (d, J = 17.2 Hz, 1H), 2.92 (d, J = 18.0 Hz, 1H), 1.25 (t, J = 7.2 Hz, 3H), 
0.86 (t, J = 8.0 Hz, 9H), 0.58-0.52 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 210.1, 169.5, 
168.5, 150.4, 147.1, 134.2, 128.8, 128.7, 128.5, 126.4, 123.6, 83.7, 69.0, 68.2, 61.2, 47.0, 42.5, 
14.1, 6.7, 5.6;  LRMS (ESI+) Calcd. for C28H37NO9Si+Na, 582.2; Found, 582.2; IR (thin film, 
cm-1) 3502, 2057, 2877, 2360, 2341, 1732, 1606, 1521, 1347, 1214, 1009, 854;  TLC(75:25 
Hex:EtOAc): Rf = 0.36. 
 
1-benzyl 4-ethyl 2-(4-(benzyloxy)-3-hydroxybutanoyl)-2-((triethylsilyl)oxy)succinate 
(1.29e): The title compound was prepared according to General Procedure B using LiCl (38 
mg, 0.9 mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 1.0 equiv), and (S)-4-
((benzyloxy)methyl)oxetan-2-one (1.19c, 56 mg, 0.29 mmol, 1.6 equiv). Purification via flash 
chromatography (85:15 to 75:25 petroleum ether: diethyl ether) provided the desired product 
as a light yellow oil with > 20:1 diastereomeric ratio (49 mg, 49%). Analytical data: 1H NMR  
(400 MHz, CDCl3): δ 7.34-7.27 (m, 10H), 5.18 (d, J = 12.0 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 
4.57 (s, 2H), 4.37-4.31 (m, 1H), 4.07 (q, J = 7.2 Hz, 2H), 3.55-3.43 (m, 2H), 3.47 (d, J = 22.0 
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Hz, 1H), 3.19 (dd, J = 20.0, 4.0 Hz, 1H), 2.93 (d, J = 18.4 Hz, 2H), 2.91 (d, J = 16.8 Hz, 1H), 
1.21 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 8.0 Hz, 9H), 0.57 (q, J = 7.6 Hz, 6H); 13C NMR (125 
MHz, CDCl3): δ 209.4, 169.2, 168.7, 138.1, 134.4, 128.6, 128.5, 128.4, 128.3, 127.6, 127.5, 
83.7, 73.3, 73.2, 68.0, 66.6, 60.9, 42.4, 41.8, 14.0, 6.7, 5.7;  LRMS (ESI+) Calcd. for 
C30H42O8Si+Na, 581.3; Found, 581.2; IR (thin film, cm
-1) 3459, 3065, 3032, 2955, 2876, 2360, 
1737, 1455, 1213, 1117, 1021, 736;  TLC(75:25 Hex:EtOAc): Rf = 0.29. 
 
1-benzyl 4-ethyl 2-(4-((tert-butyldiphenylsilyl)oxy)-3-hydroxybutanoyl)-2-
((triethylsilyl)oxy)succinate (1.29f): The title compound was prepared according to General 
Procedure B using LiCl (38 mg, 0.9 mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 
1.0 equiv), and (S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)oxetan-2-one (1.19d, 98 mg, 0.29 
mmol, 1.6 equiv). Purification via flash chromatography (93.5:7.5 to 85:15 petroleum ether: 
diethyl ether) provided the desired product as a light yellow oil with > 20:1 diastereomeric 
ratio (77 mg, 60%). Analytical data: 1H NMR  (500 MHz, CDCl3): δ 7.68-7.66 (m, 4H), 7.49-
7.29 (m, 11H), 5.18 (d, J = 12.0 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 4.27-4.25 (m, 1H), 4.08-
4.03 (m, 2H), 3.66-3.65 (m, 2H), 3.47 (d, J = 17.0 Hz, 1H), 3.25 (dd, J = 18.0, 3.0 Hz, 1H), 
2.97-2.88 (m, 3H), 1.19 (t, J = 7.0 Hz, 3H), 1.06 (s, 9H), 0.89 (t, J = 8.0 Hz, 9H), 0.59-0.55 
(m, 6H); 13C NMR (125 MHz, CDCl3): δ 209.4, 169.2, 168.8, 135.6, 135.5, 134.5, 133.3, 
133.2, 129.7, 128.6, 128.5, 128.4, 127.7, 127.6, 83.8, 68.0, 67.9, 67.0, 60.9, 42.4, 41.8, 26.8, 
19.2, 14.1, 6.8, 5.7;  LRMS (ESI+) Calcd. for C39H54O8Si2+Na, 729.3; Found, 729.3; IR (thin 
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film, cm-1) 3458, 2957, 2877, 2360, 2341, 1738, 1456, 1428, 1213, 1113, 740, 700;  
TLC(75:25 Hex:EtOAc): Rf = 0.42. 
General Procedure C for the Reformatsky Initiated Cascade Coupling of Silyl Glyoxylate 
and -Lactams Affording -aminoketones 1.29k-1.29l 
 
 
To an oven-dried 20-mL scintillation vial was added LiCl (38 mg, 0.9 mmol, 5 equiv). The 
vial was purged with nitrogen, and a solution of Reformatsky reagent (0.38 M, 1.09 mL, 2.3 
equiv) was added. The resulting suspension was diluted with diethyl ether (1.0 mL) and cooled 
to -30 °C in an acetone/dry ice bath (bath temperature, monitored with a thermocouple probe). 
A second oven-dried vial was charged with silyl glyoxylate 1.21 (50 mg, 0.18 mmol, 1.0 equiv) 
and purged with nitrogen, and diethyl ether (0.5 mL) was added. The resulting solution was 
added to the solution of Reformatsky reagent. The reaction was allowed to warm slowly in the 
acetone bath. Once consumption of the silyl glyoxylate was observed by TLC analysis and 
disappearance of yellow color, generally between -30 °C and -25 °C, a cooled solution of the 
-Lactam (1.20b-1.20c, 0.29 mmol, 1.6 equiv) in CH2Cl2 (1.0 mL) was added. The reaction 
was then allowed to warm to 0 °C, where it was held until judged complete by TLC analysis, 
generally 30 min. Saturated ammonium chloride (0.5 mL) was then added to quench the 
reaction, and it was stirred until clear layers were observed.  The organic layer was removed, 
and the aqueous layer was extracted with diethyl ether (3x1.0 mL).  The combined organic 
48 
extracts were washed with brine, dried with magnesium sulfate, and concentrated in vacuo. 
The crude product was purified via flash chromatography to give the desired product. 
 
1-benzyl 4-ethyl 2-(3-((tert-butoxycarbonyl)amino)-3-phenylpropanoyl)-2-
((triethylsilyl)oxy)succinate (1.29k): The title compound was prepared according to General 
Procedure C using LiCl (38 mg, 0.9 mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 
1.0 equiv), and tert-butyl 2-oxo-4-phenylazetidine-1-carboxylate (1.20b, 71 mg, 0.29 mmol, 
1.6 equiv). Purification via flash chromatography (92.5:7.5 hexanes: ethyl acetate) provided 
the desired product as a light yellow oil (62 mg, 56%), which was a 1:1 mixture of separable 
diastereomers. Analytical data: 1H NMR  (400 MHz, CDCl3): (Diastereomer 1) δ 7.35-7.19 
(m, 10H), 5.52 (br s, 1H), 5.11 (br s, 1H), 5.05-4.90 (m, 2H), 4.05 (q, J = 7.2 Hz, 2H), 3.47-
3.28 (m, 3H), 2.86 (d, J = 16.8 Hz, 1H), 1.41 (s, 9H), 1.20 (t, J = 6.8 Hz, 3H), 0.88 (t, J = 8.0 
Hz, 9H), 0.55-0.51 (m, 6H); (Diastereomer 2) δ 7.35-7.20 (m, 10H), 5.44 (br s, 1H), 5.10-5.02 
(m, 2H), 4.10-4.08 (m, 2H), 3.54-3.41 (m, 2H), 3.05-2.93 (m, 1H), 2.87 (d, J = 20.0 Hz, 1H), 
1.38 (br s, 9H), 1.22 (t, J = 7.2 Hz, 3H), 0.86 (t, J = 8.0 Hz, 9H), 0.56-0.54 (m, 6H); 13C NMR 
(125 MHz, CDCl3), major diastereomer: δ 207.0, 168.9, 168.6, 155.2, 134.4, 128.6, 128.5, 
128.3, 126.8, 126.1, 83.8, 79.3, 68.0, 60.9, 50.1, 43.2, 42.0, 28.3, 14.0, 6.8, 5.7;  LRMS (ESI+) 
Calcd. for C33H47NO8Si+Na, 636.3; Found, 636.3; IR (thin film, cm
-1) 3417, 2959, 2877, 2086, 
1641, 1495, 1455, 1367, 1343, 1167, 1018, 734, 698;  TLC(75:25 Hex:EtOAc): Rf = 0.34. 
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1-benzyl 4-ethyl 2-(3-(4-methylphenylsulfonamido)-3-phenylpropanoyl)-2-
((triethylsilyl)oxy)succinate (1.29l): The title compound was prepared according to General 
Procedure C using LiCl (38 mg, 0.9 mmol, 5 equiv), silyl glyoxylate (1.21, 50 mg, 0.18 mmol, 
1.0 equiv), and 4-phenyl-1-tosylazetidin-2-one (1.20c, 87 mg, 0.29 mmol, 1.6 equiv). 
Purification via flash chromatography (CH2Cl2) provided the desired product as a light yellow 
oil (64 mg, 53%), which was a 1:1 mixture of separable diastereomers. Analytical data: 1H 
NMR  (400 MHz, CDCl3): (Diastereomer 1) δ 7.56 (d, J = 8.0 Hz, 2H), 7.33-7.31 (m, 3H), 
7.22-7.12 (m, 9H),  5.56 (d, J = 6.4 Hz, 1H), 4.99 (d, J = 12.4 Hz, 1H), 4.94 (d, J = 12.0 Hz, 
1H), 4.68 (q, J = 6.0 Hz, 1H), 4.03 (q, J = 6.8 Hz, 2H), 3.37 (dd, J = 18.8, 6.4 Hz, 1H), 3.31 
(d, J = 16.8 Hz, 1H), 3.18 (dd, J = 18.8, 4.8 Hz, 1H), 2.81 (d, J = 16.8 Hz, 1H), 2.34 (s, 3H), 
1.18 (t, J = 7.2 Hz, 3H), 0.82 (t, J = 7.6 Hz, 9H), 0.48 (q, J = 8.0 Hz, 6H); (Diastereomer 2) δ 
7.52 (d, J = 8.4 Hz, 2H), 7.32-7.30 (m, 3H), 7.22-7.12 (m, 9H),  5.58 (d, J = 3.6 Hz, 1H), 5.05-
4.95 (m, 2H), 4.71-4.66 (m, 1H), 4.10 (q, J = 6.8 Hz, 2H), 3.60 (dd, J = 18.8, 8.8 Hz, 1H), 3.38 
(d, J = 17.2 Hz, 1H), 2.88-2.79 (m, 2H), 2.34 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 0.81 (t, J = 7.6 
Hz, 9H), 0.47 (q, J = 7.6 Hz, 6H); 13C NMR (100 MHz, CDCl3), mixture of diastereomers: δ 
206.7, 206.5, 169.7, 169.0, 168.5, 142.9, 142.8, 140.7, 140.1, 134.4, 129.3, 129.1, 128.7, 128.6, 
128.5, 128.3, 128.2, 127.4, 127.3, 126.9, 126.7, 83.8, 83.5, 68.1, 68.0, 61.4, 61.0, 53.7, 53.4, 
44.8, 44.1, 42.8, 42.1, 21.4, 14.0, 6.7, 6.6, 5.8, 5.7;  LRMS (ESI+) Calcd. for 
C35H45NO8SSi+Na, 690.3; Found, 690.2; IR (thin film, cm
-1) 3436, 3033, 2957, 2877, 1737, 
1455, 1372, 1333, 1213, 1160, 1020, 739, 699, 666;  TLC(75:25 Hex:EtOAc): Rf = 0.22. 
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Stereochemical Analysis of -hydroxyketone Products: 
Calculation of Diastereomeric Ratios: 
A sample calculation of 
diastereomeric ratio is 
shown at right for 1.29h. 
The relative integration 
of the methyl groups of 
the two diastereomers in 
the crude reaction 
mixture is shown to be 
5:1. 
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Determination of Relative Stereochemistry: 
 
(S)-1-benzyl 4-ethyl 2-((tert-butyldimethylsilyl)oxy)-2-((1S,3S)-1,3-dihydroxy-5-
(trimethylsilyl) pent-4-yn-1-yl)succinate (1.25):  An oven-dried 20-mL scintillation vial 
equipped with a magnetic stir bar was charged with MeCN (1 mL), Me4NHB(OAc)3 (147 mg, 
0.56 mmol, 5.0 equiv), and dry HOAc (0.45 mL).  The resulting solution was cooled to -35 °C 
in a Cryocool apparatus.  A solution of ketone 1.24 (46 mg, 0.112 mmol, 1.0 equiv) in MeCN 
(1 mL) was added to the reaction dropwise, and additional MeCN (0.5 mL) was used to rinse 
the vial.  The reaction was allowed to warm to -25 °C and was maintained at the same 
temperature for 60 h.  The reaction was quenched by the addition of a 25% saturated aqueous 
solution of sodium potassium tartrate (0.3 mL) and was allowed to warm slowly to room 
temperature.  A saturated aqueous solution of NaHCO3 was added until the pH of the reaction 
was neutral. The resulting suspension was extracted with CH2Cl2.  The combined organic 
extracts were washed with saturated aqueous NaHCO3, dried with MgSO4, and concentrated 
in vacuo to afford a colorless oil.  The material was purified via column chromatography, 
eluting with 80:20 hexanes:EtOAc, to give the title compound as a viscous light yellow oil 
with >25:1 diastereomeric ratio.  Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.43-7.26 
(m, 5H), 5.22 (d, J = 12.0 Hz, 1H), 5.18 (d, J = 12.4 Hz, 1H), 4.61 (br. s, 1H), 4.32 (dd, J = 
9.2, 8.4 Hz, 1H), 4.06 (q, J = 7.2 Hz, 2H), 3.13 (d, J = 7.2 Hz, 1H), 3.01 (d J = 7.2 Hz, 1H), 
2.93 (d, J = 15.2 Hz, 1H), 2.86 (d, J = 15.2 Hz, 1H), 1.88 (ddd, J = 17.6, 14.4, 3.2 Hz, 1H), 
1.67 (dd, J = 14.4, 6.4 Hz, 1H), 1.20 (t, J = 7.2 Hz, 3H) 0.85 (s, 9H), 0.16 (s, 9H), 0.15 (s, 3H), 
0.09 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 172.0, 170.3, 135.3, 128.7, 128.6, 128.5, 106.2, 
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89.9, 80.7, 73.6, 67.6, 61.0, 60.9, 41.7, 37.8, 25.9, 18.7, 14.0, -0.1, -2.9, -3.1; LRMS (ESI+) 
Calcd. for C27H44O7Si2+Na, 559.2; Found, 559.2; IR (thin film, cm
-1): 3853, 2089, 1647, 1541, 
1457, 1250, 1175, 1031, 521, 509, 496;  TLC(80:20 Hexanes:EtOAc): Rf = 0.38. 
 
(2S,3S)-benzyl 3-((tert-butyldimethylsilyl)oxy)-2-((S)-2-hydroxy-4-(trimethylsilyl)but-3-
yn-1-yl)-5-oxotetrahydrofuran-3-carboxylate (1.27):  An oven-dried and cooled vial 
equipped with a magnetic stir bar was charged with diol 1.25 (12 mg, 0.022 mmol) and toluene 
(0.75 mL).  TsOH (cat.) was added, and the vial was sealed with a Teflon-lined cap.  The 
solution was heated to 80 °C in a sand bath for 1 h.  After cooling to rt, the solvent was removed 
in vacuo, and the crude residue was purified via column chromatography, eluting with 80:20 
hexanes:EtOAc.  The title compound was obtained as a colorless oil (5 mg, 45%). Analytical 
data: []D25.4 -17.3 (c 0.23, CHCl3); 1H NMR  (500 MHz, CDCl3): δ 7.37 (br. s., 5H), 5.23 (d, 
J = 12.0 Hz, 1H), 5.18 (d, J = 12.0 Hz, 1H), 4.86 (dd, J = 9.5, 3.0 Hz, 1H), 4.53 (br. s., 1H), 
3.30 (d, J = 17.5 Hz, 1H), 2.66 (d, J = 17.0 Hz, 1H), 2.187 (ddd, J = 14.5, 9.5, 3.5 Hz, 1H), 
2.00 (ddd, J = 12.5, 9.0, 3.0 Hz, 1H), 1.92 (d, J = 5.5, 1H) 0.85 (s, 9H), 0.17 (s, 9H), 0.08 (s, 
3H), 0.04 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 172.7, 170.1, 128.8, 90.4, 83.3, 81.0, 68.3, 
59.4, 42.6, 36.8, 25.6, -0.2, -3.5, -3.7;  LRMS (ESI+) Calcd. for C25H38O6Si2+Na, 513.2; 
Found, 513.2; IR (thin film, cm-1) 3433, 3021, 2961, 2330, 2089, 1646, 1361, 1215, 775, 668;  
TLC(80:20 Hexanes:EtOAc): Rf = 0.40.   
Spectral analysis (NOESY) supported the structural assignment shown for 1.27:  A 
strong nOe was observed between the C2 methine CH and the -CH at C4 as well as 
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between the C2 methine CH and the CO2CH2Ph benzyl protons (interactions A and C, 
respectively).  Additionally, an nOe was observed between the -CH at C4 and the methyl 
and tert-butyl substituents of the TBS ether, which suggested their relative syn orientation 
(interaction B). 
  
 
(S)-1-benzyl 4-ethyl 2-((tert-butyldimethylsilyl)oxy)-2-((1R,3S)-1,3-dihydroxy-5-
(trimethylsilyl)pent-4-yn-1-yl)succinate (1.26): The title compound was prepared 
analogously to 1.22a (vide infra).  Yield = 95%, > 25:1 dr.  Analytical data: 1H NMR  (400 
MHz, CDCl3): δ 7.34 (br. s, 5H), 5.19 (s, 2H), 4.58 (br. s, 1H), 4.09-3.95 (m, 1H), 4.07 (t, J = 
7.6 Hz, 2H), 2.96 (br. s, 1H), 2.72 (d J = 15.2 Hz, 1H), 1.95 (dd, J = 13.6, 6.4 Hz, 1H), 1.77 
(dd, J = 17.6, 10 Hz, 1H), 1.19 (t, J = 7.2 Hz, 3H), 0.85 (s, 9H), 0.17 (s, 3H), 0.14 (s, 9H), 0.10 
A 
B 
 C 
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(s, 3H); 13C NMR (100 MHz, CDCl3): δ 172.0, 169.8, 135.0, 128.5, 128.5, 128.4, 105.7, 89.7, 
80.8, 75.2, 67.5, 61.7, 60.8, 41.3, 38.7, 25.9, 18.7, 13.9, -0.3, -2.9, -3.2;  LRMS (ESI+) Calcd. 
for C27H44O7Si2+Na, 559.3; Found, 559.2; IR (thin film, cm
-1): 3436, 2957, 2856, 2360, 1739, 
1637, 1457, 1372, 1251, 1188, 1112, 840;  TLC(80:20 Hexanes:EtOAc): Rf = 0.38. 
 
(3aS,6S,7aR)-3a-((tert-butyldimethylsilyl)oxy)-6-((trimethylsilyl)ethynyl)tetrahydro-2H-
furo[3,2-c]pyran-2,4(6H)-dione (1.28):  An oven-dried and cooled vial equipped with a 
magnetic stir bar was charged with diol 1.26 (15 mg, 0.0275 mmol) and toluene (1 mL).  TsOH 
(cat.) was added, and the vial was sealed with a Teflon cap.  The solution was heated to 80 °C 
in a sand bath for 1 h.  After cooling to rt, the solvent was removed in vacuo, and the crude 
residue was purified via column chromatography, eluting with 10:90 to 20:80 EtOAc: hexanes.  
The title compound was obtained as a colorless oil (6.4 mg, 60%).  Analytical data: []D25.1 -
13.1 (c 0.15, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 5.15 (dd, J = 7.2, 3.6 Hz, 1H), 4.89 (dd, 
J = 6.8, 4.8 Hz, 1H), 2.94 (d, J = 18.4 Hz, 1H), 2.81 (d, J = 18.0 Hz, 1H), 2.48 (ddd, J = 12.4, 
7.6, 4.8 Hz, 1H), 2.26 (ddd, J = 10.4, 7.2, 3.6 Hz, 1H), 0.88 (s, 9H), 0.26 (s, 3H), 0.19 (s, 9H), 
0.14 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 171.6, 169.1, 98.5, 95.1, 82.6, 76.3, 65.8, 42.0, 
34.0, 25.5, 18.1, -0.5, -3.5, -3.7;  LRMS (ESI+) Calcd. for C18H30O5Si2+Na, 405.2; Found, 
405.2; IR (thin film, cm-1) 3433, 3019, 1645, 1215, 771, 669;  TLC(80:20 Hexanes:EtOAc): 
Rf = 0.50.  
 Spectral analysis (HMBC, NOESY) supported the stereochemical assignment shown 
for compound 1.28:  The NOESY spectrum shows an nOe between the methine C–H at C6 and 
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the -C–H  at C3 (interaction A), which suggests their orientation on the concave face of the 
bicycle.  Additionally, both the -C3 CH proton on the convex face of the bicycle and the 
C7a methine CH show an nOe with the tert-butyl group of the TBS ether, which suggests 
their mutual orientation on the convex face of the molecule (interactions D and C).  The 
assignment of the C7a and C6 methine CH protons was a result of the observation of a mutual 
correlation between the latter and the TMS methyl groups with the distal alkyne carbon 
(indicated by interactions E and F) in the HMBC spectrum. 
NOESY          HMBC  
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Diester Functionalization of -hydroxyketone Products: 
 
(S)-1-benzyl 4-ethyl 2-((1R,3S)-1,3-dihydroxy-5-(trimethylsilyl)pent-4-yn-1-yl)-2-
((triethylsilyl)oxy)succinate (1.22a): A flame-dried and N2-purged 500-mL round-bottomed 
flask was charged with ketone 1.22 (6.0 g, 11.2 mmol, 1.0 equiv).  Tetrahydrofuran (200 mL) 
and methanol (50 mL) were added.  The solution was cooled to -78 °C (acetone/dry ice), and 
diethylmethoxyborane (1 M in tetrahydrofuran, 14.6 mL, 14.6 mmol) was added dropwise.  
After stirring for 45 minutes at -78 °C, sodium borohydride (1.27 g, 33.7 mmol, 3.0 equiv) was 
added in one portion and the reaction was maintained at the same temperature.  Once TLC 
analysis indicated complete consumption of the starting material (3.5 h), the reaction was 
quenched with acetic acid (9.0 mL).  After warming to room temperature, the reaction was 
stirred for 1.5 h and was then concentrated in vacuo.  Methanol (30 mL) was added, and the 
solution was again concentrated in vacuo; this procedure was repeated with four additional 
portions of methanol (30 mL).  The residue was partitioned between ethyl acetate and saturated 
sodium bicarbonate, and the organic layer was washed with saturated sodium bicarbonate, 
water, and brine.  The organic extracts were dried with magnesium sulfate and concentrated in 
vacuo to give a light yellow viscous oil (5.7 g, 95%) that was used without additional 
purification.  Analytical data: []D25.2 -1.74 (c 1.25, CHCl3); 1H NMR  (500 MHz, CDCl3): δ 
7.36-7.33 (m, 5H), 5.20 (s, 2H), 4.60 (br. s., 1H), 4.10-3.99 (m, 3H), 3.05 (d, J = 6.0 Hz, 1H), 
2.87 (d, J = 4.0 Hz, 1H), 2.83 (d, J = 9.0 Hz, 2H), 1.98 (dd, J = 13.5, 5.5 Hz, 1H), (dd, J = 
10.5, 2.5 Hz, 1H), 1.21 (t, J = 7.0 Hz, 3H), 0.91 (t, J = 8.0 Hz, 9H), 0.67-0.62 (m, 6H), 0.15 (s, 
9H); 13C NMR (100 MHz, CDCl3): δ 172.1, 169.9, 135.0, 128.6, 128.5, 128.4, 105.6, 89.7, 
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80.6, 75.3, 67.6, 62.1, 60.9, 41.2, 38.7, 14.0, 7.1, 6.4, -0.2;  LRMS (ESI+) Calcd. for 
C27H44O7Si2+Na, 559.3; Found, 559.3; IR (thin film, cm
-1) 3470, 2957, 2876, 2172, 1740, 
1185, 1022, 844, 734;  TLC(80:20 Hex:EtOAc): Rf = 0.21. 
 
 
(S)-1-benzyl-4-ethyl-2-((4R,6S)-2,2-dimethyl-6-((trimethylsilyl)ethynyl)-1,3-dioxan-4-
yl)-2-((triethylsilyl)oxy) succinate (1.32)  A 500-mL round-bottomed flask was charged with 
diol 1.22a (11.0 g, 20.6 mmol, 1.0 equiv), acetone (250 mL) and 2,2-dimethoxypropane (250 
mL).  CSA (0.716 g, 3.09 mmol, 0.15 equiv) was added, and the reaction was allowed to stir 
at room temperature for 16 h.  The reaction was quenched by the addition of 0.5 mL of 
triethylamine and was concentrated in vacuo.  The residue was purified via column 
chromatography (90:10 hexanes: ethyl acetate) to give the product as a white solid (8.6 g, 
73%).  Analytical data: []D25.4 -13.96 (c 1.5, CHCl3); melting point: 75-79 °C; 1H NMR  (500 
MHz, CDCl3): δ 7.35-7.33 (m, 5H), 5.30 (d, J = 12.5 Hz, 1H), 5.05 (d, J = 12.0 Hz, 1H), 4.62 
(dd, J = 12.0, 2.5 Hz, 1H), 4.12-4.06 (m, 3H), 2.74 (d, J = 14.5 Hz, 1H), 2.65 (d, J = 14.0 Hz, 
1H), 1.88-1.60 (m, 2H), 1.33 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H), 1.19 (s, 3H), 0.95 (t, J = 16.0 
Hz, 9H), 0.74-0.65 (m, 6H), 0.17 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 171.6, 169.4, 135.6, 
128.7, 128.4, 128.3, 103.7, 99.6, 89.4, 80.2, 72.9, 67.0, 60.7, 60.5, 41.9, 30.8, 29.5, 18.8, 14.0, 
7.3, 6.7, -0.21;  LRMS (ESI+) Calcd. for C30H48O7Si2+Na, 599.3; Found, 599.3; IR (thin film, 
cm-1) 2956, 2875, 2181, 1739, 1457, 1379, 1251, 1163, 844, 734;  TLC(80:20 Hex:EtOAc): 
Rf = 0.30. 
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Benzyl 2-(2,2-dimethyl-6-((trimethylsilyl)ethynyl)-1,3-dioxan-4-yl)-4-hydroxy-2-
((triethylsilyl)oxy)butanoate  (1.33): An oven-dried and cooled 20-mL scintillation vial was 
charged with diester 1.32 (95 mg, 0.164 mmol, 1.0 equiv) and THF (4 mL).  The resulting 
solution was cooled to -78 °C, and a solution of DIBAL-H (1.46 mL, 0.562 M in THF, 0.820 
mmol, 5.0 equiv) was added dropwise.  When the addition of DIBAL-H was complete, the 
reaction was maintained at -78 °C for 20 min then was allowed to warm to 0 °C  for 30 min.  
The reaction was quenched by the addition of saturated aqueous sodium potassium tartrate (3 
mL) and was diluted with Et2O (5 mL).  The resulting biphasic mixture was stirred vigorously 
until clear layers were observed.  Additional diethyl ether was added, and the layers were 
separated.  The aqueous layer was extracted with Et2O (3x 5 mL), and combined organic 
extracts were washed with water and brine, dried (MgSO4), and concentrated in vacuo to give 
a light yellow oil, which was purified via column chromatography, eluting with 70:30 hexanes: 
EtOAc , to afford the title compound as a colorless oil (52 mg, 60%). Analytical data: 1H NMR  
(500 MHz, CDCl3): δ 7.38-7.33 (m, 5H), 5.32 (d, J = 12.0 Hz, 1H), 4.99 (d, J = 12.0 Hz, 1H),  
4.63 (dd, J = 12.0, 3.0 Hz, 1H), 4.11 (dd, J = 12.0, 2.5 Hz, 1H), 3.71-3.68 (m, 2H), 1.92-1.87 
(m, 4H), 1.67 (dt, J = 13.0, 2.5 Hz, 1H), 1.32 (s, 3H), 1.19 (s, 3H), 0.97 (t, J = 8.0 Hz, 9H), 
0.81-0.75 (m, 6H), 0.16 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 173.1, 135.5, 128.8, 128.5, 
128.4, 103.7, 99.5, 89.4, 81.7, 73.0, 67.0, 60.5, 58.7, 38.5, 30.6, 29.4, 18.8, 7.3, 6.8, -0.2; 
LRMS (ESI+) Calcd. for C28H48O6Si2+Cs, 667.2; Found, 667.2; IR (thin film, cm
-1) 3432, 
2958, 2911, 2875, 2248, 2181, 1752, 1641, 1457, 1381, 1251, 1194, 1160, 1112, 909, 845, 
732;  TLC(75:25 Hex:EtOAc): Rf = 0.23. 
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(R)-2-((4R,6S)-2,2-dimethyl-6-((trimethylsilyl)ethynyl)-1,3-dioxan-4-yl)-2-((triethylsilyl) 
oxy)butane-1,4-diol (1.34):  A flame-dried and cooled 1L round-bottomed flask was charged 
with acetonide 1.32 (5.0 g, 8.7 mmol, 1.0 equiv).  The flask was purged with N2, and CH2Cl2 
(500 mL) was added.  The solution was cooled to -30 °C, and lithium triethylborohydride (1M 
in THF, 57 mmol, 57 mL) was added dropwise over 15 min via syringe pump.  The reaction 
temperature was maintained for 2 h, at which point the temperature was increased to -20 °C 
for 1 h.  The reaction was quenched by the dropwise addition of HOAc (8 mL) and MeOH (30 
mL).  The resulting suspension was warmed to room temperature and concentrated in vacuo, 
keeping the bath temperature at or below 30 °C to avoid migration of the triethylsilyl group.  
The residue was redissolved in MeOH (30 mL) and concentrated in vacuo an additional four 
times.  The residue was partitioned between ethyl acetate and saturated aqueous sodium 
bicarbonate, and the organic extracts were washed successively with saturated sodium 
bicarbonate (x2), water, and brine.  The combined organic extracts were dried with sodium 
sulfate and concentrated in vacuo.  The resulting crude oil was purified via column 
chromatography, eluting with a gradient of 80:20 to 70:30 hexanes: ethyl acetate to give the 
desired diol as a white solid (2.1 g, 56%).  Analytical data: []D25.2 -2.82 (c 1.8, CHCl3); 1H 
NMR  (500 MHz, CDCl3): δ 4.67 (dd, J = 11.5, 2.5 Hz, 1H), 3.93 (dd, J = 11.5, 2.5 Hz, 1H), 
3.86-3.73 (m, 3H), 3.50 (dd, J = 11.0, 3.0 Hz, 1H), 2.83 (s, 1H), 2.65 (s, 1H), 1.98-1.70 (m, 
4H), 1.46 (s, 6H), 0.95 (t, J = 3.5 Hz, 9H), 0.74-0.65 (dq, J = 16.0, 3.0 Hz 6H), 0.17 (s, 9H); 
13C NMR (100 MHz, CDCl3): δ 103.7, 99.6, 89.6, 78.0, 73.2, 65.6, 60.9, 58.3, 37.7, 31.3, 29.9, 
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19.2, 7.1, 6.8, -0.2; LRMS (ESI+) Calcd. for C21H42O5Si2+Na, 453.3; Found, 453.4; IR (thin 
film, cm-1) 3389, 2956, 2876, 2183, 1739, 1460, 1380, 1250, 1161, 1055, 844, 733;  
TLC(75:25 Hex:EtOAc): Rf = 0.09. 
 
Leustroducsin B Synthesis: 
 
(S)-4-((tert-butyldimethylsilyl)oxy)-2-((4R,6S)-2,2-dimethyl-6-((trimethylsilyl)ethynyl)-
1,3-dioxan-4-yl)-2-((triethylsilyl)oxy)butanal (1.35): A 100-mL oven-dried round bottomed 
flask was charged with diol 1.34 (0.840 g, 1.95 mmol, 1.0 equiv) and CH2Cl2 (60 mL).  The 
solution was cooled to 0 °C, and triethylamine (0.540 mL, 3.9 mmol, 2.0 equiv), tert-
butyldimethylsilyl chloride (0.339 g, 2.25 mmol, 1.15 equiv), and DMAP (0.071 g, 0.585 
mmol, 0.3 equiv) were added successively.  The reaction was allowed to warm slowly to room 
temperature over 1 h. Once TLC analysis indicated complete consumption of the starting 
material (5 h), the reaction was quenched by the addition of 5 mL of saturated aqueous sodium 
bicarbonate.  The organic layer was washed with saturated NaHCO3, water, and brine and was 
then dried with sodium sulfate.  After concentration in vacuo, the resulting oil was used without 
further purification: 
 The unpurified oil was dissolved in dry CH2Cl2 (30 mL) in an oven-dried 250-mL 
round-bottomed flask, and Dess-Martin Periodinane (1.32 g, 3.12 mmol, 1.6 equiv) was added 
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in one portion at room temperature.  The reaction was stirred at the same temperature under an 
N2 atmosphere.  Once TLC analysis indicated complete consumption of the monoalcohol (1.5 
h), the reaction was diluted with diethyl ether (30 mL).  Saturated aqueous sodium bicarbonate 
(20 mL) and saturated aqueous sodium thiosulfate (20 mL) were added, and biphasic mixture 
was stirred vigorously for 15 minutes.  After partitioning the layers, the aqueous layer was 
extracted with diethyl ether (3x10 mL), and the combined organic extracts were washed with 
water and brine and dried with sodium sulfate.  The combined extracts were concentrated in 
vacuo to give an oil that was purified via column chromatography (95:5 hexanes: ethyl acetate) 
to give the desired product 1.35 as a colorless oil (0.880 g, 83% over two steps).   
Mono alcohol 1.34a: Analytical data: []D25.6 -7.1 (c = 2.15, CHCl3); 1H NMR  (500 MHz, 
CDCl3): δ 4.66 (dd, J = 12.0, 3.0 Hz, 1H), 3.90 (dd, J = 12.0, 2.5 Hz, 1H), 3.88-3.80 (m, 1H), 
3.75-3.65 (m, 2H), 3.48-3.39 (m, 2H), 1.87-1.64 (m, 4H), 1.45 (s, 6H), 0.94 (t, J = 8.0 Hz, 9H), 
0.90 (s, 9H), 0.71-0.56 (m, 6H), 0.17 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 104.1, 99.4, 89.1, 78.3, 72.1, 64.7, 60.9, 58.7, 37.4, 31.0, 29.9, 25.8, 19.3, 18.1, 7.2, 
6.8, -0.2, -5.6;  HRMS (ESI+) Calcd. for C27H56O5Si3+Cs, 677.2491; Found, 677.2477; IR 
(thin film, cm-1) 3492, 2955, 2877, 2360, 2183, 1463, 1414, 1251, 1107, 841, 736;  TLC(85:15 
Hex:EtOAc): Rf = 0.54.  
Aldehyde 1.35:  Analytical data: []D25.2 -15.0 (c = 1.25, CHCl3); 1H NMR  (400 MHz, 
CDCl3): δ 9.56 (s, 1H), 4.68 (dd, J = 12.0, 2.8 Hz, 1H), 4.13 (dd, J = 12.0, 2.8 Hz, 1H), 3.74 
(ddd, J = 12.0, 4.0, 2.8 Hz, 1H), 3.62 (ddd, J = 12.0, 4.0, 2.8 Hz, 1H), 1.90-1.65 (m, 4H), 1.40 
(s, 3H), 1.39 (s, 3H), 0.98 (t, J = 8.0 Hz, 9H), 0.86 (s, 9H), 0.81-0.66 (m, 6H), 0.17 (s, 9H), 
0.02 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 203.2, 103.9, 99.5, 89.4, 83.7, 72.3, 60.7, 57.8, 
38.7, 30.9, 29.6, 25.8, 19.1, 18.1, 7.2, 6.9, -0.2, -5.5, -5.6;  HRMS (ESI+) Calcd. for 
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C27H54O5Si3+Cs, 675.2352; Found, 675.2354; IR (thin film, cm
-1) 2955, 2876, 2360, 2342, 
1736, 1462, 1415, 1380, 1251, 1110, 842, 738;  TLC(85:15 Hex:EtOAc): Rf = 0.67.   
 
(R,E)-6-((tert-butyldimethylsilyl)oxy)-4-((4R,6S)-2,2-dimethyl-6-
((trimethylsilyl)ethynyl)-1,3-dioxan-4-yl)-4-((triethylsilyl)oxy)hex-2-enenitrile (1.35a):  A 
flame-dried 25-mL round-bottomed flask was charged with the Horner-Wadsworth-Emmons 
reagent (0.320 g, 1.81 mmol, 1.05 equiv).  THF (11.0 mL) was added and the solution was 
cooled to 0 °C.  n-Butyllithium (1.2 mL, 1.5 M in hexanes, 1.05 equiv) was added dropwise, 
and the resulting orange solution was stirred for 1 h at the same temperature.  A second flame-
dried 100-mL round-bottomed flask was charged with the aldehyde (1.35) (0.917 g, 1.69 
mmol, 1.0 equiv) and THF (25 mL).  The aldehyde solution was cooled to 0 °C, and the solution 
of the metalated Horner-Wadsworth-Emmons reagent was added via cannula.  After the 
addition was complete, the reaction was warmed to room temperature for 30 minutes, at which 
point the starting material had been completely consumed as indicated by TLC analysis.  The 
reaction was quenched by the addition of saturated ammonium chloride (0.3 mL), and the 
resulting suspension was concentrated to approximately 3 mL in vacuo.  The remaining 
suspension was loaded directly onto a short silica plug and eluted with 95:5 hexanes: ethyl 
acetate to give the desired nitrile (0.920 g, 96%) with greater than 25:1 diastereoselectivity for 
the (E)-isomer.  Analytical data: []D25.7 +2.9 (c = 0.50, CHCl3); 1H NMR  (400 MHz, CDCl3): 
δ 6.81 (d, J = 16.0 Hz, 1H), 5.61 (d, J = 16.0 Hz, 1H), 4.60 (dd, J = 11.6, 2.0 Hz, 1H), 3.70 
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(dd, J = 10.8, 2 Hz, 1H), 2.14 (ddd, J = 21.2, 14.4, 7.2 Hz, 1H), 1.81 (ddd, J = 19.6, 13.6, 6.8 
Hz, 1H), 1.70 (d, J = 12.8 Hz, 1H), 1.55-1.46 (m, 1H), 1.44 (s, 3H), 1.43 (s, 3H), 0.98 (t, J = 
7.6 Hz, 9H), 0.89 (s, 9H), 0.65 (q, J = 8.0 Hz, 6H), 0.18 (s, 9H), 0.04 (s, 6H); 13C NMR (100 
MHz, CDCl3): δ 156.8, 117.6, 103.2, 99.5, 99.2, 89.8, 79.1, 74.2, 60.6, 58.3, 40.3, 32.0, 29.8, 
25.9, 19.1, 18.2, 7.1, 6.7, -0.2, -5.3, -5.4; HRMS (ESI+) Calcd. for C29H55NO4Si3+Cs, 
698.2494; Found, 698.2470; IR (thin film, cm-1) 2956, 2878, 2224, 1461, 1379, 1251, 1106, 
840, 740;  TLC(90:10 Hex:EtOAc): Rf = 0.46. 
 
(R,E)-6-((tert-butyldimethylsilyl)oxy)-4-((4R,6S)-2,2-dimethyl-6-
((trimethylsilyl)ethynyl)-1,3-dioxan-4-yl)-4-((triethylsilyl)oxy)hex-2-enal (1.36):  A 50-
mL oven dried and cooled round-bottomed flask was charged with the nitrile 1.35a (0.920 g, 
1.63 mmol, 1.0 equiv), and the flask was purged with N2.  Dry toluene (20 mL) was added, 
and the resulting solution was cooled to -78 °C in an acetone/dry ice bath.  A solution of 
DIBAL-H (0.56 M in toluene, 4.9 mL, 1.7 equiv) was added dropwise, and the reaction was 
stirred at the same temperature for 1.5 h.  Methanol (2.5 mL) was added at -78 °C, and the 
solution was warmed to 0 °C.  Ice cold 1M HCl (20 mL) was added, and the biphasic mixture 
was stirred vigorously for 10 min at room temperature.  Diethyl ether (20 mL) was added and 
the layers were separated.  The aqueous layer was extracted with additional ether (3x5 mL), 
and the combined organic extracts were washed with saturated sodium bicarbonate, water, and 
brine and dried with magnesium sulfate.  The dried extracts were concentrated in vacuo to give 
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a light yellow oil, which was purified via column chromatography (93.5:7.5 hexanes: ethyl 
acetate) to give enal 1.36 as a colorless oil (0.745 g, 81%).  Analytical data: []D25.4 +6.2 (c = 
0.45, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 9.60 (d, J = 8.0 Hz, 1H), 6.88 (d, J = 15.6 Hz, 
1H), 6.30 (dd, J = 15.6, 8.0 Hz, 1H), 4.62 (dd, J = 11.6, 1.6 Hz, 1H), 3.77 (dd, J = 11.6, 1.6 
Hz, 1H), 3.76-3.52 (m, 2H), 2.20-2.13 (m, 1H), 1.92-1.85 (m, 1H), 1.76 (d, J = 13.2 Hz, 1H), 
1.53 (dd, J = 24.4, 12.0 Hz, 1H), 1.44 (s, 6H), 0.97 (t, J = 8.0 Hz, 9H), 0.86 (s, 9H), 0.65 (q, J 
= 8.0 Hz, 6H), 0.16 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 193.6, 
159.5, 131.7, 103.5, 99.5, 89.7, 79.0, 60.8, 58.6, 40.7, 32.1, 29.9, 25.9, 19.2, 18.2, 7.1, 6.9, -
0.2, -5.3, -5.4;  HRMS (ESI+) Calcd. for C29H56O5Si3+Na, 591.3334; Found, 591.3333; IR 
(thin film, cm-1) 2956, 2878, 1694, 1462, 1379, 1251, 1105, 842;  TLC(90:10 Hex:EtOAc): Rf 
= 0.33. 
 
(3S,4S,7R,E)-9-((tert-butyldimethylsilyl)oxy)-7-((4R,6S)-2,2-dimethyl-6-
((trimethylsilyl)ethynyl)-1,3-dioxan-4-yl)-3-ethyl-7-((triethylsilyl)oxy)nona-1,5-dien-4-ol 
(1.37): 
Preparation of (+)-Ipc2BH: 
 A flame-dried and cooled 200-mL round-bottomed flask equipped with a magnetic stir 
bar was charged with ()--pinene (5 mL, 4.28 g, 31.4 mmol, 2.4 equiv) and THF (4 mL).  
The flask was purged with N2 and was placed into a room temperature water bath.  
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Borane•DMS (2M in THF, 6.5 mL, 0.981 g, 13.08 mmol, 1.0 equiv) was added dropwise with 
vigorous stirring over 2 min.  Stirring of the reaction was ceased, and the stir bar was removed.  
The flask was again purged with N2, and the resulting solution was allowed to sit at room 
temperature for 16 h.  Crystals were observed on the side of the flask after 1 h at room 
temperature.  The solvent was removed from the flask via cannula, and the remaining solid 
was washed with dry hexanes (2x20 mL), which was removed via cannula transfer.  The flask 
was evacuated to remove residual solvent, and the resulting white solid was removed to a dry 
box freezer.  The reagent was able to be stored without degradation for months when prepared 
and stored in this manner (2.7 g, 73%). 
(+)-Ipc2BOMe was prepared in situ according to the following: 
 An oven-dried and cooled 50-mL round-bottomed flask was charged with Ipc2BH (2.95 
g, 10.32 mmol, 2.5 equiv) under a nitrogen atmosphere and dry THF (30 mL).  Dry MeOH 
(0.417 mL, 10.32 mmol, 2.5 equiv) was added dropwise, and the resulting solution was stirred 
at room temperature for 4 h.  A second 250-mL oven-dried round-bottomed flask was charged 
with potassium tert-butoxide (0.926 g, 8.26 mmol, 2.0 equiv) under a nitrogen atmosphere.  
Dry THF (45 mL) and cis-2-pentene (2.68 mL, 24.8 mmol, 6.0 equiv) were added, and the 
solution was cooled to -50 °C in an acetone/dry ice bath.  nButyllithium (1.5 M, 5.5 mL, 2.0 
equiv) was added dropwise, and the resulting orange solution was stirred at the same 
temperature for 5 minutes before cooling to -78 °C.  The solution of (+)-Ipc2BOMe was added 
dropwise via cannula transfer, and the resulting colorless solution was stirred at -78°C for 20 
minutes.  BF3•OEt2 (1.02 mL, 8.26 mmol, 2.0 equiv) was added, followed by a solution of the 
aldehyde (1.36) (2.35 g, 4.13 mmol, 1.0 equiv) in dry THF (10 mL + 5 mL rinse).  The bath 
temperature was maintained at -78 °C until complete consumption of the starting material was 
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indicated by TLC analysis (2 h).  The reaction was quenched by the dropwise addition of 3M 
NaOH (6.0 mL) and 30% H2O2 (3.2 mL).  After warming to room temperature, the suspension 
was refluxed for 1 h.  The cooled biphasic mixture was partitioned between ether and water, 
and the combined ethereal extracts were washed with water and brine and dried with 
magnesium sulfate.  The organic extracts were concentrated in vacuo to give a crude oil, which 
was purified via flash chromatography (93.5:7.5 to 90:10 petroleum ether: ether) to give the 
desired product as a viscous colorless oil (2.23 g, 85%).  The title compound was obtained as 
a diastereomeric mixture whose ratio was dependent on the initial enantiomeric ratio of the β-
lactone used in the initial 3-component coupling.  This diastereomeric mixture was progressed 
without separation until the final compound (1.46), at which point separation of the isomers 
via HPLC afforded diastereomerically pure material.  Analytical data: []D25.2 1.8 (c = 0.50, 
CHCl3); 1H NMR  (500 MHz, CDCl3): δ 5.73 (dd, J = 16.0, 5.5 Hz, 1H), 5.66 (dd, J = 15.5, 
10.5 Hz, 1H), 5.55 (ddd, J = 17.5, 9.5, 6.0 Hz, 1H), 5.17 (d, J = 10.0 Hz, 1H), 5.11 (d, J = 17.0 
Hz, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.13 (t, J = 6.0 Hz, 1H), 3.66-3.61 (m, 3H), 1.94-1.91 (m, 
2H), 1.59-1.42 (m, 2H), 1.42 (s, 3H), 1.41 (s, 3H), 0.96 (t, J = 7.5 Hz, 9H), 0.89 (s, 9H), 0.63 
(q, J = 7.5 Hz, 6H), 0.17 (s, 9H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 138.3, 132.8, 
130.6, 118.0, 104.1, 99.1, 89.1, 78.2, 74.1, 74.0, 60.9, 59.4, 52.7, 40.0, 31.9, 29.9, 26.0, 23.3, 
19.2, 18.3, 11.9, 7.2, 6.9, -0.2, -5.2, -5.3;  HRMS (ESI+) Calcd. for C34H66O5Si3+Na, 
661.4116; Found, 661.4091; IR (thin film, cm-1) 3465, 2956, 2877, 2183, 1461, 1378, 1251, 
1090, 842;  TLC(90:10 Hex:EtOAc): Rf = 0.30.     
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(3S,4S,7R,E)-9-((tert-butyldimethylsilyl)oxy)-3-ethyl-7-((4R,6S)-6-ethynyl-2,2-dimethyl-
1,3-dioxan-4-yl)-7-((triethylsilyl)oxy)nona-1,5-dien-4-ol (1.37a): Silyl alkyne 1.37 (2.2 g, 
3.46 mmol, 1.0 equiv) was dissolved in methanol (20 mL), and potassium carbonate (0.2 g, 
1.45 mmol, 0.42 equiv) was added at room temperature.  Once the starting material was 
completely consumed as indicated by TLC analysis (Rf = 0.30, 90:10 Hex:EtOAc; 1 h), the 
suspension was loaded directly onto a short silica plug and eluted with 80:20 hexanes:ethyl 
acetate to give the crude alkyne.  Analytical data: []D25.3 +6.2 (c = 1.70, CHCl3); 1H NMR  
(500 MHz, CDCl3): δ 5.72 (dd, J = 16.0, 5.5 Hz, 1H), 5.65 (d, J = 14.0 Hz, 1H), 5.55 (dd, J = 
9.5, 7.5 Hz, 1H), 5.17 (d, J = 15.0 Hz, 1H), 5.11 (d, J = 17.0 Hz, 1H), 4.60 (d, J = 11.5 Hz, 
1H), 4.13 (br. s., 1H), 3.68-3.63 (m, 3H), 2.46 (s, 1H), 2.14-2.12 (m, 1H), 1.94-1.91 (m, 6H), 
1.43 (s, 3H), 1.41 (s, 3H), 0.96 (t, J = 7.5 Hz, 9H), 0.89 (s, 9H), 0.63 (q, J = 7.5 Hz, 6H), 0.04 
(s, 6H); 13C NMR (100 MHz, CDCl3): δ 138.3, 132.7, 130.7, 118.1, 99.2, 82.7, 78.1, 73.9, 
73.8, 72.7, 60.3, 59.4, 52.7, 40.1, 31.6, 29.9, 26.0, 23.3, 19.2, 18.3, 11.9, 7.2, 6.8, -5.2, -5.3;  
HRMS (ESI+) Calcd. for C31H58O5Si2+Cs, 825.3379; Found, 825.3399; IR (thin film, cm
-1) 
3433, 3032, 2958, 2359, 2253, 1637, 908, 725, 650, 452;  TLC(75:25 Hex:EtOAc): Rf = 0.39.   
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(3S,4S,7R,E)-9-((tert-butyldimethylsilyl)oxy)-3-ethyl-7-((4R,6S)-6-ethynyl-2,2-dimethyl-
1,3-dioxan-4-yl)-7-((triethylsilyl)oxy)nona-1,5-dien-4-yl acrylate (1.38): A flame-dried and 
cooled 100-mL round-bottomed flask equipped with a magnetic stir bar was charged with the 
crude allylic alcohol (1.37b) (1.95 g, 3.46 mmol, 1.0 equiv) and dry CH2Cl2 (40 mL), and the 
solution was cooled to 0 °C.  Hünig’s base (1.82 mL, 10.73 mmol, 3.1 equiv) and acryloyl 
chloride (0.846 mL, 10.37 mmol, 3.0 equiv) were added dropwise.  After maintaining the 
solution at 0 °C for 1.5, TLC analysis indicated complete consumption of the starting material 
(Rf = 0.39, 75:25 Hex:EtOAc).  The reaction was quenched by the addition of saturated sodium 
bicarbonate (10.0 mL), and the organic layer was washed with additional saturated sodium 
bicarbonate (3x 10.0 mL), water, and brine and was dried with magnesium sulfate.  
Concentration in vacuo yielded a colorless oil (2.14 g) that was used without additional 
purification.  Analytical data: []D25.0 +24.9 (c = 0.21, CHCl3); 1H NMR  (400 MHz, CDCl3): 
δ 6.40 (d, J = 17.6 Hz, 1H), 6.12 (dd, J = 17.2, 10.4 Hz, 1H), 5.81 (d, J = 13.0, Hz, 1H), 5.70-
5.52 (m, 3H), 5.32 (t, J = 7.5 Hz, 1H), 5.14 (d, J = 12.5 Hz, 1H), 5.05 (d, J = 16.8 Hz, 1H), 
4.58 (d, J = 12.0 Hz, 1H), 3.66-3.59 (m, 3H), 2.45 (s, 1H), 2.32-2.19 (m, 1H), 1.99-1.80 (m, 
2H), 1.77-1.61 (m, 2H), 1.41 (s, 3H), 1.39 (s, 3H), 1.35-1.15 (m, 2H), 0.94 (t, J = 9.5 Hz, 9H), 
0.88 (s, 9H), 0.60 (q, J = 7.6 Hz, 6H), 0.03 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 165.2, 
137.4, 135.2, 130.5, 128.7, 126.7, 117.6, 99.2, 82.7, 778.0, 76.2, 73.8, 72.6, 60.3, 59.3, 49.8, 
40.0, 31.2, 29.9, 26.0, 23.2, 19.2, 18.3, 11.5, 7.2, 6., -5.2, -5.3;  HRMS (ESI+) Calcd. for 
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C34H60O6Si2+Cs, 753.2983; Found, 753.3014; IR (thin film, cm
-1) 3426, 2956, 2877, 2359, 
1798, 1725, 1634, 1402, 1097, 981, 836, 630;  TLC(80:20 Hex:EtOAc): Rf = 0.63.   
 
Protected Alkyne 1.39: The crude acrylate 1.38 (2.14 g, 3.46 mmol, 1.0 equiv) was dissolved 
in dry CH2Cl2 (40 mL) under an atmosphere of nitrogen, and dicobalt octacarbonyl (1.18 g, 
3.46 mmol, 1.0 equiv) was added.  The reaction was stirred at room temperature for 1.5 h, at 
which point TLC analysis indicated complete consumption of the starting material (Rf = 0.63, 
80:20 Hex:EtOAc).  The reaction was concentrated in vacuo, and the crude material was 
purified via flash chromatography (95:5 petroleum ether: ether) to give the desired product as 
a dark red oil (2.7 g, 89% over 3 steps). Analytical data: []D24.2 -153.9 (c = 0.46, CHCl3); 1H 
NMR  (400 MHz, CDCl3): δ 6.38 (d, J = 17.2 Hz, 1H), 6.10 (dd, J = 28.0, 10.4 Hz, 1H), 5.96 
(s, 1H), 5.80 (d, J = 10.4 Hz, 1H), 5.74-5.54 (m, 3H), 5.36 (t, J = 5.2 Hz, 1H), 5.10 (d, J = 10.4 
Hz, 1H), 5.04 (d, J = 17.2 Hz, 1H), 4.85 (d, J = 10.8 Hz, 1H), 3.78 (dd, J = 10.8, 7.2 Hz, 1H), 
3.68-3.63 (m, 2H), 2.27-2.20 (m, 1H), 1.95-1.90 (m, 2H), 1.82 (d, J = 12.4 Hz, 1H), 1.49-1.32 
(m, 3H), 1.45 (s, 3H), 1.36 (s, 3H), 0.92 (t, J = 8.0 Hz, 9H), 0.89 (s, 9H), 0.63-0.56 (m, 6H), 
0.04 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 199.7, 165.1, 137.5, 134.6, 130.5, 128.7, 126.3, 
117.3, 99.2, 77.9, 75.9, 74.0, 70.4, 69.6, 59.4, 49.8, 40.1, 34.0, 29.5, 26.0, 22.9, 19.8, 18.4, 
11.6 7.2, 6.8, 6.7, -5.2, -5.3;  HRMS (ESI+) Calcd. for C40H60Co2O12Si2+Cs, 1039.1342; 
Found, 1039.1344; IR (thin film, cm-1) 2956, 2929, 2877, 2857, 2095, 2054, 2030, 1726, 1462, 
1404, 1190, 1098, 836;  TLC(80:20 Hex:EtOAc): Rf = 0.71. 
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Dihydropyrone 1.39a:  A 250-mL flame-dried and cooled round-bottomed flask was charged 
with acrylate 1.39 (0.530 g, 0.543 mmol, 1.0 equiv).  Under a nitrogen atmosphere, dry toluene 
(125 mL) and Grubbs’s 2nd generation catalyst (0.092 g, 0.122 mmol, 0.15 equiv) were added, 
and the reaction was stirred under nitrogen for 16 h at room temperature.  The solvent was 
removed in vacuo, and the resulting crude oil was purified via column chromatography (90:10 
to 80:20 hexanes:ethyl acetate) to give the dihydropyrone as a dark red oil (0.340 g, 66%).   
Analytical data: []D24.7 -29.5 (c = 2.55, CHCl3); 1H NMR  (500 MHz, CDCl3): δ 6.93 (dd, J 
= 9.5, 5.0 Hz, 1H), 6.04 (d, J = 9.5 Hz, 1H), 5.98 (s, 1H), 5.93 (d, J = 16.0 Hz, 1H), 5.74 (dd, 
J = 15.5, 5.5 Hz, 1H), 4.99 (t, J = 4.5 Hz, 1H), 4.87 (d, J = 11.5 Hz, 1H), 3.82 (d, J = 11.0 Hz, 
1H), 3.66 (t, J = 8.0 Hz, 2H), 2.43-2.34 (m, 1H), 2.07-1.82 (m, 3H), 1.68-1.56 (m, 1H), 1.47 
(s, 3H), 1.37 (s, 3H), 0.96 (t, J = 8.0 Hz, 9H), 0.95 (t, J = 7.0 Hz, 9H), 0.89 (s, 9H), 0.63 (q, J 
= 7.5 Hz 6H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 199, 6, 164.0, 149.8, 135.7, 124.6, 
120.9, 99.4, 97.0, 80.1, 78.1, 74.4, 40.6, 69.6, 59.3, 40.5, 39.4, 34.0, 29.5, 25.9, 21.6, 19.7, 
18.3, 11.0, 7.2, 6.8, -5.2, -5.3;  HRMS (ESI+) Calcd. for C38H56Co2O12Si2+Cs, 1011.1029; 
Found, 1011.1057; IR (thin film, cm-1) 2928, 2856, 2360, 2095, 2054, 2029, 1732, 1462, 1379, 
1254, 1099, 835, 776;  TLC(80:20 Hex:EtOAc): Rf = 0.48. 
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(5S,6S)-6-((R,E)-5-((tert-butyldimethylsilyl)oxy)-3-((4R,6S)-6-ethynyl-2,2-dimethyl-1,3-
dioxan-4-yl)-3-((triethylsilyl)oxy)pent-1-en-1-yl)-5-ethyl-5,6-dihydro-2H-pyran-2-one 
(1.40):  A 50-mL round-bottomed flask was charged with 1.39a (0.340 g, 0.400 mmol, 1.0 
equiv) and acetone (20 mL).  The flask was cooled to -10 °C (acetone-ice), and ceric 
ammonium nitrate (0.988 g, 1.8 mmol, 4.5 equiv) was added in small portions.  The reaction 
was stirred at -10 °C for 45 minutes, at which time TLC analysis indicated complete 
consumption of the starting material.  The reaction was poured into saturated aqueous sodium 
bicarbonate (20 mL) and was extracted with diethyl ether (3x 20 mL).  The combined organic 
extracts were washed with saturated bicarbonate, water, and brine and were dried with 
magnesium sulfate.  Removal of the solvent in vacuo afforded a light yellow oil (220 mg, 93%) 
that was used without further purification.  Analytical data: []D25.3 -57.6 (c = 0.49, CHCl3); 
1H NMR  (500 MHz, CDCl3): δ 6.96 (dd, J = 10.0, 5.5 Hz, 1H), 6.06 (d, J = 10.0 Hz, 1H), 
5.90 (d, J = 15.5 Hz, 1H), 5.76 (dd, J = 15.5, 5.5 Hz, 1H), 5.03 (t, J = 5.0 Hz, 1H), 4.59 (d, J 
= 12.0 Hz, 1H), 3.69 (d, J = 11.5 Hz, 1H), 3.63 (t, J = 8.0 Hz, 2H), 2.46 (s, 1H), 2.42-2.41 (m, 
1H), 1.76 (d, J = 13.0 Hz, 1H), 1.60-1.41 (m, 3H), 0.96 (t, J = 8.0 Hz, 9H), 0.96 (t, J = 8.0 Hz, 
3H); 2 coincident resonances, 0.95 (t, J = 7.0 Hz, 9H), 0.88 (s, 9H), 0.64 (dq, J = 8.0, 4.0 Hz, 
6H), 0.04 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 164.0, 149.9, 135.2, 124.8, 120.8, 103.8, 
99.2, 89.2, 80.0, 78.2, 74.2, 60.7, 59.2, 39.7, 39.6, 32.0, 29.9, 25.9, 21.5, 19.2, 18.2, 11.0, 7.2, 
6.8, -0.2, -5.3, -5.4;  HRMS (ESI+) Calcd. for C32H56O6Si2+Na, 615.3513; Found, 615.3515; 
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IR (thin film, cm-1) 3420, 3029, 2874, 2359, 1645, 1384, 1112, 821, 581;  TLC(75:25 
Hex:EtOAc): Rf = 0.32.  
 
(5S,6S)-5-ethyl-6-((3R,4R,6S,E)-3,4,6-trihydroxy-3-(2-hydroxyethyl)oct-1-en-7-yn-1-yl)-
5,6-dihydro-2H-pyran-2-one (1.41):  A 20-mL scintillation vial was charged with alkyne 
1.40 (150 mg, 0.253 mmol, 1.0 equiv) and methanol (5 mL).  CSA (24 mg, 0.101 mmol, 0.4 
equiv) was added, and the reaction was allowed to stir at room temperature for 1 h.  The 
reaction was quenched with triethylamine (0.050 mL) and was concentrated in vacuo.  The 
crude material was pushed through a short silica plug (95:5 to 92.5:7.5 CH2Cl2: MeOH, SiO2 
deactivated with TEA) to give the crude tetraol as a yellow oil that was used without further 
purification.  Analytical data: []D25.4 +78.3 (c = 0.5, CHCl3); 1H NMR  (400 MHz, CDCl3): 
δ 6.99 (dd, J= 5.5, 10.0 Hz, 1H), 6.06 (d, J = 10.0 Hz, 1H), 6.00 (dd, J = 5.0, 15.5 Hz, 1H), 
5.95 (d, J = 16.0 Hz, 1H), 5.09 (t, J = 4.5 Hz, 1H), 4.62 (br. s., 1H), 4.34 (br. s., 1H), 3.87 (br. 
s., 2H), 3.75 (d, J = 9.5 Hz, 1H), 3.65 (br. s., 1H), 3.00 (br. s., 1H), 2.50 (d, J = 1.5 Hz, 1H), 
2.50-2.46 (m, 1H), 2.12-1.42 (m, 6H), 0.97 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ 164.4, 150.4, 135.4, 126.0, 120.6, 84.1, 80.3, 77.9, 76.3, 73.2, 61.8, 59.7, 39.2, 38.2, 35.9, 
29.7, 21.5, 11.0;  HRMS (ESI+) Calcd. for C17H24O6+Na, 347.1485; Found, 347.1471; IR 
(thin film, cm-1) 3433, 3019, 2400, 1645, 1521, 1215, 928, 768, 669;  TLC(90:10 
CH2Cl2:MeOH): Rf = 0.37. 
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(5S,6S)-6-((3R,4R,6S,E)-6-((tert-butyldimethylsilyl)oxy)-3-(2-((tert-butyldimethylsilyl) 
oxy)ethyl)-3,4-dihydroxyoct-1-en-7-yn-1-yl)-5-ethyl-5,6-dihydro-2H-pyran-2-one 
(1.41a):  An oven-dried 20-mL scintillation vial was charged with crude tetraol 1.41 (82 mg, 
0.218 mmol, 1.0 equiv) and CH2Cl2 (6.0 mL).  The solution was cooled to -78 °C in an acetone-
dry ice bath, and 2,6-lutidine (0.060 mL, 54 mg, 0.501 mmol, 2.3 equiv) and TBSOTf (0.105 
mL, 121 mg, 0.458 mmol, 2.1 equiv) were added successively.  The reaction was maintained 
at -78 °C for 10 min, at which point TLC indicated complete consumption of the starting 
material and clean formation of the desired diol.  The reaction was quenched by the addition 
of MeOH (0.100 mL) and was warmed to room temperature.  After diluting with diethyl ether 
(20 mL), the solution was washed with 1 M HCl (3x5 mL), saturated aqueous NaHCO3 (5 mL), 
water (5 mL), and brine (5 mL) and was dried with sodium sulfate.  Concentration in vacuo 
gave a light yellow oil (110 mg) that was used without additional purification.  Analytical data: 
[]D25.6 +41.2 (c = 0.3, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 6.89 (dd, J= 10.0, 4.8 Hz, 
1H), 6.04-5.88 (m, 3H), 5.03 (t, J = 4.4 Hz, 1H), 4.55 (dd, J = 13.6, 1.6 Hz, 1H), 4.53 (br. s. 
1H), 3.83 (t, J = 3.6 Hz, 2H), 3.66 (d, J = 9.2 Hz, 1H), 2.48-2.42 (m, 1H), 2.40 (d, J = 2.0 Hz, 
1H), 2.01-1.36 (m, 6H), 0.94 (t, J = 7.6 Hz, 3H), 0.88 (s, 9H), 0.86 (s, 9H), 0.15 (s, 3H), 0.13 
(s, 3H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 163.8, 149.5, 136.3, 125.4, 
120.9, 84.6, 80.6, 80.0, 77.4, 75.8, 73.0, 62.9, 60.8, 39.4, 36.5, 25.7, 25.7 (2 coincident 
resonances), 21.6, 18.0, 17.9, 11.0, -4.5, -5.2, -5.7, -5.8;  HRMS (ESI+) Calcd. for 
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C29H52O6Si2+Cs, 685.2357; Found, 685.2366; IR (thin film, cm
-1): 3433, 3019, 2930, 2359, 
1646, 1472, 1212, 983, 769, 668; TLC(90:10 CH2Cl2:MeOH): Rf = 0.79.    
 
(5S,6S)-6-((E)-2-((4R,5S)-5-((S)-2-((tert-butyldimethylsilyl)oxy)but-3-yn-1-yl)-4-(2-
((tert-butyldimethylsilyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)vinyl)-5-ethyl-5,6-
dihydro-2H-pyran-2-one (1.42): A 20-mL scintillation vial was charged with crude diol 
1.41a (110 mg, 0.200 mmol, 1.0 equiv).  Dry acetone (6.0 mL) and 2,2-dimethoxypropane (6.0 
mL) were added, followed by CSA (10.0 mg, 0.040 mmol, 0.22 equiv). The reaction was 
allowed to stir at room temperature  for 1.5 h, at which point TLC analysis indicated complete 
consumption of the diol (Rf = 0.45, 60:40 hexanes:EtOAc).  The reaction was quenched with 
triethylamine (4 drops) and was concentrated in vacuo.  The resulting crude oil was purified 
via flash chromatography, eluting with 80:20 hexanes: ethyl acetate to give the desired product 
in 73% yield over 3 steps (109 mg) as a colorless oil.  Analytical data: []D24.3 +43.9 (c = 0.3, 
CHCl3); 1H NMR  (400 MHz, CDCl3): δ 6.94 (dd, J= 9.6, 5.6 Hz, 1H), 6.03 (d, J = 10.0 Hz, 
1H), 5.90-5.72 (br. s., 2H), 4.98 (t, J = 3.6 Hz, 1H), 4.50 (dd, J = 8.0, 5.6 Hz, 1H), 3.87 (d, J = 
8.8 Hz, 1H), 3.75-3.56 (m, 2H), 2.44-2.23 (m, 1H), 2.44 (s, 1H), 2.00-1.31 (m, 6H), 0.92 (t, J 
= 7.6 Hz, 3H), 0.88 (s, 9H), 0.86 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.01 (s, 6H); 13C NMR 
(100 MHz, CDCl3): δ 163.6, 149.5, 134.3, 124.5, 121.0, 108.1, 108.0, 84.4, 82.8, 80.4, 79.6, 
73.2, 61.3, 59.4, 39.3, 37.5, 37.2, 28.3, 26.3, 25.9, 25.7, 21.6, 18.3, 18.1, 10.9, -4.6, -5.0, -5.3;  
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HRMS (ESI+) Calcd. for C32H56O6Si2+Na, 615.3513; Found, 615.3554; IR (thin film, cm
-1): 
3019, 1521, 1215, 930, 758, 669, 521, 509;  TLC(97.5:2.5 CH2Cl2:MeOH): Rf = 0.72. 
 
(5S,6S)-5-ethyl-6-((E)-2-((4R,5S)-5-((S)-2-hydroxybut-3-yn-1-yl)-4-(2-hydroxyethyl)-2,2-
dimethyl-1,3-dioxolan-4-yl)vinyl)-5,6-dihydro-2H-pyran-2-one (1.42a): A plastic 
scintillation vial equipped with a magnetic stir bar was charged with 1.42 (97 mg, 0.163 mmol, 
1.0 equiv) and acetonitrile (4 mL).  The resulting solution was cooled to 0°C, and HF●pyridine 
(70% HF, 0.25 mL) was added dropwise.  The solution was allowed to warm to room 
temperature and was stirred for 90 min.  The reaction was quenched by the addition of saturated 
aqueous NaHCO3 (5.0 mL).  The resulting suspension was diluted with EtOAc, and the layers 
were separated.  The aqueous layer was extracted with EtOAc, and the combined organic 
extracts were washed with 1M HCl, NaHCO3, and brine and dried with MgSO4.  The solvent 
was removed in  vacuo to afford a crude white solid that was used without additional 
purification (65 mg).  Analytical data: []D25.6 +99.4 (c = 0.45, CHCl3);1H NMR  (500 MHz, 
CDCl3): δ 6.98(dd, J = 9.5, 5.5 Hz, 1H), 6.07(d, J = 9.5 Hz, 1H), 6.00-5.87 (m, 2H), 5.06 (t, J 
= 3.5 Hz, 1H), 4.57 (br. s, 1H), 3.96 (d, J = 10.5 Hz, 1H), 3.81 (dt, J = 10.5, 4.0 Hz, 1H), 3.79-
3.71 (m, 1H), 3.79-3.71 (m, 1H),2.69 (br. s, 1H), 2.55 (br s, 1H), 2.49 (d, J = 1.5 Hz, 1H),2.46-
2.43 (m, 1H), 2.17-1.53 (m, 4H), 1.53 (s, 3H), 1.38 (s, 3H), 0.96 (t,J = 7.5 Hz, 3H; 13C NMR 
(100 MHz, CDCl3): δ 163.8, 150.0, 132.6, 125.4, 120.8, 109.0, 85.3, 83.5, 81.4, 79.3, 73.6, 
61.1, 59.5, 39.1, 36.4, 35.4, 28.1, 26.3, 21.6, 11.0;  HRMS (ESI+) Calcd. for C20H28O6+Na, 
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387.1784; Found, 387.1773; IR (thin film, cm-1) 3433, 2389, 2095, 1900, 1690, 1641, 1549, 
1501, 1217;  TLC(75:25 Hex:EtOAc): Rf = 0.17. 
 
(5S,6S)-5-ethyl-6-((E)-2-((4R,5S)-5-((S)-2-hydroxybut-3-yn-1-yl)-2,2-dimethyl-4-(2-
(trityloxy)ethyl)-1,3-dioxolan-4-yl)vinyl)-5,6-dihydro-2H-pyran-2-one (1.43): 
An oven-dried and cooled 20-mL scintillation vial equipped with a magnetic stir bar was 
charged with diol 1.42a (35 mg, 0.097 mmol, 1.0 equiv), TrCl (81 mg, 0.290 mmol, 3.0 equiv), 
and DMAP (cat.).  CH2Cl2 (2.0 mL) and pyridine (0.2 mL) were added, and the resulting 
solution was allowed to stir at rt for 16 h.  The reaction was quenched by the addition of 
saturated aqueous NaHCO3 and was diluted with Et2O.  The resulting suspension was washed 
with aqueous NaHCO3 and brine and dried with MgSO4.  After concentration in vacuo, the 
crude product was purified via flash chromatography, eluting with a gradient of 80:20 to 60:40 
hexanes:EtOAc, to yield the title compound as a colorless oil (44.5 mg, 76% from 
13).Analytical data: []D24.4 +48.0 (c = 0.70, CHCl3);1H NMR  (500 MHz, CDCl3): δ 7.41-
7.19 (m, 15H), 6.87 (dd, J = 9.5, 5.5 Hz, 1H), 5.97 (d, J = 10.0 Hz, 1H), 5.73 (d, J = 22.5 Hz, 
1H), 5.67 (dd, J = 19.5 4.0 Hz, 1H), 4.91 (t, J = 3.5 Hz, 1H), 4.55 (t, J = 3.0 Hz, 1H), 3.82 (dd, 
J = 10.5, 2.0 Hz, 1H), 3.32-3.31 (m, 1H), 3.07-3.05 (m, 1H), 2.68 (d, J = 3.0 Hz, 1H), 2.49 (d, 
J = 1.5 Hz, 1H), 2.30-1.62 (m, 5H), 1.36-1.30 (m, 2H),1.36 (s, 3H), 1.30 (s, 3H), 0.76 (t, J = 
7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 163.9, 149.9, 144.2, 144.2, 132.9, 128.6, 128.6, 
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127.7, 127.7, 126.9, 124.6, 120.7, 108.7, 86.8, 83.6, 83.1, 81.9, 79.2, 73.3, 61.4, 59.8, 38.9, 
36.4, 34.2, 28.2, 26.5, 21.4, 10.9;  HRMS (ESI+) Calcd. for C39H42O6+Na, 629.2879; Found, 
629.2871; IR (thin film, cm-1) 3434, 3019, 2849, 2399, 2083, 1900, 1724, 1612, 1482, 1216, 
1045, 755;  TLC(75:25 Hex:EtOAc): Rf = 0.77. 
 
(R)-1-((4S,5R)-5-((E)-2-((2S,3S)-3-ethyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)vinyl)-2,2-
dimethyl-5-(2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)but-3-yn-2-yl 2-chloroacetate (1.44):  
An oven-dried and cooled 20-mL scintillation vial equipped with magnetic stir bar was charged 
with alcohol 1.43 (85 mg, 0.141 mmol, 1.0 equiv), chloroacetic acid (53 mg, 0.566 mmol, 4.0 
equiv), and PPh3 (78 mg, 0.296 mmol, 2.1 equiv).  The vial was purged with N2, and toluene 
(2.0 mL) was added.  DEAD (43 µL, 49 mg, 0.282 mmol, 2.0 equiv) was added dropwise.  The 
reaction was allowed to stir at 60 °C for 30 min and was quenched by the addition of a saturated 
aqueous solution of ammonium chloride (3 drops).  The resulting suspension was loaded 
directly onto a silica gel column and was purified via flash chromatography, eluting with 100:0 
to 95:5 CH2Cl2:Et2O, to afford the title compound as a colorless oil (74 mg, 77%).  Analytical 
data: []D25.7 +56.7 (c = 0.16, CHCl3);1H NMR  (500 MHz, CDCl3): δ 7.47-7.24 (m, 15H), 
6.91 (dd, J = 9.6, 5.6 Hz, 1H), 6.02(d, J = 10.0 Hz, 1H), 5.77 (d, J = 16.4 Hz, 1H), 5.70 (dd, J 
= 15.2, 3.6 Hz, 1H), 5.58 (dd, J = 8.8, 2.0 Hz, 1H), 4.96 (t, J = 3.2 Hz, 1H), 4.12 (s, 2H), 3.78 
(dd, J = 10.0, 2.4 Hz, 1H), 3.37 (ddd, J = 14.4, 9.6, 4.8 Hz, 1H), 3.12 (ddd,J = 15.2, 9.6, 4.8 
Hz, 1H), 2.61 (d, J = 2.0 Hz, 1H), 2.35-2.01 (m, 4H), 1.80-1.56 (m, 1H), 1.39 (s, 3H), 1.30 (s, 
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3H), 1.20-1.05 (m, 1H), 0.81 (t,J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 166.1, 163.6, 
149.7, 144.2, 133.0, 128.6, 128.6, 127.7, 126.8, 124.7, 120.7, 108.3, 86.8, 82.5, 79.9, 79.2, 
78.7, 74.7, 62.9, 59.8, 40.6, 39.0, 34.1, 34.0, 28.1, 26.3, 21.3, 10.8;  HRMS (ESI+) Calcd. for 
C41H43ClO7+Cs, 815.1752; Found, 815.1796; IR (thin film, cm
-1) 3434, 3019, 2849, 1737, 
1658, 1442, 1331, 1215, 755, 668;  TLC(50:50Hex:EtOAc): Rf = 0.63. 
 
(5S,6S)-5-ethyl-6-((E)-2-((4R,5S)-5-((R)-2-hydroxybut-3-yn-1-yl)-2,2-dimethyl-4-(2-
(trityloxy)ethyl)-1,3-dioxolan-4-yl)vinyl)-5,6-dihydro-2H-pyran-2-one (1.44a): A 20-mL 
scintillation vial equipped with magnetic stir bar was charged with chloroacetate 1.44 (69 mg, 
0.102 mmol, 1.0 equiv).  MeOH (2 mL) was added, and the resulting solution was cooled to -
10 °C in an acetone-ice bath.  Saturated NH4OH (4 drops) was added, and the solution was 
allowed to stir at the same temperature for 10 min.   The solution was diluted with Et2O and 
brine, and the layers were separated.  The organic layer was washed successively with saturated 
aqueous NaHCO3 and brine and dried with MgSO4.  Concentration in vacuo yielded a colorless 
oil that was used without additional purification (59 mg, 96%).Analytical data: []D24.6 +53.3 
(c = 0.24, CHCl3);1H NMR  (400 MHz, CDCl3): δ 7.57-7.12 (m, 15H), 6.89 (dd, J = 8.8, 5.2 
Hz, 1H), 6.00 (d, J = 9.6 Hz, 1H), 5.77 (d, J = 17.6 Hz, 1H), 5.70 (d, J = 16.4 Hz, 1H), 4.95 (s, 
1H), 4.64 (br. s, 1H), 4.14 (d, J = 10.8), 3.37 (br. s, 1H), 3.12-2.94 (m, 2H), 2.52 (s, 1H), 2.31-
2.11 (m, 1H), 2.07-1.72 (m, 4H), 1.40-1.36 (m, 1H), 1.40 (s, 3H), 1.36 (s, 3H), 1.17-1.05 (m, 
1H), 0.80 (t,J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 163.7, 149.7, 144.3, 133.1, 128.6, 
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127.6, 126.8, 124.6, 120.7, 108.5, 86.8, 83.9, 82.9, 79.9, 79.2, 73.2, 60.1, 59.9, 39.0, 35.3, 34.3, 
28.1, 26.4, 21.3, 10.8;  HRMS (ESI+) Calcd. for C39H42O6+Na, 629.2879; Found, 629.2990; 
IR (thin film, cm-1) 3435, 2390, 1936, 1786, 1723, 1630, 1426, 1212, 521;  
TLC(50:50Hex:EtOAc): Rf = 0.48. 
 
(5S,6S)-6-((E)-2-((4R,5S)-5-((R)-2-((tert-butyldimethylsilyl)oxy)but-3-yn-1-yl)-2,2-
dimethyl-4-(2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)vinyl)-5-ethyl-5,6-dihydro-2H-pyran-2-
one (1.45): An oven-dried and cooled 20-mL scintillation vial equipped with magnetic stir bar 
was charged with alcohol 1.44a (59 mg, 0.098 mmol, 1.0 equiv).  CH2Cl2 (1.0 mL) was added, 
and the resulting solution was cooled to -78 °C in an acetone-dry ice bath.  2,6-lutidine (23 µL, 
21 mg, 0.196 mmol, 2.0 equiv) was added, followed by a dropwise addition of TBSOTf (27 
µL, 31 mg, 0.118 mmol, 1.2 equiv).  The reaction was allowed to stir at the same temperature 
for 2 h, at which point it was quenched by the addition of MeOH (0.25 mL) and warmed to rt.  
After dilution with Et2O and 1M HCl, the layers were separated and the organic layer was 
washed with saturated aqueous NaHCO3, water, and brine and dried with MgSO4.  The solvent 
was removed in vacuo, and the resulting crude oil was purified via flash chromatography, 
eluting with 100:0 to 80:20 hexanes:EtOAc, to afford the title compound as a colorless oil (59 
mg, 84%).Analytical data: []D25.1 +41.2 (c = 0.20, CHCl3);1H NMR  (400 MHz, CDCl3): δ 
7.45-7.22 (m, 15H), 6.88 (dd, J = 9.6, 5.6 Hz, 1H), 6.00 (d, J = 9.6 Hz, 1H), 5.77-5.67 (m, 2H), 
4.90 (t, J = 4.0 Hz, 1H), 4.54 (d, J = 10.0 Hz, 1H), 3.89 (dd, J = 10.4, 2.0 Hz, 1H), 3.39-3.31 
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(m, 1H), 3.15-3.09 (m, 1H), 2.45 (d, J = 2.0 Hz, 1H), 2.31-2.26 (m, 1H), 2.10-1.61 (m, 4H), 
1.37 (s, 3H), 1.30 (s, 3H), 1.30-1.10 (m, 2H), 0.91 (s, 9H), 0.82 (t,J = 7.2 Hz, 3H), 0.18 (s, 3H), 
0.13 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 163.6, 149.5, 144.4, 133.9, 128.6, 127.7, 126.8, 
124.4, 120.9, 108.0, 86.8, 85.4, 82.6, 79.5, 79.0, 72.1, 60.0, 59.5, 39.3, 37.8, 34.4, 28.2, 26.5, 
25.7, 21.3, 18.1, 10.9, -4.6, -5.3;  HRMS (ESI+) Calcd. for C45H56O6Si+Cs, 853.2901; Found, 
853.2925; IR (thin film, cm-1) 3435, 2917, 2848, 2393, 2002, 1725, 1611, 1530, 1381, 1218, 
1060, 707;  TLC(50:50Hex:EtOAc): Rf = 0.83. 
 
(5S,6S)-6-((E)-2-((4R,5S)-5-((R,Z)-2-((tert-butyldimethylsilyl)oxy)-4-iodobut-3-en-1-yl)-
2,2-dimethyl-4-(2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)vinyl)-5-ethyl-5,6-dihydro-2H-
pyran-2-one (1.45a):  An oven-dried and cooled 20-mL scintillation vial equipped with 
magnetic stir bar was charged with alkyne 1.45 (54 mg, 0.076 mmol, 1.0 equiv), NIS (20 mg, 
0.091 mmol, 1.2 equiv), and THF (2.0 mL).  AgNO3 (powdered, cat.) was added, and the 
resulting suspension was stirred vigorously in the dark at rt for 12 h.  The suspension was 
filtered through a short SiO2 plug, eluting with 100:0 to 75:25 hexanes:EtOAc, to afford the 
crude alkynyl iodide as a light yellow oil (57 mg, 90% crude yield) that was used without 
additional purification. 
 An oven-dried and cooled 20-mL scintillation vial equipped with magnetic stir bar was 
charged with the crude iodide (57 mg, 0.068 mmol, 1.0equiv), iPrOH (2.0 mL), and THF (2.0 
mL).  The vial was purged with N2, and TEA (29 µL, 21 mg, 0.204 mmol, 3.0 equiv) and 
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NBSH (25 mg, 0.116 mmol, 1.7equiv) were added successively.  The vial was sealed with a 
Teflon-lined cap and covered with foil, and the reaction was allowed to stir at rt for 16 h.  1H 
NMR analysis of an aliquot revealed complete consumption of the starting material, and the 
reaction was concentrated in vacuo.  The resulting crude yellow oil was purified via column 
chromatography, eluting with 100:0 to 70:30 petroleum ether:Et2O, to afford the title 
compound as a colorless oil (54 mg, 85% over two steps).  Analytical data: []D23.8 +33.6 (c = 
0.23, CHCl3);1H NMR  (400 MHz, CDCl3): δ 7.54-7.06 (m, 15H), 6.87 (dd, J = 9.6, 5.2 Hz, 
1H), 6.27-6.21 (m, 2H), 5.98 (d, J = 10.0 Hz, 1H), 5.74-5.63 (m, 2H), 4.90 (t, J = 4.0 Hz, 1H), 
4.53 (m, 1H), 3.89 (d, J = 10.0 Hz, 1H), 3.35-3.31 (m, 1H), 3.09-3.06 (m, 1H), 2.27 (dd, J = 
9.6, 4.8 Hz, 1H), 2.04 (ddd, J = 4.4, 4.0, 4.0 Hz, 1H), 1.71-1.49 (m, 4H), 1.38-1.05 (m, 2H), 
1.37 (s, 3H), 1.30 (s, 3H), 0.86 (s, 9H), 0.78 (t,J = 7.6 Hz, 3H), 0.09 (s, 3H), 0.06 (s, 3H); 13C 
NMR (100 MHz, CDCl3): δ 163.7, 149.6, 144.4, 133.9, 128.6, 127.6, 126.8, 124.1, 120.8, 
107.9, 86.8, 82.7, 79.8, 79.5, 79.0, 72.8, 60.1, 39.2, 35.3, 34.2, 28.3, 26.6, 25.7, 25.7, 21.3, 
18.0, 10.9, -4.3, -4.9;  HRMS (ESI+) Calcd. for C45H57IO6Si+Cs, 981.2024; Found, 981.2055; 
IR (thin film, cm-1) 3435, 2956, 2928, 2855, 1726, 1675, 1612, 1379, 1251, 1063, 835, 705;  
TLC(50:50 Et2O:Petroleum Ether): Rf = 0.63. 
 
(5S,6S)-6-((E)-2-((4R,5S)-5-((R,Z)-2-((tert-butyldimethylsilyl)oxy)-4-iodobut-3-en-1-yl)-
4-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)vinyl)-5-ethyl-5,6-dihydro-2H-pyran-
2-one (1.46): An oven-dried and cooled 20-mL scintillation vial was charged with vinyl iodide 
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1.45a (40 mg, 0.048 mmol, 1.0 equiv) and CH2Cl2 (8.0 mL).  The resulting solution was cooled 
to -20 °C in an acetone-dry ice bath, and BCl3 (0.123 M in CH2Cl2, 2.6 mL, 0.031 mmol, 0.66 
equiv) was added dropwise.  A bright yellow color was initially observed but disappeared 
during the course of the reaction.  The reaction was allowed to stir at the same temperature for 
30 min and was quenched by the addition of saturated aqueous NaHCO3 (1.0 mL).  The 
resulting suspension was warmed to rt, and the layers were separated.  The organic layer was 
dried with Na2SO4 and concentrated in vacuo to afford a colorless oil that was purified via 
column chromatography, eluting with 70:30 to 50:50 petroleum ether:Et2O, to afford the title 
compound (16 mg, 56%) as a 5:1 mixture of diastereomers. The diastereomers were separated 
via HPLC to afford diastereomerically pure material, whose spectral data were consistent with 
those reported in the literature for the title compound.29 Analytical data: []D25.3 +64.5 (c = 
0.14, CHCl3), lit:
3 []D22.0 +68.6 (c = 1.60, CHCl3); 1H NMR  (400 MHz, CDCl3): δ 6.99 (dd, 
J = 9.6, 5.2 Hz, 1H), 6.25-6.19 (m, 2H), 6.07 (d, J = 10.0 Hz, 1H), 5.95 (dd, J = 15.2, 4.4 Hz, 
1H), 5.87 (d, J = 15.6 Hz, 1H), 5.05 (t, J = 4.0 Hz, 1H), 4.54 (ddd, J = 16.8, 9.6, 2.8 Hz, 1H), 
4.01 (d, J = 10.0 Hz, 1H), 3.83 (dt, J = 11.2, 3.6 Hz, 1H), 3.70 (m, 1H), 2.66 (br s, 1H), 2.43 
(dd, J = 9.2, 4.8 Hz, 1H), 2.02 (ddd, J = 14.4, 9.6, 5.6 Hz, 1H), 1.71-1.42(m, 6H), 1.54 (s, 3H), 
1.37 (s, 3H), 0.96 (t,J = 7.6 Hz, 3H), 0.86 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 163.9, 150.0, 144.3, 133.2, 125.0, 120.9, 108.4, 85.1, 80.1, 79.5, 78.8, 72.7, 
59.7, 39.2, 35.3, 35.2, 28.2, 26.4, 25.8, 21.5, 18.0, 11.0, -4.2, -4.9;  HRMS (ESI+) Calcd. for 
C26H43IO6Si+Na, 629.1772; Found, 629.1771; IR (thin film, cm
-1) 3434, 2390, 2083, 1936, 
1785, 1709, 1641, 1427, 1250, 1081, 780, 507;  TLC(50:50Hex:EtOAc): Rf = 0.32. 
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CHAPTER TWO 
 
SYNTHETIC STUDIES TOWARD THE PACTAMYCIN CORE*
 
 
2.1  Introduction 
 Natural product synthesis is a fundamental contribution of the synthetic organic 
chemist toward the advancement of science. This facet of chemistry allows for the 
demonstration of synthetic methodology, exposes the shortcomings and needs of the synthetic 
toolbox, and consistently perpetuates the art and creativity of chemists. The Johnson laboratory 
selects total synthesis targets based upon biological relevance and where opportunity is seen 
to drastically improve the state-of-the-art, typically in a manner which relies on methods 
developed by our group. Particularly, we are interested in medium-sized targets which possess 
dense functional and stereochemical challenges. Among the targets completed or being 
pursued in our lab, pactamycin stands as the epitome of these criteria. Our long interest in this 
target stems from its exceptional biological properties, dense functionalization, and the 
stereochemical challenges presented for its total synthesis. In this chapter, we present myriad 
synthetic routes investigated in pursuit of a total synthesis. Key results and observations on the 
                                                          
* Reprinted in part with permission from Malinowski, J. T.; McCarver, S. J.; Johnson, J. 
S. Org. Lett. 2012, 14, 2878.   
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behavior of advanced intermediates are discussed including a partial synthesis of the 
pactamycin core.  
2.2  Background 
2.2.1  Biological Activity and Biosynthetic Proposal for Pactamycin Synthesis 
 The majority of antibiotic therapeutics in use today were discovered between 1940 and 
1970 during the so-called “Golden Age” of antibiotics. During this period, screening of various 
bacteria and fungi produced approximately 12,000 discoveries which ultimately led to 160 
drugs for clinical use.1 An astounding 55% of these natural products were obtained from a 
single genus, Streptomyces. Pactamycin (2.1, Figure 2-1) was isolated during this period in 
1961 by researchers at the former Upjohn Company from a fermentation broth of Streptomyces 
pactum var pactum.2 This unique molecule displayed a plethora of biological activity including 
antitumor, antimicrobial, antiviral, and antiprotozoal properties. In vivo studies revealed that 
pactamycin mimicked a dinucleotide, using its anilino and salicylate moieties to interact with 
the 16S RNA.3 This activity inhibited translocation and ultimately, protein synthesis.4 
Unfortunately the pharmaceutical value of this natural product is severely attenuated by high 
cytotoxicity (IC50 95 nM against human diploid embryonic cell line MRC-5),
5 precluding its 
medicinal use. 
Figure 2-1.  Structure of Pactamycin 
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 The structure of pactamycin was proposed in 1970 by the Upjohn researchers,6 but later 
revised after X-ray crystallographic analysis in 1972.7 This aminocyclopentitol features six 
contiguous stereocenters, including three fully-substituted carbons (C1, C5, and C4). The core 
is adorned with unique 1,1-dimethylurea, salicylate, and meta-acetylanilino functionality 
lending to its biological activity. In addition, pactamycin is heteroatom-rich with multiple 
hydroxyl and amino sites, providing means for an intricate hydrogen bonding network within 
the ribosomal subunit with which it interacts. This dense, highly-functionalized target piqued 
our interest as it presented several challenges to organic chemists and, at the genesis of this 
research program, had not yet succumbed to total synthesis. It is of important note that 
pactamycin is efficiently produced by bacterial cultures to the point that it is available for 
purchase from Sigma-Aldrich ($82/5 mg).8 The purpose of total synthesis of this target was 
not to provide significant quantities of material for testing, as is typically the case for natural 
products, but to provide a flexible template for its synthesis wherein structural modifications 
may be incorporated. Due to the toxicity issues associated with pactamycin, structural 
analogues and subsequent structure activity relationship (SAR) studies are imperative in order 
to find medicinal applications for this active natural product. 
 A biosynthetic pathway to pactamycin has recently been reported by Mahmud, et al.9 
The truncated route is shown in Scheme 2-1 and specifically highlights the number of selective 
transformations Nature is capable of performing on small molecules. While this would be a 
challenging route for an organic chemist to mimic, a great deal can be learned about the activity 
and stability of pre-pactamycin intermediates. In brief, the bulk of the carbon core is derived 
from UDP-N-acetyl--D-glucosamine (2.2) and meta-acetylaniline. The compounds are united 
and undergo several biocatalyzed, selective redox steps as side-chain functional groups are 
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gradually added in a stepwise fashion. Pactamycin is efficiently reached in short order, 
showcasing Nature’s “ideal” synthesis. 
Scheme 2-1.  Biosynthetic Synthesis of Pactamycin 
 
2.2.2  Prior Syntheses of Pactamycin 
 Since its discovery in 1961, there had been very little synthetic activity surrounding 
pactamycin. Recently, activity has flourished with several partial syntheses and the first total 
synthesis by Hanessian and coworkers in 2011 during our pursuit.10 Additionally, a 
bioengineering approach was recently disclosed, highlighting the value of biosynthetic 
machinery. These routes will be discussed in this section in chronological order making note 
of our progress at the time of release. The complexity of the pactamycin core allows for great 
flexibility and creativity in approaches and, for this reason, it is challenging to group or 
comment on general strategies featured in prior synthetic endeavors as each drastically differed 
in approach.  
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 Our group began this work on pactamycin in late 2008 with Andrew Satterfield 
exploring early synthetic approaches. I joined the project in early 2009 and worked on the 
routes which will be presented in the Results and Discussion section. At the point of our 
entrance, two synthetic studies had been published on the core, each failing to achieve full 
functionalization. First reported in 2005, Isobe, et al. presented an approach beginning with a 
glucose derivative using a Pauson-Khand cyclization strategy to construct the five membered 
core. The synthesis is outlined in Scheme 2-2.11 
Scheme 2-2.  Isobe Pactamycin Core Approach 
 
 From known protected sugar derivative 2.3, Isobe and coworkers used four steps to set 
up an Overman rearrangement to assemble the C1 stereocenter (2.5). This was then elaborated 
in six steps to provide oxazolidinone 2.6, with the C7 hydroxyl installed and protected. 
Selective deprotection of the acetonide at C2 and elimination provided a vinyl functional 
handle from which to build up the cyclopentane core (2.7). In three subsequent steps the 
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remaining protected sugar backbone was cleaved to β-hydroxy aldehyde 2.8 and subjected to 
diastereoselective acetylide addition affording propargyl alcohol 2.9. After diol protection, a 
key Pauson Khand cyclization was used to construct tricycle 2.11, the final intermediate 
reported in this communication. While this initial approach was effective in the installation of 
the northeast C1 and C7 stereocenters, the majority of the core was incomplete, left with 
functional handles requiring significant manipulation to reach the native form.  
Scheme 2-3.  Knapp Pactamycin Core Approach 
 
 The next approach was published by Knapp and coworkers in 2007 where a 
significantly different strategy was pursued.12 In this report, synthesis commenced with the 
carbon core pre-assembled, beginning from 2-methyl-cyclopentenone to which functionality 
would be installed in a linear fashion (Scheme 2-3). In four initial steps, diastereoselective 
anti-diol installation completed the C5 stereocenter (2.12). Next, a methylene 
Wittig/epoxidation sequence was used to install a C4 epoxide which underwent subsequent 
elimination/ring-opening to provide an endocyclic alkenyl functional handle (2.14). A second 
epoxidation/elimination/ring-opening sequence was then used to install the tertiary C4 alcohol 
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and install an endocyclic Michael acceptor (2.15). A creative C4 carbamoylation/directed aza-
Michael cascade approach was employed to furnish the C3 amino functionality affording cis-
fused bicycle 2.16. The C1–C7 bond was then constructed using organometallic coupling 
chemistry to ultimately provide the C7 ketone 2.19 from which no further manipulations were 
reported. 
The Knapp approach reached a significantly advanced core intermediate, completing 
functionalization at C3, C4, and C5 although an epimerization was required at the C3 amide. 
While a Michael acceptor functional handle was left to assist C1/C2 diamine installation, this 
undoubtedly posed a significant challenge as a more advanced intermediate was never reported 
by these researchers.  
Scheme 2-4.  Hanessian Cyclopentenone Assembly 
 
 Three years into our research program, the first total synthesis was realized by 
Hanessian, et al. Reported in mid-2011, the molecule was completed as a single enantiomer in 
32 total steps. As this synthesis was somewhat lengthy, it will be broken into three segments 
for presentation. Hanessian began from the chiral pool, synthesizing oxazoline 2.20 in three 
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steps from L-threonine (Scheme 2-4). Diastereoselective aldol addition constructed the C1-C5 
bond and provided a vinyl functional handle (2.21). Three-step conversion of the C1 benzyl 
ester to a methyl ketone set up an intramolecular aldol cyclization to assemble the five-
membered core (2.23). Although C4 was set up with the correct stereochemistry, the tertiary 
alcohol was eliminated to provide cyclopentenone 2.24 for further manipulation. 
Scheme 2-5.  Hanessian Core Completion 
 
Functionalization of the western portion of the molecule commenced with 
diastereoselective nucleophilic epoxidation followed by Luche reduction providing 
epoxyalcohol 2.26 (Scheme 2-5). Activation of the C2 alcohol followed by displacement by 
azide installed the important amino functionality (2.27). Deprotection of the C5 alcohol and 
oxidation furnished a competent electrophile for methyl addition which proceeded with high 
diastereoselectivity to give carbinol 2.29. At this stage, Hanessian, et al. were working with an 
inverted epoxide that required a stereochemical correction. A zinc triflate-promoted Payne 
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rearrangement/nucleophilic ring-opening was used to correct the C4 stereochemistry and 
provide a secondary alcohol at C3 (2.30). Subsequent activation induced epoxidation, 
providing the desired C3-C4 epoxide 2.31.  
Scheme 2-6.  Hanessian Endgame 
 
Three challenges remained at this stage of the synthesis: installation of the salicylate, 
dimethylurea, and aniline moieties (Scheme 2-6). The endgame began with a Yb-catalyzed 
aniline epoxide ring-opening to provide the anti-product 2.32 with the aniline acetyl substituent 
masked as a propene. Acid hydrolysis of the oxazoline provided a free amine that could only 
be acylated after the C4 hydroxyl was protected as an acetonide due to undesired 
intramolecular reactivity. This allowed for smooth introduction of the C1 dimethylurea group 
(2.35). The aniline acetyl group was revealed by oxidation, followed by a global deprotection 
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providing tetraol 2.36. A ketene-mediated acylation protocol was then used to install the 
salicylate fragment leaving only a reduction of the C2 azide to reach pactamycin. This 
synthesis was accomplished in 32 steps and an overall yield of 1.09%.  
Shortly after our initial publication on a pactamycin core study in 2012, Looper and 
coworkers reported an approach reminiscent of the Hanessian core construction (Scheme 2-
7).13 They began with a similar oxazoline building block (2.38) and performed a C1 alkylation 
followed by ester  methyl ketone conversion to provide alkene 2.40. Subsequent ozonolysis 
set the stage for an intramolecular aldol condensation, establishing a cyclopentene core via C4-
C5 bond construction (2.41). A three-step sequence was then used to install a hydroxyl 
functional handle at C3 and to reduce the C4 aldehyde, setting up a directed epoxidation. After 
hydrolysis of the oxazoline and amino acylation, epoxidation with m-CPBA provided desired 
epoxide 2.46, with correct stereochemistry at C4. 
Scheme 2-7.  Looper Pactamycin Core Approach 
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 It is important to note that the C7 stereocenter has been inverted throughout the 
synthesis – this was intentional and part of a key epoxide-opening cascade developed to set the 
C7/C5/C4 stereotriad (Scheme 2-8). Treatment of epoxide 2.46 with boron trifluoride induced 
intramolecular ring-opening by the C7 benzoate, which was in turn displaced by the C1 
carbamate. Finally, a 1,3-acyl migration from the tertiary to primary alcohol occurred to give 
triol 2.47. This cascade completed the majority of core functionalization, leaving a C3 
hydroxyl as a functional handle for C3/C2 diamino introduction. 
Scheme 2-8.  Epoxide-Opening Cascade 
 
 Isobe appeared again in the literature in 2012 with a follow-up publication building on 
the route disclosed in 2005 (Scheme 2-9).14 Building from their previous enyne intermediate 
2.9, a nitrone was installed in order to execute a [3 + 2] dipolar cycloaddition/ring-contraction 
to arrive at aziridine 2.49. This cyclization approach allowed for greater flexibility and 
introduction of functionality. In five subsequent steps, diol 2.50 was reached. This advanced 
intermediate had most of the necessary functionality in place, but contained stereochemical 
errors at C3 and C4. 
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Scheme 2-9.  Isobe’s Alternate Cyclization Strategy 
 
 The final approach to pactamycin to be discussed was a bioengineering effort by 
Mahmud, et al.15 In this work, the biosynthesis of pactamycin was studied and numerous 
mutant strains of bacteria were cultured in order to obtain pactamycin analogs. Four of the 
most relevant congeners obtained are shown in Figure 2-2. The bioactivity of these natural 
products was assayed and it was found that they were 10-30 times less toxic than pactamycin. 
This important study renewed hope for ultimate therapeutic use as structural derivatives may 
possess the selectivity required for a drug without potent cytotoxicity properties.  
Figure 2-2.  Mahmud Bioengineering Synthesis 
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In closing, Mahmud brings to light an important problem. They claimed that their 
bioengineering studies had been successful in “generating pactamycin analogues that have 
been deemed inaccessible by synthetic organic chemistry.” The complexity of pactamycin and 
lack of a concise total synthesis at the time showed a significant shortcoming in synthetic 
organic chemistry. We argue a chemical total synthesis would provide a highly-flexible means 
for production of pactamycin analogues in a manner far superior to that of bioengineering. The 
synthesis, however, must develop the complexity present in pactamycin in a highly-efficient 
manner in order to hold any value. 
2.3  Results and Discussion 
2.3.1  Preliminary Retrosynthetic Analysis 
The cytotoxicity problems associated with pactamycin mandated a synthetic route 
amenable to analogue synthesis. This central goal was considered in all retrosynthetic analyses. 
The initial strategy we pursued involved a key conjugate addition/intramolecular aldol addition 
to an -ketoester, a well-studied area in our laboratory. Figure 2-3 outlines this approach in 
which pactamycin would be simplified to the highly-functionalized core 2.51. The only site 
requiring significant manipulation would be the C3 ester  aniline conversion. To effect this 
transformation we proposed saponification followed by Curtius rearrangement which could 
stereospecifically install the C3 amino group for further manipulation. All other stereocenters 
of the core would be set after a ring-closing aldol cascade reaction performed on Michael 
acceptor 2.52. We proposed initiation of this cascade by conjugate addition of TMSN3
16 
followed by cyclization of the resultant C3 enolate onto the C4 ketone. The Michael acceptor 
of 2.52 could be installed via manipulation of an allyl group, and the -ketoester moiety could 
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be installed by the nucleophilic addition of its equivalent to a C5 ketone, simplifying our initial 
synthetic target to β-hydroxyketone 2.54. We believed we could access enantioenriched 2.54 
in short order from feedstock material – methyl acetoacetate. 
Figure 2-3.  Retrosynthetic Analysis – Aldol Cascade Approach 
 
 Of great importance in the early steps of our synthesis was an enantioselective 
installation of the C1 stereocenter, which would allow for subsequent diastereocontrolled 
introduction of functionality. We envisioned a Tsuji-Trost allylation of an -ureido-β-ketoester 
to accomplish this goal, a transformation which had some precedent for a simpler -acetamido 
substrate.17 The decision to install the dimethylurea moiety early in our synthesis posed 
significant risk due to the potential effects this polar, electron-rich group might have on 
subsequent transformations; however, it was our intent to keep the synthesis concise and 
alternative strategies would require significant downstream manipulation steps to reveal this 
functionality.  
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2.3.2  Construction of the Northeast Quadrant – C1/C7 Stereocenters 
The initial strategy for alpha amination involved a three-step protocol beginning with 
oxime formation from methyl acetoacetate (Scheme 2-10). This occurred uneventfully upon 
treatment with sodium nitrite under acidic conditions to give oxime 2.55. Next, we attempted 
reduction of the oxime using a variety of conditions, temperatures, and pressures of H2, but 
were never able to isolate the salt product 2.56 cleanly. One-pot procedures including the 
addition of an electrophile to the crude salt also failed to afford the desired ureido substitution 
(although they were effective to isolate the –NHAc product). 
Scheme 2-10.  Construction of Allylation Precursor   
 
 We next turned to a modification of a procedure developed by Janda and coworkers18 
wherein carbene precursors were subjected to rhodium-catalyzed N–H insertion chemistry to 
provide our desired product scaffold. First the -diazo-methyl acetoacetate derivative 2.57 was 
synthesized using para-acetamidobenzenesulfonyl azide (p-ABSA) in quantitative yield. 
Using Janda’s conditions, we were pleased to see formation of the desired urea 2.58. Further 
optimization revealed the catalyst loading could be decreased significantly without a 
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detrimental effect on reaction yield. This was an important discovery, as a somewhat-
expensive rhodium complex was being used on large-scale early in our synthesis. 
 With the allylation precursor in hand, we pursued an enantioselective allylation. The 
conditions reported by Ito, et al.17 were adapted for our substrate. Upon reaction screening with 
racemic BINAP, we obtained the allylation product 2.59 in 77% yield after an overnight 
reaction (Scheme 2-11). The asymmetric variant was run at reduced temperatures and provided 
good enantioselectivity (92:8 er) with comparable yield. For screening purposes throughout 
the remainder of the synthesis, racemic material was processed as a cost-saving measure. We 
were inspired by a secondary transformation in the Ito publication, a diastereoselective ketone 
reduction with L-Selectride. Although they enjoyed complete diastereoselectivity on the 
related -acetamido substrate, we failed to surpass diastereomeric ratios of 3.5:1 for this 
reduction (2.60). However, the reaction was high-yielding and the diastereomers were 
separable by column chromatography, so when a short screen of reducing agents showed no 
improvement, we continued synthesis with a 72% yield of the major diastereomer.  
Scheme 2-11.  Asymmetric Allylation   
 
 We chose a tert-butyldimethylsilyl protecting group for the C7 alcohol for stability as 
we anticipated removal of this ether much later in the synthesis. The silylation proceeded 
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smoothly in excellent yield providing silyl ether 2.61. At this stage of the synthesis we were 
operating under the assumption that the reduction provided the major diastereomer with 
stereochemistry assigned analogously to the products Ito obtained. This would not be 
confirmed until a much later intermediate (vide infra).  
2.3.3  Progress Toward a C5 Ketone Electrophile 
Scheme 2-12.  Methylation Attempts 
 
The next goal was a conversion of the methyl ester to a methyl ketone. This ketone 
would serve as the C5 electrophile for the proposed nucleophilic addition of the -ketoester 
surrogate (Scheme 2-12). Unfortunately, a variety of methylation attempts failed to produce 
the desired product, an outcome we attributed to the highly-congested methyl ester 
environment. The only clean reaction product we isolated came from treatment with excess 
methyl Grignard which gave oxazolinone product 2.62. This undesired product presumably 
resulted from an urea N–H deprotonation followed by intramolecular cyclization. We reasoned 
2.62 might be a competent electrophile for methyl addition itself, and tested a variety of 
conditions, ultimately finding no success. 
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Due to the impasse we faced in methyl additions, we considered an alternate approach 
where we would begin with acetylacetone (2.63) instead of methyl acetoacetate and follow the 
same sequence. This route sacrificed the opportunity for asymmetric allylation, but we 
believed an asymmetric reduction might be possible to set both the C1 and C7 stereocenters. 
To this end, diketone 2.66 was synthesized in a sequence analogous to our previous route 
(Scheme 2-13). A minor divergence in reactivity was observed during the allylation step, where 
a retro-Claisen pathway was dominant at higher base concentrations, resulting in the loss of 
one of the methyl ketones and proceeding with a second allylation in some experiments. This 
could be due, in part, to the increased stabilization of the ketone as compared to the ester. 
Reducing the stoichiometry of the base solved this problem.   
Scheme 2-13.  Diketone Strategy 
 
 We then sought out to find a diastereoselective mono-reduction of our diketone 
substrate. We began with a screen of available reducing agents summarized in Table 2-1. This 
reaction required careful conditions as a retro-aldol pathway was typically dominant at higher 
temperature. The bulky tri-sec-butylboronate product of L-Selectride reduction, not 
surprisingly, suffered from this pathway even at cryogenic temperature. Lithium aluminum 
hydride (LAH) typically gave over-reduction products, but lithium tri-tert-butoxyaluminum 
hydride (LTBA) provided a single diastereomer in 75% yield. This diastereomer was later 
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shown to have the stereochemistry depicted in Table 2-1. After a TBS silylation of 2.67, we 
had reached our desired methyl ketone electrophile to test nucleophilic additions. 
Table 2-1.  Diketone Monoreduction Screen 
 
Conditions Result 
L-Selectride, -78 °C  retro-aldol 
NaBH4, -60 °C, DME no reaction, SM recovered 
Red-Al, -78 °C  no reaction, SM recovered 
LAH, -78 °C, 0 °C diol, urea reduced  
LTBA, -60 °C no reaction, SM recovered 
LTBA, -40 °C 75%, single diastereomer 
 
2.3.4  Intermolecular C5 Nucleophilic Addition Approaches 
A summary of addition results is presented in Table 2-2. Nucleophile screens began 
with ethyl diazoacetate (EDA) as, after diazo oxidation, this would be the most direct route to 
the -ketoester functionality we desired. While we observed addition to aldehydes and simple 
ketones in model studies, no reaction was observed at low temperature with our desired 
substrate. Upon warming, only decomposition was observed without product formation. 
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Table 2-2.  Nucleophilic Additions to the Methyl Ketone Electrophile 
 
Nucleophile Conditions Result 
EDA LDA, -78 °C No reaction 
EDA LDA, -78 °C  50 °C Decomposition 
 
nBuLi, 0 °C  RT Trace product 
 
MeMgBr, 0 °C  RT Me addition to ketone 
 
MeMgBr, 0 °C, 3h, then ketone No reaction 
 
ZnI2, NEt3, 0 °C No reaction 
 Large excess, 0 °C  RT Desired product, <40% yield, 1.3:1 dr 
 
TiCl4, 0 °C No reaction 
 
tBuLi, -78 °C No reaction 
 
 We then shifted our focus to less sterically-demanding nucleophiles as we believed the 
congested C5 carbonyl was once-again to blame for low-reactivity. Trimethysilylacetylene 
was deprotonated by nBuLi or MeMgBr and added to solution of ketone 2.68. Only trace 
product was observed in one case, although the excess methyl Grignard in solution participated 
in a smooth addition to the C5 ketone. Other metal counterions were tested as well as Lewis 
acidic conditions, but none produced the desired addition product. The only successful reaction 
we observed was a vinyl Grignard addition in large excess. This proceeded to give poor yields 
with an average dr of 1.3:1.  
2.3.5  Intramolecular C5 Nucleophilic Addition Approaches 
In addition to the congestion at our electrophilic site, we believed a deprotonation of 
the methyl ketone might be occurring under our reaction conditions, rendering the addition 
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pathway impossible. Encouraged by intramolecular chemistry we observed in earlier studies 
(i.e. 2.62, Scheme 2-12), we decided to pursue intramolecular addition strategies exploiting 
either the C7 hydroxyl or the allyl group as functional handles (Figure 2-4). The first approach 
(A, Figure 2-4) would involve an esterification of the C7 hydroxyl followed by deprotonation 
and intramolecular aldol addition, forming a six-membered lactone. Hydrolysis would then 
provide a new ester functional handle. An alternative approach (B, Figure 2-4) would use a 
cross metathesis reaction to install a Michael acceptor onto the allyl substituent. Nozaki-
Hiyama-Kishi chemistry or conjugate addition/aldol cyclization would each form the 
cyclopentanol core. 
Figure 2-4.  Intramolecular Addition Approaches 
 Figure 2-5 summarizes our attempted intramolecular aldol approaches. The -
benzyloxy derivative 2.69 was prepared and subjected to a variety of basic conditions. Bases 
tested in this transformation included LDA, KOtBu, K2CO3, and NaH. Of these promoters, 
potassium carbonate did not provide any reaction, and all others led to decomposition or 
deacylation of the -benzyloxy ester. It is reasonable to assume the aldol addition may have 
been taking place, but the retro process or other subsequent reactivity remained dominant in 
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these studies. Next, we attempted a Darzens cyclization with the related -chloro ester 
derivative 2.70. Once again, upon screening of basic conditions, conversion to the desired 
epoxide or 1,2-chloro-alcohol was never observed. We surmised the acidity of the C5 methyl 
ketone could again be hampering these additions and synthesized malonate pronucleophile 
2.71. The enhanced acidity of this substrate would theoretically allow for its selective 
enolization in the presence of the methyl ketone electrophile. We tested weaker bases and soft 
enolization conditions on this substrate, but failed to observe the desired product. The retro-
aldol process may have been even more prevalent in this study, as the malonate was doubly 
stabilizing of negative charge. 
Figure 2-5.  Hydroxyl Tethered Additions  
 
 With these negative results in hand, we chose to abandon the hydroxyl tether strategy 
and move on to the olefin functional handle. A cross metathesis reaction was used to install a 
methyl acrylate moiety onto the allyl group (Figure 2-6). Although it was difficult to achieve 
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high conversion with this reaction, the starting material was easily reisolated providing a 
reasonable yield of Michael acceptor 2.72. With this intermediate we envisioned three possible 
approaches: (1) -halogenation to provide a substrate amenable to NHK conditions, (2) 
epoxidation followed by aldol cyclization to provide an oxobicyclo[3.1.0]hexane system (an 
aggressive strategy which would quickly provide access to a functionalized pactamycin core), 
or (3) conjugate reduction/cyclization (vide infra).  
Figure 2-6.  Olefin Tethered Additions  
 
 We screened a variety of bromination conditions and were unable to isolate the desired 
vinyl bromide 2.73. The reactions were often messy or sometimes provided an intractable 
dibromide species. We quickly moved on to epoxidation strategies, in which we observed the 
desired reactivity although clean epoxide products were never isolated, and the reactions 
appeared to be occurring without diastereoselectivity. Met with multiple failures, we pursued 
our final reduction strategy (Table 2-3).  
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Table 2-3.  Conjugate Reduction/Cyclization Strategy 
 
Conditions 2.72 : 2.75 : 2.76 dr 
SmI2, MeOH/THF, 0 °C, 1 h 1:0:1 N/A 
SmI2, MeOH/THF, 0 °C, 6 h 0:1:1 N/D 
Stryker’s reagent, PhMe, 
0 °C  RT, 24 h 
1:1:0.5 4:1 
Stryker’s reagent, PhMe, 
RT, 48 h 
1.5:10:1 1:1 
  
The conjugate reduction strategy yielded some successful, yet intriguing results. We 
began screening with single-electron reductants. Samarium diiodide (SmI2) provided 50% 
conversion to the reduced acrylate 2.76 when quenched after one hour. Longer reaction times 
led to the observation of the desired cyclized product 2.75, albeit as a 1:1 mixture with the 
uncyclized reduction product 2.76. Unfortunately, we never developed conditions to favor 
formation of the cyclized product using samarium diiodide. A switch to Stryker’s reagent 
([(PPh3)CuH]6) led to cleaner reactions than SmI2, but still gave mixtures of products. After 24 
h we obtained 60% conversion with a 2:1 mix of products favoring the cyclization. Although 
the stereochemistry was never confirmed, the product was formed with a 4:1 dr. This was an 
exciting result, and we set out to optimize this preliminary finding but were disappointed to 
find that, while longer reaction times pushed closer to full conversion, the diastereoselectivity 
dropped to 1:1. This may be attributed to formation of a Cu-enolate species leading to 
epimerization at C4. Although these results gave us our first access to the pactamycin core, 
this strategy left two saturated methylenes at C2 and C3. Functionalization at these two sites 
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would require significant manipulation, a feature not in line with our goal of expedient 
synthesis. 
2.3.6  Key Discoveries Enabling Nucleophile Introduction 
Concurrent with the aforementioned cyclization approaches, two important discoveries 
were made involving C5 methyl additions. First, shown in Figure 2-7 A, the Peterson reagent 
(TMSCH2Li) was found to provide the desired methyl ketone from our corresponding methyl 
ester 2.61, a transformation that had eluded us for some time (vide supra). This transformation 
provided a transient enolsilane after Brook rearrangement and methoxide elimination which 
was subsequently hydrolyzed in situ via methanolysis to obtain the desired ketone. Although 
we had access to 2.68 through the alternate diketone route, this provided machinery for 
throughput of enantioenriched material by means of the Tsuji-Trost asymmetric allylation. 
Figure 2-7.  Two Important Discoveries 
 
 The second and more valuable discovery was nucleophilic addition promotion by 
cerium trichloride (CeCl3). The formation of organocerium compounds has been well-studied 
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and proper application of these reagents presents a drastic effect on reactivity.19 Two proposed 
features of organocerium reagents are enhanced Lewis acidic activation of carbonyls (due to 
high trivalent cerium oxophilicity), and a marked decrease in basicity of the nucleophilic 
reagent. Both of these properties proved important in our case and the result is succinctly 
presented in Figure 2-7 B. Generation of the organocerium reagent required carefully 
developed conditions, with preparation of anhydrous CeCl3 proving most important. 
Commercial cerium trichloride is sold as a heptahydrate and required a strict drying protocol 
to provide the desired advantageous effects.20 The granular, hydrated solid was placed under 
high-vacuum and heated successively at elevated temperatures up to 140 °C overnight to 
ensure complete dryness. The temperature had to be increased gradually to avoid the formation 
of cerium oxychloride derivatives. Once cooled, the bright white powder was stored 
indefinitely in a nitrogen-filled glovebox without decrease in activity. Storage on the laboratory 
benchtop, or even weighing the powder out under atmospheric conditions led to an unusable 
reagent.  
 With this strategy in hand, we were able to achieve highly diastereoselective, clean 
reaction with simple nucleophiles and returned to our original proposal, the addition of ethyl 
diazoacetate (EDA). Optimal conditions emerged wherein a LDA solution was added dropwise 
to a mixture of CeCl3, EDA, and the methyl ketone electrophile 2.68 at cryogenic temperature. 
Here, we observed high-yielding formation of the product as a single diastereomer (Figure 2-
8). While mass spectra suggested product formation and 1H NMR analysis contained all 
necessary peaks, the chemical shifts of some of these peaks caused concern. Subsequent 
transformations of the adduct were necessary to reveal the true identity of the EDA addition 
product, pyrazole 2.77.   
112 
Figure 2-8.  Ethyl Diazoacetate Addition - Revisited 
 
 This surprising and impressive transformation most likely resulted from a 1,3-dipolar 
cycloaddition of the diazo group and alkene. Tethered delivery of the enolate to the ketone 
electrophile gave the observed product with accompanying, unexpected formation of the 
pactamycin core. Although we were initially excited about the impact of this transformation, 
scores of subsequent experiments proved fruitless in manipulating the pyrazole ring into 
workable functionality for the C3/C4 amino alcohol. At this stage in our pactamycin synthesis, 
we came to realize the aldol cyclization approach laid out in our initial retrosynthesis (Figure 
2-3) was no longer realistic. Armed with our discovery of the valuable CeCl3 reagent, we 
revisited synthetic planning and outlined a new approach.  
2.3.7  Revised Retrosynthetic Strategy – RCM Approach 
We felt strongly that methyl ketone 2.68 was an important intermediate in the 
pactamycin synthesis, but believed we would benefit by changing the nucleophilic addition 
(Figure 2-9). Addition of a functionalized vinyl nucleophile would provide diene 2.80, which 
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could undergo ring-closing metathesis to construct cyclopentene 2.79. Allylic-site amination 
and oxidation of the alkene could install the C2/C3/C4 functionality leading to the completed 
core 2.78, which would require minimal manipulation to reach pactamycin. 
Figure 2-9.  Modified Retrosynthetic Approach – RCM Strategy 
 
2.3.8  Screening of Vinyl Nucleophiles and Stereochemical Model 
We began the next series of experiments aimed at testing vinyl additions and assaying 
stereochemical outcomes. An important model study performed with isopropenyl Grignard is 
summarized in Scheme 2-14. With the assistance of cerium trichloride, the Grignard addition 
proceeded in good yield to give tertiary alcohol 2.81 with a modest 2.7:1 dr. To determine the 
stereochemistry and advance the synthesis we attempted the proposed ring-closing metathesis. 
Grubb’s second generation catalyst (GII) proved effective for this transformation, cleanly 
providing cyclopentene 2.82 in 78% yield. 2D NMR analysis of the product presented 
conclusive evidence supporting the incorrect stereochemistry at C5. 
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Scheme 2-14.  Nucleophilic Addition to C5 Ketone Model Study 
 
While this result was disappointing, we noted the modest 2.7:1 dr achieved in the 
addition and believed there was an opportunity to reverse the selectivity by altering reaction 
conditions. We launched a screen of reaction parameters including Lewis acid identity, ligands, 
temperature, and solvent. The conversion was never improved and the diastereomeric ratio was 
only increased to 4.4:1 when using tetramethylethylenediamine (TMEDA) as an ancillary 
ligand.  
We next questioned whether step order of nucleophile addition would perturb our 
stereochemical outcome. Since our synthesis first required a methyl addition to the C5 carbonyl 
(Peterson’s reagent), and we had developed a subsequent vinyl nucleophilic addition to the 
same carbon, the steps could theoretically be reversed. In this sense, we would first synthesize 
a vinyl ketone species, then add a methyl nucleophile to form the C5 carbinol. If the mode of 
stereochemical induction was independent of nucleophile identity, we could potentially 
observe the opposite stereochemical outcome at C5.  
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Scheme 2-15.  Reversed Nucleophilic Addition at C5 
 
 We set out to test this hypothesis by synthesizing a vinyl-substituted C5 ketone with 
which we would test methyl additions (Scheme 2-15). Due to the poor electrophilicity of the 
C5 methyl ester (2.61), a reduction to the aldehyde was necessary to facilitate isopropenyl 
Grignard addition (2.83). After a Dess-Martin oxidation of the resultant secondary alcohol we 
had obtained desired vinyl ketone electrophile 2.84. Upon treatment with methyl Grignard in 
the presence of cerium trichloride, we were excited to observe a single diastereomer of the 
addition product. Subsequent RCM conversion to the cyclopentene and 2D NMR nOesy 
analysis led to the opposite stereochemical assignment depicted for carbinol 2.85, the desired 
C5 orientation. 
 We reasoned this stereochemical outcome could be justified by the following proposed 
model for selectivity (Figure 2-10). Independent of the “R” substituent on the ketone 
electrophile, we invoke a five-membered metal chelate (M = Ce and/or Mg) between the 
deprotonated urea nitrogen and C5 carbonyl (2.86). This rigid complex would present two 
differentiated diastereotopic faces: the Re face would be blocked by the allyl substituent, and 
the Si face would be severely encumbered by the secondary tert-butyldimethylsilyl ether. 
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Approach of the nucleophile (R', independent of identity) from the more-accessible Re face 
would provide the observed stereochemical outcome. Therefore, the diastereomer of choice 
may be accessed simply by order of addition of the desired R and R' nucleophiles. Moreover, 
the strategic decision to install the dimethylurea moiety early in our synthesis presented many 
challenges in subsequent steps, but proved crucial to obtain the desired stereochemical 
outcome at C5. 
Figure 2-10.  Stereochemical Selectivity Model 
 
2.3.9  Construction of Cyclopentene Core via RCM Approach 
With a grasp of the stereochemical control surrounding the C5 nucleophilic additions 
we next moved to prepare an appropriate vinyl nucleophile. To incorporate the 
hydroxymethylene at C4 we chose 2-bromopropenol (2.87) as a possible precursor. Described 
by Corey, this building block could be synthesized in one step from propargyl alcohol by 
adding HBr gas across the alkyne (Figure 2-11, A).21 This toxic gas was generated by the 
117 
dropwise addition of bromine to tetraline, which was then bubbled into the reaction mixture. 
Although the reaction was reported to occur in near-quantitative yield, in our hands at >10 
gram-scale, yields were typically around 70%.  
Figure 2-11.  Functionalized Vinyl Addition 
 
 We planned on using lithium-halogen exchange to generate a reactive nucleophilic 
species, but upon investigation of the literature, this appeared to be problematic. A report by 
Myles and coworkers described elimination as a common issue when 2-bromopropenol was 
treated with excess tert-butyllithium to effect halogen exchange.22 In addition to the desired 
nucleophilic species, a large concentration of propargyl alcohol dianion was obtained. 
Empirical results by the Myles group showed that the alkoxy counterion displayed a profound 
effect on the undesired elimination pathway. When MeMgBr was used for deprotonation with 
successive treatment of tert-butyllithium, the elimination pathway was shut down and 
nucleophilic addition to a variety of ketones and aldehydes was presented (Figure 2-11, B). 
Taking these results into account, we embarked on the next phase of synthetic progress toward 
the pactamycin core (Scheme 2-16). 
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 Addition of 2-bromopropenol to aldehyde 2.83 proceeded in modest yield and was 
unable to be optimized further. The oxidation of the resultant secondary alcohol to the desired 
ketone required selective protection of the newly-introduced C4 primary alcohol. This was 
accomplished via treatment with triethylsilyl chloride (a TBS protecting group was also 
installed and tested but presented complications during downstream transformations). After a 
Dess-Martin oxidation, the desired ketone 2.89 was in hand for the important methyl addition. 
Gratifyingly, optimized conditions gave an 88% yield with complete selectivity for the correct 
diastereomer, as was proven after a subsequent high-yielding ring-closing metathesis (2.91).  
Scheme 2-16.  Synthesis of Pactamycin Cyclopentene Core 
 
2.3.10  Proposal for C2/C3/C4 Functionalization 
At this point we had reached an important core intermediate in our synthesis, complete 
with stereointegrity at C5, C1, and C7. Three challenging installations remained: (1) the C4 
tertiary hydroxyl, (2) C3 anilino group, and (3) the C2 free amine. We laid out two plausible 
routes for these introductions (Figure 2-12). The first method (similar to the later Hanessian 
route) involved epoxidation of the olefin followed by a ring-opening aniline addition to 
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construct the anti-anilino alcohol relationship (2.92  2.94). The second proposal would be 
dihydroxylation of the olefin followed by selective activation of the secondary alcohol to an 
appropriate nucleofuge for aniline displacement (2.93  2.94). We believed we could use the 
rhodium-catalyzed C–H activation chemistry developed by Du Bois to install the C2 amine 
with direction by the C4 hydroxyl (2.95  2.96).23  
Figure 2-12.  Proposed Core Completion 
 
2.3.11  Alkene Oxidation Studies 
The results of our epoxidation studies are summarized in Table 2-4. It was quickly 
discovered that the absence of a protecting group on the C5 tertiary alcohol led to complex 
product mixtures, necessitating silyl protection. The TES/TBS/TBS tris-protected substrate 
provided full conversion when treated with m-CPBA at room temperature. Unfortunately, a 
70% yield of a corresponding, SiO2-stable isocyanate product (B) was obtained without 
epoxidation. Presumably, the high electron density of the dimethylamino group allowed for an 
oxidation event followed by Cope-type elimination to provide the observed outcome (Figure 
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2-13). We found it perplexing that m-CPBA was never able to provide the epoxide in ensuing 
experiments and decided to explore stronger oxidants.  
Table 2-4.  Epoxidation Studies 
 
R R' Conditions Result 
TES H m-CPBA, rt, 24 h complex mixture 
TES TBS m-CPBA, rt, 24 h B, 70% 
TES TBS TFPA, rt, 24 h C, 5:1 dr, 38% 
H H Ti(OiPr)4, DET,  
tBuOOH, rt, 24 h 
inconsistent results 
 
Figure 2-13.  Potential Mechanism for Isocyanate Formation 
 
 Our laboratory had recently obtained positive results using trifluoroperacetic acid 
(TFPA), so we tested that in our system. This reagent provided an epoxide product (C) as an 
inseparable 5:1 diastereomeric mixture in low yield with accompanying isocyanate formation. 
The urea could be reformed upon treatment with dimethylamine, but we deemed this result 
unsatisfactory due to low yields. As a final option, we tested Sharpless epoxidation conditions 
on the corresponding free diol (for direction), but this reaction was sluggish and results varied 
widely. With the small amount of desired epoxide we obtained, we performed a short screen 
of acid-catalyzed aniline additions to no avail and decided to turn to the dihydroxylation 
strategy. 
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 We began dihydroxylation screens with ruthenium trichloride as the precatalyst. As 
shown in Table 2-5, these conditions provided extreme reactivity. Using sodium periodate as 
a stoichiometric reoxidant, we observed complete oxidative cleavage of the alkene in under 
twelve minutes. Decreasing the reaction time to six minutes gave the diol product, but with a 
1:1 dr. We concluded this system would only provide reactivity, not selectivity, and moved to 
Sharpless dihydroxylations.24 Unfortunately, we observed the opposite outcome in these 
experiments as the commercial AD-mix-, under a variety of standard conditions, provided no 
reactivity in our system. As a final option we decided to try the original Upjohn 
dihydroxylation conditions25 and obtained the desired product, as a single diastereomer, in 61% 
yield. While the use of osmium tetroxide was not optimal, we were unable to match these 
results with any other procedure. 
Table 2-5.  Dihydroxylation Studies 
 
Conditions Result 
RuCl3 (cat.), NaIO4, EtOAc/H2O/ACN,  
0 °C, 12 min 
oxidative cleavage 
RuCl3 (cat.), NaIO4, EtOAc/H2O/ACN,  
0 °C, 6 min 
desired product, 
1:1 dr  
AD-mix-, tBuOH/H2O,  
RT, 24 h 
no reaction 
 
AD-mix-, MeSO2NH2, tBuOH/H2O,  
RT, 24 h 
no reaction 
OsO4 (cat.), NMO, H2O/
tBuOH/acetone, 
RT, 48 h 
61% yield, 
 correct diastereomer 
 With diol 2.93 in hand, we decided the best course of action would be attempt 
installation of the C2 amino group using the C3 hydroxyl as a functional handle. The directing 
carbamate group was selectively installed on the C3 hydroxyl using a two-step sequence 
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beginning with acylation with trichloroacetyl isocyanate. Cleavage of the resultant 
trichloroacetyl protecting group on nitrogen proved challenging in our system using published 
conditions. A screen of reagents was commenced, with aqueous sodium bicarbonate in 
methanol emerging as most effective. The carbamate was then subjected to the Du Bois 
conditions only to observe a complex mixture and decomposition of the urea moiety. 
Alternative catalysts were tested and control experiments were run to determine the source of 
decomposition. The carbamate intermediate was stable at elevated temperatures, but the 
oxidant seemed incompatible with the urea functionality. To obviate the oxidative 
decomposition issues, a pre-oxidized nitrene source was synthesized and tested in an 
intermolecular amination reaction. These experiments gave successful amination, but 
surprisingly, showed complete selectivity for the methyl groups of the urea, rather than the C2 
methylene. 
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Table 2-6.  Rh-Catalyzed C–H Amination Attempts 
 
Conditions Result 
Rh2Oct4, PhI(OAc)2, MgO,  
CH2Cl2, 40 °C, 16 h 
complex mixture, urea lost  
Rh2esp2, PhI(OAc)2, MgO,  
CH2Cl2, 40 °C, 16 h 
complex mixture, urea lost  
CH2Cl2, 50 °C, 16 h clean starting material 
Rh2Oct4, PhI(OAc)2, MgO,  
CH2Cl2, RT, 48 h 
complex mixture, urea lost  
 
2.3.12  Protecting Group Strategies and Acquisition of Crystal Structure 
Meeting failure in our C–H amination studies we considered alternative introduction 
strategies from the current stage of the synthesis as well as the cyclopentene intermediate 2.91. 
We believed oxidation of secondary alcohol 2.93 to the corresponding ketone would provide 
a useful functional handle; the now-enolizable C2 could in principle participate in electrophilic 
amination. The oxidation of 2.93 proved challenging in that oxidative cleavage decomposition 
pathways dominated using Dess-Martin and PCC oxidation protocols, although the Swern 
conditions provided ketone 2.99 uneventfully in high yields. We were concerned about the 
effect two free hydroxyls might have under anionic enolization conditions and 
functionalizations, and desired a protection scheme which would mask all four alcohols. After 
some experimentation, we discovered the deprotection of both silyl groups could be effected 
in a one-pot diacetonide formation reaction. This provided diacetonide 2.100 in 74% yield 
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(Scheme 2-17). This transformation also gave a white crystalline solid and an X-ray crystal 
analysis by Dr. Peter White (UNC) confirmed all stereochemical assignments previously 
determined by NMR analysis (Figure 2-14).26 
Scheme 2-17.  Ketone and Protecting Group Schemes 
 
Figure 2-14.  Diacetonide Crystal Structure 
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2.3.13  Electrophilic Ketone -Functionalization Studies 
We immediately launched a broad screen of electrophilic amine sources with the Li-
enolates derived from ketones 2.99 and 2.100. Additionally, the TBS enolsilane of 2.100 was 
synthesized for screening purposes using Lewis acidic activation (A, Figure 2-15). 
Unfortunately, none of the nitrogen sources we tested were compatible with our hindered 
system (B, Figure 2-15). We unable to observe any degree of C–N bond formation in 
subsequent studies. 
Figure 2-15.  Electrophilic Amination Studies 
 
 At this juncture, we decided to attempt alternative -carbonyl functionalizations that 
might provide access to the desired C2 amine (Scheme 2-18). We began with the Rubottom 
oxidation. Somewhat surprisingly to us, this was successful as silyl ether 2.102 was isolated 
upon treatment with m-CPBA. This was accompanied by isocyanate formation at the urea 
which was treated with dimethylamine to provide the desired -oxidized product 2.103. 
Subsequent deprotection and activation steps for azide substitution at C2 failed, but these 
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experiments were helpful in showing that large functionality could be tolerated at the C2 
position.  
Scheme 2-18.  Non-Amine C2 Functionalizations 
 
 After screening of -halogenation conditions, we settled on dichlorohydantoin 2.104. 
While treatment of ketone 2.100 with LDA and hydantoin 2.104 provided -chlorination, 
dichlorination and side reactions were also prevalent. The preformed enolsilane 2.101, 
however, cleanly provided the mono-chlorinated product 2.105. To our surprise, the TBS 
group remained incorporated on the molecule, presumably on the urea, although other 
possibilities could not be ruled out. We next attempted a chloride displacement with sodium 
azide, only to isolate aziridine 2.106, likely the result of a TBS deprotection/intramolecular 
SN2 pathway. While this intermediate could potentially serve as an electrophile for azide 
aziridine-opening, this transformation was never realized under a variety of experimental 
conditions.  
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2.3.14  Manipulation of C3 Ketone 
These experiments marked the end of our attempted C2 aminations by means of ketone 
-functionalizations. Before giving up on C3 ketone-mediated strategies, however, we wanted 
to probe the electrophilicity of the ketone itself. As we ultimately needed aniline functionality 
at C3 we screened reductive amination chemistry, finding no success. We were, however, able 
to condense hydroxylamine onto the C3 ketone to provide oxime 2.107 (Scheme 2-19). We 
were encouraged by the possibility of executing a Neber rearrangement which could ultimately 
produce -amino ketone 2.110. The first step was formation of a tosyl-oxime. Unfortunately, 
under a variety of basic conditions, we were never able to install an activating group on the 
oxime, precluding the Neber chemistry.  
Scheme 2-19.  Neber Rearrangement 
 
 The final C3 ketone manipulation strategy to be discussed strictly involved aniline 
installation from the ketone using Buchwald-Hartwig palladium coupling chemistry. First, we 
needed an activated coupling partner and decided a vinyl triflate was most reasonable to reach. 
To this end, screening of conditions identified Comins’s reagent as a unique promoter of this 
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transformation, cleanly providing triflate 2.111 (Scheme 2-20). This coupling partner was 
subjected to the Buchwald conditions using aniline as a test nucleophile. We observed 
complete conversion, but upon analysis were puzzled by the isolation of ketone 2.100. This 
was likely due to rapid hydrolysis of the imine product, or decomposition of the vinyl triflate 
under the reaction conditions. We tested for the presence of a fleeting imine intermediate by 
immediate reduction upon reaction completion with sodium cyanoborohydride. Expecting to 
see the aniline product 2.112, we obtained complete decomposition in this experiment. 
Scheme 2-20.  Pd-Catalyzed Aniline Coupling 
 
2.3.15  C2 Allylic Functionalization 
With hopes waning for completion of the pactamycin core via the route described thus 
far, we turned to a final approach for C2 functionalization. This involved going back to the 
cyclopentene intermediate 2.91, prior to oxidation. We believed we might be able to install the 
amine via allylic functionalization at this stage and resume the synthesis with C2 completed. 
We pursued two approaches, the first beginning with allylic bromination (A, Figure 2-16). We 
were pleased to effect radical bromination under standard conditions to provide allylic bromide 
2.113 as a mixture of diastereomers. We continued on with this mix, hoping to converge later 
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in the synthesis, perhaps by enolization of a C3 ketone. Next, we attempted azide substitution. 
To our surprise, this was ineffective for azide installation but induced aziridination by the urea 
with the diastereomer in the proper anti orientation (2.114). The TES protecting groups were 
also cleaved, unable to withstand the reaction conditions. Once again, any subsequent 
manipulation of the azirdine intermediate proved fruitless. 
Figure 2-16.  Allylic Functionalization 
 
 Our final allylic functionalization approach involved direct azide installation using 
oxidative protocols. In keeping with our trend of effective highly-toxic reagents, lead 
tetraacetate (Pb(OAc)4) emerged as a viable oxidant. Treatment of cyclopentene 2.91 with 
superstoichiometric Pb(OAc)4 and excess TMS azide provided a mixture of three products. 
These were identified by mass spectral analysis as aziridine 2.116, mono-azide 2.117, and 
diazide 2.118. We were never successful in exerting control of this product distribution in 
subsequent experiments and were forced to abandon the allylic approach. These studies marked 
the completion of experimentation with this synthetic route to pactamycin. We were forced to 
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concede in our late-stage introduction of the C2 amine campaign and moved on to pursue 
alternate strategies for its early incorporation. 
2.4  Conclusion 
 Toward our goal of completing a total synthesis of pactamycin, we have presented a 
partial synthesis of the cyclopentane core. Diacetonide 2.100 was synthesized in fifteen steps 
with an appropriate ketone functional handle for installation of the C2 amino and C3 anilino 
moieties. En route we explored an aldol cascade retrosynthetic strategy which was ultimately 
abandoned due to challenging precursor synthesis. A ring-closing metathesis route was then 
developed leading to our advanced intermediate 2.100 after an interesting study uncovered a 
unique stereochemical model for C5 ketone nucleophilic additions. Various failed C2 
amination approaches ultimately led to the conclusion that this important substituent would 
need to be installed early in our synthetic route to proceed by analogous strategy. Ongoing 
experiments are focused on these endeavors. 
Figure 2-17.  Summary 
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2.5  Experimental Details 
Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker model Avance 400 (1H NMR at 400 MHz and 13C at 100 
MHz), Bruker model Avance 500 (1H NMR at 500 MHz and 13C NMR at 125 MHz), or a 
Bruker Avance III 600 (1H NMR at 600 MHz and 13C NMR at 150 MHz) spectrometer with 
solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 
77.0 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, br s 
= broad singlet, d = doublet, br d = broad doublet, t = triplet, q = quartet, m = multiplet), 
coupling constants (Hz), and integration. Mass spectra were obtained using a Bruker BioTOF 
II spectrometer with electrospray ionization calibrated with CsOAc or an Agilent Technologies 
6520, Accurate – Mass QTOF LCMS, 1200 series LC with dual spray ESI source. All samples 
were prepared in methanol. Analytical thin layer chromatography (TLC) was performed on 
Sorbent Technologies 0.20 mm Silica G TLC plates. Visualization was accomplished with UV 
light, KMnO4, and/or aqueous ceric ammonium nitrate solution followed by heating. 
Purification of the reaction products was carried out by flash chromatography using Siliaflash-
P60 silica gel (40-63μm) purchased from Silicycle. Supercritical fluid chromatography was 
performed on a Berger SFC system equipped with a Chiralcel OD column. Samples were 
eluted with SFC grade CO2 at the indicated percentage of MeOH. Unless otherwise noted, all 
reactions were carried out under an atmosphere of dry nitrogen in oven-dried glassware with 
magnetic stirring. Yield refers to isolated yield of analytically pure material unless otherwise 
noted. Yields are reported for a specific experiment and as a result may differ slightly from 
those found in the tables, which are averages of at least two experiments. 
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Materials: General.  Tetrahydrofuran, diethyl ether, dichloromethane, and toluene were dried 
by passage through a column of neutral alumina under nitrogen prior to use. Cerium trichloride 
was dried under high-vacuum at 60 °C for 2 h, 80 °C for 2 h, and 140 °C for 12 h prior to 
storage in a nitrogen-filled glove box.27 Triethylamine was freshly distilled from calcium 
hydride prior to use. Pentane was freshly distilled from sodium hydride prior to use. Methyl 
diazoacetoacetate (7) was prepared by a known procedure.28 2-bromopropenol (15) was 
prepared via the procedure of Corey.29 All other reagents were purchased from commercial 
sources and were used as received unless otherwise noted. 
Experimental Procedures: 
 
Methyl 2-(3,3-dimethylureido)-3-oxobutanoate (2.58):  A 1-L round-bottomed flask was 
charged with methyl diazoacetoacetate 2.57 (13.17 g, 92.0 mmol, 1.00 equiv) and finely 
ground 1,1-dimethylurea (12.16 g, 138 mmol, 1.50 equiv). Toluene (275 mL) and 1,2-
dichlorethane (275 mL) were added and the suspension was heated to 80 °C in a sand bath with 
magnetic stirring. The solution gradually became homogenous upon heating. Four portions of 
Rh2(Oct)4 (0.071 g, 0.001 mmol, 0.001 equiv, each portion) suspended in toluene were added 
over 30 min. The reaction was allowed to stir until consumption of starting material was 
indicated by TLC analysis, typically 1 h. The reaction was allowed to cool to rt; excess 1,1-
dimethylurea precipitated upon cooling. The urea was removed via filtration (cotton) and the 
filtrate was concentrated in vacuo. The product was purified via flash chromatography (70:30 
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to 60:40 petroleum ether/acetone) to give the desired product as a yellow solid (14.78 g, 79%).  
Analytical data: mp 61-64 °C; 1H NMR (600 MHz, CDCl3): δ 5.59 (s, 1H), 5.17 (d, J = 6.0 
Hz, 1H), 3.78 (s, 3H), 2.92 (s, 6H), 2.35 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 199.8, 167.6, 
156.8, 64.3, 53.1, 36.1, 28.0; HRMS (ESI+) Calcd. for C8H14N2O4+Na, 225.0852; Found, 
225.0844; IR (thin film, cm-1) 3431, 2955, 1751, 1647, 1522, 1382, 1270, 1206; TLC (70:30 
petroleum ether/acetone): Rf = 0.20. 
 
Methyl 2-acetyl-2-(3,3-dimethylureido)pent-4-enoate (2.59):  In a nitrogen-filled glove box 
a flame-dried 100-mL round-bottomed flask was charged with allylpalladium chloride dimer 
(0.120 g, 0.328 mmol, 0.005 equiv) and rac-BINAP (0.432 g, 0.695 mmol, 0.0106 equiv). 
Toluene (20 mL) was added and the suspension was stirred for 10 min, capped with a rubber 
septum, and removed from the glove box. Allyl acetate (7.85 mL, 72.13 mmol, 1.10 equiv) 
was added and the catalyst solution was stirred for an additional 10 min. A separate flame-
dried 1000-mL round-bottomed flask was charged with -keto ester 2.58 (13.26 g, 65.57 
mmol, 1.00 equiv) and KOtBu (7.72 g, 68.84 mmol, 1.05 equiv). Toluene (360 mL) was added 
and the suspension was stirred under a nitrogen atmosphere. The catalyst solution was 
introduced via cannula transfer, and the reaction was stirred for 12 h. The reaction was 
quenched with 1 M HCl (200 mL) and extracted with EtOAc (2 x 100 mL). The combined 
organic extracts were washed with brine, dried with magnesium sulfate, and concentrated in 
vacuo. The product was purified via flash chromatography (70:30 petroleum ether/acetone) to 
give the desired product as a pale yellow oil (12.27 g, 77%).  Analytical data: 1H NMR  (600 
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MHz, CDCl3): δ 5.95 (s, 1H), 5.54-5.48 (m, 1H), 5.10-5.06 (m, 2H), 3.75 (s, 3H), 3.15 (dd, J 
= 14.4, 6.6 Hz, 1H), 2.99 (dd, J = 14.4, 7.8 Hz, 1H), 2.90 (s, 6H), 2.16 (s, 3H); 13C NMR (150 
MHz, CDCl3): δ 200.1, 169.5, 156.0, 131.6, 119.3, 72.0, 53.3, 36.9, 36.0, 24.7; HRMS (ESI+) 
Calcd. for C11H18N2O4+Cs, 375.0321; Found, 375.0319; IR (thin film, cm
-1) 3429, 2953, 1726, 
1653, 1517, 1368, 1280, 1226; TLC (70:30 petroleum ether/acetone): Rf = 0.30. 
 
Methyl 2-(3,3-dimethylureido)-2-(1-hydroxyethyl)pent-4-enoate (2.60):  A flame-dried 
250-mL round-bottomed flask was charged with ketone 2.59 (3.56 g, 14.71 mmol, 1.00 equiv) 
and THF (60 mL). The solution was cooled to -78 °C, and L-Selectride (1 M in THF, 22.07 
mL, 22.07 mmol, 1.50 equiv) was added dropwise. The reaction was stirred under a nitrogen 
atmosphere until consumption of starting material was indicated by TLC analysis, typically 4 
h. The reaction was quenched by the sequential addition (5 mL) of H2O, EtOH, 1 M NaOH, 
and 30% H2O2 and allowed to warm to rt. Saturated aqueous Na2S2O4 (30 mL) was added and 
the solution was then extracted with EtOAc (3 x 20 mL). The combined organic extracts were 
washed with brine, dried with magnesium sulfate, and concentrated in vacuo. The product was 
purified via flash chromatography (80:20 to 60:40 petroleum ether/acetone) to give the product 
diastereomers as pale yellow solids (major, 2.59 g, 72%, minor, 0.737 g, 21%). Analytical 
data: mp 71-74 °C; 1H NMR  (600 MHz, CDCl3): δ 6.18 (d, J = 10.2 Hz, 1H), 5.60-5.57 (m, 
1H), 5.23-5.20 (m, 2H), 4.86 (s, 1H), 4.06-4.03 (m, 1H), 3.78 (s, 3H), 2.92 (s, 6H), 2.75 (d, J 
= 13.2, 1H), 2.34 (t, J = 12.6, 1H), 1.18 (d, J = 6.0, 3H); 13C NMR (150 MHz, CDCl3): δ 172.8, 
158.7, 132.5, 120.8, 71.4, 68.1, 52.6, 40.4, 36.6, 18.1; HRMS (ESI+) Calcd. for 
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C11H20N2O4+Cs, 377.0477; Found, 377.0464; IR (thin film, cm
-1) 3421, 2980, 1753, 1636, 
1524, 1457, 1377, 1220, 1120; TLC (70:30 petroleum ether/acetone): Rf = 0.20. 
Crude 1H NMR Spectrum of 2.60: 
 
 
 
 
 
 
 
 
Methyl 2-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(3,3-dimethylureido)pent-4-enoate 
(2.61):  A flame-dried 500-mL round-bottomed flask was charged with alcohol 2.60 (8.50 g, 
35.12 mmol, 1.00 equiv) and CH2Cl2 (175 mL). 2,6-lutidine (12.10 mL, 105 mmol, 3.00 equiv) 
was added and the solution was cooled 0 °C. TBSOTf (16.11 mL, 70.24 mmol, 2.00 equiv) 
was added dropwise and the reaction was allowed to slowly warm to rt over 12 h by allowing 
the ice-water bath to expire. The reaction was quenched by the addition of saturated aqueous 
NaHCO3 (100 mL). The solution was extracted with Et2O, washed with 1 M HCl and brine. 
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The organic extracts were dried with magnesium sulfate, and concentrated in vacuo. The 
product was purified via flash chromatography (95:5 to 90:10 petroleum ether/acetone) to give 
the desired product as a pale yellow oil (11.06 g, 88%).  Analytical data: 1H NMR  (600 MHz, 
CDCl3): δ 5.84-5.76 (m, 1H), 5.31 (s, 1H), 4.98-4.95 (m, 2H), 4.28 (q, J = 6.0, 1H), 3.70 (s, 
3H), 3.01 (dd, J = 13.8, 6.0 Hz, 1H), 2.86 (s, 6H), 2.73 (dd, J = 13.8, 7.8 Hz, 1H), 1.10 (d, J = 
6.0, 3H), 0.85 (s, 9H), 0.04 (s, 6H); 13C NMR (150 MHz, CDCl3): δ 173.4, 157.1, 134.5, 177.2, 
72.0, 67.2, 52.3, 36.1, 35.3, 25.58, 18.75, 17.72, -4.1, -5.1; HRMS (ESI+) Calcd. for 
C17H34N2O4Si+Cs, 491.1342; Found, 491.1341; IR (thin film, cm
-1) 3437, 2954, 2857, 1739, 
1655, 1509, 1380, 1264, 1128, 834, 739; TLC (70:30 petroleum ether/acetone): Rf = 0.60.      
 
3-(2-((tert-butyldimethylsilyl)oxy)-3-formylhex-5-en-3-yl)-1,1-dimethylurea (2.83): A 
flame-dried 500-mL round-bottomed flask was charged with ester 2.61 (9.87 g, 27.7 mmol, 
1.00 equiv) and CH2Cl2 (150 mL). The solution was cooled -78 °C and a solution of DIBAL-
H was added (10.87 mL in 50 mL CH2Cl2, 61.0 mmol, 2.20 equiv). The reaction was allowed 
to warm to 0 °C was stirred at that temperature under a nitrogen atmosphere under a nitrogen 
atmosphere until consumption of starting material was indicated by TLC analysis, typically 2 
h. The reaction was then cooled to -78 °C and acetone (300 mL) was added. Stirring continued 
for 10 min and 10% aqueous Rochelle’s salt (200 mL) was added. The reaction was allowed 
to warm to rt and stirred for 1 h. The organic layer was extracted with Et2O, washed with brine, 
dried with magnesium sulfate, and concentrated in vacuo. The crude alcohol product was taken 
on directly to the next step. 
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A 500-mL round-bottomed flask was charged with the crude alcohol and CH2Cl2 (150 mL). 
Dess Martin’s periodinane (12.91 g, 30.50 mmol, 1.10 equiv) was added. The reaction was 
stirred at rt until consumption of starting material was indicated by TLC analysis, typically 30 
min. Saturated NaHCO3, Na2S2O4, and Et2O (50 mL, each) were added and stirring was 
continued until two clear layers formed. The organic layer was extracted with Et2O, washed 
with brine, dried with magnesium sulfate, and concentrated in vacuo. The product was purified 
via flash chromatography (90:10 to 85:15 petroleum ether/acetone) to give the desired product 
as a waxy solid (8.04 g, 89%).  Analytical data: 1H NMR  (600 MHz, CDCl3): δ 9.61 (s, 1H), 
5.64-5.57 (m, 1H), 5.42 (s, 1H), 5.04 (d, J = 6.6, 1H), 5.02 (s, 1H), 4.57 (q, J = 6.0, 1H), 3.07 
(dd, J = 14.4, 7.2 Hz, 1H), 2.91 (s, 6H), 2.84 (dd, J = 14.4, 7.8 Hz, 1H), 1.09 (d, J = 6.6, 3H), 
0.91 (s, 9H), 0.14 (s, 3H), 0.09 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 202.0, 156.9, 133.0, 
118.4, 70.9, 68.7, 36.2, 33.8, 25.8, 19.0, 17.9, -4.2, -5.0; HRMS (ESI+) Calcd. for 
C16H32N2O3Si+Na, 351.2080; Found, 351.2076; IR (thin film, cm
-1) 2930, 2858, 1731, 1652, 
1515, 1377, 1256, 1103, 836; TLC (90:10 petroleum ether/acetone): Rf = 0.20. 
 
3-(1-((tert-butyldimethylsilyl)oxy)ethyl)-3-hydroxy-2-(hydroxymethyl)hepta-1,6-dien-4-
yl)-1,1-dimethylurea (2.88): A flame-dried 250-mL round-bottomed flask was charged with 
2-bromopropenol 2.87 (2.49 g, 18.17 mmol, 2.20 equiv) and Et2O (100 mL). The solution was 
cooled to 0 °C under a nitrogen atmosphere. Methylmagnesium bromide (3.0 M, 6.05 mL, 
18.17 mmol, 2.20 equiv) was added dropwise and the reaction was cooled to -78 °C. tert-
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Butyllithium (1.5 M, 24.0 mL, 36.34 mmol, 4.40 equiv) was added over 1 h via syringe pump. 
After the addition was complete the solution was warmed to 0 °C and stirred for 3 h. The 
reaction was cooled to -78 °C, and a solution of aldehyde 2.83 in Et2O (15 mL) was added 
(2.71 g, 8.26 mmol, 1.00 equiv). The reaction was allowed to warm to rt over 12 h. Saturated 
NH4Cl was added (50 mL) and the organic layer was extracted with Et2O, washed with brine, 
dried with magnesium sulfate, and concentrated in vacuo. The product diastereomers (~1:1, 
inconsequential, not separated) were purified via flash chromatography (90:10 to 70:30 
petroleum ether/diethyl ether) to give the desired product as a colorless oil (1.99 g, 60%).  
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.72 (d, J = 8.8 Hz), 7.67 (d, J = 9.6 Hz), 
6.18-6.12 (m), 6.00-5.95 (m), 5.12 (s), 5.35 (s), 5.31 (s), 5.17-4.96 (m), 4.86 (q, J = 6.4 Hz), 
4.78 (s), 4.33-4.27 (m), 4.18-4.07 (m), 3.12 (dd, J = 14.8, 9.6 Hz), 2.90 (s), 2.86 (s), 2.55 (dd, 
J=13.6, 9.6 Hz), 2.41 (dd, J=15.2, 6.0 Hz), 2.17 (dd, J = 14.4, 9.2 Hz), 1.32 (d, J = 6.0 Hz), 
1.29 (d, J = 6.0 Hz), 0.89 (s), 0.87 (s), 0.10 (s), 0.07 (s), 0.07 (s), -0.07(s); 13C NMR (100 
MHz, CDCl3): δ 159.6, 159.0, 149.6, 149.4, 136.2, 135.2, 118.8, 116.8, 115.3, 115.0, 79.8, 
77.9, 71.9, 67.8, 64.6, 64.2, 62.7, 37.4, 36.9, 36.6, 34.3, 25.8, 19.0, 18.9, 17.9, 17.9, -4.1, -4.2, 
-4.2, -5.5; HRMS (ESI+) Calcd. for C19H38N2O4Si+H, 387.2679; Found, 387.2685; IR (thin 
film, cm-1) 3410, 2930, 1630, 1527, 1265, 838, 739; TLC (70:30 petroleum ether/acetone): Rf 
= 0.30. 
 
3-(6-allyl-11,11-diethyl-2,2,3,3,5-pentamethyl-8-methylene-7-oxo-4,10-dioxa-3,11-
disilatridecan-6-yl)-1,1-dimethylurea (2.89): A flame-dried 250-mL round-bottomed flask 
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was charged with diol 2.88 (0.90 g, 2.33 mmol, 1.00 equiv), DMAP (0.085 g, 0.699 mmol, 
0.30 equiv), and CH2Cl2 (60 mL). The solution was cooled to 0 °C under a nitrogen atmosphere 
and triethylamine (0.65 mL, 4.66 mmol, 2.00 equiv) was added. Triethylsilyl chloride (0.47 
mL, 2.79 mmol, 1.20 equiv) was added dropwise and the reaction was allowed to slowly warm 
to rt over 12 h. Saturated NaHCO3 was added (50 mL) and the organic layer was extracted 
with Et2O, washed with brine, dried with magnesium sulfate, and concentrated in vacuo. The 
crude monoalcohol was taken on directly to the next step. 
A 100-mL round-bottomed flask was charged with the crude monoalcohol and CH2Cl2 (40 
mL). Dess Martin’s periodinane (1.48 g, 3.50 mmol, 1.50 equiv) was added. The reaction was 
stirred at rt until consumption of starting material was indicated by TLC analysis, typically 1 
h. Saturated NaHCO3, Na2S2O4, and Et2O (15 mL, each) were added and stirring was continued 
until two clear layers formed. The organic layer was extracted with Et2O, washed with brine, 
dried with magnesium sulfate, and concentrated in vacuo. The product was purified via flash 
chromatography (90:10 petroleum ether/acetone) to give the desired product as a colorless oil 
(0.793 g, 68%).  Analytical data: 1H NMR (500 MHz, CDCl3): δ 6.50 (s, 1H), 6.01 (s, 1H), 
5.88-5.79 (m, 1H), 5.58 (s, 1H), 4.97-4.89 (m, 2H), 4.53 (q, J = 6.5 Hz, 1H), 4.36 (s, 2H), 2.93 
(dd, J = 14.0, 6.5 Hz, 1H), 2.86 (s, 6H), 2.78 (dd, J = 14.5, 14.0 Hz, 1H), 1.08 (d, J = 6.0 Hz, 
3H), 0.95 (t, J = 8.0 Hz, 9H), 0.93 (s, 9H), 0.61 (q, J = 8.0 Hz), 0.15 (s, 3H), 0.11 (s, 3H); 13C 
NMR (100 MHz, CDCl3): δ 199.4, 157.2, 145.1, 135.4, 120.8, 117.0, 71.4, 70.7, 61.9, 36.2, 
35.4, 25.7, 18.8, 17.9, 6.7, 4.4, -4.1, -4.8; HRMS (ESI+) Calcd. for C25H50N2O4Si2+H, 
499.3387; Found, 499.3391; IR (thin film, cm-1) 3427, 2955, 1655, 1502, 1097, 950, 834, 738; 
TLC (90:10 Petroleum Ether/Acetone): Rf = 0.30. 
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3-(6-allyl-11,11-diethyl-7-hydroxy-2,2,3,3,5,7-hexamethyl-8-methylene-4,10-dioxa-3,11-
disilatridecan-6-yl)-1,1-dimethylurea (2.90): In a nitrogen-filled glove box a flame-dried 
100-mL round-bottomed flask was charged with cerium trichloride (1.29 g, 5.25 mmol, 5.00 
equiv).1 The flask was capped with a rubber septum and removed from the glove box. THF (20 
mL) was added at 0 °C and stirred at that temperature for 3 h. The solution was cooled to -78 
°C and methylmagnesium bromide (3.0 M, 1.75 mL, 5.25 mmol, 5.00 equiv) was added. The 
reaction was stirred for 1 h followed by the addition of a THF solution (5 mL) of enone 2.89 
(0.524 g, 1.05 mmol, 1.00 equiv). The reaction was then stirred at -78 °C for 5 h. Aqueous 
acetic acid (0.5 M, 20 mL) was added and the solution was warmed to rt. The organic layer 
was extracted with Et2O, washed with saturated NaHCO3, brine, dried with magnesium sulfate, 
and concentrated in vacuo. The product was purified via flash chromatography (95:5 petroleum 
ether/acetone) to give the desired product with >20:1 diasteromeric ratio as a colorless oil 
(0.476 g, 88%).  Analytical data: 1H NMR (600 MHz, CDCl3): δ 7.81 (s, 1H), 6.02-5.94 (m, 
1H), 5.53 (s, 1H), 5.42 (s, 1H), 5.08 (d, J = 17.4 Hz, 1H), 5.05 (d, J = 10.2 Hz, 1H), 4.98 (s, 
1H), 4.58 (q, J = 6.0 Hz, 1H), 4.39 (d, J = 15.6 Hz, 1H), 4.21 (d, J = 15.6 Hz, 1H), 2.88 (dd, J 
= 12.0, 6.0 Hz, 1H), 2.85 (s, 6H), 2.58 (dd, J = 15.0, 5.4 Hz, 1H), 1.33 (d, J = 6.0 Hz, 3H), 1.32 
(s, 3H), 0.94 (t, J = 8.4 Hz, 9H), 0.87 (s, 9H), 0.59 (q, J = 7.8 Hz, 6H), 0.11 (s, 3H), 0.02 (s, 
3H); 13C NMR (150 MHz, CDCl3): δ 159.4, 154.4, 135.9, 117.7, 110.6, 79.3, 69.0, 67.2, 62.9, 
36.7, 34.4, 27.8, 21.5, 17.9, 6.8, 4.4, -4.1, -4.6; HRMS (ESI+) Calcd. for C26H54N2O4Si2+Na, 
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537.3520; Found, 537.3525; IR (thin film, cm-1) 3390, 2955, 1631, 1265, 1080, 837, 740; TLC 
(90:10 petroleum ether/acetone): Rf = 0.30. 
 
3-(1-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-hydroxy-2-methyl-3-
(((triethylsilyl)oxy)methyl)cyclopent-3-en-1-yl)-1,1-dimethylurea (2.91): In a nitrogen-
filled glove box a flame-dried 250-mL round-bottomed flask was charged with Grubbs’s 
second generation catalyst (0.152 g, 0.18 mmol, 0.15 equiv). The flask was capped with a 
rubber septum and removed from the glove box. CH2Cl2 (70 mL) was added followed by a 
CH2Cl2 solution (5 mL) of diene 2.90 (0.618 g, 1.20 mmol, 1.00 equiv). The reaction stirred 
for 12 h under a nitrogen atmosphere. The reaction was then concentrated in vacuo. The 
product was purified via flash chromatography (90:10 to 80:20 hexanes/ethyl acetate) to give 
the desired product as white solid (0.495 g, 85%). Analytical data: mp 67-70 °C;  1H NMR 
(500 MHz, CDCl3): δ 5.45 (s, 1H) 4.90 (s, 1H), 4.67 (s, 1H), 4.56 (q, J = 6.0 Hz, 1H), 4.31 (d, 
J = 16.0, 1H), 4.27 (d, J = 16.5, 1H), 2.90 (s, 6H), 2.80 (d, J = 15.5 Hz, 1H), 1.91 (d, J = 15.0 
Hz, 1H), 1.25 (s, 3H), 1.09 (d, J = 6.5 Hz, 3H), 0.95 (t, J = 8.0 Hz, 9H), 0.87 (s, 9H), 0.61 (q, 
J = 8.0 Hz, 6H), 0.04 (s, 3H), -0.08 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 159.0, 149.5, 
118.9, 83.7, 73.1, 68.0, 59.3, 36.6, 36.4, 25.9, 24.8, 21.8, 17.9, 6.7, 4.3, -4.1, -5.4; HRMS 
(ESI+) Calcd. for C24H50N2O4Si2+H, 487.3387; Found, 487.3386; IR (thin film, cm
-1) 3417, 
2955, 1632, 1517, 1265, 1084, 834, 739; TLC (90:10 hexanes/EtOAc): Rf = 0.40. 
 
142 
1H nOesy analysis of 2.91: 
 
 
3-(1-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2,3,4-trihydroxy-2-methyl-3-
(((triethylsilyl)oxy)methyl)cyclopentyl)-1,1-dimethylurea (2.93): A 20-mL scintillation vial 
was charged with N-methylmorpholine N-oxide (0.40 g, 3.45 mmol, 5.00 equiv) and H2O (7 
mL). tBuOH (2 mL) was then added followed by OsO4 (0.002 g, 0.007 mmol, 0.01 equiv). The 
mixture was stirred and an acetone solution (3 mL) of cyclopentene 2.91 (0.336 g, 0.69 mmol, 
1.00 equiv) was added. The suspension was stirred vigorously until consumption of starting 
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material was indicated by TLC analysis, typically 24-48 h. Talc (0.5 g) was added followed by 
Na2S2O4 (5 mL). The solids were filtered off and the organics were removed in vacuo. The 
aqueous solution was extracted with CH2Cl2 (3 x 5 mL), washed with brine, dried with 
magnesium sulfate, and concentrated in vacuo. The product was purified via flash 
chromatography (70:30 hexanes/ethyl acetate) to give the desired product with >20:1 
diasteromeric ratio as a pale brown oil (0.218 g, 61%).  Analytical data: 1H NMR (400 MHz, 
CDCl3): δ 5.66 (s, 1H), 5.55 (s, 1H), 5.09 (s, 1H), 4.68 (q, J = 6.4 Hz, 1H), 4.37-4.31 (m, 1H), 
3.75 (d, J = 10.0 Hz, 1H), 3.68 (d, J = 10.4 Hz, 1H), 3.48 (d, J = 9.6 Hz, 1H), 2.89 (s, 6H), 
2.40 (dd, J = 14.8, 6.4 Hz, 1H), 2.17 (dd, J = 14.8, 9.2 Hz, 1H), 1.28 (s, 3H), 1.14 (d, J = 6.0 
Hz, 3H), 0.95 (t, J = 8.0 Hz, 9H), 0.87 (s, 9H), 0.62 (q, J = 8.0 Hz, 6H), 0.13 (s, 3H), 0.09 (s, 
3H); 13C NMR (100 MHz, CDCl3): δ 158.7, 85.7, 79.6, 71.0, 69.0, 64.1, 37.6, 36.2, 25.9, 19.6, 
19.4, 17.8, 6.5, 4.0, -4.2, -4.4; HRMS (ESI+) Calcd. for C24H52N2O6Si2+Na, 543.3262; Found, 
543.3264; IR (thin film, cm-1) 3420, 2955, 1628, 1535, 1375, 1253, 1051, 829, 738; TLC 
(60:40 hexanes/EtOAc): Rf = 0.40. 
 
3-(1-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2,3-dihydroxy-2-methyl-4-oxo-3-
(((triethylsilyl)oxy)methyl)cyclopentyl)-1,1-dimethylurea (2.99): A flame-dried 20-mL 
scintillation vial was charged with oxalyl chloride (0.023 mL, 0.265 mmol, 1.20 equiv) and 
CH2Cl2 (4 mL). The solution was cooled to -78 °C and DMSO (0.038 mL, 0.528 mmol, 2.40 
equiv) was added dropwise. The reaction was stirred for 10 min and a CH2Cl2 solution (2 mL) 
of triol 2.93 (0.115 g, 0.22 mmol, 1.00 equiv) was added. Stirring was continued for 30 min 
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followed by the dropwise addition of triethylamine (0.153 mL, 1.10 mmol, 5.00 equiv). The 
reaction was allowed to warm slowly in the dry ice/acetone bath until consumption of starting 
material was indicated by TLC analysis, typically 1-2 h. H2O was added (5 mL) and the organic 
layer was extracted with Et2O, washed with brine, dried with magnesium sulfate, and 
concentrated in vacuo. The product was purified via flash chromatography (60:40 
hexanes/ethyl acetate) to give the desired product as a pale brown oil (0.100 g, 88%).  
Analytical data: 1H NMR (400 MHz, CDCl3): δ 5.95 (s, 1H), 5.80 (s, 1H), 5.15 (s, 1H), 4.80 
(q, J = 6.4 Hz, 1H), 3.97 (d, J = 10.4 Hz, 1H), 3.79 (d, J = 10.4 Hz, 1H), 2.87 (s, 6H), 2.72 (d, 
J = 18.4 Hz, 1H), 2.24 (d, J = 18.4 Hz, 1H), 1.36 (s, 3H), 1.11 (d, J = 6.0 Hz, 3H), 0.92 (t, J = 
8.0 Hz, 9H), 0.90 (s, 9H), 0.60 (q, J = 8.0 Hz, 6H), 0.17 (s, 3H), 0.13 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 213.6, 159.0, 84.0, 78.9, 69.9, 66.2, 64.8, 44.6, 36.2, 25.9, 19.7, 19.7, 17.7, 
6.5, 4.0, -4.2; HRMS (ESI+) Calcd. for C24H50N2O6Si2+Na, 541.3105; Found, 541.3107; IR 
(thin film, cm-1) 3419, 2956, 1752, 1623, 1532, 1265, 1077, 740; TLC (60:40 hexanes/EtOAc): 
Rf = 0.50. 
 
3-(2,2,2',2',4,7a-hexamethyl-6-oxotetrahydro-4H-spiro[cyclopenta[d][1,3]dioxine-7,4'-
[1,3]dioxolan]-4a-yl)-1,1-dimethylurea (2.100): A flame-dried 20-mL scintillation vial was 
charged with diol 2.99 (0.165 g, 0.318 mmol, 1.00 equiv) and 1:1 acetone/2,2-
dimethoxypropane (6 mL). CSA (0.007 g, 0.032 mmol, 0.10) was added and the vial was 
capped. The reaction was allowed to stir at rt for 48 h. The solvent was then removed in vacuo. 
The product was purified via flash chromatography (60:40 hexanes/ethyl acetate) to give the 
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desired product as a white solid (0.093 g, 79%).  Analytical data: mp 137-139 °C;   1H NMR 
(400 MHz, CDCl3): δ 5.20 (s, 1H), 4.35 (q, J = 6.4 Hz, 1H), 4.18 (d, J = 9.6 Hz, 1H), 4.11 (d, 
J = 9.6 Hz, 1H), 3.48 (d, J = 20.0 Hz, 1H), 2.85 (s, 6H), 2.72 (d, J = 20.0 Hz, 1H), 1.59 (s, 3H), 
1.44 (s, 3H), 1.43 (s, 3H), 1.39 (d, J = 6.4 Hz, 3H), 1.35 (s, 3H), 1.24 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 212.6, 157.7, 112.1, 99.7, 86.7, 79.9, 73.2, 65.3, 61.0, 47.9, 36.0, 30.6, 26.3, 
25.3, 25.1, 18.7, 15.4; HRMS (ESI+) Calcd. for C18H30N2O6+H, 371.2182; Found, 371.2186; 
IR (thin film, cm-1) 3430, 3055, 2988, 1754, 1657, 1523, 1382, 1265, 740; TLC (60:40 
hexanes/EtOAc): Rf = 0.30. 
 
3-(1-((tert-butyldimethylsilyl)oxy)ethyl)-3-((1-(dimethylamino)vinyl)amino)hex-5-en-2-
one (2.68): A flame-dried 50-mL round-bottomed flask was charged with ester 2.61 (0.665 g, 
1.86 mmol, 1.00 equiv) and pentane (10 mL). The solution was cooled to 0 °C and TMSCH2Li 
(1 M, 5.57 mL, 5.57 mmol, 3.00 equiv) was added dropwise. The reaction was stirred until 
consumption of starting material was indicated by TLC analysis, typically 3 h. MeOH (3 mL) 
was then added and the reaction was warmed to rt and stirred for 1 h.  H2O (10 mL) was added 
and the organic layer was extracted with Et2O, washed with brine, dried with magnesium 
sulfate, and concentrated in vacuo. The product was purified via flash chromatography (90:10 
to 70:30 petroleum ether/acetone) to give the desired product as a white solid (0.541 g, 85%).  
Analytical data: mp 41-42 °C;  1H NMR (400 MHz, CDCl3): δ 5.89 (s, 1H), 5.53-5.42 (m, 
1H), 5.02-4.95 (m, 2H), 4.67 (q, J = 6.4 Hz, 1H), 3.33 (dd, J = 14.4, 6.8 Hz, 1H), 2.87 (s, 6H), 
2.77 (dd, J = 14.4, 8.0 Hz, 1H), 2.29 (s, 3H), 0.96 (d, J = 6.4 Hz, 3H), 0.89 (s, 9H), 0.15 (s, 
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3H), 0.07 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 208.5, 156.6, 133.1, 117.9, 71.9, 69.3, 36.1, 
34.7, 27.2, 25.8, 18.7, 17.8, -4.4, -4.9; HRMS (ESI+) Calcd. for C17H34N2O3Si+Na, 365.2237; 
Found, 365.2245; IR (thin film, cm-1) 3412, 2931, 2858, 1656, 1510, 1374, 1257, 1101, 981, 
832; TLC (70:30 petroleum ether/acetone): Rf = 0.60. 
 
4-(1-((tert-butyldimethylsilyl)oxy)ethyl)-4-((1-(dimethylamino)vinyl)amino)-2,3-
dimethylhepta-1,6-dien-3-ol (2.81): In a nitrogen-filled glove box a flame-dried 20-mL 
scintillation vial was charged with cerium trichloride (0.718 g, 2.92 mmol, 5.00 equiv).1 The 
vial was capped with a rubber septum and removed from the glove box. THF (8 mL) was added 
at 0 °C and stirred at that temperature for 3 h. The solution was cooled to -78 °C and 
isopropenylmagnesium bromide (0.5 M, 5.85 mL, 2.92 mmol, 5.00 equiv) was added. The 
reaction was stirred for 1 h followed by the addition of a THF solution (2 mL) of ketone 2.68 
(0.200 g, 0.585 mmol, 1.00 equiv). The reaction was then stirred at -78 °C for 5 h. Aqueous 
acetic acid (0.5 M, 5 mL) was added and the solution was warmed to rt. The organic layer was 
extracted with Et2O, washed with saturated NaHCO3, brine, dried with magnesium sulfate, and 
concentrated in vacuo. Crude NMR indicated a 2.7:1 diasteromeric ratio. The product was 
purified via flash chromatography (90:10 to 80:20 hexanes/ethyl acetate) to give the major 
diastereomer as a colorless oil (0.132 g, 59%).  Analytical data: 1H NMR (500 MHz, CDCl3): 
δ 7.15 (s, 1H), 6.07-5.98 (m, 1H), 5.52 (s, 1H), 5.10 (s, 1H), 5.04 (d, J = 6.0 Hz, 1H), 5.02 (s, 
1H), 4.87 (s, 1H), 4.40 (q, J = 6.0 Hz, 1H), 2.94 (dd, J = 14.5, 10.0 Hz, 1H), 2.84 (s, 6H), 2.51 
(dd, J = 15.0, 5.0 Hz, 1H), 1.87 (s, 3H), 1.34 (s, 3H), 1.32 (d, J = 6.0 Hz, 3H), 0.88 (s, 9H), 
147 
0.09 (s, 3H), 0.02 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 159.1, 150.1, 136.7, 117.4, 113.8, 
79.1, 70.8, 66.7, 36.6, 34.2, 25.9, 25.6, 21.9, 21.0, 18.0, -4.4, -4.4; HRMS (ESI+) Calcd. for 
C20H40N2O3Si+Na, 407.2706; Found, 407.2717; IR (thin film, cm
-1) 3403, 3055, 1631, 1422, 
1265, 1070, 739; TLC (70:30 petroleum ether/acetone): Rf = 0.70. 
 
2-(1-((tert-butyldimethylsilyl)oxy)ethyl)-2-((1-(dimethylamino)vinyl)amino)-1,5-
dimethylcyclopentanol (2.82): In a nitrogen-filled glove box a flame-dried 20-mL 
scintillation vial was charged with Grubbs’s second generation catalyst (0.003 g, 0.003 mmol, 
0.05 equiv). The vial was capped with a rubber septum and removed from the glove box. 
CH2Cl2 (3 mL) was added followed by a CH2Cl2 solution (2 mL) of diene 2.81 (0.02 g, 0.052 
mmol, 1.00 equiv). The reaction stirred for 6 h under a nitrogen atmosphere. The reaction was 
then concentrated in vacuo. The product was purified via flash chromatography (75:25 
hexanes/ethyl acetate to 70:30 petroleum ether/acetone) to give the desired product as a white 
solid (0.014 g, 78%). Analytical data: mp 143-146 °C;  1H NMR (400 MHz, CDCl3): δ 5.62 
(s, 1H), 5.28 (s, 1H), 4.32 (q, J = 6.4 Hz, 1H), 3.53 (d, J = 16.0 Hz, 1H), 2.88 (s, 6H), 2.54 (s, 
1H), 2.03 (d, J = 16.0 Hz, 1H), 1.66 (s, 3H), 1.33 (s, 3H), 1.26 (d, J = 6.4 Hz, 3H), 0.89 (s, 
9H), 0.11 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 158.5, 143.5, 122.4, 86.4, 72.6, 71.0, 36.3, 
33.8, 26.0, 21.7, 20.1, 18.0, 11.7, -3.1, -4.5; HRMS (ESI+) Calcd. for C18H36N2O3Si+H, 
357.2573; Found, 357.2575; IR (thin film, cm-1) 3315, 3054, 2931, 2857, 2305, 1613, 1520, 
1265, 1172, 739; TLC (70:30 petroleum ether/acetone): Rf = 0.60. 
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1H nOesy analysis of 2.82: 
 
Preparation of Enantioenriched (R)-2.59: 
 
(R)-methyl 2-acetyl-2-(3,3-dimethylureido)pent-4-enoate ((R)-2.59): In a nitrogen-filled 
glove box a flame-dried 4-mL vial was charged with allylpalladium chloride dimer (0.001 g, 
0.002 mmol, 0.005 equiv) and (R)-BINAP (0.003 g, 0.005 mmol, 0.0106 equiv). Toluene (0.5 
mL) was added and the suspension was stirred for 10 min, capped with a rubber septum, and 
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removed from the glove box. Allyl acetate (0.056 mL, 0.52 mmol, 1.10 equiv) was added and 
the catalyst solution was stirred for an additional 10 min. A separate flame-dried 20-mL 
scintillation vial was charged with 2.58 (0.095 g, 0.47 mmol, 1.00 equiv) and KOtBu (0.055 g, 
0.49 mmol, 1.05 equiv). Toluene (1.5 mL) was added and the suspension was stirred under a 
nitrogen atmosphere at -35 °C. The catalyst solution was introduced via cannula transfer, and 
the reaction was stirred for 24 h at -35 °C. The reaction was quenched with 1 M HCl (1 mL), 
and extracted with EtOAc (2 x 5 mL). The combined organic extracts were washed with brine, 
dried with magnesium sulfate, and concentrated in vacuo. The product was purified via flash 
chromatography (80:20 to 70:30 petroleum ether/acetone) to give the desired product as a 
colorless oil (0.085 g, 75%, e.r. 92:8). The enantiomer ratio was determined by SFC analysis 
(Chiralcel, OD, 2.0% MeOH, 1.5 mL/min, 150 bar, 210 nm; tR-minor 8.5 min, tR-major 9.9 
min).  
SFC Trace: 
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Miscellaneous Intermediate Characterization Data: 
 
Pyrazole 2.77: Dried cerium trichloride (1.18 g, 4.8 mmol, 4.1 equiv) was stirred in THF at 0 
°C for 4 h. The mixture was cooled to -78 °C. Freshly prepared lithium diisopropylamide (4.0 
equiv) was introduced along with ketone 2.68 (0.4 g, 1.17 mmol, 1 equiv) and 
ethyldiazoacetate (0.533 g, 4.68 mmol, 4 equiv). The reaction was stirred at -78 °C until 
complete consumption of the ketone was observed by TLC analysis. The reaction was 
quenched by the addition of NH4Cl(aq.) and extracted with Et2O. Aqueous acetic acid was used 
to break up emulsions when applicable. The organic extracts were dried (MgSO4) and purified 
via column chromatography (10 to 30% EtOAc/hexanes) to give the desired product in 70% 
yield with 24% SM recovery. 1H NMR (400 MHz, CDCl3): δ 5.61 (s, 1H), 4.56 (d, J = 18.4 
Hz, 1H), 4.36-4.16 (m, 5H), 3.74 (s, 1H), 3.46 (br t, J = 8.8 Hz, 1H), 3.08 (q, J = 9.2 Hz, 1H), 
2.92 (s, 6H), 1.61 (s, 3H), 1.34 (tr, J = 6.4 Hz, 3H), 1.23 (d, J = 6.4 Hz, 3H), 0.89 (s, 9H), 0.08 
(s, 6H). 
 
Carbamate 2.97: Diol 2.93 (8 mg, 0.015, 1 equiv) was cooled to 0 °C in THF (0.5 mL). 
Trichloroacetyl isocyanate (0.0024 mL, 0.02 mmol, 1.3 equiv) was added. Reaction was stirred 
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15 min and quenched by the addition of water (0.1 mL). Methanol (0.5 mL) was added 
followed by saturated sodium bicarbonate solution (3 drops) and the reaction was stirred 2 h. 
The crude product was extracted with EtOAc and dried (MgSO4). Column chromatography 
(50 to 75% EtOAc/hexanes) gave the desired product in 63% yield. 1H NMR (400 MHz, 
CDCl3): δ 6.70 (br s, 1H), 5.60 (s, 1H), 5.34 (tr, J = 8.0 Hz, 1H), 5.15 (s, 1H), 4.75 (br s, 2H), 
4.74 (q, J = 6.0 Hz, 1H), 3.74 (d, J = 2.0 Hz, 2H), 2.91 (s, 6H), 2.76-2.70 (m, 1H), 2.30-2.24 
(m, 1H), 1.28 (s, 3H), 1.18 (d, J = 6.4 Hz, 3H), 0.96 (tr, J = 7.6 Hz, 9H), 0.89 (s, 9H), 0.63 (q, 
J = 7.6 Hz, 6H), 0.14 (s, 3H), 0.10 (s, 3H). 
 
Enolsilane 2.101: Lithium diisopropylamide (2.1 equiv) was prepared at 0 °C. The solution 
was cooled to -78 °C and a THF solution of ketone 2.100 (37 mg, 0.1 mmol, 1 equiv) was 
added dropwise. The reaction was stirred for 0.5 h and a THF solution of TBSCl (30 mg, 0.2 
mmol, 2 equiv) was added. The cold bath was allowed to expire and the reaction warmed to rt 
until completion was indicated by TLC analysis. Standard workup with sodium bicarbonate 
gave analytically pure product. 1H NMR (400 MHz, CDCl3): δ 5.11 (s, 1H), 5.01 (s, 1H), 4.45 
(d, J = 8.0 Hz, 1H), 3.82 (d, J = 8.0 Hz, 1H), 3.73 (q, J = 6.0 Hz, 1H), 2.90 (s, 6H), 2.88 (s, 
1H), 1.48 (s, 3H), 1.43 (s, 3H), 1.41 (s, 3H), 1.37 (s, 3H), 1.33 (s, 3H), 1.16 (d, J = 6.4 Hz, 
3H), 0.94 (s, 9H), 0.25 (s, 3H), 0.22 (s, 3H). 
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Chloride 2.105: Enolsilane 2.101 (10 mg, 0.02 mmol, 1 equiv) and dichlorohydantoin (12 mg, 
0.06 mmol, 3 equiv) were dissolved in dichloromethane (0.5 mL). The reaction was allowed 
to stir at rt for 16 h. The solvent was removed and the crude residue was purified by column 
chromatography 2.5 to 10% EtOAc/hexanes to give the desired product in 60% yield.  1H 
NMR (400 MHz, CDCl3): δ 4.64 (d, J = 9.2 Hz, 1H), 4.51 (q, J = 6.8 Hz, 1H), 4.23 (d, J = 9.2 
Hz, 1H), 3.82 (s, 1H), 2.85 (s, 6H), 1.44 (s, 3H), 1.43 (s, 3H), 1.41 (s, 3H), 1.40 (s, 3H), 1.33 
(s, 3H), 1.23 (d, J = 6.4 Hz, 3H), 0.97 (s, 9H), 0.21 (s, 6H). 
 
Aziridine 2.106: Chloride 2.105 (1 equiv) and sodium azide (5 equiv) suspended in acetone. 
The reaction was stirred at rt for 12 h. The mixture was filtered through cotton and the solvent 
removed to give analytically pure aziridine. 1H NMR (400 MHz, CDCl3): δ 4.18 (d, J = 9.6 
Hz, 1H), 4.14 (s, 1H), 4.09 (d, J = 9.2 Hz, 1H), 3.90 (q, J = 6.8 Hz, 1H), 2.88 (s, 6H), 1.55 (s, 
3H), 1.47 (s, 3H), 1.36 (s, 3H), 1.29 (s, 3H), 1.23 (s, 3H), 1.22 (d, J = 7.6 Hz, 3H). 
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Oxime 2.107: Ketone 2.100 (1 equiv) and hydroxylamine hydrochloride (6 equiv) were 
suspended in EtOH. Sodium hydroxide in water (1M, 10 equiv) was added and the reaction 
was stirred 12 h. The mixture was neutralized and the solvents removed. The crude residue 
was taken up in Et2O and water, extracted, and dried (MgSO4). The product was analytically 
pure without further purification. 1H NMR (400 MHz, CDCl3): δ 7.62 (br s, 1H), 5.32 (s, 1H), 
4.44 (q, J = 6.4 Hz, 1H), 4.29 (s, 2H),  3.65 (d, J = 20.0 Hz, 1H), 2.91 (d, J = 20.0 Hz, 1H), 
2.88 (s, 6H), 1.57 (s, 3H), 1.45-1.40 (m, 12H), 1.29 (s, 3H). 
 
Vinyl triflate 2.111: Lithium diisopropylamide (2.5 equiv) was prepared at 0 °C. The solution 
was cooled to -78 °C and a THF solution of ketone 2.100 (17 mg, 0.046 mmol, 1 equiv) was 
added dropwise. The reaction was stirred for 1 h and a solution of Comins’s reagent (54 mg, 
0.138 mmol, 3 equiv) was added. The cold bath was allowed to expire and the reaction warmed 
to rt until completion was indicated by TLC analysis. Standard workup with NH4Cl(aq.) and 
column chromatography (30% EtOAc/hexanes) gave the desired product in 70% yield. 1H 
NMR (400 MHz, CDCl3): δ 6.11 (s, 1H), 5.30 (s, 1H), 4.54 (d, J = 9.2 Hz, 1H), 3.93 (d, J = 
9.2 Hz, 1H), 3.50 (q, J = 6.4 Hz, 1H), 2.93 (s, 6H), 1.50 (s, 3H), 1.45 (s, 3H), 1.41 (s, 6H), 1.35 
(s, 3H), 1.19 (d, J = 6.4 Hz, 3H). 
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CHAPTER THREE 
 
-AMINATION OF KETO-NITRONES VIA MULTIHETERO- 
COPE REARRANGEMENT* 
 
3.1  Introduction 
 An unpredictable benefit of total synthesis studies is the discovery of opportunities for 
new method development. Often, impasses reached in synthetic routes require transformations 
that do not exist or are unworkable in the context of interest. We were presented with this 
circumstance in our pactamycin core study (Chapter Two) in a case where myriad synthetic 
methods existed for a specific transformation, but were ineffective in our system. This required 
a de novo approach limited by the functional handles available and the specific goal. In this 
chapter we detail the design and development of novel -amination protocol via [3,3]-
sigmatropic rearrangement of imidoyl-functionalized nitrones. Installation of amino 
functionality bearing synthetically-practical protecting groups such as carboxybenzyl (Cbz) or 
trifluoroacetyl (TFA) moieties was important for application of this chemistry. The scope and 
limitations of this methodology will be discussed as well as attempted application to the 
pactamycin -amination problem.  
 
 
* Reprinted in part with permission from Malinowski, J. T.; Malow, E. J.; Johnson, J. S. Chem. 
Commun. 2012, 48, 7568. 
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3.2  Background 
3.2.1  Pactamycin C2 Amination Problem  
 As discussed in Chapter Two, we encountered a challenging late-stage amination 
during the pactamycin core synthesis (Figure 3-1). When all conventional approaches to this 
transformation failed, we acknowledged the need for new methodology. While our initial goal 
was to design a solution specific to our system, we also envisioned application of this chemistry 
in a broad sense as methodology for -amination.  
Figure 3-1.  Failed C2 Amination 
 
 The constraints and requirements of the proposed method were as follows: (1) an amine 
or its surrogate would be installed at a methylene carbon with a vicinal fully-substituted center, 
(2) the available functional handle was a sterically-hindered, enolizable ketone, (3) oxidative 
conditions would be incompatible with our system, and (4) the amination would have to occur 
via intramolecular delivery (prior studies had revealed selectivity challenges with 
intermolecular deliveries). Additionally, while not critical for a single transformation, the 
ketone would ultimately need to be converted to an aniline moiety. With these thoughts in 
mind, we turned to a literature survey before devising a new method of ketone -amination. 
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3.2.2  Extant Methods for Ketone -Amination 
 -Amination of carbonyls is a well-studied research area.1 The central challenge lies 
in the fact that a nucleophilic enolate is being coupled with traditionally nucleophilic nitrogen 
species. Several catalytic modes have been invented leading to the development of asymmetric 
methods for C–N bond construction. Common to many of these methods is the class of 
electrophilic nitrogen source, azodicarboxylates.2 These privileged reagents display 
exceptional electrophilicity at nitrogen allowing for umpolung reactivity on a traditionally 
nucleophilic species. A general transformation is shown in Figure 3-2.  
Figure 3-2.  Azodicarboxylates as Electrophilic Amination Reagents 
 
 The most common catalysis modes are proline (or related 2° amine) organocatalysis,3 
Cu (Mg) BOX catalysis,4 and H–bonding organocatalysis.5 Although these methods can 
provide high yields and enantioselectivity, they operate within a narrow substrate class and 
lack generality in complex, congested systems like pactamycin core intermediates. Most 
copper-catalyzed methods require two-point binding with the substrate, limiting the substrate 
classes to - or -ketoesters (in some cases activation of the electrophile circumvents this 
issue).4 Secondary nucleophilic amine catalysis requires exceptionally electrophilic ketone 
substrates with low substitution tolerance, and organocatalyzed H–bonding methods typically 
involve highly-regulated substrate/catalyst/electrophile interactions, leaving little room for 
structural negotiation. Additionally, azodicarboxylates are atom-inefficient and require 
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subsequent deacylation and N–N reductive bond cleavage steps to present the desired amino 
functionality. 
It should be noted that azodicarboxylates are not the single source of electrophilic 
nitrogen. Other reagents such as Chloramine-T,6 sodium azide,7 and activated 
hydroxylamines,8 for example, are effective in certain circumstances, but were all ineffective 
in our studies.  
3.2.3  -Oxidation by Rearrangement  
 With a ketone functional handle present in our desired platform, we considered 
condensation of nitrogen functionality to install an intramolecular rearrangement precursor. 
Replacing the ketone oxygen with nitrogen would allow for covalently-bound functionality in 
both the imine (ketone) and enamine (enolate) tautomers avoiding charged intermediates. 
Precedent existed in the literature for -oxidations proceeding through this scaffold. In 1969, 
House and Richey described a multistep process for a -acetoxylation of ketones using a [3,3]-
multihetero-Cope rearrangement (Scheme 3-1).9 The sequence began with ketoxime formation 
and acylation (3.3). Treatment with trimethyloxonium tetrafluoroborate and triethylamine 
proceeded first with N-methylation forming a transient iminium species which underwent rapid 
deprotonation to give the intermediate enehydroxylamine 3.4. A concerted [3,3]-
rearrangement then took place to give -acetyloxy imine 3.5. Acid-catalyzed hydrolysis of the 
imine delivered the desired -oxidized ketone 3.6.  
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Scheme 3-1.  House and Richey -Acetoxylation 
 
 Fifteen years later, Cummins and Coates reported a similar transformation delivering 
the same product through the same mechanism, but with a reversed order of substrate 
construction (Scheme 3-2).10 Their procedure began with ketonitrone formation via 
condensation of alkyl hydroxylamines. Treatment with acetyl chloride (AcCl) and 
triethylamine effected the same [3,3]-rearrangement observed by House and Richey, delivering 
identical products. Interestingly, in both cases the reaction would only proceed via covalent 
activation of the imine to an iminium species, other non-covalent activation modes 
(Brønsted/Lewis acids) failed to promote the desired reactivity. 
Scheme 3-2.  Cummins and Coates -Acetoxylation 
 
 More recently, Tomkinson and coworkers reported a direct approach by condensing 
acylated hydroxylamines onto ketones and aldehydes marking a one-pot protocol for -
acetoxylation (Scheme 3-3).11 This work displayed a broad substrate scope and typically 
proceeded in 70-90% yield with high functional group tolerance. Additionally, when two 
nonsymmetrical enolizable sites were present, the acetoxylation preferred the more-substituted 
position with high discrimination. This could be attributed to the thermodynamic control the 
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reaction proceeds within. A key limitation, however, was the inability to oxidize primary 
carbons. 
Scheme 3-3.  Single Step -Acetoxylation 
 
3.2.4  Preliminary Reports of -Amination by Multihetero-Cope Rearrangement 
 In theory, the application of the -acetoxylation methods to -amination should require 
only a change in the acylating reagent used. Shown in Figure 3-3, treatment of a nitrone with 
an acyl chloride results in an -oxidation product. The use of an imidoyl chloride (3.7) should, 
in principle, provide the -amido product 3.8. The most obvious degree of complexity incurred 
by the choice of imidoyl chloride is the additional nitrogen functional group (R') which must 
be appropriately tuned in order to provide the proper reactivity and desired product structure. 
A search of the literature revealed this high-value transformation is significantly more 
challenging than the -acetoxylation, as evidenced by the scarcity of examples reported.  
Figure 3-3.  -Oxidation and -Amination by [3,3]-Rearrangement 
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 The multihetero-Cope rearrangement in aryl systems to give ortho-amido anilines is 
well-established.12 Treatment of hydroxyanilines with imidoyl chlorides (3.7) or 
trichloroacetonitrile under mild, basic conditions resulted in efficient, reliable formation of 
functionalized arenes (Figure 3-4). The analogous reaction using alkyl substrates is less 
established. Two publications from 1985 and 1994 represented the only methods reported for 
this transformation prior to our entrance into the field.13 Between the two, only five product 
compounds are reported with yields ranging from 23-76% (Figure 3-5). More importantly, we 
viewed the substituents present on nitrogen (N–Me, N–Ph) as “dead ends” synthetically. An 
-amination protocol would only be practical if synthetically-attractive protecting groups were 
present on the products obtained, allowing for subsequent deprotection and further 
functionalization, if desired.  
Figure 3-4.  Aryl vs. Alkyl -Amination by [3,3]-Rearrangement 
 
Figure 3-5.  Substrate Scope of Extant -Amination Reports 
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3.3  Results and Discussion 
3.3.1  Mechanistic Proposal 
 We began our studies with a mechanistic proposal analogous to the -oxidation reports 
(Figure 3-6). Ketonitrone 3.9 would be treated with an imidoyl chloride 3.7 providing a fleeting 
charged intermediate (3.10). Under mildly basic conditions, deprotonation would then form 
enehydroxylamine 3.11. Next, the proposed multihetero-Cope [3,3]-rearrangement would 
occur, generating -amido imine product 3.12. If desired, acid-catalyzed hydrolysis should 
provide the corresponding -amido ketone 3.13.  
Figure 3-6.  Proposed Mechanism of -Amination 
 
 We believed the first two steps of our proposed mechanism would be facile, but were 
concerned about the favorability of the [3,3]-rearrangement, especially in regards to 
developing a mild protocol. As Cope rearrangements are typically governed by 
thermodynamics, we considered the relative bond energies of the product and reactant species 
(Table 3-1).14 Tabulation of the additive bond energies of the starting and rearranged species 
reveals a thermodynamically-downhill process by approximately 289 kJ/mol. This is 
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accompanied by the observation that the breaking of a weak N–O bond and formation of a 
strong carbonyl species is critical to the design and successful implementation of this 
rearrangement. We were satisfied with the results of this analysis predicting a stabilized 
product, but the activation barrier of reaction was unknown. This would be left to empirical 
investigation. 
Table 3-1.  Thermodynamic Analysis 
 
Bond 
Broken 
Energy 
(kJ/mol) 
Bond 
Formed 
Energy 
(kJ/mol) 
C=C 602 C–C 346 
C–N 305 C=N 615 
N–O 201 O=C 799 
O–C 358 O–N 305 
C=N 615 N–C 305 
 2,081  2,370 
 
3.3.2  Synthesis of Original Imidoyl Chloride Reagent 
 We began by searching the literature for known imidoyl chlorides, finding very few 
options which would satisfy our goal of synthetically-attractive protected species. Upon 
investigation of the patent literature, we discovered a phthalimido-derived imidoyl chloride 
preparation from 1955.15 Shown in Scheme 3-4, treatment of phthalimide with excess 
phosphorous pentachloride under thermal conditions provided the corresponding imidoyl 
chloride. Though these researchers reported a 95% yield after multiple complex distillations, 
in our hands pure material was never obtained and yields were poor. 
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Scheme 3-4.  Phthalimido Imidoyl Chloride 
 
 Nevertheless, we tested the crude material with various alcohols and oximes and 
observed facile addition. The products obtained could be purified via column chromatography, 
removing any impurities obtained in the prior step. After an extensive period of imidoyl 
chloride synthesis optimization, we were unable to find an improved route for its preparation, 
although the corresponding tosyl- and triflyl-activated imidoyl species could be prepared 
cleanly and would be screened (Figure 3-7). 
Figure 3-7.  Possible Imidoyl Chloride Surrogates  
 
 While we believed nitrones would be optimal substrates for the proposed multihetero-
Cope amination, we were also attracted to oximes due to their relative ease of synthesis. We 
began our studies by testing our crude imidoyl chloride with a cyclopentyl oxime substrate. 
This compound was synthesized via a two-step protocol beginning with cyclopentenone 
condensation with hydroxylamine to give oxime 3.17 (Scheme 3-5). Treatment of the oxime 
with crude imidoyl chloride 3.14 in excess gave the corresponding imidoyl oxime 3.18 in 
excellent yield. Even in crude form, the imidoyl chloride 3.14 outperformed the tosyl and triflyl 
derivatives 3.15 and 3.16, each of which provided no desired product. 
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Scheme 3-5.  Synthesis of an Oxime Test Substrate 
 
 We then began screening thermal and basic conditions to execute the [3,3]-
rearrangement (Table 3-2). Heating the substrate to 100 °C resulted in clean recovery of 
starting material. The presence of base additives was tested at ambient as well as elevated 
temperatures but gave significant decomposition in all cases. These negative results were not 
completely unexpected based upon the limited precedent for oxime-based [3,3]-
rearrangements, so we decided to move on to the promising nitrone substrate class and revisit 
oximes at a later point. 
Table 3-2.  Oxime [3,3]-Rearrangement Trials 
 
Conditions Result 
100 °C No reaction 
NaH, 80 °C Decomposition 
NaH, rt Decomposition 
tBuOK, 100 °C Decomposition 
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3.3.3  Nitrone Synthetic Studies 
 There are two major approaches to nitrone synthesis: (1) oxidation of imine or amine 
substrates,16 or (2) condensation of hydroxylamines with carbonyl compounds such as that 
described by Pfeiffer and Beauchemin.17 We chose the latter method due to the one-step 
protocol and excellent availability of ketones. Early experiments were run with commercially 
available hydroxylamines and adapted literature procedures, but did not provide the desired 
nitrones (Figure 3-8).  
Figure 3-8.  Commercial Hydroxylamine Results 
 
 We attributed this issue to poor hydroxylamine nucleophilicity and set out to synthesize 
known benzyl-derived reagents. This was achieved via a two-step route beginning with 
hydroxylamine condensation onto the desired benzaldehyde followed by oxime reduction with 
sodium(cyano)borohydride in acidic methanol (Scheme 3-6). The yields of these 
hydroxylamines ranged between 41-92% over two steps on multigram scale.  
Scheme 3-6.  Synthesis of a Benzyl-Hydroxylamine Series 
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 We selected the parent benzylhydroxylamine 3.20 and subjected it to the Beauchemin 
conditions17 with cyclopentanone (Scheme 3-7). We were pleased to observe complete 
conversion to the nitrone after refluxing overnight. Purification was challenging due to the 
extreme polarity of nitrone 3.24, but conditions were developed to enable purification by SiO2 
column chromatography. Unfortunately, the yield was only 46%, an attribute we hoped to 
optimize in further studies.  
Scheme 3-7.  Initial Nitrone Result 
 
3.3.4  Scope of Benzylhydroxylamine Condensation - Nitrone Synthesis 
 A brief period of optimization revealed conditions applicable to the synthesis of a 
variety of nitrones. Generally, the reactions were performed in a sealed vessel at 110 °C 
overnight with a 2:1 excess of the ketone substrate. After removal of volatiles in vacuo, the 
crude reaction was loaded directly onto SiO2 and purified. The nitrones were typically obtained 
as single diastereomers. The results of the nitrone library synthesis are presented in Table 3-3. 
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Table 3-3.  Nitrone Scope 
 
Nitrone  Yield (%) Nitrone  Yield (%) 
 
3.24 75 
 
3.30 77 
 
3.25 49 
 
3.31 78 
 
3.26 
13 
(6:1 dr) 
 
3.32 71 
 
3.27 32 
 
3.33 76 
 
3.28 31 
 
3.34 8718 
 
3.29 88 
 
3.35 44 
 
An obvious trend is the relatively high yields obtained with aliphatic, cyclic ketones 
(3.24, 3.29-3.34) ranging from 71-88%. Aryl ketones performed poorly in this synthesis (3.25-
3.28) with yields ranging from 13-49%. Chiral nitrone 3.34 was also synthesized for the 
purpose of testing for diastereochemical direction which would potentially lead to 
enantioenriched products.18 Not all ketones were compatible with the nitrone condensation 
conditions. A selection of substrates which failed or gave product mixtures is shown in Figure 
3-9. Typically these reactions failed due to nature of the highly-reactive ketones which suffered 
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from subsequent undesired transformations under the harsh conditions. We adjudged these 
results adequate to move forward to test the subsequent [3,3]-rearrangement chemistry. 
Figure 3-9.  Incompatible Ketones for Nitrone Formation  
 
3.3.5  Initial [3,3]-Rearrangement Results 
 From our analysis of the literature, we believed that if we could install the imidoyl 
chloride on a nitrone substrate, enehydroxylamine formation would be rapid and the [3,3]-
rearrangement could then proceed in one-pot. We did not believe any intermediate species 
would be isolable. A summary of early reaction attempts is presented in Table 3-4.  
Table 3-4.  Initial [3,3]-Rearrangement Results 
 
3.14 (eq) NEt3 (eq) Solvent (temp) Time (h) Result  
4 5 CH2Cl2 (0 °C to rt) 15 complex mixture  
5 5 THF (rt) 15 low yield 3.36  
5 5 CH2Cl2 (0 °C to rt) 5 clean reaction - low yield 
3.36 + 3.19 
 
2 3 CH2Cl2 (0 °C to rt) 3 3.19 - 26%  
2 3 CH2Cl2 (0 °C) 0.5 3.19 - 32%  
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Due to the use of crude imidoyl chloride 3.14, most reactions were messy and difficult 
to follow by TLC (extreme polarity of substrate and products). Additionally, different workup 
and purification conditions led to varied product distributions. Often, pure products obtained 
did not match crude NMRs; this was sometimes attributed to imine hydrolysis. As “optimal” 
conditions emerged, we determined the reaction was indeed facile, running to full conversion 
in 30 minutes or less at 0 °C. Triethylamine was an effective base promoter, although pyridine 
also showed promising results. With these encouraging results in hand, we identified the need 
for a better imidoyl chloride source which would potentially lead to cleaner reactions.  
3.3.6  Second Generation Imidoyl Chloride 
 Considering alternate imidoyl chlorides that would provide attractive nitrogen 
protecting groups, we returned to the literature. A report by Osipov and coworkers outlined a 
two-step preparation of imidoyl chloride 3.37.19 We synthesized this reagent on multigram 
scale and found the procedure reproducible, although the reported yield of 95% was never 
matched. Imidoyl chloride 3.37 was a yellow liquid which was somewhat unstable under 
ambient conditions but was stored indefinitely in the freezer in a sealed vial. This reagent 
would ideally provide a differentially bis-protected amine product with carboxylbenzyl (Cbz) 
and trifluoroacetyl protecting groups. 
Scheme 3-8.  Second Generation Imidoyl Chloride Synthesis 
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3.3.7  Development of the Multihetero-Cope -Amination 
 We applied the best conditions from our studies with phthalimido-derived imidoyl 
chloride 3.14 to our new imidoyl chloride 3.37. Shown in Scheme 3-9, we obtained clean 
conversion of the nitrone, although the product obtained was somewhat unexpected. Instead of 
the desired ketone 3.38, we obtained -amido-enamide product 3.39 in 65% yield.  
Scheme 3-9.  Initial Result 
 
 Although unanticipated, we saw value in this differentiated diamino product as these 
are commonly found in biologically-relevant molecules and decided to continue studies. We 
proposed the following mechanism for this transformation (Figure 3-10). After imidoylation 
and deprotonation to form enehydroxylamine 3.40, the [3,3]-rearrangement occurred giving 
rise to product 3.41. This was followed by a 1,4-acyl transfer of the labile 
trifluoromethylacetamide with accompanying -deprotonation by exogenous base to relieve 
the charge generated at the imine nitrogen. Although shown in one step, this is presumably a 
stepwise process. This acyl transfer mechanism was surprisingly facile and occurred in all 
cases; we never observed formation of the bis-protected--amino species. 
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Figure 3-10.  Proposed Mechanism for Enamide Formation  
 
 Having found success with an acyclic substrate we next tested aryl nitrone 3.25 (Figure 
3-11). Under identical conditions we observed product formation with a similar acyl transfer 
to give enediamide 3.42 in 59% yield. In this case, due to the lack of an '-proton, the geminal 
hydrogen to the amine is deprotonated (3.44) providing the observed outcome with complete 
diastereoselectivity.  
Figure 3-11.  Enediamide Formation from Aryl Nitrones  
 
3.3.8  Scope of the -Amination Methodology 
 Having determined the product outcome for two substrate classes, we set out to 
determine the scope and limitations of the -amination. The results are tabulated in Table 3-5 
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for aliphatic substrates, and Table 3-6 for the aryl nitrones. First we examined the identity of 
the benzyl protecting group on the nitrone (3.39, 3.45-3.47). This had little effect on yield as 
the unsubstituted, para-Cl and para-OMe gave nearly identical yields. The toluyl-derived 
substrate 3.46 gave a significant boost in efficiency with a 78% yield, an unexplained result. 
Cyclohexyl rings were tested giving similar moderate yields. The presence of a 4-tBu 
substituent did not provide significant diastereoselection (1.5:1 dr, 3.49). Unfortunately the use 
of the chiral nitrone also proceeded without diastereoselectivity, giving a 1:1 mix of 
diastereomers (3.50).  
Table 3-5.  Substrate Scope – Aliphatic Nitrones 
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 We were excited to see reaction with an acetone-derived substrate (3.51) albeit in 
reduced yield, as functionalization of methyl groups was problematic in the Tomkinson 
studies. This particular substrate also showed orthogonal reactivity in that an enediamide was 
formed rather than the expected -amino enamide. This could be due to thermodynamic 
control favoring the more-substituted olefin species. Finally, a cyclohexanone-derived nitrone 
provided -chloro product 3.52. This may have occurred via fast chloride conjugate addition 
to iminium adduct 3.53 forming ene-hydroxylamine 3.54 without the typical deprotonation; an 
observation suggesting the initial -deprotonation may be the rate-determining step (Figure 3-
12). 
Figure 3-12.  Plausible Mechanism for -Chloro Product Formation  
 
 We next tested aryl nitrones (Table 3-6). Here, the corresponding enediamides were 
formed in yields ranging from 49-68%. The propiophenone-based substrate 3.57 was the only 
product with a tetrasubstituted olefin and gave a reversed E-geometry. This could be attributed 
to increased A1,3 strain between the methyl substituent and aryl ring vs. the flexible carbamate.   
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Table 3-6.  Substrate Scope – Aryl Nitrones 
 
3.3.9  Secondary Transformations of Diamido Products  
 It was our original intention to develop an -amination of ketones with retention of the 
ketone functional handle for further manipulation. We were satisfied with the products 
obtained through this transformation but determined to develop a protocol to hydrolyze the 
enamide/imine functionality to the ketone. During reaction optimization we tested various 
acidic and basic workup strategies in an effort to obtain the ketones directly, but the products 
were surprisingly resistant to hydrolysis. We undertook a comprehensive screen of hydrolysis 
conditions to effect this transformation on the clean, isolated product (Table 3-7). 
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Table 3-7.  Hydrolysis of Enamide Products 
 
Conditions Result 
1 M NaOH, THF 40% 
Sat KOH NDP 
1 M HCl, reflux NR, SM recovered 
K2CO3, MeOH Decomposition 
KOH, MeOH, reflux Complex mixture 
NaSBn, MeOH 85% 
  
While resistant to harsh, acidic conditions, hydrolysis was realized under certain basic 
conditions. Although sodium hydroxide was effective, this reaction provided a mixture of 
products leading to a low yield of the desired ketone. Potassium hydroxide and potassium 
carbonate proved effective, but too reactive in our system, decomposing the eneamide product. 
Sodium benzylthiolate (formed by the treatment of benzylmercaptan with sodium metal in 
methanol) provided the optimal reactivity, cleanly providing the ketone hydrolysis product in 
85% yield. 
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Figure 3-13.  Thiolate Hydrolyses  
 
 The sodium thiolate hydrolysis conditions were effective on the enediamide products 
only when followed by acidic workup (Figure 3-13). Protected -amino ketone product 3.59 
was obtained in a combined 52% yield with partial conversion of the carbamyl group to the 
methyl (Moc) congener. We were interested in the possibility of a one-pot -amino ketone 
synthesis and tested conditions beginning from nitrone 3.24. The typical [3,3]-rearrangement 
was conducted followed by removal of volatiles in vacuo. The crude residue was redissolved 
in methanol and subjected to the sodium benzylthiolate conditions. We were pleased to observe 
formation of the desired ketone product in a 69% yield after column chromatography, a yield 
not only higher than the combined two-step sequence, but the single-step [3,3]-rearrangement 
itself. We attributed this feature to difficulty purifying the enamide 3.39 and slight instability 
on silica.  
 While not anticipated, formation of -amido enamide and enediamide products 
provided a means for potential 1,2-differentiated diamino synthesis. We proposed this 
functionality could be revealed after hydrogenation of the alkene present in both product 
classes. Formation of valuable amino functionality from enamines is well-precedented and 
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may be performed asymmetrically in some cases.20 The challenge we initially identified was 
the variety of potentially labile protecting groups present on our products under reductive 
conditions. This feature was indeed an issue as we screened numerous protocols for alkene 
reduction (Table 3-8). 
Table 3-8.  Hydrogenation/Reduction of Enamide Products 
 
Conditions Result 
Pd/C, H2 (600 psi) Complex mixture 
Pd/C, H2 (600 psi), then NaOH Complex mixture 
Rh/C, H2 (600 psi) NR, SM recovered 
Pd(OH)2/C, H2 (600 psi) NDP 
Ni, H2 (600 psi) NR, SM recovered 
Pt/C, H2 (600 psi) Low conv. 
Pd/Alumina, H2 (600 psi) NDP 
Et3SiH, TFA Complex mixture 
NBSH, NEt3 NR, SM recovered 
Crabtree’s cat., H2 (1 atm) NR, SM recovered 
Et3SiH, TfOH Complex mixture 
Raney Ni, EtOH, reflux NR, SM recovered 
DIBAL-H NR, SM recovered 
LAH Complex mixture 
Na(CN)BH3 NR, SM recovered 
 
 Hydrogenations were screened with a variety of available catalysts and metals, 
typically providing complex mixtures from which no pure products could be isolated. Rh, Ni, 
and Ir based catalysts provided no reaction. Other hydride sources were also unreactive except 
in harsh cases (Et3SiH-TfOH, LAH) where complex mixtures were obtained. After completing 
a thorough screen of these hydrogenative conditions, we conceded in our diamine synthesis 
efforts and moved toward other useful transformations.  
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 The presence of enamide functionality in our products offered the opportunity to 
perform electrophilic functionalization at the '-position. While not as reactive as the related 
enamine, we believed proper deprotective conditions would give a reactive species to 
participate in electrophilic coupling (Table 3-9). We began by studying methylation using 
iodomethane. Without base we observed no reaction, but under basic conditions we observed 
a complex product mixture devoid of methylation. We next tested oxidations to provide the -
hydroxyketone moiety. Osmium tetroxide/NMO gave high reactivity, but no desired product, 
and m-CPBA was unreactive. Finally we tested -halogenations. While hydantoin electrophilic 
sources were ineffective, treatment with bromine gave a clean unidentified product in good 
yield with a 2.5:1 diastereomeric ratio.  
Table 3-9.  -Functionalization of Enamide Products 
 
Conditions Result 
MeI, 60 °C NR, SM recovered 
MeI, NaOH NDP 
OsO4, NMO Complex mixture 
m-CPBA NR, SM recovered 
Dichlorohydantoin Complex mixture 
Br2, CH2Cl2 77%, 2.5:1 dr ? 
 
 The structure of the bromination product was eventually assigned by a preliminary X-
ray crystal structure as oxazolidinone 3.60 (Figure 3-14). This probably occurs via -
bromination of the enamide to generate iminium species 3.61. Intramolecular trapping by the 
carboxybenzyl protecting group could give oxonium 3.62. Debenzylation, presumably via 
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bromide substitution, would provide the observed product 3.60. While unanticipated, this 
reaction showed an interesting transformation made possible by the protecting groups present 
on our enamide products. 
Figure 3-14.  Bromination Cascade  
 
3.3.10  Application to Pactamycin C3 -Amination Problem 
 As the initial intent of this methodology was to solve the challenging pactamycin C3 
amination, we immediately attempted to apply our findings to the pactamycin system. We 
knew that formation of a nitrone from our ketone functional handle would be a challenge due 
to the fact that our intermediate was unstable to oxidative conditions, leaving only thermal 
condensation as feasible. Subjection to the typical nitrone-forming protocol resulted in 
decomposition of our intermediate, usually with loss of the urea moiety and no nitrone 
formation. These disappointing results led us to the oxime substrate we had previously 
synthesized (3.63, Scheme 3-10). We were able to install the imidoyl group on this substrate, 
although not cleanly, and attempted to induce the rearrangement. Not surprisingly, as we did 
not find success with simple oxime [3,3]-rearrangements, conditions we screened were 
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ineffective on our complex pactamycin intermediate. This marked the conclusion of our 
research on this project.   
Scheme 3-10.  Application to Pactamycin 
 
3.4  Conclusion 
 We have developed a multihetero-Cope [3,3]-rearrangement employing imidoyl 
chloride reagents and nitrones. This transformation provided -carbamoyl enamides, or 
enediamide products based upon the ketone substitution pattern with synthetically-attractive 
nitrogen protecting groups. The initial products are somewhat stable and resistant to 
hydrolysis, but the ketone functionality may be revealed upon treatment with sodium 
benzylthiolate. While initially designed with application to the pactamycin -amination in 
mind, this method ultimately failed due to pactamycin substrate complexity. Future 
experiments will be focused on extension to oxime reactivity and the aldehyde substrate class. 
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3.5  Experimental Details 
Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker model Avance 400 (1H NMR at 400 MHz and 13C at 100 
MHz) or a Bruker model Avance 600 (1H NMR at 600 MHz and 13C NMR at 150 MHz) 
spectrometer with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 77.0 ppm). 
1H NMR data are reported as follows: chemical shift, 
multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, br t = broad triplet, q = 
quartet, m = multiplet), coupling constants (Hz), and integration. Mass spectra were obtained 
using a Bruker BioTOF II spectrometer with electrospray ionization calibrated with CsOAc or 
an Agilent Technologies 6520, Accurate – Mass QTOF LCMS, 1200 series LC with dual spray 
ESI source. All samples were prepared in methanol. Analytical thin layer chromatography 
(TLC) was performed on Sorbent Technologies 0.20 mm Silica G TLC plates. Visualization 
was accomplished with UV light and/or aqueous ceric ammonium nitrate solution followed by 
heating. Purification of the reaction products was carried out by flash chromatography using 
Siliaflash-P60 silica gel (40-63μm) purchased from Silicycle. Unless otherwise noted, all 
reactions were carried out under an atmosphere of dry nitrogen in oven-dried glassware with 
magnetic stirring. Yield refers to isolated yield of analytically pure material unless otherwise 
noted. Yields are reported for a specific experiment and as a result may differ slightly from 
those found in the tables, which are averages of at least two experiments. Nitrone 
stereochemistry assigned by 1H NOESY analysis. 
Materials: General.  Dichloromethane was dried by passage through a column of neutral 
alumina under nitrogen prior to use. Triethylamine was freshly distilled from calcium hydride 
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prior to use. Benzyl-hydroxylamine,21 p-methoxy-benzylhydroxylamine,22 p-methyl-
benzylhydroxylamine,23 p-chloro-benzylhydroxylamine, and (S)--methyl-
benzylhydroxylamine24  were prepared according to the published procedures. Imidoyl 
chloride (3.37) was prepared via the literature method.25 All other reagents were purchased 
from commercial sources and were used as received unless otherwise noted. 
General Procedure A for Nitrone Synthesis: 
 
An oven-dried 4-mL scintillation vial equipped with magnetic stir bar was charged with the 
appropriate ketone (2.0 mmol, 2.0 equiv) and hydroxylamine (1.0 mmol, 1 equiv). The vial 
was purged with nitrogen and tert-butanol (2.0 mL) was added. The septum was replaced with 
a Teflon-sealed cap and the reaction was stirred at 110 °C for 14 h. The reaction was cooled to 
23 °C and volatiles were removed in vacuo. The crude product was purified via flash 
chromatography (SiO2) to give the desired product. 
N-Cyclopentylidene-1-phenylmethanamine oxide (3.24): The title compound 
was prepared according to General Procedure A using cyclopentanone (1.00 mL, 
11.3 mmol, 2.0 equiv) and benzylhydroxylamine (695 mg, 5.64 mmol, 1.0 equiv) 
in tBuOH (10 mL). Purification by flash chromatography (dichloromethane to 98:2 
dichloromethane/methanol) furnished 3.24 as a tan solid (800 mg, 4.23 mmol, 75%). 
Analytical data: mp 64-67.5 °C; 1H NMR (400 MHz, CDCl3): δ 7.38 (d, J = 7.2 Hz, 2H,), 
7.33-7.27 (m, 3H), 4.90 (s, 2H), 2.65 (br s, 2H), 2.50 (br s, 2H), 1.83-1.74 (m, 4H); 13C NMR 
(100 MHz, CDCl3): δ 155.9, 133.2, 128.5, 128.0, 127.9, 65.0, 30.9, 30.8, 26.1, 24.3; HRMS 
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(ESI+) Calcd. for C12H15NO+H, 190.1232; Found, 190.1229; IR (thin film, cm
-1) 3398, 2965, 
2876, 1632, 1454, 1136, 960; TLC (95:5 dichloromethane/methanol): Rf = 0.20. 
(Z)-1-Phenyl-N-(1-phenylethylidene)methanamine oxide (3.25): The title 
compound was prepared according to General Procedure A using acetophenone 
(0.234 mL, 2.0 mmol, 2.0 equiv) and benzyl-hydroxylamine (123 mg, 1.0 mmol, 1.0 equiv) in 
tBuOH (2 mL). Purification by flash chromatography (100:0 to 98:2 
dichloromethane/methanol) furnished 3.25 as a pale yellow oil (111 mg, 0.493 mmol, 49%). 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.42-7.39 (m, 3H), 7.31-7.28 (m, 5H), 7.21-
7.19 (m, 2H), 4.97 (s, 2H), 2.45 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 147.6, 136.2, 134.2, 
129.1, 128.8, 128.4, 128.1, 128.0, 127.5, 63.8, 20.6;  HRMS (ESI+) Calcd. for C15H15NO+Na, 
248.1052; Found, 248.1050; IR (thin film, cm-1) 3223, 3060, 1579, 1495, 1453, 1265, 1178; 
TLC (95:5 dichloromethane/methanol): Rf = 0.1.  
(Z)-1-(4-Methoxyphenyl)-N-(1-(4-methoxyphenyl)ethylidene) 
methanamine oxide (3.26): The title compound was prepared according to 
General Procedure A using p-methoxyacetophenone (300 mg, 2.0 mmol, 2.0 equiv) and p-
methoxy-benzylhydroxylamine (153 mg, 1.0 mmol, 1.0 equiv) in tBuOH (2 mL). Purification 
by flash chromatography (100:0 to 98:2 dichloromethane/methanol) furnished 3.26 as a yellow 
oil with a 6:1 diastereomeric ratio (37 mg, 0.130 mmol, 13%). Analytical data: 1H NMR  (400 
MHz, CDCl3): δ 7.23 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 
6.83 (d, J = 8.8 Hz, 2H), 4.89 (s, 2H), 3.82 (s, 3H), 3.76 (s, 3H), 2.39 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 160.0, 159.3, 147.0, 130.4, 130.1, 129.7, 129.0, 128.5, 126.5, 114.2, 114.1, 
113.8, 113.1, 63.0, 55.3, 55.2, 55.2, 20.7, 19.2;  HRMS (ESI+) Calcd. for C17H19NO3+H, 
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286.1443; Found, 286.1444; IR (thin film, cm-1) 3349, 2958, 2837, 2220, 1609, 1512, 1441, 
1249, 1175; TLC (95:5 dichloromethane/methanol): Rf = 0.1. 
(Z)-1-(4-Methoxyphenyl)-N-(1-(naphthalen-2-yl)ethylidene) 
methanamine oxide (3.27): The title compound was prepared 
according to General Procedure A using 2-acetonaphthone (340 mg, 2.0 
mmol, 2.0 equiv) and p-methoxy-benzylhydroxylamine (153 mg, 1.0 mmol, 1.0 equiv) in 
tBuOH (2 mL). Purification by flash chromatography (98:2 dichloromethane/methanol) 
furnished 3.27 as a yellow oil (97.1 mg, 0.318 mmol, 32%). Analytical data: 1H NMR (400 
MHz, CDCl3): δ 7.50-7.45 (m, 2H), 7.41-7.38 (m, 1H), 7.17-7.13 (m, 2H), 6.91 (d, J = 8.4 Hz, 
1H), 6.83 (d, J = 8.8 Hz, 2H), 6.43 (d, J = 8.8 Hz, 2H), 4.53 (s, 2H), 3.37 (s, 3H), 2.09 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ 159.5, 147.1, 133.6, 133.1, 132.8, 129.9, 128.9, 128.2, 127.8, 
127.4, 127.3, 127.1, 126.5, 124.8, 113.9, 63.5, 55.3, 20.8; HRMS (ESI+) Calcd. for 
C20H19NO2+Na, 328.1314; Found, 328.1324; IR (thin film, cm
-1) 3408, 3053, 2986, 1513, 
1265, 1213, 1176; TLC (95:5 dichloromethane/methanol): Rf = 0.14. 
(Z)-1-(4-Methoxyphenyl)-N-(1-phenylpropylidene)methanamine oxide 
(3.28): The title compound was prepared according to General Procedure A 
using propiophenone (0.26 mL, 2.0 mmol, 2.0 equiv) and p-methoxy-
benzylhydroxylamine (153 mg, 1.0 mmol, 1.0 equiv) in tBuOH (2 mL). Purification by flash 
chromatography (98:2 dichloromethane/methanol) furnished 3.28 as a pale yellow oil (83.2 
mg, 0.309 mmol, 31%). Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.44-7.42 (m, 3H), 
7.20-7.15 (m, 4H), 6.82 (d, J = 8.8 Hz, 2H), 4.80 (s, 2H), 3.78 (s, 3H), 2.88 (q, J = 7.2, 7.6 Hz, 
2H), 1.02 (t, J = 7.4 Hz, 3H) ; 13C NMR (100 MHz, CDCl3): δ 159.4, 151.6, 135.1, 129.9, 
129.1, 128.9, 128.0, 126.4, 113.8, 63.8, 55.2, 26.2, 9.3; HRMS (ESI+) Calcd. for 
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C17H19NO2+H, 270.1495; Found, 270.1497; IR (thin film, cm
-1) 3409, 3053, 2985, 1612, 1493, 
1265, 1177; TLC (95:5 dichloromethane/methanol): Rf = 0.16. 
N-Cyclopentylidene-1-(4-methoxyphenyl)methanamine oxide (3.29): The 
title compound was prepared according to General Procedure A using 
cyclopentanone (0.177 mL, 2.0 mmol, 2.0 equiv) and p-methoxy-
benzylhydroxylamine (153 mg, 1.00 mmol, 1.0 equiv) in tBuOH (2 mL). Purification by flash 
chromatography (100:0 to 95:5 dichloromethane/methanol) furnished 3.29 as a brown oil (192 
mg, 0.876 mmol, 88%). Analytical data: 1H NMR (400 MHz, CDCl3): δ 7.32 (d, J = 8.8 Hz, 
2H), 6.82 (d, J = 8.8 Hz, 2H), 4.82 (s, 2H), 3.73 (s, 2H), 2.61 (t, J = 7.2 Hz, 2H), 2.50 (t, J = 
7.2 Hz, 2H), 1.81-1.72 (m, 4H); 13C NMR (100 MHz, CDCl3): δ 159.4, 155.0, 129.5, 125.5, 
113.9, 64.5, 55.1, 30.9, 26.2, 24.3; HRMS (ESI+) Calcd. for C13H17NO2+H, 220.1337; Found, 
220.1338; IR (thin film, cm-1) 3388, 2963, 1612, 1513, 1250, 1179, 1133, 1029; TLC (95:5 
dichloromethane/methanol): Rf = 0.15. 
N-Cyclopentylidene-1-(p-tolyl)methanamine oxide (3.30): The title 
compound was prepared according to General Procedure A using 
cyclopentanone (0.18 mL, 2.0 mmol, 2.0 equiv) and p-methyl-
benzylhydroxylamine (137 mg, 1.0 mmol, 1.0 equiv) in tBuOH (2 mL). Purification by flash 
chromatography (98:2 to 95:5 dichloromethane/methanol) furnished 3.30 as an off-white semi-
solid (160 mg, 0.787 mmol, 77%). Analytical data: 1H NMR (400 MHz, CDCl3): δ 7.29 (d, J 
= 8.0 Hz, 2H), 7.13 (d, J = 9.6 Hz, 2H), 4.88 (s, 2H), 2.65 (t, J = 7.2, 2H), 2.51 (t, J = 6.8 Hz, 
2H), 2.31 (s, 3H), 1.85-1.75 (m, 4H); 13C NMR (100 MHz, CDCl3): δ 155.2, 137.8, 130.3, 
129.2, 128.0, 64.9, 30.9, 30.9, 26.2, 24.3, 20.9; HRMS (ESI+) Calcd. for C13H17NO+Na, 
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226.1208; Found, 226.1208; IR (thin film, cm-1) 3388, 2964, 2875, 2207, 1627, 1514, 1452, 
1142; TLC (95:5 dichloromethane/methanol): Rf = 0.4. 
1-(4-Chlorophenyl)-N-cyclopentylidenemethanamine oxide (3.31): 
The title compound was prepared according to General Procedure A 
using cyclopentanone (0.18 mL, 2.0 mmol, 2.0 equiv) and p-
chlorobenzylhydroxylamine (157 mg, 1.0 mmol, 1.0 equiv) in tBuOH (2 mL).  Purification by 
flash chromatography (98:2 dichloromethane/methanol) furnished 3.31 as an off-white solid 
(175 mg, 0.784 mmol, 78%). Analytical data: mp 104-107 °C; 1H NMR (400 MHz, CDCl3): 
δ 7.39 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 4.92 (s, 2H), 2.69 (t, J = 7.2 Hz, 2H), 2.54 
(t, J = 7.0 Hz, 2H), 1.90-1.80 (m, 4H); 13C NMR (100 MHz, CDCl3): δ 155.8, 134.2, 131.9, 
129.6, 128.9, 64.3, 31.1, 31.1, 26.3, 24.5; HRMS (ESI+) Calcd. for C12H14ClNO+H, 224.0841; 
Found, 224.0843; IR (thin film, cm-1) 3388, 2964, 2875, 2207, 1627, 1514, 1452, 1142; TLC 
(95:5 dichloromethane/methanol): Rf = 0.12. 
N-Cyclohexylidene-1-(4-methoxyphenyl)methanamine oxide (3.32): The title 
compound was prepared according to General Procedure A using cyclohexanone 
(0.2 mL, 2.00 mmol, 2.0 equiv) and p-methoxybenzylhydroxylamine (153 mg, 
1.00 mmol, 1.0 equiv) in tBuOH (2 mL). Purification by flash chromatography (100:0 to 95:5 
dichloromethane/methanol) furnished 3.32 as a yellow oil (167 mg, 0.716 mmol, 71%). 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.30 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.4 Hz, 
2H), 4.98 (s, 2H), 3.74 (s, 3H), 2.71 (t, J = 6.4, 2H), 2.46 (t, J = 6.0 Hz, 2H), 1.65-1.59 (m, 
2H), 1.56-1.48 (m, 4H); 13C NMR (100 MHz, CDCl3): δ 159.3, 149.3, 129.0, 126.2, 114.0, 
63.0, 55.1, 29.9, 26.8, 25.5, 24.5;  HRMS (ESI+) Calcd. for C14H19NO+H, 234.1494; Found, 
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234.1484; IR (thin film, cm-1) 3400, 2937, 2860, 1612, 1513, 1249, 1032, 734; TLC (95:5 
dichloromethane/methanol): Rf = 0.2. 
N-(4-(Tert-butyl)cyclohexylidene)-1-(4-methoxyphenyl)methanamine oxide 
(3.33): The title compound was prepared according to General Procedure A using 
4-butylcyclohexanone (308 mg, 2.0 mmol, 2.0 equiv) and p-
methoxybenzylhydroxylamine (153 mg, 1.0 mmol, 1.0 equiv) in tBuOH (2 mL). Purification 
by flash chromatography (100:0 to 98:2 dichloromethane/methanol) furnished 3.33 as a pale 
yellow solid (220 mg, 0.761 mmol, 76%). Analytical data: mp 74-77.5 °C; 1H NMR (400 
MHz, CDCl3): δ 7.34 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 5.03 (d, J = 14.0 Hz, 1H), 
4.99 (d, J = 14.0 Hz, 1H), 3.79 (s, 3H), 3.60-3.56 (m, 1H), 2.88-2.84 (m, 1H), 2.01-1.86 (m, 
3H), 1.25-1.15 (m, 3H), 0.812 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 159.3, 149.3, 129.1, 
126.1, 114.0, 63.0, 55.1, 46.1, 32.3, 29.8, 27.3, 27.0, 26.2, 25.0; HRMS (ESI+) Calcd. for 
C18H27NO2+H, 290.2120; Found, 290.2121; IR (thin film, cm
-1) 3409, 3053, 2985, 1612, 1493, 
1265, 1177; TLC (95:5 dichloromethane/methanol): Rf = 0.16. 
(S)-N-Cyclopentylidene-1-phenylethanamine oxide (3.34): The title 
compound was prepared according to General Procedure A using 
cyclopentanone (0.18 mL, 2.0 mmol, 2.0 equiv) and (S)-α-methyl-benzyl-
hydroxylamine4 (137 mg, 1.0 mmol, 1.0 equiv) in tBuOH (2 mL).  Purification by flash 
chromatography (98:2 dichloromethane/methanol) furnished 3.34 as an off-white solid (177.0 
mg, 0.871 mmol, 87%).  Analytical data: mp 76-79 °C; 1H NMR (400 MHz, CDCl3): δ 7.47 
(d, J = 7.6 Hz, 2H), 7.35-7.28 (m, 3H), 5.15 (q, J = 6.8 Hz, 1H), 2.75-2.49 (m, 4H), 1.88-1.78 
(m, 4H), 1.75 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 154.2, 139.1, 128.6, 128.1, 
127.0, 67.7, 31.2, 30.6, 26.3, 24.3, 19.3;  HRMS (ESI+) Calcd. for C13H17NO+Na, 226.1208; 
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Found, 226.1214; IR (thin film, cm-1) 3399, 2967, 2876, 2190, 1622, 1454, 1255, 1172, 1141, 
1055; TLC (95:5 dichloromethane/methanol): Rf = 0.13. 
1-(4-Methoxyphenyl)-N-(propan-2-ylidene)methanamine oxide (3.35): The 
title compound was prepared according to General Procedure A using acetone 
(0.44 mL, 6.0 mmol, 2.0 equiv) and p-methoxy-benzylhydroxylamine (459 mg, 3.0 mmol, 1.0 
equiv) in tBuOH (6 mL). Purification by flash chromatography (98:2 to 95:5 
dichloromethane/methanol) furnished 3.35 as a pale brown oil (257 mg, 1.33 mmol, 44%). 
Analytical data: 1H NMR  (400 MHz, CDCl3): δ 7.32 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 
2H), 4.95 (s, 2H), 3.75 (s, 3H), 2.11 (d, J = 5.6 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 159.4, 
143.1, 129.1, 125.8, 114.0, 63.2, 55.2, 20.4, 19.9;  HRMS (ESI+) Calcd. for C11H15NO2+H, 
194.1181; Found, 194.1182; IR (thin film, cm-1) 3348, 2958, 2213, 1612, 1513, 1441, 1304, 
1177, 1156; TLC (95:5 dichloromethane/methanol): Rf = 0.05. 
General Procedure B for [3,3]-Rearrangement: 
 
An oven-dried 4-mL scintillation vial equipped with magnetic stir bar was charged with 
imidoyl chloride 3.37 (0.26 g, 0.1 mmol, 1.0 equiv) and purged with nitrogen. 
Dichloromethane (0.5 mL) was added and the solution was cooled to 0 °C in an ice/water bath. 
Triethylamine (0.028 mL, 0.2 mmol, 2.0 equiv) was then added, followed by a cooled 
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dichloromethane solution (0.5 mL) of the nitrone (0.1 mmol, 1.0 equiv). The reaction was 
stirred at 0 °C until judged complete by TLC analysis, generally 30 min. Upon completion, 
volatiles were removed in vacuo. The crude product was purified via flash chromatography 
(SiO2) to give the desired product.  
Benzyl (2-(N-benzyl-2,2,2-trifluoroacetamido)cyclopent-2-en-1-yl) 
carbamate (3.39): The title compound was prepared according to General 
Procedure B using nitrone 3.24 (57 mg, 0.305 mmol, 1.0 equiv), imidoyl 
chloride 3.37 (81 mg, 0.305 mmol, 1.0 equiv) and triethylamine (85 µL, 0.61 mmol, 2.0 equiv) 
in CH2Cl2 (2 mL). Purification by flash chromatography (90:10 petroleum ether/acetone) 
furnished 3.39 as a yellow oil (82 mg, 0.196 mmol, 65%).  Analytical data: 1H NMR (400 
MHz, CDCl3): δ 7.38-7.25 (m, 10H), 5.56 (s, 1H), 5.21 (d, J = 14.4 Hz, 1H), 5.16 (d, J = 12.4 
Hz, 1H), 5.08 (d, J = 12.0 Hz, 1H), 5.05-4.99 (m, 1H), 4.74 (d, J = 9.6 Hz, 1H), 4.28 (d, J = 
14.8 Hz, 1H), 2.49-2.44 (m, 1H), 2.36-2.30 (m, 1H), 2.21-2.15 ( m, 1H), 1.70-1.63 (m, 1H); 
13C NMR (100 MHz, CDCl3): δ 157.1, 156.8, 155.9, 137.8, 136.1, 135.1, 132.9, 128.6, 128.6, 
128.2, 128.1, 127.9, 67.0, 54.0, 49.6, 30.9, 27.1; HRMS (ESI+) Calcd. for C22H21F3N2O3+Na, 
441.1402; Found, 441.1402; IR (thin film, cm-1) 3428, 3352, 3064, 2950, 1693, 1512, 1208, 
1157, 1051; TLC (60:40 petroleum ether/acetone): Rf = 0.60. 
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1H COSY analysis of 3.39 supporting acyl transfer: 
 
(Z)-Benzyl (2-(N-benzyl-2,2,2-trifluoroacetamido)-2-phenylvinyl) 
carbamate (3.42): The title compound was prepared according to General 
Procedure B using nitrone 3.25 (22 mg, 0.10 mmol, 1.0 equiv), imidoyl 
chloride 3.37 (26.5 mg, 0.1 mmol, 1.0 equiv) and triethylamine (28 µL, 0.20 mmol, 2.0 equiv) 
in CH2Cl2 (1 mL). Purification by flash chromatography (90:10 petroleum ether/acetone) 
furnished 3.42 as a colorless oil (28 mg, 0.062 mmol, 61%). Analytical data: 1H NMR (400 
MHz, CDCl3): δ 7.40-7.15 (m, 15H), 5.70 (d, J = 10.8 Hz, 1H), 5.60 (d, J = 13.2 Hz, 1H), 5.10 
(d, J = 12.4 Hz, 1H), 4.92 (d, J = 12.0 Hz, 1H), 3.76 (d, J = 13.6 Hz, 1H); 13C NMR (100 
MHz, CDCl3): δ 158.7, 158.3, 152.6, 135.6, 135.3, 133.6, 129.5, 129.1, 129.0, 128.8, 128.4, 
128.4, 128.0, 127.7, 123.8, 123.5, 117.7, 67.5, 51.6; HRMS (ESI+) Calcd. for 
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C25H21F3N2O3+H, 455.1582; Found, 455.1585; IR (thin film, cm
-1) 3409, 3053,1691, 1665, 
1482, 1265, 1211, 1174; TLC (75:25 hexanes/ethyl acetate): Rf = 0.30. 
(Z)-Benzyl (2-(4-methoxyphenyl)-2-(2,2,2-trifluoro-N-(4-methoxy 
benzyl)acetamido)vinyl) carbamate (3.55): The title compound was 
prepared according to General Procedure B using nitrone 3.26 (30 mg, 
0.105 mmol, 1.0 equiv), imidoyl chloride 3.37 (28 mg, 0.105 mmol, 1.0 equiv) and 
triethylamine (30 µL, 0.21 mmol, 2.0 equiv) in CH2Cl2 (1 mL). Purification by flash 
chromatography (90:10 petroleum ether/acetone) furnished 3.55 as a pale yellow oil (37 mg, 
0.072 mmol, 69%). Analytical data: 1H NMR (600 MHz, CDCl3): δ 7.39-7.22 (m, 9H), 6.92 
(d, J = 9.0 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 5.72 (d, J = 11.4 Hz, 1H), 5.50 (d, J = 13.2 Hz, 
1H), 5.06 (d, J = 12.6 Hz, 1H), 4.97 (d, J = 12.6 Hz, 1H), 3.83 (s, 3H), 3.72 (d, J = 13.8 Hz, 
1H), 3.67 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 160.0, 159.4, 152.8, 135.4, 130.9, 128.8, 
128.6, 128.3, 127.7, 126.0, 125.4, 121.8, 117.9, 114.5, 114.5, 67.5, 55.3, 55.2, 50.9; HRMS 
(ESI+) Calcd. for C27H25F3N2O5+H, 515.1794; Found, 515.1794; IR (thin film, cm
-1) 3403, 
3057, 2959, 1693, 1611, 1483, 1215, 1033; TLC (70:30 petroleum ether/acetone): Rf = 0.60. 
(Z)-Benzyl (2-(naphthalen-2-yl)-2-(2,2,2-trifluoro-N-(4-
methoxy benzyl)acetamido)vinyl) carbamate (3.56): The title 
compound was prepared according to General Procedure B using 
nitrone 3.27 (30.5 mg, 0.10 mmol, 1.0 equiv), imidoyl chloride 3.37 (26.5 mg, 0.1 mmol, 1.0 
equiv) and triethylamine (27.9 µL, 0.20 mmol, 2.0 equiv) in CH2Cl2 (1 mL). Purification by 
flash chromatography (90:10 hexanes/ethyl acetate) furnished 3.56 as an off-white solid (21.7 
mg, 0.041 mmol, 51%).  Analytical data: mp 50-51 °C; 1H NMR (400 MHz, CDCl3): δ 7.84 
(q, J = 8.4, 6.8 Hz, 3H), 7.59 (br s, 1H), 7.52-7.50 (m, 4H), 7.40-7.27 (m, 3H), 6.83 (d, J = 8.8, 
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2H), 5.87 (d, J = 11.2 Hz, 1H), 5.61 (d, J = 13.6 Hz, 1H), 5.10 (d, J = 12.4 Hz, 1H), 5.01 (d, J 
= 12.0 Hz, 1H), 3.84 (d, J = 13.6 Hz, 1H), 3.67 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 160.1, 
152.8, 135.2, 133.4, 132.7, 131.0, 130.9, 128.9, 128.6, 128.4, 128.1, 127.8, 127.6, 126.8, 126.3, 
123.9, 122.7, 121.6, 118.0, 117.0, 115.1, 114.6, 67.7, 55.2, 51.3; HRMS (ESI+) Calcd. for 
C30H25F3N2O4+H, 535.1845; Found, 535.1838; IR (thin film, cm
-1) 3408, 3054, 2986, 2305, 
1692, 1659, 1512, 1484, 1265, 1213; TLC (70:30 hexanes/ethyl acetate): Rf = 0.51. 
(E)-Benzyl (1-phenyl-1-(2,2,2-trifluoro-N-(4-
methoxybenzyl)acetamido) prop-1-en-2-yl) carbamate (3.57): The title 
compound was prepared according to General Procedure B using nitrone 
3.28 (27 mg, 0.10 mmol, 1.0 equiv), imidoyl chloride 3.37 (27 mg, 0.10 mmol, 1.0 equiv) and 
triethylamine (28 µL, 0.20 mmol, 2.0 equiv) in CH2Cl2 (1 mL). Purification by flash 
chromatography (90:10 hexanes/ethyl acetate) furnished 3.57 as a pale yellow oil (31.1 mg, 
0.062 mmol, 62%) as a 5.5:1 mixture of inseparable diastereomers.  Analytical data: 1H NMR 
(400 MHz, CDCl3): (Major diastereomer) δ 7.44-7.28 (m, 10H), 7.24 (d, J = 7.2 Hz, 2H), 6.84 
(d, J = 8.8 Hz, 2H), 5.72 (s, 1H), 5.30 (d, J = 13.6 Hz, 1H), 4.98 (d, J = 12.4 Hz, 1H), 4.92 (d, 
J = 12.4 Hz, 1H), 3.69 (s, 3H), 3.51 (d, J = 13.6 Hz, 1H), 2.31 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 160.0, 152.5, 135.8, 135.5, 133.9, 130.8, 129.8, 129.7, 128.7, 128.6, 128.5, 128.3, 
128.1, 127.9, 127.7, 127.5, 119.0, 114.7, 114.1, 66.7, 55.2, 50.1, 16.5; HRMS (ESI+) Calcd. 
for C27H25F3N2O4+Na, 521.1665; Found, 521.1664; IR (thin film, cm
-1) 3387, 2593, 1690, 
1641, 1512, 1482, 1250, 1167, 1110; TLC (70:30 hexane/ethyl acetate): Rf = 0.58. 
Benzyl (2-(2,2,2-trifluoro-N-(4-methoxybenzyl)acetamido) cyclopent-
2-en-1-yl)carbamate (3.45): The title compound was prepared according 
to General Procedure B using nitrone 3.29 (38 mg, 0.173 mmol, 1.0 equiv), 
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imidoyl chloride 3.37 (46 mg, 0.173 mmol, 1.0 equiv) and triethylamine (48 µL, 0.346 mmol, 
2.0 equiv) in CH2Cl2 (2 mL). Purification by flash chromatography (90:10 petroleum 
ether/acetone) furnished 3.45 as a colorless oil (52 mg, 0.116 mmol, 67%). Analytical data: 1H 
NMR (600 MHz, CDCl3): δ 7.38-7.34 (m, 5H), 7.18 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 9.0 Hz, 
2H), 5.52 (s, 1H), 5.16 (d, J = 12.0 Hz, 1H), 5.07 (d, J = 12.0 Hz, 1H), 5.02-4.98 (m, 1H), 4.68 
(d, J = 9.6 Hz, 1H), 4.17 (d, J = 14.4 Hz, 1H), 3.78 (s, 3H), 2.50-2.47 (m, 1H), 2.35-2.30 (m, 
1H), 2.20-2.17 (m, 1H), 1.66-1.62 (m, 1H); 13C NMR (150 MHz, CDCl3): δ 159.3, 155.9, 
137.7, 136.1, 132.9, 130.1, 128.6, 128.5, 128.4, 128.1, 127.2, 113.9, 68.1, 67.1, 55.2, 54.0, 
49.1, 30.9, 27.1; HRMS (ESI+) Calcd. for C23H23F3N2O4+Na, 471.1508; Found, 471.1508; IR 
(thin film, cm-1) 3426, 3054, 1691, 1513, 1265, 1207, 1175; TLC (70:30 petroleum 
ether/acetone): Rf = 0.80. 
Benzyl (2-(2,2,2-trifluoro-N-(4-methylbenzyl)acetamido) 
cyclopent-2-en-1-yl)carbamate (3.46): The title compound was 
prepared according to General Procedure B using nitrone 3.30 
(20 mg, 0.10 mmol, 1.0 equiv), imidoyl chloride 3.37 (27 mg, 0.10 mmol, 1.0 equiv) and 
triethylamine (28 µL, 0.20 mmol, 2.0 equiv) in CH2Cl2 (1 mL). Purification by flash 
chromatography (90:10 petroleum ether/acetone) furnished 3.46 as a colorless oil (34 mg, 
0.079 mmol, 79%). Analytical data: 1H NMR (400 MHz, CDCl3): δ 7.40-7.33 (m, 5H), 7.15-
7.10 (m, 4H), 5.55 (s, 1H), 5.16 (d, J = 12.4 Hz, 2H), 5.08 (d, J = 12.0 Hz, 1H), 5.04-4.98 (m, 
1H), 4.70 (d, J = 9.2 Hz, 1H), 4.22 (d, J = 14.8, 1H), 2.51-2.45 (m, 1H), 2.32 (s, 4H), 2.22-
2.16 (m, 1H), 1.70-1.60 (m, 1H); 13C NMR (100 MHz, CDCl3): δ 157.0, 156.7, 155.9, 137.8, 
137.7, 136.2, 132.9, 132.1, 129.2, 128.7, 128.6, 128.2, 128.0, 67.0, 54.0, 49.5, 30.9, 27.1, 21.1; 
HRMS (ESI+) Calcd. for C21H21ClF3N2O4+H, 433.1739; Found, 433.1741; IR (thin film, cm
-
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1) 3439, 3353, 3034, 2950, 2253, 1692,1513, 1209, 1175; TLC (70:30 petroleum 
ether/acetone): Rf = 0.70. 
Benzyl (2-(N-(4-chlorobenzyl)-2,2,2-trifluoroacetamido) 
cyclopent-2-en-1-yl)carbamate (3.47): The title compound was 
prepared according to General Procedure B using nitrone 3.31 (23 
mg, 0.10 mmol, 1.0 equiv), imidoyl chloride 3.37 (27 mg, 0.10 mmol, 1.0 equiv) and 
triethylamine (28 µL, 0.20 mmol, 2.0 equiv) in CH2Cl2 (1 mL). Purification by flash 
chromatography (90:10 hexanes/ethyl acetate) furnished 3.31 as a colorless oil (31.8 mg, 0.070 
mmol, 70%). Analytical data: 1H NMR (400 MHz, CDCl3): δ 7.38-7.34 (m, 5H), 7.28 (d, J = 
8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 5.56 (s, 1H), 5.15 (d, J = 12.0 Hz, 1H), 5.13 (d, J = 14.4 
Hz, 1H), 5.07 (d, J = 12.0 Hz, 1H), 5.02-4.96 (m, 1H), 4.69 (d, J = 9.2 Hz, 1H), 4.25 (d, J = 
14.8 Hz, 1H), 2.52-2.45 (m, 1H), 2.38-2.32 (m, 1H), 2.24-2.17 (m, 1H), 1.71-1.59 (m, 1H); 
13C NMR (100 MHz, CDCl3): δ 157.2, 156.8, 155.9, 137.8, 136.1, 133.9, 133.7, 133.0, 130.1, 
128.8, 128.6, 128.3, 128.1, 67.1, 54.0, 49.0, 30.8, 27.2; HRMS (ESI+) Calcd. for 
C22H20ClF3N2O3+H, 453.1194; Found, 453.1191; IR (thin film, cm
-1) 3431, 2096, 1690, 1641, 
1512, 1265, 1207, 1157, 1051; TLC (70:30 hexanes/ethyl acetate): Rf = 0.48. 
Benzyl (2-(2,2,2-trifluoro-N-(4-methoxybenzyl)acetamido)cyclohex-2-
en-1-yl)carbamate (3.48): The title compound was prepared according to 
General Procedure B using nitrone 3.32 (23 mg, 0.10 mmol, 1.0 equiv), 
imidoyl chloride 3.37 (27 mg, 0.10 mmol, 1.0 equiv) and triethylamine (28 µL, 0.20 mmol, 2.0 
equiv) in CH2Cl2 (1 mL). Purification by flash chromatography (90:10 petroleum 
ether/acetone) furnished 3.48 as a pale yellow oil (32 mg, 0.069 mmol, 69%).  Analytical data: 
1H NMR (600 MHz, CDCl3): δ 7.40-7.33 (m, 8H), 7.20 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.4 
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Hz, 2H), 5.41 (s, 1H), 5.29 (d, J = 10.8 Hz, 1H), 5.25 (d, J = 14.4 Hz, 1H), 5.16 (d, J = 12.6 
Hz, 1H), 5.06 (d, J = 12.0 Hz, 1H), 4.75 (d, J = 9.6 Hz, 1H), 4.62-4.59 (m, 1H), 4.04 (d, J = 
14.4 Hz, 1H), 3.79 (s, 3H), 2.04 (t, J = 16.8 Hz, 2H), 1.94 (d, J = 18.0 Hz, 1H), 1.62-1.59 (m, 
3H); 13C NMR (150 MHz, CDCl3): δ 159.2, 156.1, 136.1, 133.4, 132.9, 130.6, 128.6, 128.5, 
128.3, 128.1, 127.3, 113.8, 67.1, 55.2, 49.0, 46.1, 30.6, 24.7, 19.9; LRMS (ESI+) Calcd. for 
C24H25F3N2O4+H, 463.18; Found, 463.22; IR (thin film, cm
-1) 3356, 3064, 2948, 1691, 1512, 
1454, 1323, 1208, 1177; TLC (80:20 petroleum ether/acetone): Rf = 0.30. 
Benzyl (5-(tert-butyl)-2-(2,2,2-trifluoro-N-(4-
methoxybenzyl)acetamido) cyclohex-2-en-1-yl) carbamate (3.49): The 
title compound was prepared according to General Procedure B using 
nitrone 3.33 (30.5 mg, 0.10 mmol, 1.0 equiv), imidoyl chloride 3.37 (26.5 
mg, 0.01 mmol, 1.0 equiv) and triethylamine (27.9 µL, 0.20 mmol, 2.0 equiv) in in CH2Cl2 (1 
mL). Purification by flash chromatography (90:10 hexanes/ethyl acetate) furnished 3.49 as an 
off-white solid (21.7 mg, 0.041 mmol, 51%) as a 1.5:1 mixture of separable diastereomers.  
Analytical data: 1H NMR (600 MHz, CDCl3): (Major Diastereomer) δ 7.37-7.34 (m, 5H), 7.17 
(d, J = 6.6 Hz, 2H), 7.10 (d, J = 8.4 Hz, 1H), 6.83 (d, J = 7.2 Hz, 3H), 5.52 (br s, 1H), 5.14 (d, 
J = 12.0 Hz, 1H), 5.08 (d, J = 13.2 Hz, 1H), 5.00-4.66 (m, 1H), 4.66 (br s, 1H), 4.15 (d, J = 
15.0 Hz, 1H), 3.79 (s, 3H), 3.12-3.10 (m, 1H), 2.10-2.07 (m, 1H), 1.97-1.95 (m, 1H), 1.72-1.68 
(m, 1H), 1.40-1.30 (m, 1H), 1.20-1.15 (m, 1H), 0.85 (s, 9H); (Minor Diastereomer) δ 7.39-7.35 
(m, 5H), 7.21 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 5.38-5.36 (m, 1H), 5.22 (d, J = 14.4 
Hz, 1H), 5.17 (d, J = 12.0 Hz, 1H), 5.06 (d, J = 12.0 Hz, 1H), 4.64 (s, 2H), 3.99 (d, J = 14.4 
Hz, 1H), 3.80 (s, 3H), 2.20 (d, J = 12.0 Hz, 1H), 1.99-1.96 (m, 1H), 1.83-1.78 (m, 1H), 1.42-
1.41 (m, 1H), 1.21-1.17 (m, 1H), 0.86 (s, 9H); 13C NMR (150 MHz, CDCl3): (Minor 
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Diastereomer) δ 159.2, 156.2, 136.1, 133.7, 132.2, 130.6, 128.6, 128.3, 128.1, 127.4, 113.8, 
67.2, 55.2, 49.1, 48.1, 43.2, 32.6, 32.1, 26.9, 26.3; HRMS (ESI+) Calcd. for 
C28H33F3N2O4+Na, 541.2291; Found, 541.2290; IR (thin film, cm
-1) 3487, 3035, 2962, 1803, 
1712, 1612, 1498, 1455, 1251; TLC (70:30 hexanes/ethyl acetate): Rf = 0.49. 
Benzyl (2-(2,2,2-trifluoro-N-((S)-1-
phenylethyl)acetamido)cyclopent -2-en-1-yl)carbamate (3.50): 
The title compound was prepared according to General Procedure B 
using nitrone 3.34 (40 mg, 0.20 mmol, 1.0 equiv), imidoyl chloride 3.37 (53 mg, 0.20 mmol, 
1.0 equiv) and triethylamine (56 µL, 0.40 mmol, 2.0 equiv) in CH2Cl2 (2 mL). Purification by 
flash chromatography (90:10 hexanes/ethyl acetate) furnished 3.50 as a pale yellow oil which 
was a 1:1 mixture of separable diastereomers (Diastereomer 1: 20.2 mg, 0.047 mmol, 23%; 
Diastereomer 2: 19 mg, 0.043, 22%).  Analytical data: 1H NMR (400 MHz, CDCl3): 
(Diastereomer 1) δ 7.38-7.31 (m, 10H), 5.73-5.68 (m, 1H), 5.48 (br s, 1H), 5.13 (d, J = 12.4 
Hz, 1H), 5.09 (d, J = 8.4 Hz, 1H), 4.84 (d, J = 7.2 Hz, 1H), 2.35-2.21 (m, 2H), 1.99 (br s, 1H), 
1.63 (d, J = 7.2 Hz, 3H), 1.59-1.48 (m, 1H); (Diastereomer 2) δ 7.39-7.27 (m, 10H), 5.84 (s, 
1H), 5.45-5.40 (m, 1H), 5.01 (s, 2H), 4.60 (br s, 1H), 4.30 (br s, 1H), 2.38-2.30 (m, 4H), 1.62 
(d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, CDCl3): (Diastereomer 1) 156.6, 156.4, 155.9, 138.1, 
136.8, 136.2, 135.9, 128.6, 128.4, 128.3, 128.2, 67.0, 56.5, 32.1, 26.8, 16.3; (Diastereomer 2) 
δ 155.3, 138.3, 137.5, 136.2, 134.8, 128.5, 128.2, 128.1, 127.6, 66.8, 56.4, 55.2, 32.0, 27.1, 
16.4; HRMS (ESI+) Calcd. for C23H23F3N2O3+H, 433.1740; Found, 433.1750; IR (thin film, 
cm-1) 3422, 3054, 2986, 2305, 1685, 1508, 1420, 1265, 1206, 1155; TLC (70:30 hexane/ethyl 
acetate): Rf = Diastereomer 1: 0.55; Diastereomer 2: 0.45. 
199 
(Z)-Benzyl (2-(2,2,2-trifluoro-N-(4-methoxybenzyl)acetamido) prop-
1-en-1-yl)carbamate (3.51): The title compound was prepared according 
to General Procedure B using nitrone 3.35 (20 mg, 0.10 mmol, 1.0 equiv), 
imidoyl chloride 3.37 (27 mg, 0.10 mmol, 1.0 equiv) and triethylamine (28 µL, 0.20 mmol, 2.0 
equiv) in CH2Cl2 (1 mL). Purification by flash chromatography (95:5 to 90:10 petroleum 
ether/acetone) furnished 3.51 as a pale yellow oil (19 mg, 0.045 mmol, 45%). Analytical data: 
1H NMR (600 MHz, CDCl3): δ 7.37-7.29 (m, 3H), 7.24 (d, J = 7.2 Hz, 2H), 6.83 (d, J = 8.4 
Hz, 2H), 6.52 (d, J = 10.8 Hz, 1H), 5.62 (d, J = 11.4 Hz, 1H), 5.12 (d, J = 13.8 Hz, 1H), 5.03 
(d, J = 12.0 Hz, 1H), 4.96 (d, J = 12.0, 1H), 4.02 (d, J = 13.8 Hz, 1H), 3.68 (s, 3H), 1.85 (s, 
3H); 13C NMR (150 MHz, CDCl3): δ 159.9, 152.7, 135.4, 130.7, 128.6, 128.3, 127.9, 127.8, 
123.7, 114.4, 113.7, 67.4, 55.2, 49.8, 18.9; HRMS (ESI+) Calcd. for 
C21H21ClF3N2O4+Na,445.1351; Found, 445.1354; IR (thin film, cm
-1) 3415, 2958, 2253, 1693, 
1513, 1213, 1173, 1034; TLC (70:30 petroleum ether/acetone): Rf = 0.70. 
Benzyl (2-(N-benzyl-2,2,2-trifluoroacetamido)-1-chlorocyclohex-2-en-
1-yl)carbamate (3.52): The title compound was prepared according to 
General Procedure B using cyclohexenyl nitrone (23 mg, 0.10 mmol, 1.0 
equiv), imidoyl chloride 3.37 (27 mg, 0.10 mmol, 1.0 equiv) and triethylamine (28 µL, 0.20 
mmol, 2.0 equiv) in CH2Cl2 (1 mL). Purification by flash chromatography (90:10 petroleum 
ether/acetone) furnished 3.52 as a pale yellow oil (39 mg, 0.084 mmol, 84%). Analytical data: 
1H NMR (600 MHz, CDCl3): δ 7.39-7.30 (m, 11H), 5.53 (s, 1H), 5.27 (d, J = 15.0 Hz, 1H), 
5.19 (d, J = 12.0 Hz, 1H), 5.11 (d, J = 6.0 Hz, 1H), 5.09 (d, J = 7.8 Hz, 1H), 4.90 (d, J = 9.0 
Hz, 1H), 4.74-4.67 (m, 1H), 4.11 (d, J = 14.4 Hz, 2H), 2.23 (br s, 1H), 2.16-2.13 (m, 1H), 2.07-
2.05 (m, 1H), 2.01-1.96 (m, 1H); 13C NMR (150 MHz, CDCl3): δ 156.1, 135.8, 134.8, 132.8, 
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130.5, 129.3, 128.8, 128.7, 128.6, 128.6, 128.5, 128.4, 128.1, 127.9, 67.5, 58.9, 53.0, 49.7, 
27.6, 22.0; HRMS (ESI+) Calcd. for C23H22ClF3N2O3+Na, 467.1271; Found, 467.1361; IR 
(thin film, cm-1) 3439, 3068, 2960, 2253, 1692, 1500, 1442, 1213, 1158; TLC (70:30 
petroleum ether/acetone): Rf = 0.50. 
1H NOESY analysis of 3.52 supporting stereochemical assignment: 
The cis chloro/amino stereochemistry was supported by NOESY spectroscopy. The -methine 
(R2CHCl) showed two nOe’s: a strong interaction (a) with the amino methine (RNHCbz), and 
interaction (b) with the allylic methine proton (R2CHNHCbz). Additionally, the allylic methine 
displayed an interaction (c) with the -alkyl methylene, an interaction that would not be 
observed if the allylic methine occupied the pseudoequitorial position – the only orientation 
that would support a trans relationship based upon the dual nOe observed with the -methine 
(R2CHCl).  
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Secondary Transformations: 
 
Benzyl (2-oxocyclopentyl)carbamate (3.58): A oven-dried 4-mL vial equipped with 
magnetic stir bar was charged with '-amino enamide 3.39 (0.065 g, 0.15 mmol, 1.0 equiv). 
Methanol (1.0 mL) was added, followed by freshly prepared sodium benzylthiolate (0.112 g, 
0.77 mmol, 5.0 equiv). The vial was sealed with a Teflon-lined cap and the reaction was stirred 
at rt for 14 h. Volatiles were removed in vacuo and the crude product was purified via flash 
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chromatography (90:10 to 80:20 petroleum ether/acetone) to provide 3.58 as a pale yellow oil 
(29 mg, 85%). Analytical data: 1H NMR (600 MHz, CDCl3): δ 7.38-7.31 (m, 5H), 5.22 (br s, 
1H), 5.11 (s, 2H), 3.99-3.96 (m, 1H), 2.64-2.62 (m, 1H), 2.42 (dd, J = 19.8, 9.0 Hz, 1H), 2.21-
2.14 (m, 1H), 2.09-2.04 (m, 1H), 1.86-1.84 (m, 1H), 1.67-1.63 (m, 1H); 13C NMR (150 MHz, 
CDCl3): δ 214.6, 156.2, 136.2, 128.5, 128.2, 128.1, 67.0, 59.2, 34.8, 30.2, 17.8; MS (ESI+) 
Calcd. for C13H15NO3+Na, 256.10; Found, 256.10; IR (thin film, cm
-1) 3414, 3055, 2978, 
2885, 2305, 1719, 1509, 1455, 1266, 1063; TLC (60:40 petroleum ether/acetone): Rf = 0.40. 
 
Benzyl (2-oxo-2-phenylethyl)carbamate and Methyl (2-oxo-2-phenylethyl)carbamate 
(3.59): A oven-dried 20-mL scintillation vial equipped with magnetic stir bar was charged with 
enediamine 3.42 (0.160 g, 0.346 mmol, 1.0 equiv). Methanol (4.0 mL) was added, followed 
by freshly prepared sodium benzylthiolate (0.202 g, 1.38 mmol, 4.0 equiv). The vial was sealed 
with a Teflon-lined cap and the reaction was stirred at rt for 2 h. Volatiles were removed in 
vacuo. THF (1.5 mL) and 1 M HCl (aq.) were added to the vial and the reaction was allowed 
to stir at rt for 0.5 h. The organic layer was extracted with Et2O (3 x 2 mL) and dried with 
MgSO4. Volatiles were removed in vacuo and the crude product was purified via flash 
chromatography (85:15 to 75:25 hexanes/ethyl acetate) to provide two products. Cbz: colorless 
oil, 38 mg, 41%, OMe: white solid, 7 mg, 11%. Analytical data: Cbz Product: 1H NMR (400 
MHz, CDCl3): δ 7.96 (d, J = 7.6 Hz, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 
5.85 (br s, 1H), 5.16 (s, 2H), 4.73-4.69 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 193.2, 156.2, 
136.3, 134.0, 128.9, 128.5, 128.1, 128.0, 127.8, 126.9, 67.0, 47.8; MS (ESI+) Calcd. for 
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C16H15NO3+H, 270.10; Found, 270.07; IR (thin film, cm
-1) 3417, 3061, 1692, 1511, 1354, 
1266, 1218, 1057; TLC (70:30 hexanes/ethyl acetate): Rf = 0.30. OMe Product: mp 77-82 
°C; 1H NMR (400 MHz, CDCl3): δ 7.96 (d, J = 7.6 Hz, 2H), 7.62 (t, J = 7.6 Hz, 1H), 7.49 (t, 
J = 7.6 Hz, 2H), 5.74 (br s, 1H), 4.71 (d, J = 4.4 Hz, 2H), 3.72 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 194.1, 156.9, 134.3, 134.0, 128.9, 127.8, 52.4, 47.8; MS (ESI+) Calcd. for 
C10H11NO3+Na, 216.06; Found, 216.01; IR (thin film, cm
-1) 3426, 1692, 1518, 1536, 1265, 
737, 701; TLC (70:30 hexanes/ethyl acetate): Rf = 0.20.  
 
Benzyl (2-oxocyclopentyl)carbamate (3.58): The title compound was prepared according to 
General Procedure B using nitrone 3.24 (71 mg, 0.377 mmol, 1.0 equiv), imidoyl chloride 3.37 
(100 mg, 0.377 mmol, 1.0 equiv) and triethylamine (100 µL, 0.755 mmol, 2.0 equiv) in CH2Cl2 
(2 mL). Upon completion, volatiles were removed in vacuo. Methanol was immediately added 
to the vial (3.0 mL) followed by the addition of freshly prepared sodium benzylthiolate (0.165 
g, 1.13 mmol, 3.0 equiv). The vial was sealed with a Teflon-lined cap and the reaction was 
stirred at rt for 14 h. Volatiles were removed in vacuo and the crude product was purified via 
flash chromatography (90:10 to 80:20 petroleum ether/acetone) to provide the desired product 
as a pale yellow oil (58 mg, 67%). 
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N-benzyl-N-(6-bromo-2-oxohexahydro-2H-cyclopenta[d]oxazol-6a-yl)-2,2,2-
trifluoroacetamide (3.60): A oven-dried 4-mL scintillation vial equipped with magnetic stir 
bar was charged with '-amino enamide 3.39 (0.020 g, 0.048 mmol, 1.0 equiv). The vial was 
purged with nitrogen and dichloromethane (1.2 mL) was added. Bromine (0.007 mL, 0.14 
mmol, 3.0 equiv) was then added dropwise and the reaction was stirred at 23 °C for 45 min. 
Upon completion, volatiles were removed in vacuo. The crude product was purified via flash 
chromatography (90:10 to 80:20 petroleum ether/acetone) to provide the desired product as a 
white solid with 2.5:1 diastereomeric ratio (15 mg, 79%). Analytical data: mp 176.5-178 °C; 
1H NMR (600 MHz, CDCl3): (Major Diastereomer) δ 7.38-7.22 (m, 5H), 6.01 (s, 1H), 5.49 (s, 
1H), 5.01 (d, J = 19.8 Hz, 1H), 4.68 (d, J = 18.0 Hz, 1H), 4.28 (d, J = 4.2 Hz, 1H), 2.38-2.21 
(m, 3H), 1.66 (d, J = 12.6 Hz, 1H); 13C NMR (150 MHz, CDCl3): (Major Diastereomer) δ 
156.7, 135.5, 129.1, 128.6, 128.1, 125.5, 116.8, 114.9, 105.2, 57.8, 56.2, 50.6, 32.5, 31.4; 
HRMS (ESI+) Calcd. for C15H14BrF3N2O3 +Na, 429.0038; Found, 429.0039; IR (thin film, 
cm-1) 3054, 2986, 2305, 1778, 1719, 1292, 1209, 1149, 740; TLC (60:40 hexanes/ethyl 
acetate): Rf = 0.30. 
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CHAPTER FOUR 
 
TOTAL SYNTHESIS OF PACTAMYCIN* 
 
4.1  Introduction 
 A partial synthesis of the pactamycin core was presented in Chapter Two. During these 
studies we assembled the bulk of the central core of this target, but failed in the installation of 
the C2 amino group at an unfunctionalized methylene carbon. This work, while insightful, was 
ultimately abandoned for a more “aggressive” approach including a rapid buildup of 
functionality with early installation of the problematic C2 amino group. In this final chapter, 
we detail a full synthetic route to pactamycin. This work described was completed in a joint 
effort with Robert Sharpe and represents the second total synthesis of pactamycin to date, 
completed in less than half the steps of the previous state-of-the-art. 
Figure 4-1.  Structure of Pactamycin 
 
 
* Reprinted in part with permission from Malinowski, J. T.; Sharpe, R. J.; Johnson, J. 
S. Science 2013, 340, 180. 
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4.2  Background 
4.2.1  Summary/Analysis of the Hanessian Total Synthesis 
 The first total synthesis of pactamycin was published in 2011 by Hanessian and 
coworkers.1 Their route was described in detail in Chapter Two and is summarized here in 
Figure 4-2. This approach began from the chiral pool with L-threonine (4.2) which was 
elaborated to enone 4.3 with the C1 and C7 stereocenters completed. In eleven subsequent 
steps, the core functionalization was completed, giving epoxide 4.4. Introduction of the 
dimethylurea and aniline groups was accomplished in five steps providing advanced 
intermediate 4.5 with the acetophenone functionality masked as an isopropene. Five final steps 
gave pactamycin in a grand total of 32 linear transformations and a 1.1% overall yield.  
Figure 4-2.  Abridged Hanessian Synthesis 
 
 The Hanessian route to pactamycin was an important accomplishment in the field of 
total synthesis. In analyzing this work we identified both opportunities for improvement and 
areas from which to draw inspiration. The challenges presented in pactamycin made for a 
synthesis rich in protection/deprotection and oxidation/reduction chemistry, as well as 
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stereochemical mistakes which required significant refunctionalization. Additionally, bulk 
functionality was typically introduced in protected form, a feature detrimental to route 
efficiency. For example, the dimethylurea group was introduced as a protected amine early in 
the synthesis and carried through 20+ steps. Its late-stage assembly required deprotection and 
a two-step acylation/amination sequence to reveal the nascent functionality. A highly-reactive 
isocyanate intermediate was used, and as a consequence of this decision, Hanessian, et al. 
encountered significant undesired intramolecular reactivity preventing the desired 
transformation. Ultimately, additional protecting groups were installed on distal hydroxyls in 
order to permit construction of the urea. A second opportunity we identified for improvement 
was the introduction of the m-acetylaniline in a protected form. While this undoubtedly made 
for a smoother C–N bond construction, a subsequent oxidation sequence was necessary to 
reveal the latent ketone functionality. However, we were inspired by the synthetic strategy 
used to build the western portion of the molecule. The epoxidation/aniline ring-opening 
sequence was something we attempted in the past, but failed to realize. We hoped to apply 
these conditions, along with the protection strategy, to our synthesis in the late stage as we 
recognized the high efficiency.  
 With the Hanessian accomplishment marking the state-of-the-art in pactamycin’s 
synthesis we knew we would have to find a significantly shorter route to impact the synthetic 
community. We were specifically interested in minimizing step-count by presenting 
functionality in its correct oxidation state2 and without protection3 when possible. Also, 
modular delivery of functional groups was an important goal along with the expectation of a 
strategic manipulation at each step, enabling a concise synthetic route.4 
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4.2.2  Summary of Our Partial Core Synthesis 
 Prior to the work described in this chapter, we had put significant effort into the 
pactamycin synthesis problem, making great strides (Figure 4-3). Numerous synthetic 
approaches culminated with advanced core intermediate 4.6 from which we had hoped to 
perform a ketone -amination. All conventional methods failed to deliver this functionality, 
including the methodology developed for this purpose (Chapter Three). We ultimately decided 
this approach was inadequate, not only because of the C2 amination failure, but in its overall 
route efficiency.  
Figure 4-3.  Our Previous Failed Route 
 
 Of the fifteen steps used to reach ketone 4.6, eight transformations were unstrategic 
redox or protecting group manipulations. This was mainly a consequence of the challenges we 
faced in the nucleophilic additions to construct the C5 carbinol, and protection schemes we 
used in order to test harsh reaction conditions on advanced intermediates in an effort to pursue 
the amination chemistry. Nevertheless, this route did not satisfy our desire for an efficient 
synthesis of pactamycin.  
 We did, however, learn a great deal about inherent reactivity of pactamycin-like 
intermediates and the unique properties afforded by the strategic decision to incorporate the 
dimethylurea group early in the synthesis. For example, we proposed this group played a key 
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role in nucleophilic additions to a C5 electrophile by forming an activated, five-membered 
chelate promoting diastereoselective facial approach. Additionally, the electron-rich urea 
presumably played a role in the facial direction of our dihydroxylation, providing a syn 
approach. The decision to install the urea early also came with negative consequences, such as 
its propensity to fragment under oxidative conditions, its intramolecular trapping of 
electrophilic functionality, and perhaps ultimate inhibition of introduction of the vicinal C2 
amino group. These considerations were all important in the formulation of a new synthetic 
strategy.  
4.2.3  Flexibility for Analogue Synthesis 
 Due to the exciting results reported by Mahmud et al. regarding the potential viability 
of pactamycin analogues as therapeutics,5 we understood the value of a flexible chemical route 
to pactamycin. While synthesis of the native natural product was indeed our goal, future 
application of pactamycin itself for any medicinal use would be impossible due to its inherent 
cytotoxicity. With ultimate medicinal application in mind, we approached the pactamycin 
synthesis problem with three criteria at the outset: 
1. The route must begin from cheap, commercial reagents. 
2. The route must be sufficiently short in order to be run on scale that could provide 
reasonable quantities of material. 
3. We must demonstrate viability of analogue synthesis and flexibility by the introduction 
of complex functionality in its final desired form, minimizing protecting group 
manipulation.  
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We believed a synthesis achieving these goals would not only be of high-value to the field, but 
realistic if the approach was guided by knowledge we obtained in prior studies and new 
proposed methodology could be realized in our aim for a concise route. 
4.2.4  Note on Stereochemistry 
 The majority of concrete stereochemical information relating to our intermediates en 
route to pactamycin was obtained at a late stage. As the synthetic studies will typically be 
presented in chronological order, absolute stereochemical relationships will be left ambiguous 
until proven. We will comment (with a degree of uncertainty) on predictions and anticipated 
outcomes, but presentation in this manner will allow the reader to better understand the purpose 
and timeline of the experiments run during our synthetic studies toward pactamycin.  
4.3  Results and Discussion 
4.3.1  Retrosynthesis – Early C2 Amino Introduction 
 Our initial retrosynthesis is somewhat-reminiscent of our previous plan with two early, 
important distinctions (Figure 4-4). First, we planned to begin from symmetrical acetylacetone-
derived urea 4.9 rather than the corresponding methyl acetoacetate. This eliminated the 
possibility for an asymmetric C1 stereocenter formation via C1 – C2 bond construction. (A 
Tusji-Trost AAA was employed in Chapter 2.) Second, we proposed installation of the C2 
amine early in the synthesis via Mannich addition to an appropriately-functionalized N-acyl 
aldimine. A key, diastereoselective symmetry-breaking monoreduction would provide 
monoalcohol 4.10. If the Mannich addition was rendered asymmetric (an unknown reaction 
for this substrate class), the absolute stereochemistry could be set at C2 and parlayed to the C1 
and C7 stereocenters during the ensuing desymmetrizing monoreduction. The strategy of using 
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a symmetrical dicarbonyl simplified the development of the asymmetric Mannich reaction as 
diastereochemical considerations were obviated, but seriously complicated the stereochemical 
possibilities of the reduction (vide infra).  
Figure 4-4.  Pactamycin Retrosynthesis 
 
 We anticipated the early sequence outlined above would take a significant portion of 
our total effort in the pactamycin synthesis, and we believed this was justified by the rapid 
buildup of complexity (half the stereochemistry of the molecule assembled in one step, and all 
carbons of the cyclopentane introduced). Based on our previous studies, we felt the 
advancement of monoalcohol 4.9 could follow a similar path to that of our former partial core 
synthesis. A functionalized vinyl nucleophile addition to the C5 methyl ketone would provide 
diene 4.10 which could undergo ring-closing metathesis to give the cyclopentene core 4.11. 
Alkene functionalization to install the trans-anilino alcohol would complete the core 
functionalization (4.12) leaving only a benzoylation to install the salicylate side chain, 
completing the target (4.1). 
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4.3.2  Synthesis of Mannich Precursors 
 We began our synthetic efforts with preparation of the urea pronucleophile 4.9 (Scheme 
4-1). We first tested a route involving reduction of oxime 4.13 to the amino salt 4.14 by means 
of a Pd/C-catalyzed hydrogenation. This reaction proceeded in high yield to give a 
hydrochloride salt which could never be advanced to the desire urea 4.9. We then turned to a 
Rh-catalyzed N–H insertion analogous to previous studies to deliver pronucleophile 4.9 in a 
slightly reduced 67% yield on multigram scale.   
Scheme 4-1.  Synthesis of Urea Pronucleophile 
 
 We next focused attention on synthesis of our aldimine electrophile. There were two 
important requirements for this substrate. First, the imine would have to carry a vinyl 
substituent, as this would be necessary for the subsequent RCM reaction. Next, the imino 
nitrogen would have to be protected with an appropriate group which would provide both 
sufficient electrophilicity for the Mannich addition as well as a means for facile removal later 
in the synthesis. To satisfy these requirements we settled on known cinnamyl-derived imine 
4.17. 
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 Although aldimine 4.17 is known in the literature, its synthesis is not straightforward 
nor described in detail in any account.6 Development of a workable protocol for its synthesis 
occurred over several months while preparing large batches of material for subsequent reaction 
testing. The synthesis of imine 4.17 was challenging due to purification issues. The material 
was not stable to SiO2 chromatography, and we encountered difficulty in crystallization and 
trituration attempts. Due to these issues, we used the material in its crude form, a viscous 
orange/brown oil. When employed in an excess, this procedure was sufficient for testing during 
early screening studies. Eventually, a procedure was developed to obtain pure imine (Scheme 
4-2).  
Scheme 4-2.  Synthesis of Imine Electrophile 
 
 We began by forming lithium bis(trimethylsilyl)amide (LiHMDS) neat (except for 
hexane from solution of nBuLi, 1.6 M). Addition of freshly distilled hydrocinnimaldehyde 
rapidly formed the condensation product 4.16. The volatiles were removed and the crude silyl 
imine was treated with benzyl chloroformate (CbzCl) to afford crude aldimine 4.17. Treatment 
of the crude material with an ethyl acetate/hexanes solution induced crystallization of a pale 
yellow solid, pure by NMR analysis. Yields were low and variable for this sequence, but could 
not be further optimized.  
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4.3.3  Development of an Asymmetric Mannich Reaction 
 With our coupling partners in hand, we set out to develop an asymmetric Mannich 
reaction. A search of the literature revealed promising work by Schaus and coworkers which 
we judged as a good starting point (Figure 4-5).7 Particularly relevant to our studies was the 
reaction of -ketoesters and cyclic diketones with acyl imine electrophiles (4.18), which was 
reported in excellent yield and enantioselectivity when certain cinchona alkaloids were 
employed. Diastereoselectivity, however, was uniformly low for these reactions. The products 
resembled the framework we desired and because of our choice of a symmetrical diketone 
substrate, the low diastereoselectivity observed was irrelevant. Importantly, the only -
substitution previously reported on the nucleophiles was the carbon framework of the cyclic 
substrates. To the best of our knowledge, the only example of a successful Mannich reaction 
on acylic, -substituted substrates was reported by Ishihara, using a chiral phosphoric acid 
catalyst.8 In this report, three substrates bearing only an -methyl group were shown. With the 
lack of precedent for -substitution (specifically -ureido in our case) we were somewhat 
apprehensive of the potential reaction outcome and enantioselection. 
Figure 4-5.  Schaus Organocatalyzed Mannich Additions 
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 As a proof of principle experiment, we began our studies with a racemic tertiary-amino 
catalyzed Mannich addition (Scheme 4-3). We choose Hünig’s base (DIPEA) and applied the 
conditions reported by Schaus, et al. After an overnight reaction, we were pleased to observe 
full conversion to the desired Mannich product. This was an exciting result due to the 
unreported functionality we subjected to the reaction conditions: (1) -amino substituted 
dicarbonyl nucleophile, (2) N-carboxylbenzyl imine, and (3) vinyl-substituted imine (previous 
reports were only aryl aldimines). The highly-congested product we obtained was stable to 
SiO2 chromatography and isolated in a 90% yield, amenable to multigram scale-up.  
Scheme 4-3.  Mannich Reaction Initial Result 
 
 Racemic material was useful for testing of subsequent reactions and carried up to the 
natural product during the course of our studies; however, development of an asymmetric 
variant was critical for the success of our synthesis. Schaus and coworkers had screened a 
variety of chiral amines in their studies, revealing cinchonine as an optimal promoter. Inspired 
by these studies, we began catalyst screening with cinchona alkaloids. The results of the 
catalyst and reaction optimization are summarized in Table 4-1. The top performer in our initial 
testing was cinchonidine, providing a moderate enantiomeric ratio of 24:76 (er reported 
arbitrarily based on the relative integration of the two resolved enantiomer peaks by chiral SFC 
analysis) (Entry 1). We had no way of determining the absolute configuration at the developing 
C2 stereocenter at this point, but decided to optimize for the second enantiomer peak as more 
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positive results were obtained with this selectivity. If this enantiomer was incorrect, we would 
use the pseudo-enantiomeric catalyst cinchonidine and re-optimize from that initial hit (Entry 
4).  
 Unable to increase the enantioselectivity by slight manipulations in reaction conditions, 
we decided to synthesize a variety of catalysts shown to be effective in dicarbonyl addition 
reactions (Figure 4-6). Chiral phosphoric acids 4.21a and 4.21b were prepared but provided 
low (1:2) selectivity (Entries 9-10). A series of thiourea derivatives of cinchona alkaloids were 
synthesized (4.22a-d) showing a promising 83:17 er favoring the opposite enantiomer for the 
quinine-derived catalyst, but no additional improvement from our initial hit with cinchonidine.  
 We were somewhat surprised to see how facile the Mannich reaction occurred, running 
to full conversion with essentially every catalyst we tested. This was probably a consequence 
of the highly-enolizable -ureido-diketone 4.9. In fact, by NMR analysis this substrate existed 
as a mixture of the keto- and enol- tautomers under ambient conditions. A control experiment 
revealed that the reaction proceeded, albeit slowly, at room temperature in the absence of a 
catalyst. This was an important discovery as we determined we would always be competing 
with a background racemic reaction during catalyst screening. 
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Table 4-1.  Screening of Mannich Conditions 
 
Entry Urea 
(equiv) 
Imine 
(equiv) 
Catalyst 
(mol %) 
Conditions Result 
(er) 
1 1.0 2.5 cinchonidine (20) CH2Cl2, 1d, -35 °C 24:76 
2 1.0 2.5 cinchonidine (20) CH2Cl2, 4d, -40 °C 20:80 
3 1.0 2.5 cinchonidine (20) CH2Cl2, 1d, rt 30:70 
4 1.0 2.5 cinchonine (20) CH2Cl2, 4d, -40 °C 75:25 
5 1.0 2.5 quinine (20) CH2Cl2, 4d, -40 °C 37:63 
6 1.0 2.5 quinidine (20) CH2Cl2, 4d, -40 °C 66:34 
7 1.0 2.5 (DHQ)2PHAL (20) CH2Cl2, 4d, -40 °C 60:40 
8 1.0 2.5 (DHQD)2PHAL  (20) CH2Cl2, 4d, -40 °C rac. 
9 1.0 2.5 4.21a (20) CH2Cl2, 1d, -40 °C 44:56 
10 1.0 2.5 4.21b (20) CH2Cl2, 1d, -40 °C 33:67 
11 1.0 2.5 4.22a (20) CH2Cl2, 1d, -40 °C 83:17 
12 1.0 2.5 4.22b (20) CH2Cl2, 1d, -40 °C 20:80 
13 1.0 2.5 4.22c (20) CH2Cl2, 1d, -40 °C 39:61 
14 1.0 2.5 4.22d (20) CH2Cl2, 1d, -40 °C 72:28 
15 1.0 1.0 4.23 (20) CH2Cl2, 1d, -40 °C rac. 
16 1.0 1.0 4.24 (20) CH2Cl2, 1d, 0 °C 49:51 
17 1.0 1.0 4.24 (20) THF, 1d, 0 °C 54:46 
18 1.0 1.0 4.24 (20) toluene, 1d, 0 °C rac. 
19 1.0 1.0 4.25 (20) CH2Cl2, 1d, 0 °C 49:51 
20 1.0 1.0 4.25 (20) THF, 1d, 0 °C 46:54 
21 1.0 1.0 4.25 (20) toluene, 1d, 0 °C 47:53 
22 1.0 1.5 4.26 (20) CH2Cl2, 1d rac. 
23 1.0 1.5 4.27 (20) THF, 1d, -20 °C rac. 
24 1.0 1.0 4.28 (5) acetone, 3h 67:33 
25 1.0 1.0 4.29 (20) toluene, 2d, -78 °C 52:48 
26 1.0 1.0 4.30 (20) THF, 8h rac. 
27 1.0 1.5 4.31 (10) CH2Cl2, 1d, -78 °C rac. 
28 1.0 1.0 cinchonidine (20) CH2Cl2, 1d, -65 °C 18:82 
29 1.0 1.0 cinchonidine (20) Et2O, 1d, -40 °C 35:65 
30 1.0 1.0 cinchonidine (20) toluene, 1d, -40 °C 36:64 
31 1.0 1.0 cinchonidine (20) THF, 1d, -40 °C 33:67 
32 1.0 1.0 cinchonidine (20) CH2Cl2, 17h, -45 °C 23:77 
33 2.0 1.0 cinchonidine (20) CH2Cl2, 17h, -45 °C 23:77 
34 1.0 1.5 cinchonidine (20) CH2Cl2, 14h, -78 to -65 °C 18:82 
35* 1.0 1.5 cinchonidine (20) CH2Cl2, 14h, -78 to -65 °C 16:84 
*Reaction performed on 5.0 gram scale 
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Figure 4-6. Chiral Catalysts Screened for Enantioselective Mannich Addition 
 
 Due to the high reactivity of our substrate, we screened almost every chiral catalyst we 
could justify to promote the reaction (Entries 15-27). Organocatalysts as well as organometallic 
complexes were tested including iminophosphoranes (4.27),9 Pd-BINAP complexes (4.28),10 
the Trost ligand (4.30),11 and copper(box) catalysts (4.31).12 Unfortunately, none of these 
conditions provided an enantiomeric ratio greater than 67:33, though high reactivity was 
observed.  
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 We ultimately concluded cinchonidine provided our best opportunity for high 
enantioselectivity. The racemic Mannich product obtained with Hünig’s base was a white 
solid, so we believed that we could boost the enantioselectivity by a recrystallization at the 
expense of yield, if necessary. Optimization of reaction conditions showed an improvement to 
18:82 er when the reaction was conducted at -65 °C (Entry 28). A solvent screen did not 
provide any improvement (Entries 29-31), and order of reagent addition and temperature 
manipulation failed to increase enantioselectivity. After significant experimentation we arrived 
at 16:84 er with cinchonidine on multigram scale when the reaction was set up at -78 °C and 
warmed to -65 °C overnight, with efficient stirring being critical (Entry 35).  
 This optimized enantioselectivity was still below expectation for natural product 
synthesis applications, so we tested a variety of recrystallizations. Surprisingly, the 
enantioenriched product obtained after purification was a viscous yellow oil, significantly 
different than the racemic material, a white solid. We found this to be a significant problem, 
and after extensive recrystallization studies of the pure material had failed to develop a method 
for enantioenrichment, our only hope was to resolve the material diastereomerically by a future 
enantioselective reaction in our route. 
 We experienced a serendipitous result late in our synthetic studies, after racemic 
pactamycin had been completed. Crude material from the Mannich addition was not very 
soluble in the 40% ethyl acetate/hexane solvent system used to purify the material. Typically 
dry-loading or more polar solvents were used to charge the columns with material. On one 
occasion, the 40% ethyl acetate/hexane solvent mixture was poured into a round-bottomed 
flask and stirred to dissolve the material for its introduction on to the column. After a few 
minutes the material dissolved completely, forming a yellow solution. A couple of minutes 
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later, a white, fluffy solid crashed out of the yellow solution. The solid material was filtered 
and analyzed. We were disappointed to see that this material was in fact racemic, but the low 
mass recovery (~25%) prompted us to analyze the mother liquor. Although this solution 
contained some crude impurities, the desired product was present with an enantiomeric ratio 
of 2:98. Purification of this material provided a pale yellow oil/foam in 70% yield, completing 
our optimization of the asymmetric Mannich reaction (Scheme 4-4).  
Scheme 4-4.  Optimized Mannich Addition 
 
4.3.4  Discovery of a Symmetry-Breaking Diketone Monoreduction 
 Due to the symmetric ketone strategy we used to simplify development of the Mannich 
addition, the challenging diastereoselective reaction development was deferred to a critical 
reduction step. We planned to use a monoreduction of our Mannich product 4.20 to form the 
C7 secondary alcohol and to set the relative relationship of the C2, C1, and C7 stereocenters. 
We also hoped that the chiral C2 amino group would participate as a director. The 
stereochemical possibilities for this transformation are depicted in Figure 4-7. The desired 
enantiomer is drawn for simplicity, as well as a locked syn confirmation at C1 and C2, 
highlighting the ketone selectivity. 
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Figure 4-7.  Stereochemical Possibilities for Monoreduction 
 
 The reaction was complicated by the fact that we needed a monoreduction of a diketone 
species. A successful, selective monoreduction of substrate 4.20 could then provide any of the 
four possible product diastereomers 4.33 – 4.36. Alcohol 4.33 contains the desired (1R, 2S, 
7S)-configuration or “all syn” stereotriad we hoped to assemble. At the beginning of our 
studies, we had no prediction as to what product may be favored, or if we would observe any 
diastereoselection. We began a screen of various reducing agents and reaction conditions. 
Having found success in the past with lithium tri(tert-butoxy)aluminum hydride (LTBA), we 
tested this reagent first at cryogenic temperature. Full conversion was achieved, and after an 
overnight reaction, the monoreduction product 4.32 was obtained in good yield with a 
surprising >10:1 4.32:(other diastereomers) diastereomeric ratio. Although we had no idea 
what diastereomer we had obtained at this point, we were excited by the promising result. 
Considerable effort was spent screening additional reagents and conditions, but results were 
always inferior to the initial hit we obtained with LTBA.  
 The next set of experiments we conducted were in an effort to determine stereochemical 
information about monoalcohol 4.32. We first attempted nOesy analysis of several derivatives 
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to assign the relative stereochemistry, but results were ambiguous. While most experiments 
indicated we had not obtained the desired diastereomer, the evidence was typically weak. We 
next performed a second reduction of monoalcohol product 4.32 with LTBA, which provided 
a clean transformation to the diol 4.37 (Figure 4-8). Through NMR analysis of the 
corresponding acetonide, we felt strongly that we had obtained the trans-diol product. 
Experiments on the diol revealed two symmetry-breaking oxidation protocols (Dess-Martin 
periodinane and TPAP/NMO) which provided site-selective oxidation. 
Figure 4-8.  Selective Oxidations Shed Light on Stereochemical Problem 
 
 The two possible trans-diols obtained are shown in Figure 4-7 (4.37a and 4.37b). 
Though we did not know which diastereomer we had, we knew that the two oxidation 
procedures formed two different monoalcohol products, one matching 4.32. This analysis 
allowed us to draw the following conclusion: each trans-diol (4.37a and 4.37b) would lead to 
a pair of monoalcohols, with each isomer of the pair accessible depending on the oxidation 
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chosen. One of the oxidation products from 4.37a would be the monoalcohol with the desired 
orientation, 4.38, and one of the oxidation products from 4.37b would give the C7-epimer of 
the desired monoreduction, 4.39. While these studies did not assist in the determination of the 
original LTBA reduction product 4.32, ultimately we discovered that we could access the 
desired diastereomer 4.38, or a C7 epimer, 4.39.  
 At this point we acknowledged the importance of an X-ray crystal structure to 
determine the relative configuration of our initial monoalcohol product. After scores of 
experiments in an effort to obtain a crystalline derivative of 4.32, we could not obtain material 
suitable for analysis. We tentatively conceded on these endeavors, proceeded with our 
unknown diastereomer 4.32, and hoped to obtain a crystalline intermediate later in the 
synthesis. The highly-diastereoselective monoreduction was followed by a TBS protection of 
the monoalcohol, effected with TBSOTf to provide a substrate compatible with basic, 
nucleophilic conditions (Scheme 4-5).   
Scheme 4-5.  Reduction/Protection Sequence 
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4.3.5  Testing Nucleophilic Addition to the C5 Methyl Ketone 
 During the course of our Mannich and reduction optimization, we tested the addition 
of various nucleophiles to the diketone species. Since we had encountered significant difficulty 
in prior studies adding anything other than methide to the hindered, acidic electrophile, we 
approached this problem with great apprehension. Summarized results from Grignard 
additions are shown in Figure 4-9. We selected isopropenyl Grignard as a model nucleophile 
and were surprised to observe formation of decomposition product 4.41 under all conditions 
screened, including reactions run in the presence of cerium trichloride. Presumably this product 
was formed via a two-step retro-aldol/urea elimination pathway followed by a 1,2-Grignard 
addition to the intermediate dienone species. We were also disappointed, but not surprised to 
find the functionalized bromo-allylic alcohol used in previous studies failed to react with the 
diketone. 
Figure 4-9.  Grignard Additions to the Diketone 
 
 We quickly realized that if the addition was going to be successful, the reaction 
conditions would need to be significantly altered. To this end we screened a variety of 
nucleophilic additions under more “mild” conditions (Figure 4-10). First we tested a 
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Mukaiyama aldol reaction, which led to decomposition of the diketone (other studies revealed 
diketone 4.20 was very unstable in the presence of acid). Treatment with a Reformatsky reagent 
induced a retro-Mannich pathway followed by nucleophilic addition to the resultant imine. The 
mild Nozaki-Hiyama-Kishi reaction was attempted, but did not react with our diketone 
electrophile, and a methyllithium addition proceeded through the familiar retro-Mannich 
pathway. 
Figure 4-10.  Alternative Diketone Additions 
 
 Without successful results in our intermolecular approaches, we spent some time 
studying intramolecular chemistry to no avail. At this juncture, we considered alternative 
mechanisms for installing the requisite C4 vinyl group for our proposed RCM reaction. Noting 
the apparent acidity of the C5 methyl ketone, we questioned whether this moiety could serve 
as a nucleophile for electrophilic functionalization of the methyl group. This could be followed 
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with a downstream methyl addition to a higher-order ketone to provide the C5 carbinol. The 
results of this hypothesis are presented in the following section. 
4.3.6  C5 Enolate Additions 
 We found early success in our formation of a reactive enolate species from the methyl 
ketone 4.40. Two successful carbonyl additions are shown in Scheme 4-6, the latter of which 
was discovered some time after the initial hit. First, ketone 4.40 was treated with an excess of 
LDA. We assumed the two amino protons would be sufficiently acidic to be removed under 
these conditions and found 3.5 equivalents of base were optimal for enolate formation. 
Addition of Mander’s reagent (4.42) at -78 °C allowed the reaction to proceed to full 
conversion, typically after 3-5 hours. This important reaction provided a useful -ketoester 
handle for -functionalization. We tested several routes with -ketoester 4.43 in an effort to 
install an alkylidene for the RCM reaction (4.44), but were never able to install this 
functionality.  
Scheme 4-6.  C5 Enolate Nucleophilic Additions 
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 Although the -ketoester was useful for a variety of cyclization studies (vide infra), we 
found ourselves interested in a reduced form of this structure, the correct oxidation state seen 
in pactamycin. While we could reach primary alcohol 4.45 via an elaborate reduction/oxidation 
scheme, a more-direct route was desired. To this end, the lithium enolate of 4.40 was treated 
with formaldehyde (CH2O) gas
13 to give the aldol product 4.45 in good yield. This particular 
eaction was enabled by the sparging of CH2O(g), generated in situ from the heating of 
paraformaldehyde, into the reaction via nitrogen stream. This C–C bond construction offered 
a useful, enolizable species for future manipulation.   
4.3.7  Cyclization Studies 
 While we originally envisioned a RCM strategy to form the cyclopentenone core of 
pactamycin, difficulties encountered in constructing the C4 alkylidene precursor prompted us 
to consider alternatives. Looking at -ketoester 4.43, specifically the manner in which we had 
always drawn this structure, it suggested a styrene ozonolysis/intramolecular aldol cyclization 
might provide the cyclopentyl core (Figure 4-11). 
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Figure 4-11.  Aldol Cyclization Strategy 
 
 We pursued this strategy by first subjecting styrene 4.43 to ozonolysis conditions. We 
were pleased to observe clean conversion to the desired aldehyde. Although this material was 
unstable to SiO2 chromatography, it was judged sufficiently pure to take on for future 
experiments. During our initial cyclization studies we decided to go for the “home run” and 
attempted an -halogenation of the -ketoester prior to ozonolysis. The hope was to then 
perform a Darzens cyclization to, not only close the ring, but form a C3–C4 epoxide 
intermediate. The extent of our studies toward this goal are presented in Table 4-2. 
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Table 4-2.  -Halogenation Studies 
 
Conditions Result 
SO2Cl2, CH2Cl2 decompostion 
Br2, CHCl3 mess 
NCS, DMSO silyl deprotection 
dichlorohydantoin, CH2Cl2 mess 
Ni cat. 4.24, NCS (1.5 equiv), THF gem-dichloro product 
Ni cat. 4.24, NBS (1.1 equiv), THF intramolecular trap 4.49 
Ni cat. 4.24, NCS (1.1 equiv), THF 4.48 - 42% yield 
 
 A variety of electrophilic halogenations were attempted, typically providing complex 
mixtures. However, clean reactions were obtained when the NiII catalyst 4.24 was used. In 
combination with NCS or NBS, the Ni-enolate displayed mild reactivity, eventually delivering 
the desired product (4.48) under carefully controlled conditions. Interestingly, when using 
NBS we observed an intramolecular trapping, presumably by the carbamate at N or O 
providing 4.49. This was observed only in trace amounts when using the chloride source. With 
the desired monochlorinated product 4.48 in hand, we moved on to ozonolysis. This was 
successfully achieved, but subsequent spontaneous reactivity delivered a complex mixture of 
products and diastereomers. Subjecting the ozonolysis product to basic conditions never 
revealed a procedure to select for a single product leading to the conclusion of the Darzens 
studies.  
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 We took a step back and decided to attempt cyclization with the unsubstituted -
ketoester 4.46 in an effort to access cyclopentenone 4.47. After smooth conversion to the 
aldehyde via ozonolysis, we observed a surprisingly facile C–C bond formation (Table 4-3). 
Table 4-3.  Aldol Cyclization of the -Ketoester 
 
Conditions Result 
MsCl, DMAP, NEt3 mess 
TsCl, DMAP, NEt3 mess 
TFAA, DMAP, NEt3 mess 
pyridine mess 
pyridine, MsCl, DMAP mess 
AcOH trace 4.47 
Ni cat. 4.24 oxidized product? 4.50 
TFA mess 
TsOH mess 
HCl(aq) mess 
DIPEA, TMSCl, TiCl4 mess 
TiCl4 mess 
TMSOTf mess 
CeCl3-7H2O 4.47 – 55% yield (2 steps) 
65 °C, neat 4.47 
 
 The extreme reactivity of the aldehyde substrate made for very messy reactions under 
most circumstances. Bases such as triethylamine (NEt3) and pyridine promoted the cyclization, 
but gave mixtures of diastereomers and product distributions. Elimination of the resultant 
hydroxyl via activation with MsCl, TsCl, or trifluoroacetic anhydride was attempted in an 
effort to simplify the potential outcome, but failed to provide clean product. A variety of 
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Brønsted and Lewis acids were screened, typically providing equally complex mixtures. The 
presence of acetic acid showed the most promise, delivering a trace amount of the desired 
product, but could not be purified. The bis(cyclohexyldiamino) NiII catalyst 4.24 screened for 
the enantioselective Mannich reaction provided a very clean conversion to what we initially 
thought was the desired cyclization product. After obtaining mass spectral data, however, we 
determined this was actually an oxidized version probably corresponding to enol 4.50. We 
spent considerable time trying to advance the enol intermediate, ultimately finding no success.  
 During Lewis acid screens we found that cerium trichloride effected clean 
transformation to the desired cyclopentenone 4.47, occurring in a 55% yield over the 
ozonolysis and cyclization steps. Further studies revealed it was possible to cyclize the product 
simply under thermal conditions, although yields obtained by this method were inferior. In an 
effort to confirm the product identity as well as advance the synthesis, we tested several 
epoxidation protocols (Figure 4-12). Treatment with m-CPBA under basic conditions provided 
a clean product, which we assigned as pyranone 4.51. Presumably, this reaction proceeded 
through a fleeting epoxide which fragments to carbonyl ylide 4.52 due to ring-strain and the 
excellent negative charge stabilization afforded by the -ketoester. Elimination then occurred 
to relieve the oxonium giving the pyranone product after workup.   
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Figure 4-12.  Surprising Epoxidation Result 
 
 With our epoxidation failure, we began to test other necessary transformations on the 
enone (Figure 4-13).  First, we attempted a selective 1,2-methyl addition to the ketone 
promoted by CeCl3. In several attempts, we were never able to isolate the clean addition 
product. We believed conjugate addition of aniline to the Michael acceptor would be an 
excellent means for C3 C–N bond formation, but this addition was never realized. Next, a 
dihydroxylation similar to the method reported on our partial core synthesis was tested. 
Electronics were indeed important in this event, as the electron-deficient enone was a poor 
candidate for oxidation. We began to realize that our system was too reactive, and attributed 
this to the pendant ester functionality. We attempted reduction to the desired primary alcohol, 
but with multiple sites for potential reduction, were not surprised to obtain only complex 
mixtures of products.   
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Figure 4-13.  Failed Enone Transformations 
 
 The electronics problem we were facing forced us to return to our pre-cyclization 
substrates. We decided to attempt the aldol condensation with a substrate at a lower oxidation 
state for synthetic efficiency as well as practical purposes. Aldehydes 4.46, 4.53, and 4.55 were 
synthesized and screened for cyclization under a variety of conditions (Figure 4-14).  
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Figure 4-14.  Aldol Cyclization of Other Ketones 
 
A simple methyl ketone substrate 4.46 showed some promise as intramolecular 
reactions occurred, as noted by the disappearance of the aldehyde. In the end, however, this 
substrate did not provide a clean cyclized product and would require significant manipulation 
to install the hydroxymethylene at C4. We moved next to a silyl-protected derivative (4.53) 
with the hydroxymethylene in place. Unfortunately, access to this material was challenging at 
the time of its screening limiting us to two experiments for the cyclization, neither of which 
provided the desired product. Finally, we attempted what we considered highly unlikely - 
condensation of a -hydroxyketone (4.55) with an aldehyde – a transformation which lacks 
significant precedent.14 This reaction proceeded cleanly when treated with alkoxide bases; 
sodium methoxide provided the best result at 50% yield over two steps. Finally, we had reached 
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cyclopentenone intermediate 4.56 at the correct oxidation state with a substrate requiring the 
least steps to prepare. 
4.3.8  Completion of Core Stereochemical Functionalization 
 The cyclopentenone 4.56 was an important intermediate in our synthesis as we believed 
the functionality in place was sufficient to permit completion of the core. However, not having 
conclusive evidence for the configuration of the three stereocenters was troubling us, and we 
had yet to obtain a crystalline intermediate. We still moved forward in hopes of functionalizing 
the five ring stereocenters prior to analysis. Three groups needed to be added at this stage and 
are illustrated in Figure 4-15: (1) methide addition to the C5 carbonyl, (2) aniline addition to 
C3, and (3) hydroxylation at C4. We believed an epoxidation of the enone would be an ideal 
method to set up an aniline ring-opening similar to the strategy used in the Hanessian total 
synthesis. While a methyl Grignard addition with or without CeCl3 could finish C5, we were 
unsure about the order of these steps and what role the free primary hydroxyl would play.  
Figure 4-15.  Requirements to Complete Core 
 
 It was clear that the enone functional handle would be useful for epoxidation so we 
pursued this first. We tested standard nucleophilic epoxidation conditions and obtained a hit 
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with NaOH/H2O2 on the unprotected hydroxyl intermediate 4.56. These conditions provided 
clean conversion to a single isolable diastereomer in good yield (4.57). We used nOesy studies 
to tentatively assign the epoxidation as “all syn,” the correct stereochemistry at our four core 
stereocenters (Figure 4-16). This stereochemical result, although unconfirmed, was 
particularly exciting since we were operating on an assumption from the culmination of a 
variety of complex reduction studies earlier in the synthesis. Although the C7 stereocenter was 
still unknown, and the C5 carbinol unformed, we began to get excited about our prospects of 
completing the total synthesis. 
 
 
 
 
 
 
 
 
 
 
 
239 
Figure 4-16.  Diastereoselective Epoxidation 
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 After the successful epoxidation we tested the relative order of introduction of methyl, 
aniline, and primary alcohol protecting groups. These studies revealed a protecting group was 
not only necessary, but its identity extremely important. The addition of our methyl nucleophile 
prior to aniline also showed the most promising results which are highlighted in Table 4-4.  
Table 4-4.  C5 Methyl Additions 
 
R Group Reagent(s) Temp Result 
H MeMgBr -78 °C to rt 4.59 
H CeCl3, MeMgBr (8 equiv) -78 °C SM + 4.58 + 4.59 
H CeCl3, MeMgBr (8 equiv) -35 °C 4.59 
H CeCl3, MeMgBr (10 equiv) -78 °C to rt 4.59 
H CeCl3, MeMgBr (10 equiv) -78  to -40 °C low conv. 
H LiCl, MeMgBr (10 equiv) 0 °C 4.58 + 4.59 
Bz CeCl3, MeMgBr (8 equiv) -78 °C SM + Bz off + 4.59 
Bz CeCl3, MeMgBr (8 equiv) -35 °C Bz off + 4.59 
TES MeMgBr (10 equiv) 0 °C 4.58, TES lost, high dr 
TES MeMgBr (6 equiv) 0 °C 4.58, TES lost, 43%, >20:1 dr 
TES MeMgBr (10 equiv) -20 °C low conv. 
TBS MeMgBr (10 equiv)  0 °C 4.58, TBS lost 
TBDPS MeMgBr (10 equiv)  0 °C 4.58, TBDPS intact, high dr 
TBDPS MeMgBr (10 equiv), 2 h 0 °C 4.58, 75%, >20:1 dr 
 
 These data show that the C4 addition is favored when the C4 hydroxymethylene is 
unprotected or benzoylated. Interestingly, we also observed significant chloride or bromide 
addition to C4 along with methyl incorporation. These results are probably due to any number 
of Payne rearrangements which may occur at C4. We began to observe more positive results 
when silyl protecting groups were employed. A triethylsilyl (TES) group permitted reactivity 
241 
at 0 °C, delivering the desired C5 addition product. During certain circumstances this occurred 
with high diastereoselectivity, but the silyl group was always deprotected under the reaction 
conditions. We attempted to run the reaction at reduced temperatures to avoid the deprotection, 
but the reaction was completely shut down at -20 °C. A tert-butyldimethylsilyl (TBS) group 
performed analogously to the TES group, but was also deprotected. We moved next to the 
extreme in steric encumbrance, the tert-butyldiphenylsilyl (TBDPS) group. In these 
experiments we observed high yield, complete diastereoselection, and full integrity of the silyl 
protecting group. 
 With the final stereocenter completed on the pactamycin core, we committed all of our 
resources to obtaining a crystal structure to confirm the relative configuration of our six 
stereocenters (the enantioselective Mannich reaction was still under development at this stage 
so racemic material was carried up through the synthesis). Fortunately, the methyl addition 
product was the most “solid” material we had obtained thus far in the synthesis. Extensive 
studies found a deprotection of the Cbz group on the C2 amine gave solid material which 
crystallized from slow evaporation of a 10% solution of acetone/petroleum ether (Scheme 4-
6, Figure 4-17). X-ray crystallographic analysis indicated we had constructed the pactamycin 
core with perfect stereochemical integrity.  
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Scheme 4-7.  Route to a Crystalline Derivative 
 
Figure 4-17.  Racemic Crystal Structure Revealing Six Correct Stereocenters 
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 The excellent stereochemical result obtained from the methyl Grignard addition 
prompted us to analyze this approach. In oxobicyclo[3.1.0]hexane systems such as ketone 4.60, 
nucleophilic approach from the convex surface is typically observed.15 This approach would 
provide the wrong stereochemistry in our system, and was not dominant. The convex approach 
was, however, observed in a closely-related system in the Hanessian pactamycin synthesis. In 
this instance, an epoxide with the incorrect stereochemistry was purposely subjected to the 
methylation conditions to obtain the desired C5 configuration. This surprising selectivity 
reversal in our case could potentially be attributed to the two bulky silyl groups on the bottom 
face of the molecule blocking the undesired approach, although the crystal structure of the 
product indicates these groups are positioned in far proximity from the core (crystalline vs. 
solution confirmation could be vastly different). We also proposed the urea may act as a 
director, guiding the Grignard reagent with a syn approach to the ketone electrophile.  
4.3.9  Pactamycin Endgame 
 In this late-stage of the synthesis we were left with installation of the two biologically-
relevant aryl groups. The C3 aniline group was to be added via epoxide ring-opening, and the 
salicylate via acylation of the deprotected primary alcohol. Inspired by the Lewis acid-
catalyzed method used by Hanessian, et al. toward this goal, we envisioned a similar approach 
with the desired meta-acetyl aniline instead of the masked version they used. The results of our 
reaction screening are summarized in Table 4-5. 
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Table 4-5.  Aniline Introduction via Ring-Opening 
 
Lewis Acid Equiv Conditions Yield 
Yb(OTf)3 3.5 toluene, 80 °C, 12 h 27% BRSM 
Yb(OTf)3 3.5 toluene, 100 °C, 12 h decomp. 
Yb(OTf)3 3.5 benzene, 80 °C, 12 h 55% (small scale) 
Yb(OTf)3 3.0 toluene, 80 °C, 8 h 28% 
Sc(OTf)3 3.0 toluene, 80 °C, 8 h 41% 
Sc(OTf)3 3.0 toluene, 50 °C, 8 h low conv. 
Sc(OTf)3 3.0 toluene, rt, 8 h trace product 
Sc(OTf)3 3.0 toluene, 60 °C, 12 h 66% 
 
 Although Hanessian was able to use the Lewis acid in catalytic amounts, we 
encountered low conversion (probably due to excess of unmasked ketone present in solution) 
which necessitated superstoichiometric presence of acid promoter. Initial experiments were 
run with ytterbium(III)triflate from which we observed some conversion to product and 
disappointingly low yields. The mass recovery for these reactions was typically very low, a 
problem we attributed to decomposition of the SM/product under the thermal conditions. 
Yields were highly variable and never surpassed 55%, especially when run on larger scales. A 
large screen of transition metal catalysts identified scandium(III)triflate as a promising 
candidate, and after some optimization we found the reaction proceeded in a decent, 66% yield 
when run at exactly 60 °C. Slightly higher or lower temperatures resulted in diminished yields. 
We believed this moderate yield was acceptable based on the fact that we were introducing the 
functionalized aniline without protection and pushed forward toward the natural product. 
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Scheme 4-8.  Cyanomethyl Ester Synthesis 
 
 For installation of the salicylate moiety we applied the procedure used by Hanessian to 
our system. First we synthesized cyanomethyl ester via a known multi-step route (Scheme 4-
8).16 With the desired acylating reagent 4.64 in hand, we attempted a deprotection of both the 
C7 TBS and TBDPS protecting groups. This occurred without issue using 
tetrabutylammonium fluoride at 0 °C (4.65, Scheme 4-9). A slightly-amended protocol was 
used to perform the selective acylation of the primary alcohol according to the ketene-mediated 
process reported by Delgado17 and used by Hanessian. This installed the salicylate group, 
furnishing our penultimate intermediate 4.66, requiring only a Cbz deprotection.  
Scheme 4-9.  Salicylate Installation 
 
 We believed our substrate would be most stable to hydrogenative deprotection 
conditions to reveal the C2 amine. We began a screen of heterogeneous catalysts to effect this 
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transformation under atmospheric pressures of hydrogen in methanol (Table 4-6). The results 
we obtained were puzzling at times, frustrating, and ultimately attributed to poor catalyst 
quality and differences among suppliers. 
Table 4-6.  Cbz Deprotection Studies 
 
Catalyst Time Result 
Pd/C  1 h 3:1 SM/4.1 
Pd/BaSO4 3 h over-reduction 
Pd(OH)2/C 4 h  over-reduction 
Pd(OH)2/C 3 h SM + over-reduction 
Lindlar’s then Pd(OH)2/C 3 h 4.1 
Pd(OH)2/C + Lindlar’s 2 h decomposition 
Pd(OH)2/C (20% weight) 0.25 h 4.1, 82% yield 
 
 Our starting point was a Pd/C catalyst. Carbamate 4.66 was subjected to the 
hydrogenative conditions with a catalyst loading of approximately half the mass of SM used. 
Reactions were typically run on a 5-10 mg scale and could be monitored by TLC, although 
native pactamycin was extremely polar. Initially we observed low conversions with this 
catalyst, although pactamycin was being formed (NMR and MS analysis). Pd/BaSO4 and 
Pd(OH)2/C were then tested and provided full conversion to an unidentified compound. The 
product had a mass equal to pactamycin+2 so we termed this an “over-reduction” product, 
although it was never conclusively identified. We next tested Lindlar’s catalyst. By TLC 
analysis this was not promoting the reduction so the catalyst was removed by filtration. The 
crude material was immediately resubjected to the hydrogenative conditions with Pd(OH)2/C. 
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Somewhat serendipitously, we observed clean conversion to pactamycin. We tested 
Pd(OH)2/C on its own several times, but always observed the over-reduction product. 
However, initial treatment with Lindlar’s, filtration and resubjection with Pd(OH)2/C, 
consistently provided clean pactamycin.  
 We tried to explain this result, but could never justify our observations. This protocol 
termed the “ridiculous method” was used to produce the majority of pactamycin for analysis 
and characterization, but we were uncomfortable with the idea of publishing the procedure. 
This prompted a wide screen of catalyst sources. This eventually led to the observation that a 
new bottle of Pd(OH)2/C (20% Pd content) purchased from Oakwood Chemical would 
promote the reaction on its own. This catalyst showed high reactivity and reactions were 
complete and required workup after 15-20 minutes to avoid over-reduction. In the end, this 
protocol provided a reliable route to pactamycin in very good yield.  
4.3.10  Stereochemical Analysis 
 The development of the enantioselective Mannich reaction and trituration protocol 
ultimately allowed for the production of highly-enantioenriched pactamycin (98:2 er). We 
confirmed our stereointegrity throughout the synthesis by SFC analysis of material after the 
C5 methyl addition (4.61) when all stereocenters were completed. This consistently showed 
no enantioerosion. However, prior to reaching enantiopure pactamycin, we felt we would need 
to ascertain the absolute stereochemical outcome of the Mannich reaction. Additionally, we 
were uncomfortable with the diastereochemical analysis throughout the synthesis. We knew, 
without a doubt, that we had reached pactamycin and that the right diastereomer was in hand 
from our crystal structure. However, there were opportunities for epimerization at C2 during 
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the synthesis, and the indication of a wrong diastereomer from an early nOesy analysis of 
reduction product 4.32 concerned us.  
Figure 4-18.  Presumed Transfer of Stereochemistry Through the Synthesis 
 
 Figure 4-18 shows the important stereochemical intermediates in our synthesis. The 
only confirmed structure was epoxide 4.61. We strongly believed we had the stereochemistry 
depicted in enone 4.56, but acknowledged the possibly of ambiguity at C2 prior to this stage. 
We designed a simple deuterium labeling experiment to test the integrity of this center (Figure 
4-19). Aldehyde 4.55 was treated with sodium methoxide in deuterated methanol and run as 
usual. NMR analysis of the cyclized product revealed full incorporation of deuterium at C2. A 
similar experiment was conducted on the cyclized product 4.56. In this case, no deuterium 
incorporation was observed. These data indicated that the acidic aldehyde 4.55 is enolized 
under the basic cyclization conditions. This did not indicate whether the C2 stereochemistry 
was correct or incorrect at either intermediate, but did provide a mechanism for possible 
epimerization. 
 
 
Figure 4-19.  Deuterium Incorporation Studies 
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 Our theory of a possible stereochemical error in the reduction product 4.32 was now 
gaining traction. The only possible means for determining the stereochemical outcome would 
be to obtain a crystal structure of an intermediate between the reduction and aldol cyclization. 
This was eventually accomplished by the formation of lactol benzoate derivative 4.68 (Scheme 
4-10, Figure 4-20).  
Scheme 4-10.  Route to Crystalline Lactol Benzoate 
 
 
 
 
Figure 4-20.  Reduction Product Absolute Crystal Structure 
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 The results of this analysis were astounding (Figure 4-21). First, we had confirmed that 
we had formed the correct enantiomer of pactamycin. There was a 50% chance for this result, 
as we had no way of predicting the outcome of the Mannich addition. Second, we determined 
that the Mannich reaction was proceeding to give the wrong, (R) stereochemistry at C2. This 
feature was apparently critical to provide the necessary direction during the LTBA 
monoreduction ultimately providing diastereomer 4.35 (more easily viewed now as the correct 
enantiomer with a C2 error, rather than wrong ketone reduced). Finally, this stereochemical 
error must have been self-corrected via an epimerization (evidenced by deuterium 
incorporation studies) at the aldehyde stage (4.55) concomitant with cyclization to give the 
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correct C1, C2, C7 stereotriad. All of these serendipitous events were unknown, unplanned, 
and occurred selectively with the exact desired outcome necessary in order for us to complete 
pactamycin. Moreover, had we determined any of the actual incorrect stereochemistry during 
the synthesis rather than upon completion, we may not have proceeded, or developed 
alternative strategies for the synthesis with no guarantee of its completion.  
Figure 4-21.  Triply Serendipitous Stereochemical Conclusion 
 
 
 
 
 
4.4  Conclusion 
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 In summary, pactamycin was synthesized in fifteen steps from 2,4-pentanedione in 2% 
overall yield. This expedient synthesis is less than half the steps of the only known route to 
pactamycin reported by Hanessian, et al. Critical to the successful implementation of our 
strategy was the recognition of a hidden symmetry within the target structure, allowing for the 
development and execution of a novel enantioselective Mannich addition/ diastereoselective 
monoreduction sequence. These two steps provided half of pactamycin’s stereocenters and its 
complete carbon core framework. An emphasis was placed on introducing bulk functionality 
in its final desired form, and accomplished though significant reaction development. After 
completing the target with some uncertainty in our understanding of diastereoselectivity 
throughout the route, we discovered multiple unknown serendipitous events had occurred, 
enabling our successful campaign. We are currently using this flexible route for the synthesis 
of pactamycin analogues for biological testing.  
 
 
 
 
 
 
 
4.5  Experimental Details 
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Methods: General. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier 
transform infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 
13C NMR) were recorded on a Bruker model Avance 500 (1H NMR at 500 MHz and 13C NMR 
at 125 MHz) or a Bruker Avance III 600 (1H NMR at 600 MHz and 13C NMR at 150 MHz) 
spectrometer with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm; 
13C NMR: CDCl3 at 77.0 ppm). 
1H NMR data are reported as follows: chemical shift, 
multiplicity (s = singlet, br s = broad singlet, d = doublet, br d = broad doublet, t = triplet, q = 
quartet, m = multiplet), coupling constants (Hz), and integration. Mass spectra were obtained 
using a Micromass Quattro-II triple quadrupole mass spectrometer in combination with an 
Advion NanoMate chip-based electrospray sample introduction system and nozzle or a Thermo 
LTqFT mass spectrometer with electrospray introduction and external calibration. All samples 
were prepared in methanol. Analytical thin layer chromatography (TLC) was performed on 
Sorbent Technologies 0.20 mm Silica Gel TLC plates. Visualization was accomplished with 
UV light, KMnO4, and/or aqueous ceric ammonium nitrate solution followed by heating. 
Purification of the reaction products was carried out by flash chromatography using Siliaflash-
P60 silica gel (40-63μm) purchased from Silicycle. Supercritical fluid chromatography was 
performed on a Berger SFC system equipped with a Chiralcel OD column. Samples were 
eluted with SFC grade CO2 at the indicated percentage of MeOH. Unless otherwise noted, all 
reactions were carried out under an atmosphere of dry nitrogen in oven-dried glassware with 
magnetic stirring. Yield refers to isolated yield of analytically pure material unless otherwise 
noted. Yields are reported for a specific experiment and as a result may differ slightly from 
those found in figures, which are averages of at least two experiments.   
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Materials: General. Tetrahydrofuran (THF), diethyl ether (Et2O), dichloromethane (CH2Cl2), 
and toluene were dried by passage through a column of neutral alumina under nitrogen prior 
to use. Triethylamine (NEt3) and diisopropylamine were freshly distilled from calcium hydride 
prior to use. Cinnamaldehyde was distilled under reduced pressure and elevated temperature 
immediately prior to use. Imine 4.17 and cyanomethyl ester 4.64 were prepared by known 
procedures. All other reagents were purchased from commercial sources and were used as 
received unless otherwise noted. 
Experimental Procedures: 
 
3-diazopentane-2,4-dione (4.15): A 1-L round-bottomed flask was charged with 
acetylacetone (10.25 mL, 100 mmol, 1.0 equiv) and acetonitrile (600 mL). p-
Acetamidobenzene sulfonyl azide (p-ABSA) (24.0 g, 100 mmol, 1.0 equiv) was added and the 
reaction was cooled to 0 °C. Triethylamine (NEt3) (41.8 mL, 300 mmol, 3 equiv) was added 
dropwise and the reaction was warmed to rt for 1 hour. The resulting suspension was filtered 
through a fritted funnel and concentrated. The obtained residue was triturated with 1:1 
ether:petroleum ether and the precipitated white soilds were removed via filtration. Solvents 
were removed in vacuo providing analytically pure 4.15 as a yellow oil in quantitative yield. 
Spectral data matched those reported in the literature. 
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3-(2,4-dioxopentan-3-yl)-1,1-dimethylurea (4.9): A 1-L round-bottomed flask was charged 
with finely ground 1,1-dimethylurea (21.0 g, 237.0 mmol, 1.5 equiv). Toluene (400 mL) and 
1,2-dichlorethane (400 mL) were added followed by diazodiketone 4.15 (20 g, 158.0 mmol, 
1.0 equiv). The suspension was heated to 80 °C in a sand bath with magnetic stirring and 
gradually became homogeneous. Rh2(Oct)4 (0.492 g, 0.632 mmol, 0.004 equiv) suspended in 
toluene (10 mL) was added in four portions over 30 min. The reaction temperature was 
maintained at 80 °C and stirred until complete consumption of 4.15 was indicated by TLC 
analysis, typically 1 h. The reaction was allowed to cool to rt, precipitating the excess 1,1-
dimethylurea. Solids were removed by vacuum filtration and the filtrate was concentrated in 
vacuo. The crude product was purified via flash chromatography (70:30 to 60:40 petroleum 
ether/acetone) to provide the title compound as a yellow solid (19.8 g, 67%). Note: NMR 
analyses typically showed a ~2:1 mixture of enol:keto tautomers. Analytical data: mp 105-109 
°C; 1H NMR (600 MHz, CDCl3): keto-tautomer: δ 5.92 (br s, 1H), 5.03 (d, J = 4.8 Hz, 1H), 
2.92 (s, 6H), 2.20 (s, 6H); enol-tautomer: δ 15.77 (s, 1H), 5.99 (s, 1H), 2.94 (s, 6H), 2.03 (s, 
6H); 13C NMR (150 MHz, CDCl3): δ 201.7, 191.8, 157.5, 157.2, 112.3, 72.8, 36.5, 36.3, 36.2, 
27.2, 23.9, 21.9; HRMS (ESI+) Calcd. for C8H14N2O3+H, 187.1084; Found, 187.1091; IR 
(thin film, cm-1) 3419, 2360, 2126, 1636, 1317, 1315, 1022, 914, 889; TLC (60:40 petroleum 
ether/acetone): Rf = 0.30. 
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(R,E)-benzyl (4-acetyl-4-(3,3-dimethylureido)-5-oxo-1-phenylhex-1-en-3-yl)carbamate 
(4.20): A flame-dried 250-mL round-bottomed flask was charged with urea 4.9 (2.38 g, 12.28 
mmol, 1.0 equiv), cinchonidine (0.72 g, 2.46 mmol, 0.2 equiv), and CH2Cl2 (65 mL). The 
resulting suspension was cooled to -78 °C and a cold solution of imine 4.17 (5.1 g, 19.24 mmol, 
1.5 equiv) in CH2Cl2 (35 mL) was added via cannula transfer. The reaction was warmed to -65 
°C and stirred until complete consumption of urea 4.9 was indicated by TLC analysis, typically 
14-36 h (scale-dependent). The crude reaction was filtered through a short silica plug and 
rinsed with EtOAc (300 mL). The filtrate was concentrated in vacuo to give a pale yellow foam 
with a 84:16 enantiomeric ratio. Crystalline racemic product was isolated via trituration with 
60:40 (v/v) hexanes:EtOAc (300 mL). The analytically-pure white solid was removed by 
filtration (1.33 g, 24%) and the filtrate was concentrated in vacuo to give a yellow oil. The 
crude oil was purified by flash chromatography (60:40 to 50:50 hexanes:EtOAc) affording 
diketone 4.20 as a pale yellow foam (3.87 g, 70%, 97:3 er). The enantiomeric ratio was 
determined by SFC analysis (Chiralcel, OD, 9.0% MeOH, 1.5 mL/min, 150 bar, 210 nm; tR-
minor 12.8 min, tR-major 14.7 min). Analytical data: [α]D19 +16.5 (c = 1.00, CHCl3); mp 
(racemate) 130-134 °C; 1H NMR  (600 MHz, CDCl3): δ 7.37-7.21 (m, 10H), 7.07 (br d, J = 
6.0 Hz, 1H), 6.59 (d, J = 16.2 Hz, 1H), 6.50 (s, 1H), 5.96 (dd, J = 16.2 Hz, 7.2, 1H), 5.40 (t, J 
= 7.2 Hz, 1H), 5.14 (d, J = 12.0 Hz, 1H), 5.11 (d, J = 12.0 Hz, 1H), 2.97 (s, 6H), 2.28 (s, 3H), 
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2.14 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 200.9, 200.4, 157.6, 156.7, 136.9, 136.5, 133.2, 
128.7, 128.6, 128.2, 128.2, 128.1, 126.9, 124.6, 81.7, 67.0, 57.2, 36.8, 26.2, 25.4; HRMS 
(ESI+) Calcd. For C25H29N3O5+H, 452.2187; Found, 452.2212; IR (thin film, cm
-1) 3418, 
2243, 1702, 1635, 1507, 1371, 1249, 1066, 912, 693; TLC (60:40 Hexanes:EtOAc): Rf = 0.20.  
 
Benzyl ((3R,4R,5S,E)-4-acetyl-4-(3,3-dimethylureido)-5-hydroxy-1-phenylhex-1-en-3-yl) 
carbamate (4.32):  A flame-dried 250-mL round-bottomed flask was charged with diketone 
4.20  (8.5 g, 18.8 mmol, 1.0 equiv) and THF (188 mL). The solution was cooled to -78 °C, and 
lithium tri-tert-butoxyaluminum hydride (1.1 M in THF, 25.7 mL, 28.2 mmol, 2.0 equiv) was 
added dropwise. The resulting mixture was warmed to -35 °C and stirred until complete 
consumption of diketone 4.20 was indicated by TLC analysis, typically 12 h. The reaction was 
quenched by the addition of 1M HCl(aq) (50 mL) and the biphasic mixture was extracted with 
EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (50 mL), dried 
with magnesium sulfate, and concentrated in vacuo. The crude product was purified via flash 
chromatography (50:50 to 60:40 EtOAc/hexanes) to afford alcohol 4.32 as a yellow viscous 
oil with >10:1 ratio of 4.32:(other diastereomers) (6.2 g, 72%). Analytical data: [α]D19 +19.5 
(c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.36-7.25 (m, 10H), 6.67 (d, J = 16.2 Hz, 
1H), 6.59 (br s, 1H), 6.17 (dd, J = 15.6, 9.0 Hz, 1H), 5.47 (s, 1H), 5.11 (d, J = 12.0 Hz, 1H), 
5.07 (d, J = 12.0 Hz, 1H), 4.70 (t, J = 9.0 Hz, 1H), 4.60 (br s, 1H), 4.30 (br s, 1 H), 2.90 (s, 
6H), 2.28 (s, 3H), 1.23 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 207.9, 158.4, 
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156.1, 136.2, 135.9, 133.8, 128.5, 128.3, 128.0, 127.9, 127.8, 126.5, 125.5, 73.7, 69.8, 66.8, 
57.2, 36.5, 27.6, 18.6; HRMS (ESI+) Calcd. for C25H31N3O5+H, 454.2344; Found, 454.2368; 
IR (thin film, cm-1) 3410, 2938, 2359, 2248, 1700, 1637, 1520, 1235, 909, 731; TLC (50:50 
hexanes:EtOAc): Rf = 0.20. 
 
Benzyl ((3R,4R,5S,E)-4-acetyl-5-((tert-butyldimethylsilyl)oxy)-4-(3,3-dimethylureido)-1-
phenylhex-1-en-3-yl)carbamate (4.40): A flame-dried 100-mL round-bottomed flask was 
charged with alcohol 4.32 (6.2 g, 13.6 mmol, 1.0 equiv) and CH2Cl2 (68 mL). 2,6-Lutidine 
(4.7 mL, 40.7 mmol, 3.0 equiv) was added and the solution was cooled -78 °C. TBSOTf (3.7 
mL, 16.3 mmol, 1.2 equiv) was added dropwise and the reaction was stirred for 30 min at -78 
°C. Saturated NaHCO3(aq.) (30 mL) and EtOAc (30 mL) were added and the reaction was 
allowed to warm to rt. The layers were separated and the aqueous portion was extracted with 
EtOAc (3 x 50 mL). The combined organic extracts were washed with 1M HCl (30 mL) and 
brine (30 mL), and dried with magnesium sulfate. The crude product was concentrated in vacuo 
and purified via flash chromatography (20:80 to 30:70 EtOAc:hexanes) to give the title 
compound as a pale yellow oil (6.8 g, 88%). Analytical data: [α]D19 -1.5 (c = 1.00, CHCl3); 1H 
NMR  (600 MHz, CDCl3): δ 7.37-7.27 (m, 10H), 7.22 (t, J = 7.2 Hz, 1H), 6.63 (d, J = 16.2 
Hz, 1H), 6.32 (dd, J = 16.2, 7.8 Hz, 1H), 5.31 (s, 1H), 5.11 (d, J = 12.6 Hz, 1H), 5.06 (d, J = 
12.6 Hz, 1H), 5.03 (t, J = 8.4 Hz, 1H), 4.48 (q, J = 6.0 Hz, 1H), 2.96 (s, 6H), 2.22 (s, 3H), 1.22 
(d, J = 6.0 Hz, 3H), 0.88 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
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205.2, 158.8, 155.7, 136.8, 136.6, 132.2, 128.2, 128.1, 127.7, 127.6, 127.3, 127.1, 126.4, 71.2, 
66.3, 54.8, 36.5, 26.5, 25.5, 19.1, 17.7, -3.9, -5.2; HRMS (ESI+) Calcd. for C31H45N3O5Si+H, 
568.3208; Found, 568.3237; IR (thin film, cm-1) 3417, 2954, 1857, 1714, 1651, 1517, 1253, 
1128, 1063, 837, 737; TLC (75:25 hexanes/EtOAc): Rf = 0.30. 
 
Benzyl ((3R,4R,E)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(3,3-dimethylureido)-7-
hydroxy-5-oxo-1-phenylhept-1-en-3-yl)carbamate (4.45): A flame-dried 250-mL round-
bottomed flask was charged with diisopropylamine (5.8 mL, 41.3 mmol, 3.5 equiv) and THF 
(100 mL). The resulting solution was cooled to 0 °C and n-butyllithium (1.65 M in hexanes, 
25.0 mL, 41.3 mmol, 3.5 equiv) was added dropwise. The reaction was stirred at 0 °C for 30 
min and then cooled to -78 °C. A solution of ketone 4.40 (6.8 g, 11.8 mmol, 1.0 equiv) in THF 
(25 mL) was added dropwise, and the resulting mixture was stirred for 45 min and warmed to 
-45 °C. Formaldehyde gas (CH2O(g), prepared by heating paraformaldehyde ((CH2O)n, 5.0 g, 
166.7 mmol, 14.1 equiv) to 145 °C under a positive pressure of nitrogen) was bubbled through 
the reaction. The reaction was stirred at -45 °C until full conversion to product was indicated 
by TLC analysis, typically 1 h. The reaction was quenched by the addition of a saturated 
NH4Cl(aq.) (30 mL), and the resulting mixture was extracted with Et2O (3 x 30 mL). The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo. The 
crude product was purified via flash chromatography (50:50 to 60:40 EtOAc:hexanes) to give 
alcohol 4.45 as a clear, viscous oil (4.9 g, 70%). Analytical data: [α]D19 +11.2 (c = 1.00, CHCl3); 
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1H NMR  (500 MHz, CDCl3): δ 7.35-7.26 (m, 10H), 7.21 (t, J = 7.0 Hz, 1H), 6.59 (d, J = 16.0 
Hz, 1H), 6.28 (dd, J = 16.0, 9.0, 1H), 5.32 (s, 1H), 5.11 (d, J = 12.0 Hz, 1H), 5.02 (d, J = 12.0 
Hz, 1H), 4.98 (t, J = 8.5 Hz, 1H), 4.40 (q, J = 6.5 Hz, 1H), 3.85-3.82 (m, 1H), 3.73-3.71 (m, 
1H), 2.93 (s, 6H), 2.82-2.70 (m, 2H), 1.23 (d, J = 6.5 Hz, 3H), 0.87 (s, 9H), 0.10 (s, 3H), 0.09 
(s, 3H); 13C NMR (150 MHz, CDCl3): δ 208.5, 158.7, 155.9, 136.8, 136.6, 132.3, 128.4, 128.3, 
128.1, 127.9, 127.5, 127.1, 126.6, 74.2, 71.7, 66.6, 58.1, 55.2, 40.7, 36.6, 25.7, 19.2, 17.8, -
3.7, -5.0; HRMS (ESI+) Calcd. for C32H47N3O6Si+H, 598.3314; Found, 598.3345; IR (thin 
film, cm-1) 3429, 2954, 1716, 1646, 1507, 1252, 966, 695, 530; TLC (50:50 hexanes:EtOAc): 
Rf = 0.20. 
 
Benzyl ((1S,5R)-5-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(3,3-dimethylureido)-3-
(hydroxymethyl)-4-oxocyclopent-2-en-1-yl)carbamate (4.56): A 250-mL round-bottomed 
flask was charged with alcohol 4.45 (2.5 g, 4.1 mmol, 1.0 equiv) and CH2Cl2 (82 mL). The 
resulting solution was cooled to -78 °C, and a stream of ozone (O3) was bubbled through the 
solution until a blue color was observed, typically 5-15 min (scale dependent). The mixture 
was sparged with N2 for 5 min or until the full disappearance of blue color, and Me2S (6.0 mL, 
82.0 mmol, 20.0 equiv) was added. The reaction was warmed to rt, stirred for 12 h, and 
concentrated in vacuo affording the crude aldehyde as a yellow oil. The unpurified product 
was taken on directly to the next step.  
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The aldehyde was dissolved in THF (103 mL) and cooled to 0 °C. Sodium methoxide (NaOMe) 
(0.5 M in MeOH, 24.6 mL, 12.3 mmol, 3.0 equiv) was added dropwise. The reaction was 
stirred at 0 °C until TLC analysis indicated complete consumption of the aldehyde, typically 
30 min.  The reaction was quenched by the addition of saturated NaHCO3(aq.) (30 mL), and the 
mixture was extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed 
with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo.  The product 
was purified by flash chromatography (70:30 to 60:40 petroleum ether:acetone) to afford enone 
4.56 as a pale yellow, viscous oil with >20:1 diastereoselection (1.02 g, 50%). Analytical data: 
[α]D19 -25.9 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.35-7.29 (m. 5H), 7.22 (d, J 
= 1.2, 1H), 5.47 (d, J = 10.2 Hz, 1H), 5.21 (d, J = 12.0 Hz, 1H), 5.08 (s, 1H), 5.06 (d, J = 10.2 
Hz, 1H), 4.97 (d, J = 12.0 Hz, 1H), 4.41 (s, 2H), 4.03 (q, J = 6.6 Hz, 1H), 2.75 (s, 6H), 1.04 
(d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
203.3, 158.3, 155.9, 151.8, 146.5, 136.8, 128.4, 128.0, 128.0, 71.9, 68.5, 66.3, 57.3, 54.1, 36.3, 
25.5, 18.1, 17.8, -3.7, -4.9; HRMS (ESI+) Calcd. for C25H39N3O6Si+H, 506.2688; Found, 
506.2715; IR (thin film, cm-1) 3431, 2953, 2857, 2125, 1715, 1634, 1514, 1220, 928, 830; 
TLC (35:65 Hexanes:EtOAc): Rf = 0.20. 
 
Benzyl ((1R,2R,3R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-3-(3,3-
dimethylureido)-5-(hydroxymethyl)-4-oxo-6-oxabicyclo[3.1.0]hexan-2-yl)carbamate 
(4.57): A 200-mL round-bottomed flask was charged with enone 4.56 (1.1 g, 2.2 mmol, 1.0 
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equiv) and MeOH:CH2Cl2 (7:1, 32 mL). The resulting solution was cooled to 0 °C, and a cooled 
solution of H2O2 (30% aq., 20 mL) and NaOH (20% aq., 5 mL) was added dropwise. The 
reaction was stirred at 0 °C for 2 h, and diluted with Et2O (30 mL). The layers were separated 
and the aqueous was extracted with Et2O (3 x 15 mL). The combined organics were washed 
with H2O (3 x 30 mL), brine (20 mL), dried with magnesium sulfate, and concentrated in 
vacuo. The crude product was purified via flash chromatography (70:30 petroleum 
ether:acetone) affording the title compound as a clear, viscous oil with >20:1 diastereoselection 
(0.91 g, 81%). Analytical data: [α]D19 -22.4 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): 
δ 7.32-7.26 (m, 5H), 5.66 (d, J = 9.6 Hz, 1H), 5.20 (d, J = 12.0 Hz, 1H), 4.93 (d, J = 12.6 Hz, 
1H), 4.68 (s, 1H), 4.68-4.66 (m, 1H), 4.07-4.04 (m, 2H), 4.02-3.98 (m, 2H), 2.64 (s, 6H), 1.15 
(d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.10 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 
204.4, 156.9, 156.0, 136.6, 128.3, 128.1, 128.0, 74.0, 69.3, 66.4, 65.9, 60.7, 56.0, 52.3, 36.1, 
25.5, 18.2, 17.7, -3.9, -4.8; HRMS (ESI+) Calcd. for C25H39N3O7Si+H, 522.2637; Found, 
522.2663; IR (thin film, cm-1) 3402, 2954, 2857, 2359, 2249, 2125, 1650, 1519, 1227, 830, 
732; TLC (70:30 petroleum ether/acetone): Rf = 0.30.  
 
Benzyl ((1R,2R,3R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-oxo-6-oxabicyclo[3.1.0]hexan-
2-yl)carbamate (4.60): A flame-dried 25-mL round-bottomed flask was charged with alcohol 
4.57  (1.0 g, 1.9 mmol, 1.0 equiv) and CH2Cl2 (9.5 mL). NEt3 (0.8 mL, 5.7 mmol, 3.0 equiv) 
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and DMAP (0.023 g, 0.19 mmol, 0.1 equiv) were added and the solution was cooled 0 °C. 
TBDPSCl (1.47 mL, 5.7 mmol, 3.0 equiv) was added dropwise and the reaction was warmed 
to rt and stirred for 8 h. Saturated NH4Cl(aq.) (10 mL) was added and the mixture was extracted 
with Et2O (3 x 15 mL). The combined organic extracts were washed with brine (10 mL), dried 
with magnesium sulfate, and concentrated in vacuo. The crude product was purified via flash 
chromatography (70:30 hexanes:EtOAc) to give the title compound as a pale yellow oil (1.1 g, 
76%). Analytical data: [α]D19 -4.4 (c = 0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.67 (d, 
J = 7.2 Hz, 2H), 7.62 (d, J = 7.2 Hz, 2H), 7.44-7.30 (m, 11H), 5.68 (d, J = 10.2 Hz, 1H), 5.23 
(d, J = 12.0 Hz, 1H), 4.97 (d, J = 12.6 Hz, 1H), 4.74 (dd, J = 3.0, 7.2 Hz, 1H), 4.70 (br s, 1H), 
4.26 (d, J = 12.6 Hz, 1H), 4.11 (d, J = 3.0 Hz, 1H), 4.03 (q, J = 6.0 Hz, 1H), 3.92 (d, J = 12.0 
Hz, 1H), 2.68 (s, 6H), 1.19 (d, J = 6.0 Hz, 3H), 1.01 (s, 9H), 0.92 (s, 9H), 0.13 (s, 6H); 13C 
NMR (150 MHz, CDCl3): δ 203.9, 156.8, 156.0, 136.7, 135.5, 135.4, 132.6, 132.3, 129.8, 
129.7, 128.3, 128.1, 127.9, 127.8, 127.7, 74.1, 69.4, 66.4, 66.2, 60.8, 57.5, 52.2, 36.1, 26.6, 
25.6, 19.1, 18.3, 17.8, -3.8, -4.8; HRMS (ESI+) Calcd. for C41H57N3O7Si2+H, 760.3815; 
Found, 760.3862; IR (thin film, cm-1) 3419, 2931, 2857, 2359, 1716, 1651, 1507, 1226, 1113, 
828, 733; TLC (70:30 hexanes/EtOAc): Rf = 0.30.  
 
Benzyl ((1R,2R,3R,4R,5R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(((tert-
butyldiphenylsilyl)oxy)methyl)-3-(3,3-dimethylureido)-4-hydroxy-4-methyl-6-
oxabicyclo [3.1.0]hexan-2-yl)carbamate (4.61): A flame-dried 25-mL round-bottomed flask 
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was charged with ketone 4.60 (1.7 g, 2.3 mmol, 1.0 equiv) and THF (23 mL). The solution was 
cooled to 0 °C and MeMgBr (3M in THF, 7.6 mL, 22.9 mmol, 10.0 equiv) was added dropwise. 
The reaction was stirred at 0 °C until TLC analysis indicated complete ketone consumption, 
typically 2 h.  Saturated NH4Cl(aq.) (20 mL) was carefully added dropwise and the resulting 
mixture was extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed 
with brine (20 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude 
product was purified via flash chromatography (90:10 to 70:30 hexanes:EtOAc) to afford 
carbinol 4.61 as a clear, viscous oil with >10:1 diastereoselection (1.3 g, 75%). The 
enantiomeric ratio was assayed at this intermediate and was found to be 95:5. This composition 
was determined by SFC analysis (Chiralcel, OD, 4.0% MeOH, 1.5 mL/min, 150 bar, 210 nm; 
tR-minor 34.4 min, tR-major 37.6 min).  Analytical data: [α]D19 +7.2 (c = 0.70, CHCl3); 1H 
NMR  (600 MHz, CDCl3): δ 7.73 (d, J = 7.8 Hz, 2H), 7.70 (d, J = 7.2 Hz, 2H), 7.45-7.30 (m, 
12H), 5.55 (br s, 1H), 5.21 (d, J = 12.6 Hz, 1H), 5.17 (br s, 1H), 5.07 (d, J = 12.0 Hz, 1H), 4.77 
(br s, 1H), 4.64 (dd, J = 8.4, 3.6 Hz, 1H), 4.21 (d, J = 12.6 Hz, 1H), 4.12 (d, J = 12.6 Hz, 1H), 
3.90 (s, 1H), 2.75 (s, 6H), 1.30 (s, 3H), 1.25 (d J = 6.0 Hz, 3H), 1.07 (s, 9H), 0.97 (s, 9H), 0.11 
(s, 3H), -0.01 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 158.8, 156.5, 136.3, 135.6, 135.5, 134.7, 
133.3, 132.9, 129.6, 129.4, 128.4, 128.2, 128.1, 127.7, 127.6, 127.6, 67.1, 66.8, 62.1, 58.3, 
36.1, 26.7, 26.5, 25.7, 23.8, 19.6, 19.2, 17.8, -4.2, -5.5; HRMS (ESI+) Calcd. for 
C42H61N3O7Si2+H, 776.4128; Found, 776.4179; IR (thin film, cm
-1) 3430, 2429, 2359, 1716, 
1635, 1506, 1456, 1112, 831, 700; TLC (90:10 hexanes/EtOAc): Rf = 0.35. 
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Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-((S)-1-((tert-
butyldimethylsilyl)oxy) ethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(3,3 dimethyl 
ureido)-3,4-dihydroxy-3-methylcyclopentyl)carbamate (4.63): In a nitrogen-filled glove 
box, a flame-dried 100-mL round-bottomed flask was charged with Sc(OTf)3 (0.38 g, 0.77 
mmol, 3.0 equiv). The flask was capped with a rubber septum and removed from the glove 
box. Toluene (20 mL) was added and to the resulting suspension were added the aniline 
derivative (0.35 g, 2.6 mmol, 10.0 equiv) and a toluene solution (1.5 mL) of epoxide 4.61 (0.20 
g, 0.26 mmol, 1.0 equiv). The reaction was heated to 60 °C with vigorous stirring and 
maintained for 14 h. (Note: increased reaction times led to product decomposition). The 
reaction was cooled to rt, diluted with H2O (10 mL) and EtOAc (10 mL), and the resulting 
mixture was extracted with EtOAc (3 x 10 mL). The combined organic extracts were washed 
with 0.5 M HCl(aq.) (2 x 20 mL), saturated NaHCO3(aq.) (15 mL), dried with magnesium sulfate, 
and concentrated in vacuo. The crude product was purified via flash chromatography (90:10 
to 80:20 hexanes:EtOAc) to afford anilino-alcohol 4.63 as a yellow, viscous oil (0.16 g, 66%) 
with recovery of the unreacted epoxide 4.61 (0.04 g, 18%). Analytical data: [α]D19 -39.3 (c = 
0.70, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 8.21 (d, J = 6.6 Hz, 1H), 7.70 (d, J = 6.6 Hz, 
2H), 7.51 (d, J = 7.2 Hz, 2H), 7.39 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 2H), 7.28-7.22 (m, 
8H), 7.16 (t, J = 7.2 Hz, 2H), 7.12 (t, J = 7.8 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.13 (s, 1H), 
5.88 (s, 1H), 5.39-5.36 (m, 1H), 5.36 (s, 1H), 5.04 (d, J = 12.0 Hz, 1H), 5.01 (d, J = 12.0 Hz, 
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1H), 4.78 (dd, J = 4.6, 6.6 Hz, 1H), 4.37 (d, J = 10.2 Hz, 1H), 4.13 (s, 1H), 3.68 (dd, J = 4.6, 
3.0 Hz, 1H), 3.48 (d, J = 10.8 Hz, 1H), 2.96 (s, 6H), 2.49 (s, 3H), 1.69 (s, 3H), 1.41 (d, J = 6.6 
Hz, 3H), 0.98 (s, 9H), 0.92 (s, 9H), 0.12 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3): 
δ 198.7, 158.6, 158.4, 149.5, 137.7, 136.6, 135.6, 135.4, 132.4, 132.0, 129.6, 128.8, 128.2, 
128.1, 127.8, 127.6, 118.2, 117.0, 112.6, 83.6, 81.0, 70.3, 68.4, 66.9, 66.5, 63.0, 59.3, 36.6, 
26.7, 26.7, 25.7, 21.2, 19.4, 19.0, 17.7, -4.3, -6.1; HRMS (ESI+) Calcd. for C50H70N8Si2+H, 
911.4812; Found, 911.4867; IR (thin film, cm-1) 3361, 2953, 2358, 1716, 1698, 1652, 1539, 
1488, 1472, 1243, 1041, 829, 701; TLC (80:20 hexanes:EtOAc): Rf = 0.35.  
 
Benzyl ((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-2-(3,3-dimethylureido)-3,4-
dihydroxy-2-((S)-1-hydroxyethyl)-4-(hydroxymethyl)-3-methylcyclopentyl)carbamate 
(4.65): A 20-mL scintillation vial was charged with silyl ether 4.63 (0.25 g, 0.28 mmol, 1.0 
equiv) and THF (5.5 mL). The resulting solution was cooled to 0 °C, and TBAF (1 M solution 
in THF, 1.1 mL, 1.1 mmol, 4.0 equiv) was added. The reaction was allowed to stir at 0 °C until 
TLC analysis indicated consumption of the starting material, typically 30 min. The reaction 
was diluted with brine (3 mL) and EtOAc (3 mL) and extracted with EtOAc (3 x 7 mL). The 
combined organic extracts were dried with magnesium sulfate and concentrated in vacuo. The 
crude product was purified via flash chromatography (60:40 petroleum ether:acetone) to afford 
tetraol 4.65 as a pale yellow, viscous oil (0.14 g, 90%). Analytical data: [α]D19 +26.0 (c = 0.70, 
CHCl3); 1H NMR  (600 MHz, CDCl3): δ 7.36 (s, 4H), 7.29 (br s, 1H), 7.23 (br s, 1H), 7.12 (br 
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s, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.75 (d, J = 6.6 Hz, 1H), 6.02 (d, J = 7.2 Hz, 1H), 5.80 (br s, 
1H), 5.48 (d, J = 7.8 Hz, 1H), 5.27 (br s, 1H), 5.13 (br s, 2H), 4.14-4.10 (m, 1H), 4.06 (br s, 
2H), 3.80 (br s, 2H), 3.74-3.68 (m, 1H), 3.55 (m, 1H), 2.87 (s, 6H), 2.52 (s, 3H), 1.42 (s, 3H), 
1.25 (br s, 3H); 13C NMR (150 MHz, CDCl3): δ 198.7, 158.7, 155.8, 146.6, 138.3, 136.0, 
129.7, 128.6, 128.4, 118.4, 112.0, 88.2, 83.9, 73.2, 71.7, 67.4, 66.9, 64.2, 61.8, 61.2, 36.7, 29.7, 
26.7, 22.7, 21.2, 18.0, 14.1; HRMS (ESI+) Calcd. For C28H38N4O8+H, 559.2770; Found, 
559.2800; IR (thin film, cm-1) 3392, 2938, 1716, 1684, 1652, 1635, 1540, 1507, 1473, 1456, 
1361, 1243, 739; TLC (60:40 petroleum ether/acetone): Rf = 0.30. 
 
((1S,2R,3R,4S,5S)-5-((3-acetylphenyl)amino)-4-(((benzyloxy)carbonyl)amino)-3-(3,3-
dimethylureido)-1,2-dihydroxy-3-((S)-1-hydroxyethyl)-2-methylcyclopentyl)methyl 2-
hydroxy-6-methylbenzoate (4.66): A flame-dried 20-mL scintillation vial was charged with 
cyanomethyl ester 4.64 (0.0075 g, 0.044 mmol, 1.1 equiv) and dimethylacetamide (DMA) (0.3 
mL). K2CO3 (0.005 g, 0.04 mmol, 1.0 equiv) was added, and the resulting mixture was stirred 
for 1 h.  The in situ generated ketene solution was transferred to a stirred solution of tetraol 
4.65 (0.02 g, 0.04 mmol, 1.0 equiv) in DMA (0.7 mL). The reaction was stirred until TLC 
analysis indicated full consumption of the tetraol starting material, typically 3 h. The reaction 
was cooled to 0 °C and quenched by the dropwise addition of saturated NH4Cl(aq.) (1.5 mL). 
The resulting mixture was extracted with EtOAc (3 x 5 mL), washed with H2O (10 ml), brine 
(10 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude product was 
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purified via flash chromatography (50:50 Hexanes:EtOAc) to afford an inseparable mixture of 
salicylate 4.66 (0.02 g, 80%) and an unknown impurity (15% by NMR analysis) as a pale 
yellow, viscous oil. Analytical data: [α]D19 +33.6 (c = 0.70, CHCl3); 1H NMR  (600 MHz, 
CDCl3): δ 10.87 (s, 1H), 7.52 (br s, 1H), 7.36 (br s, 5H), 7.30-7.22 (m, 4H), 7.10 (s, 1H), 6.81 
(d, J = 8.4 Hz, 1H), 6.63 (d, J = 7.2 Hz, 1H), 6.13 (s, 1H), 5.79 (d, J = 9.0 Hz, 1H), 5.72 (d, J 
= 9.6 Hz, 1H), 5.23-5.10 (m, 3H), 4.91-4.84 (m, 2H), 4.06 (br s, 2H), 3.80 (d, J = 9.6 Hz, 1H), 
3.69 (s, 1H), 2.85 (s, 7H), 2.30 (s, 3H), 1.42 (s, 3H), 1.26 (s, 3H); 13C NMR (150 MHz, CDCl3): 
δ 198.3, 173.4, 162.9, 158.5, 155.3, 146.0, 141.6, 138.3, 135.0, 129.7, 128.6, 128.5, 123.2, 
119.4, 118.4, 115.8, 111.9, 111.6, 99.7, 88.6, 85.0, 73.9, 72.3, 67.5, 66.8, 66.6, 65.4, 62.7, 36.7, 
23.9, 21.0, 18.0, 17.4; HRMS (ESI+) Calcd. For C36H44N4O10+H, 693.3137; Found, 693.3172; 
IR (thin film, cm-1) 3392, 2965, 1867, 1698, 1670, 1541, 1456, 1374, 1249, 874, 737; TLC 
(50:50 EtOAc:Hexanes): Rf = 0.30. 
 
Pactamycin (4.1): A 4-mL vial was charged with salicylate 4.66 (0.0075 g, 0.01 mmol, 1.0 
equiv), and Pd(OH)2/C (20 wt.%, 0.005 g). MeOH (1 mL) was added and the vial was sealed 
with a Teflon cap. The atmosphere was replaced by H2 (balloon, ~1 atm.) and stirred until TLC 
analysis indicated complete consumption of the starting material, typically 20 min. The 
resulting suspension was filtered through a pad of celite and washed with MeOH. The 
homogeneous solution was concentrated in vacuo. The crude residue was purified by flash 
chromatography (98:2 CH2Cl2:MeOH) affording pactamycin (0.005 g, 82%) as a pale yellow 
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solid. Analytical data: [α]D19 +27.4 (c = 0.40, CHCl3); 1H NMR  (600 MHz, CDCl3): δ  10.98 
(br s, 1H), 7.91 (d, J = 10.8 Hz, 1H), 7.26-7.23 (m, 4H), 7.18-7.16 (m, 2H), 6.81-6.78 (m, 2H), 
6.64 (d, J = 7.2 Hz, 1H), 5.78 (br s, 1H), 5.67 (d, J = 10.8 Hz, 1H), 4.84 and 4.79 (ABq, J = 
12.6 Hz, 2H), 3.93 (m, 1H), 3.80 (d, J = 10.2 Hz, 1H), 2.99 (s, 6H), 2.95 (s, 1H), 2.55 (s, 3H), 
2.38 (s, 3H), 1.55 (s, 3H), 1.04 (d, J = 6.0 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 198.5, 
172.6, 162.8. 159.2, 146.6, 141.2, 138.3, 134.6, 129.6, 123.0, 118.7, 118.4, 115.7, 112.0, 110.8, 
88.8, 84.9, 74.3, 71.5, 68.7, 65.4, 63.2, 36.9, 29.7, 26.7, 24.1, 21.1, 18.1; HRMS (ESI+) Calcd. 
for C28H38N4O8+H, 559.2762; Found, 559.2763; IR (thin film, cm
-1) 3393, 2938, 2359, 2341, 
1698, 1652, 1520, 1473, 1418, 1338, 873, 668; TLC (95:5 CH2Cl2/MeOH): Rf = 0.30. 
Preparation of Crystalline Derivative 4.68: 
 
Benzyl ((3S,4R,5S)-4-acetyl-4-(3,3-dimethylureido)-2-hydroxy-5-methyl tetrahydro- 
furan-3-yl)carbamate (4.67): A 250-mL round-bottomed flask was charged with alcohol 4.32 
(1.4 g, 3.1 mmol, 1.0 equiv) and CH2Cl2 (62 mL). The resulting solution was cooled to -78 °C, 
and a stream of O3 was bubbled through the solution until a blue color was observed, typically 
5 min. The mixture was sparged with O2 for 5 min, and Me2S (0.9 mL, 12.4 mmol, 4.0 equiv) 
was added. The resulting mixture was warmed to rt and stirred for 12 h and concentrated in 
vacuo.  Flash chromatography (60:40 EtOAc:Hexanes) afforded an inseparable ~5:1 
diastereomeric mixture  of lactols (4.67) (0.69 g, 58%) as a viscous oil. Analytical data: [α]D19 
+18.3 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 8.08 (d, J = 12.0 Hz, 1H), 7.37-7.28 
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(m, 5H), 6.15 (br s, 1H), 5.53 (dd, J = 6.0, 6.6 Hz, 1H), 5.39 (d, J = 8.4 Hz, 1H), 5.10 (d, J = 
12.6 Hz, 1H), 4.98 (d, J = 12.6 Hz, 1H), 4.70 (q, J = 7.2 Hz, 1H), 4.63 (dd, J = 6.0, 3.0 Hz, 
1H), 2.83 (s, 1H), 2.80 (s, 6H), 2.38 (s, 3H), 1.17 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, 
CDCl3): δ 204.6, 157.0, 156.2, 136.1, 128.4, 128.1, 127.9, 95.9, 71.4, 66.7, 59.3, 36.0, 26.6, 
14.1; LRMS (ESI+) Calcd. for C18H25N3O6+H, 380.18; Found, 380.17; IR (thin film, cm
-1) 
3390, 2938, 2066, 1700, 1636, 1522, 1351, 1230, 1063, 752; TLC (60:40 EtOAc:Hexanes): 
Rf = 0.35.      
 
(3S,4R,5S)-4-acetyl-3-(((benzyloxy)carbonyl)amino)-4-(3,3-dimethylureido)-5-methyl- 
tetrahydrofuran-2-yl 4-nitrobenzoate (4.68): A flame-dried, 50-mL round-bottomed flask 
was charged with diastereomeric lactols (4.67) (0.69 g, 1.8 mmol, 1.0 equiv) and CH2Cl2 (18 
mL). The resulting solution was cooled to 0 °C and NEt3 (0.76 mL, 5.4 mmol, 3.0 equiv), 
DMAP (0.02 g, 0.18 mmol, 0.1 equiv), and 4-nitrobenzoyl chloride (0.51 g, 2.7 mmol, 1.5 
equiv) were added sequentially. The reaction was stirred at 0 °C until TLC analysis indicated 
complete consumption of the lactol, typically 30 min. H2O (10 mL) was added to the reaction 
and the resulting mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were dried with magnesium sulfate and concentrated in vacuo. The crude residue was 
purified by flash chromatography (30:70 Hexanes:EtOAc) afforded a ~5:1 diasteromeric 
mixture of 4-nitrobenzoate 4.68 (0.71 g, 74%) as a yellow powder. Slow evaporation (MeOH) 
at room temperature afforded crystals suitable for X-ray analysis. (Note: to obtain analytically 
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pure 4.68, a small portion of the fractions were collected from column chromatography, 
resulting in a discrepancy in the diastereomeric ratio [See p. S30].) Analytical data: [α]D19 -
11.8 (c = 1.00, CHCl3); 1H NMR  (600 MHz, CDCl3): δ 8.42 (d, J = 9.0 Hz, 2H), 8.27 (d, J = 
9.0 Hz, 2H), 7.31-7.24 (m, 5H), 6.82 (d, J = 6.0 Hz, 1H), 6.66 (d, J = 9.0 Hz, 1H), 5.94 (br s, 
1H), 5.13 (q, J = 6.6 Hz, 1H), 5.06 (d, J = 12.0 Hz, 1H), 5.02 (d, J = 16.2 Hz, 1H), 4.99 (m, 
1H), 2.90 (s, 6H), 2.38 (s, 3H), 1.17 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 203.8, 
163.5, 157.4, 156.6, 150.6, 136.1, 135.0, 131.2, 128.4, 128.3, 128.1, 127.9, 123.5, 95.4, 72.5, 
66.7, 57.9, 36.2, 26.4, 14.4; LRMS (ESI+) Calcd. for C25H28N4O9+H, 529.19; Found, 529.20; 
IR (thin film, cm-1) 3393, 3113, 2944, 1715, 1637, 1526, 1349, 1271, 1081, 1011, 736; TLC 
(70:30 EtOAc:Hexanes): Rf = 0.30.      
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Enantioselectivity Assays: 
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